{"dataset": "bioasq", "id": "6402c910201352f04a00000c", "messages": [{"role": "user", "content": "Can losartan reduce brain atrophy in Alzheimer's disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nLosartan is an angiotensin II receptor antagonist that is primarily used as an antihypertensive medication. It works by blocking the angiotensin II receptor, which is involved in the renin-angiotensin-aldosterone system (RAAS). The RAAS is a hormone system that regulates blood pressure and fluid balance in the body.\n\nThere is some evidence that suggests that the RAAS may be involved in the pathophysiology of Alzheimer's disease. For example, angiotensin II has been shown to increase the production of beta-amyloid, a protein that accumulates in the brains of people with Alzheimer's disease. Additionally, angiotensin II can also lead to inflammation and oxidative stress, which are also thought to contribute to the development of Alzheimer's disease.\n\nGiven this potential link between the RAAS and Alzheimer's disease, it is possible that medications that target the RAAS, such as losartan, could have a beneficial effect on brain atrophy in Alzheimer's disease. However, there is currently no strong evidence to support this hypothesis. While some studies have shown that losartan may have a neuroprotective effect in animal models of Alzheimer's disease, there is a lack of clinical trials in humans that have demonstrated a significant effect on brain atrophy in Alzheimer's disease.\n\nSo, the answer is C. Maybe. While there is some theoretical basis for the use of losartan in Alzheimer's disease, the evidence is not conclusive at this time. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "63fa13da201352f04a000001", "messages": [{"role": "user", "content": "Is PRP-40 regulation of microexons a conserved phenomenon?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nPRP-40 is a protein that is involved in the regulation of microexons, which are small exons that are typically less than 50 nucleotides in length. Microexons are important for the regulation of gene expression and can be involved in a variety of cellular processes.\n\nThe regulation of microexons is a conserved phenomenon across species. In humans, PRP-40 is known as PRPF40A and is involved in the splicing of microexons. In yeast, PRP-40 is also involved in the regulation of microexons, and its function is conserved in other eukaryotes as well.\n\nSo, the answer is A. yes. The regulation of microexons by PRP-40 is a conserved phenomenon across species. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "64178e15690f196b51000020", "messages": [{"role": "user", "content": "Is casimersen effective for the treatment of Duchenne muscular dystrophy?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nDuchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle weakness and degeneration, particularly affecting the muscles used for movement and breathing. It is caused by mutations in the gene that encodes dystrophin, a protein that helps keep muscle cells intact.\n\nCasimersen is a drug that is being investigated for the treatment of DMD. It is an antisense oligonucleotide that is designed to bind to a specific sequence of RNA and prevent the production of a protein that is toxic to muscle cells. By inhibiting the production of this protein, casimersen may help to slow the progression of DMD.\n\nClinical trials have shown that casimersen can improve muscle function and reduce the risk of respiratory failure in patients with DMD. However, the drug is not yet approved for use in the treatment of DMD. It is currently being evaluated in a phase 3 clinical trial to determine its efficacy and safety.\n\nGiven the current state of research, it is not possible to say definitively that casimersen is effective for the treatment of Duchenne muscular dystrophy. However, the evidence suggests that it may be a promising treatment option.\n\nSo, the answer is C. maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "640e2616201352f04a00002a", "messages": [{"role": "user", "content": "Is medical hydrology the same as Spa therapy?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nMedical hydrology is a branch of medicine that deals with the therapeutic use of water in the treatment of various diseases. It includes the use of mineral baths, hot springs, and other water-based therapies. Spa therapy, on the other hand, is a broader term that encompasses a variety of treatments, including hydrotherapy, but also includes other aspects such as massage, aromatherapy, and relaxation techniques.\n\nWhile medical hydrology is a specific branch of medicine that focuses on the therapeutic use of water, spa therapy is a more general term that encompasses a wider range of treatments and services. Therefore, medical hydrology is a subset of spa therapy, but spa therapy is not limited to medical hydrology.\n\nSo, the answer is B. No, medical hydrology is not the same as spa therapy. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "64178e73690f196b51000023", "messages": [{"role": "user", "content": "Is eteplirsen effective for the treatment of Duchenne muscular dystrophy?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nEteplirsen is a drug that is designed to treat Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. The drug works by skipping over the mutated section of the dystrophin gene and allowing the production of a shorter, but still functional, version of the dystrophin protein.\n\nThe drug has been the subject of much controversy due to its limited effectiveness and the high cost of treatment. While it has shown some promise in clinical trials, the results have been mixed, and the drug has not been universally accepted as a standard treatment for DMD.\n\nGiven the current state of research and the limited evidence of its effectiveness, it is difficult to say with certainty that eteplirsen is effective for the treatment of Duchenne muscular dystrophy. However, it is being studied and may prove to be a useful treatment option in the future.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "63f02a82f36125a426000013", "messages": [{"role": "user", "content": "Does CIDEB mutation protect from liver disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nCIDEB (CIDE-B) is a gene that encodes a protein involved in lipid metabolism. Mutations in this gene have been associated with a condition known as CIDE-B deficiency, which is characterized by a lack of CIDE-B protein. CIDE-B is thought to play a role in the regulation of lipid droplet formation and metabolism, particularly in the liver.\n\nWhile the exact mechanism by which CIDE-B deficiency leads to liver disease is not fully understood, it is known that CIDE-B is involved in the regulation of lipid metabolism and storage. In the absence of CIDE-B, it is possible that there could be an imbalance in lipid metabolism, which could lead to liver disease.\n\nGiven the role of CIDE-B in lipid metabolism and the fact that mutations in this gene can lead to a deficiency in the protein, it is reasonable to assume that a mutation in CIDEB could potentially protect from liver disease by disrupting the normal function of the protein and thus altering lipid metabolism in a way that might be beneficial.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "64105502201352f04a00002d", "messages": [{"role": "user", "content": "Is North Star Ambulatory Assessment score a reliable clinical outcome for disease progression assessment in Duchenne Muscular Dystrophy?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nThe North Star Ambulatory Assessment (NSAA) is a clinical outcome measure used to assess the functional abilities of children and young adults with Duchenne muscular dystrophy (DMD). It is a 17-item scale that evaluates the ability to perform activities such as running, jumping, and climbing stairs. The NSAA is designed to be used by clinicians to assess the functional abilities of patients with DMD and to monitor their progression over time.\n\nThe NSAA has been shown to be a reliable and valid measure of functional ability in DMD. It has been used in clinical trials and has been found to be sensitive to changes in functional ability over time. However, it is important to note that the NSAA is not a measure of disease progression in the sense that it does not directly assess the underlying pathology of the disease. It is a measure of functional ability, which can be affected by many factors, including the disease process but also by other factors such as the patient's motivation and the environment.\n\nSo, the answer is A. Yes, the North Star Ambulatory Assessment score is a reliable clinical outcome for disease progression assessment in Duchenne Muscular Dystrophy. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6415ca99690f196b51000019", "messages": [{"role": "user", "content": "Have chimeric antigen receptor (CAR)-T cell therapies been approved for the treatment of B cell malignancies?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.not yet\n<|assistant|>\nChimeric antigen receptor (CAR)-T cell therapy is a type of immunotherapy that uses a patient's own T cells to fight cancer. The T cells are genetically modified to recognize and attack cancer cells. This therapy has been used to treat certain types of B cell malignancies, such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma.\n\nIn 2017, the U.S. Food and Drug Administration (FDA) approved the first CAR-T cell therapy, tisagenlecleucel (Kymriah), for the treatment of children and young adults with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. In 2018, the FDA approved a second CAR-T cell therapy, axicabtagene ciloleucel (Yescarta), for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.\n\nSo, the answer is A. yes. CAR-T cell therapies have been approved for the treatment of B cell malignancies. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "64178e4b690f196b51000022", "messages": [{"role": "user", "content": "Is golodirsen effective for the treatment of Duchenne muscular dystrophy?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nGolodirsen is a drug that is used to treat Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle weakness and degeneration. It is a type of antisense oligonucleotide therapy that works by targeting the dystrophin gene and preventing the production of a protein that is toxic to muscle cells.\n\nThe drug is specifically designed to treat patients with DMD who have a mutation in the dystrophin gene that leads to skipping of exon 53 during protein production. By skipping this exon, the drug allows for the production of a shorter but functional dystrophin protein, which can help to stabilize muscle cells and slow the progression of the disease.\n\nClinical trials have shown that golodirsen can lead to an increase in dystrophin protein levels in the muscles of patients with DMD, which is associated with improvements in muscle strength and function. The drug has been approved by the FDA for the treatment of DMD in patients with a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.\n\nSo, the answer is A. yes. Golodirsen is effective for the treatment of Duchenne muscular dystrophy. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "63f043e4f36125a426000023", "messages": [{"role": "user", "content": "Is Baricitinib effective for Alopecia Areata?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nBaricitinib is a Janus kinase (JAK) inhibitor that is approved for the treatment of rheumatoid arthritis. It works by inhibiting the JAK pathway, which is involved in the signaling of various cytokines that are important in the immune response. Alopecia areata is an autoimmune disease where the immune system attacks the hair follicles, leading to hair loss. The exact mechanism by which baricitinib might be effective in alopecia areata is not well understood, but it is hypothesized that by inhibiting the JAK pathway, it could reduce the immune response that is causing the hair loss.\n\nWhile there is some evidence that JAK inhibitors may be effective in treating alopecia areata, the data is not conclusive. A small study in 2018 found that baricitinib was effective in inducing hair regrowth in patients with alopecia areata, but this was a small study and further research is needed to confirm these findings. Additionally, baricitinib is not currently approved for the treatment of alopecia areata.\n\nGiven the current state of research, it is difficult to say with certainty whether baricitinib is effective for alopecia areata. While there is some evidence to suggest it may be, more studies are needed to confirm its efficacy and safety in this condition.\n\nSo, the answer is C. maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "64137616201352f04a000041", "messages": [{"role": "user", "content": "Anemia is not associated with chronic kidney failure\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nChronic kidney failure, also known as chronic kidney disease (CKD), is a condition where the kidneys are damaged and cannot filter blood as well as they should. One of the complications of CKD is anemia, which is a condition where the body does not have enough red blood cells to carry adequate oxygen to the tissues.\n\nThe kidneys produce a hormone called erythropoietin (EPO), which stimulates the bone marrow to produce red blood cells. When the kidneys are damaged, they may not produce enough EPO, leading to anemia. Additionally, CKD can cause other issues that contribute to anemia, such as iron deficiency, vitamin B12 deficiency, and folate deficiency.\n\nTherefore, anemia is a common complication of chronic kidney failure and is not associated with it.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "64163660690f196b5100001d", "messages": [{"role": "user", "content": "Is deflazacort more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.cannot be determined\n<|assistant|>\nDuchenne muscular dystrophy is a genetic disorder characterized by progressive muscle weakness and degeneration, particularly affecting the muscles used for movement and breathing. The disease is caused by mutations in the gene that encodes dystrophin, a protein that helps keep muscle cells intact. There is no cure for Duchenne muscular dystrophy, but treatments can help manage symptoms and slow the progression of the disease.\n\nDeflazacort is a corticosteroid that is used to treat Duchenne muscular dystrophy. It is thought to work by reducing inflammation and stabilizing the muscle cell membrane, which can help to preserve muscle strength and function. Prednisone and prednisolone are also corticosteroids, but they are not specifically used for the treatment of Duchenne muscular dystrophy.\n\nSeveral studies have shown that deflazacort is more effective than prednisone or prednisolone in slowing the progression of Duchenne muscular dystrophy. These studies have shown that deflazacort can improve muscle strength, lung function, and overall quality of life in patients with Duchenne muscular dystrophy.\n\nSo, the answer is A. Yes, deflazacort is more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "64144200201352f04a000043", "messages": [{"role": "user", "content": "Is anaphylaxis a results of mast cell activation?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nAnaphylaxis is a severe, life-threatening allergic reaction that can occur within minutes of exposure to an allergen. It is characterized by a rapid onset of symptoms and signs involving the skin, mucosal tissue, respiratory tract, and cardiovascular system. The symptoms can include hives, swelling, difficulty breathing, and a sudden drop in blood pressure.\n\nThe underlying mechanism of anaphylaxis is the release of inflammatory mediators from mast cells and basophils. Mast cells are a type of immune cell that are found in tissues throughout the body, including the skin, lungs, and gastrointestinal tract. When an allergen binds to the surface of a mast cell, it triggers the release of chemicals such as histamine and leukotrienes. These chemicals cause the symptoms of anaphylaxis by dilating blood vessels, increasing the permeability of capillaries, and causing smooth muscle contraction.\n\nSo, the answer is A. yes. Anaphylaxis is a result of mast cell activation. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "64178e34690f196b51000021", "messages": [{"role": "user", "content": "Is viltolarsen effective for the treatment of Duchenne muscular dystrophy?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nViltolarsen is a drug that is used to treat Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle weakness and degeneration. DMD is caused by mutations in the dystrophin gene, which leads to the absence or deficiency of dystrophin, a protein that helps keep muscle cells intact.\n\nViltolarsen is an antisense oligonucleotide that targets the dystrophin pre-mRNA and promotes the inclusion of exon 51 during splicing, which results in the production of a partially functional dystrophin protein. This can help to stabilize the muscle cells and slow the progression of the disease.\n\nThe FDA has approved viltolarsen for the treatment of DMD in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping. This means that the drug is specifically designed to treat patients with a certain type of mutation in the dystrophin gene.\n\nSo, the answer is A. yes. Viltolarsen is effective for the treatment of Duchenne muscular dystrophy in patients with a specific mutation that is amenable to exon 51 skipping. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6410f839201352f04a000032", "messages": [{"role": "user", "content": "Can the concept of digital twins be applied in Precision Nutrition?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nA digital twin is a digital representation of a real-world object or system. It is a virtual model that is used to simulate, monitor, and optimize the performance of the real-world object or system. Digital twins are often used in industries such as manufacturing, healthcare, and transportation to improve efficiency, reduce costs, and enhance decision-making.\n\nPrecision Nutrition is a field that focuses on providing personalized nutrition recommendations to individuals based on their unique needs and goals. The concept of digital twins could potentially be applied in Precision Nutrition by creating a digital representation of an individual's nutritional status, including their dietary intake, metabolic profile, and other relevant health data. This digital twin could then be used to simulate different dietary interventions and their effects on the individual's health, allowing for more precise and personalized nutrition recommendations.\n\nSo, the answer is A. yes, the concept of digital twins can be applied in Precision Nutrition. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "64040edf201352f04a000011", "messages": [{"role": "user", "content": "Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.cannot be determined\n<|assistant|>\nPioglitazone is a medication that is used to treat type 2 diabetes. It works by increasing the body's sensitivity to insulin, which helps to lower blood sugar levels. In addition to its effects on blood sugar, pioglitazone has been studied for its potential to delay cognitive decline and the onset of Alzheimer's disease.\n\nSeveral clinical trials have investigated the use of pioglitazone in patients with mild cognitive impairment (MCI) or early Alzheimer's disease. The results of these trials have been mixed. Some studies have shown a delay in cognitive decline, while others have not. The largest and most well-known study, the Alzheimer's Disease Neuroimaging Initiative (ADNI), found that pioglitazone did not significantly delay cognitive decline in patients with MCI or mild Alzheimer's disease.\n\nGiven the conflicting results of the clinical trials, it is difficult to definitively say that pioglitazone can delay cognitive impairment for people at risk for Alzheimer's disease. While some studies suggest a potential benefit, the overall evidence is not conclusive.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "63f9cdb033942b094c000012", "messages": [{"role": "user", "content": "Does silencing of SRRM4 promote microexon inclusion?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nSRRM4 is a serine/arginine-rich (SR) protein that is involved in the splicing of pre-mRNA. SR proteins are known to play a role in the recognition of splice sites and the regulation of alternative splicing. One of the functions of SR proteins is to promote the inclusion of exons that are normally skipped during splicing. This is particularly important for the inclusion of microexons, which are small exons that are often skipped in the splicing process.\n\nSilencing of SRRM4 would likely lead to a decrease in the activity of this protein, which could potentially affect the splicing of pre-mRNA. If SRRM4 is involved in promoting the inclusion of microexons, then silencing it would likely lead to a decrease in the inclusion of these exons.\n\nSo, the answer is A. yes. Silencing of SRRM4 would likely promote microexon inclusion because SRRM4 is known to promote the inclusion of exons, including microexons. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "64040af9201352f04a00000d", "messages": [{"role": "user", "content": "Is levosimendan effective for amyotrophic lateral sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nLevosimendan is a drug that is used as an inotropic agent in the treatment of heart failure. It works by increasing the sensitivity of the heart muscle to calcium, which in turn increases the force of contraction of the heart. It is not typically used for the treatment of amyotrophic lateral sclerosis (ALS), which is a progressive neurodegenerative disease that affects the motor neurons in the brain and spinal cord.\n\nThere is no evidence that levosimendan is effective for the treatment of ALS. In fact, the use of inotropic agents like levosimendan in patients with ALS is not recommended because they can worsen the symptoms of the disease by increasing muscle activity, which can lead to hypermetabolism and further muscle breakdown.\n\nSo, the answer is B. no. Levosimendan is not effective for amyotrophic lateral sclerosis. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "641365f6201352f04a00003a", "messages": [{"role": "user", "content": "Is Iron deficiency anemia a common complication of chronic kidney disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nIron deficiency anemia is a common complication of chronic kidney disease (CKD). This is because CKD patients often have a decreased ability to produce erythropoietin, a hormone that stimulates red blood cell production. Additionally, CKD patients may have decreased iron stores due to chronic inflammation, blood loss, or dietary restrictions. Iron deficiency can lead to anemia, which can cause symptoms such as fatigue, shortness of breath, and weakness.\n\nSo, the answer is A. yes. Iron deficiency anemia is a common complication of chronic kidney disease. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6410ef9b201352f04a000031", "messages": [{"role": "user", "content": "Can modulation of KCNQ1 splicing prevent arrhythmias?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nKCNQ1 is a potassium channel that is critical for the function of the cardiac action potential. Mutations in the KCNQ1 gene can lead to long QT syndrome (LQTS), a condition that increases the risk of sudden cardiac death due to life-threatening arrhythmias. One of the mechanisms by which KCNQ1 mutations can lead to LQTS is by altering the splicing of the KCNQ1 mRNA.\n\nSplicing is the process by which introns are removed from pre-mRNA and exons are joined together to form mature mRNA. Mutations in the intronic regions of the KCNQ1 gene can affect the splicing of the mRNA, leading to the production of abnormal proteins that can disrupt the normal function of the potassium channel.\n\nBy modulating the splicing of KCNQ1, it may be possible to prevent the production of abnormal proteins and thus prevent arrhythmias. This could be achieved by targeting the splicing factors or the RNA-binding proteins that are involved in the splicing process.\n\nSo, the answer is A. yes. Modulation of KCNQ1 splicing can potentially prevent arrhythmias by correcting the splicing of the KCNQ1 mRNA and producing normal potassium channels. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6414c124690f196b51000002", "messages": [{"role": "user", "content": "Is trichotillomania encountered with equali frequency in males and females?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nTrichotillomania is a psychiatric disorder characterized by the recurrent pulling out of one's hair, leading to noticeable hair loss. It is a type of impulse control disorder and is more common in females than in males. Studies have shown that the prevalence of trichotillomania is higher in females than in males, with a ratio of approximately 3:1.\n\nSo, the answer is B. No. Trichotillomania is not encountered with equal frequency in males and females. It is more common in females. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "63f9cd2f33942b094c000011", "messages": [{"role": "user", "content": "Does microexon alternative splicing of small GTPase regulators have implication in central nervous system diseases?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nMicroexons are small exons that are typically less than 30 nucleotides in length and are often skipped during alternative splicing. These microexons are important for the regulation of gene expression and can have a significant impact on the function of the protein produced.\n\nSmall GTPase regulators are a class of proteins that control the activity of small GTPases, which are involved in a variety of cellular processes, including cell growth, division, and differentiation. The activity of these regulators is often controlled by alternative splicing, which can lead to the inclusion or exclusion of microexons.\n\nGiven the importance of alternative splicing in the regulation of small GTPase activity and the role of these proteins in the central nervous system, it is reasonable to assume that microexon alternative splicing of small GTPase regulators could have implications in central nervous system diseases. For example, mutations in the genes encoding these regulators can lead to neurological disorders.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6411b4a8201352f04a000035", "messages": [{"role": "user", "content": "Is prosopagnosia also known as lack of auditory recognition?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nProsopagnosia, also known as face blindness, is a condition where individuals have difficulty recognizing faces, including their own. This condition can affect both the recognition of familiar faces and the ability to learn new faces.\n\nAuditory recognition, on the other hand, refers to the ability to recognize sounds, such as speech or music. It is not typically associated with prosopagnosia, which is a visual recognition disorder. People with prosopagnosia can often recognize voices and sounds, as these are processed by different parts of the brain than facial recognition.\n\nSo, the answer is B. No, prosopagnosia is not also known as lack of auditory recognition. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "641357bc201352f04a000039", "messages": [{"role": "user", "content": "Do cells undergoing necroptosis show disruption of their cell membranes?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nNecroptosis is a form of programmed cell death that is distinct from apoptosis. It is characterized by the activation of a signaling pathway that leads to the activation of a caspase-independent cell death program. One of the key features of necroptosis is the disruption of the cell membrane, which is not typically seen in apoptosis.\n\nIn apoptosis, the cell membrane remains intact, and the cell shrinks and fragments into apoptotic bodies. In necroptosis, however, the cell membrane is disrupted, leading to the release of cellular contents into the extracellular space. This is a key difference between the two types of cell death.\n\nSo, the answer is A. Yes, cells undergoing necroptosis do show disruption of their cell membranes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "641ad941690f196b5100003d", "messages": [{"role": "user", "content": "Are LOQ and LOD the same?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nLOQ (Limit of Quantitation) and LOD (Limit of Detection) are both measures of the sensitivity of an analytical method. However, they are not the same.\n\nLOD is the lowest concentration of a substance that can be detected but not necessarily quantified. It is the lowest concentration of a substance that can be reliably distinguished from the background noise in the analytical method.\n\nLOQ is the lowest concentration of a substance that can be quantified with a specified degree of precision and accuracy. It is the lowest concentration of a substance that can be reliably measured and reported with acceptable levels of uncertainty.\n\nSo, the answer is B. No, LOQ and LOD are not the same. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "64179337690f196b51000034", "messages": [{"role": "user", "content": "Do machine learning-based methods outperform statistical methods for survival analysis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nMachine learning-based methods, such as deep learning, have been increasingly used in the field of survival analysis. These methods can be particularly useful when dealing with complex data sets and when the relationships between variables are not well understood or when there are many variables to consider.\n\nStatistical methods, such as Cox proportional hazards models, are well-established and have been used for decades in survival analysis. They are often considered the gold standard for analyzing survival data and are widely used in clinical research.\n\nHowever, machine learning-based methods have the potential to outperform statistical methods in certain situations. For example, they can be more flexible in handling complex data and can often extract more information from the data, leading to better predictive models. Additionally, machine learning methods can be used to identify patterns and relationships in the data that may not be apparent to a human analyst.\n\nSo, the answer is C. Machine learning-based methods may outperform statistical methods in some cases, but it depends on the specific data and the research question being addressed. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6402c868201352f04a00000b", "messages": [{"role": "user", "content": "Was erythropoietin effective for optic neuritis in the TONE trial?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.not applicable\n<|assistant|>\nErythropoietin (EPO) is a hormone that stimulates the production of red blood cells. It is used to treat anemia, particularly in patients with chronic kidney disease. However, it has also been studied for its potential neuroprotective effects in various neurological conditions, including optic neuritis.\n\nOptic neuritis is an inflammation of the optic nerve that can lead to vision loss. It is often associated with multiple sclerosis (MS), but it can also occur as an isolated event. Treatment for optic neuritis typically includes corticosteroids to reduce inflammation and improve vision.\n\nThe TONE (Trial of Oral Corticosteroids in Optic Neuritis) trial was a randomized controlled trial that compared the efficacy of oral corticosteroids to placebo in the treatment of optic neuritis. The trial found that oral corticosteroids were effective in reducing the risk of developing MS and in improving visual acuity in the short term.\n\nThe trial did not specifically evaluate the use of erythropoietin for optic neuritis. Therefore, the question of whether erythropoietin was effective for optic neuritis in the TONE trial is not applicable, as the trial did not address this issue.\n\nSo, the answer is D. not applicable. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "64299b6a57b1c7a315000001", "messages": [{"role": "user", "content": "Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.cannot be determined\n<|assistant|>\nThe Omicron variant of COVID-19, also known as B.1.1.529, was first identified in November 2021 and has since become the dominant variant worldwide. One of the key concerns with the Omicron variant is its high rate of transmission, which has led to a surge in cases in many countries.\n\nHowever, it is important to note that the severity of COVID-19 is not solely determined by the variant causing the infection. The severity of the disease is also influenced by factors such as the age and health status of the infected individual, the quality of healthcare available, and the overall public health response to the pandemic.\n\nWhile early reports suggested that the Omicron variant might be associated with less severe disease, this has not been definitively proven. In fact, some studies have shown that the Omicron variant can cause more severe disease in certain populations, such as children and those with compromised immune systems.\n\nGiven the current state of knowledge, it is not possible to definitively say that COVID-19 caused by the Omicron variant is less severe than infection caused by other variants. The severity of the disease depends on a variety of factors, and the full picture is still emerging as more data becomes available.\n\nSo, the answer is D. cannot be determined. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "64040bd8201352f04a00000e", "messages": [{"role": "user", "content": "Should be used bexarotene for relapsing-remitting multiple sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nBexarotene is a retinoid X receptor (RXR) agonist that is used to treat cutaneous T-cell lymphoma. It is not typically used for the treatment of multiple sclerosis (MS). The standard treatment for relapsing-remitting MS includes disease-modifying therapies such as interferon beta, glatiramer acetate, and natalizumab. These therapies are designed to reduce the frequency of relapses and slow the progression of disability.\n\nBexarotene is not approved for the treatment of MS and has not been shown to be effective in this condition. It is known to have significant side effects, including skin reactions, hyperlipidemia, and increased risk of malignancies. Therefore, it is not a recommended treatment for MS.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6429ee7457b1c7a31500000b", "messages": [{"role": "user", "content": "Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be taken\nD.may not be taken\n<|assistant|>\nThe side effects of COVID-19 vaccines, such as pain at the injection site, fever, fatigue, and headache, are common and typically mild to moderate. These side effects are a sign that the body is building protection against the virus that causes COVID-19.\n\nAnalgesics and antipyretics, such as acetaminophen (paracetamol) or ibuprofen, can be taken to manage these side effects if they are bothersome. However, it is important to note that there is no evidence that taking these medications affects the immune response to the vaccine.\n\nSo, the answer is C. may be taken. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "64281a47690f196b5100004f", "messages": [{"role": "user", "content": "Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nPrimary hyperoxaluria is a rare genetic disorder characterized by the overproduction of oxalate, which can lead to the formation of calcium oxalate stones in the kidneys and other organs. The condition is caused by a deficiency in one of the enzymes involved in the metabolism of glyoxylate, which leads to the accumulation of oxalate in the body.\n\nOXLUMO (lumasiran) is a medication that is used to treat primary hyperoxaluria type 1 (PH1). It works by inhibiting the production of glycolate, which is a precursor to oxalate. By reducing the production of glycolate, OXLUMO helps to reduce the levels of oxalate in the body, which can help prevent the formation of oxalate stones and other complications associated with primary hyperoxaluria.\n\nSo, the answer is A. yes. OXLUMO is used for the treatment of primary hyperoxaluria. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6429cfb557b1c7a315000005", "messages": [{"role": "user", "content": "Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nInhaled glucocorticoids are a common treatment for asthma and COPD. They are used to reduce inflammation in the airways, which can help to prevent asthma attacks and improve lung function in COPD patients. There is no evidence that inhaled glucocorticoids increase the risk of contracting COVID-19 or worsen the disease if a patient does become infected.\n\nIn fact, patients with asthma or COPD who are on inhaled glucocorticoids may actually be at a lower risk of severe COVID-19 outcomes due to the anti-inflammatory effects of these medications. However, it is important to note that the use of inhaled glucocorticoids does not protect against COVID-19 infection.\n\nTherefore, the answer is B. no, patients using inhaled glucocorticoids for asthma or COPD should not be advised to stop these medications to prevent COVID-19. They should continue to use their medications as prescribed to manage their asthma or COPD.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6432f75757b1c7a31500001d", "messages": [{"role": "user", "content": "Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nZanubrutinib is a second-generation BTK inhibitor that was approved by the US Food and Drug Administration (FDA) in 2020 for the treatment of mantle cell lymphoma (MCL) and Waldenstr\u00f6m macroglobulinemia (WM). First-generation BTK inhibitors include ibrutinib and acalabrutinib, which are also approved for the treatment of various hematologic malignancies.\n\nSo, the answer is B. no. Zanubrutinib is not a first-generation BTK inhibitor. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "63eef94ff36125a426000010", "messages": [{"role": "user", "content": "Is Cinpanemab effective for Parkinson\u2019s Disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nCinpanemab is a monoclonal antibody that targets alpha-synuclein, a protein that is implicated in the pathogenesis of Parkinson's disease (PD). Alpha-synuclein is a protein that is normally found in the brain and is involved in the release of neurotransmitters. However, in PD, alpha-synuclein misfolds and forms aggregates known as Lewy bodies, which are thought to be toxic to neurons.\n\nCinpanemab is designed to bind to alpha-synuclein and prevent it from aggregating, potentially reducing the neurotoxic effects of alpha-synuclein in PD. Clinical trials have shown that cinpanemab can reduce the levels of alpha-synuclein in the cerebrospinal fluid of patients with PD, suggesting that it may have a therapeutic effect.\n\nHowever, the long-term efficacy and safety of cinpanemab in the treatment of PD have not yet been fully established. While early results are promising, more research is needed to determine if cinpanemab is effective in slowing the progression of PD or improving symptoms.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "643306cc57b1c7a315000027", "messages": [{"role": "user", "content": "Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nCRISPR/Cas12a, also known as Cpf1, is a type V CRISPR-Cas system that can be used for genome editing. It is a relatively new tool compared to CRISPR-Cas9, which is more commonly used for genome editing. However, CRISPR/Cas12a has been shown to have some unique properties that make it attractive for certain applications.\n\nOne of the properties of CRISPR/Cas12a is its ability to detect single nucleotide polymorphisms (SNPs) and small insertions and deletions (indels) in DNA. This is because the Cas12a enzyme can be programmed to recognize specific DNA sequences and then cleave the DNA at that location. This property has been used in the development of CRISPR-based diagnostic tests, including those for detecting mutations in circulating DNA.\n\nEGFR mutations are a common target for cancer diagnostics, as they are associated with certain types of cancer, including lung cancer. The ability of CRISPR/Cas12a to detect mutations in circulating DNA makes it a potential tool for the detection of EGFR mutations in blood samples.\n\nSo, the answer is A. yes. CRISPR/Cas12a can be used for the detection of EGFR mutations in circulating DNA. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "63f9ccdc33942b094c00000f", "messages": [{"role": "user", "content": "Is PRP-40 involved in microexon splicing?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nPRP-40 is a protein that is involved in the splicing of pre-mRNA into mRNA. It is a component of the spliceosome, which is a complex of proteins and RNAs that catalyzes the splicing of pre-mRNA. The spliceosome recognizes the introns in the pre-mRNA and removes them, leaving the exons to be joined together to form the mature mRNA.\n\nMicroexons are small exons that are typically less than 30 nucleotides in length. They are often found in the 3' untranslated region (3' UTR) of genes and can be involved in various regulatory functions, such as alternative splicing, mRNA stability, and translation efficiency.\n\nPRP-40 is known to be involved in the splicing of pre-mRNA, but there is no specific evidence that it is directly involved in the splicing of microexons. While it is possible that PRP-40 could be involved in the splicing of microexons, there is no clear indication that it is a key player in this process.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6404199d201352f04a000019", "messages": [{"role": "user", "content": "Is ocrelizumab effective for primary progressive multiple sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nOcrelizumab is a monoclonal antibody that targets CD20-positive B cells. It is approved for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. However, it is not specifically approved for primary progressive MS (PPMS), which is a progressive form of MS that does not have relapses.\n\nWhile ocrelizumab has been studied in PPMS, the results of the ORATORIO trial, which compared ocrelizumab to placebo in PPMS, did not show a significant benefit in terms of slowing disability progression. The trial was stopped early due to futility, meaning that the trial did not show a clear benefit of ocrelizumab over placebo.\n\nGiven this information, we can conclude that ocrelizumab is not effective for primary progressive multiple sclerosis.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "63f9cdcc33942b094c000013", "messages": [{"role": "user", "content": "Does silencing of SRRM4 inhibit tumor growth across cancers?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nSRRM4 is a gene that encodes a protein involved in the regulation of alternative splicing, a process that can lead to the production of different protein isoforms from a single gene. Alternative splicing is a common mechanism for generating protein diversity and is important for the proper functioning of cells.\n\nIn the context of cancer, it is known that changes in alternative splicing can contribute to the development and progression of tumors. However, the specific role of SRRM4 in cancer is not well understood.\n\nSome studies have suggested that SRRM4 may be involved in the regulation of alternative splicing in cancer cells, and that its silencing could potentially inhibit tumor growth. For example, one study found that SRRM4 is overexpressed in breast cancer cells and that its silencing leads to a decrease in cell proliferation and an increase in apoptosis.\n\nHowever, other studies have not found a consistent role for SRRM4 in cancer. For instance, one study found that SRRM4 is not overexpressed in breast cancer and that its silencing does not affect cell proliferation or survival.\n\nGiven the conflicting results, it is difficult to say with certainty whether silencing of SRRM4 inhibits tumor growth across cancers. While there is some evidence to suggest that it might, more research is needed to fully understand its role in cancer.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "64041e97201352f04a00001e", "messages": [{"role": "user", "content": "Is daridorexant effective for insomnia?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nDaridorexant is a novel orexin receptor antagonist that is approved for the treatment of insomnia. Orexin receptors are involved in the regulation of sleep-wake cycles, and antagonizing these receptors can help to promote sleep. Clinical trials have shown that daridorexant is effective in improving sleep onset and sleep maintenance in adults with insomnia. It is also associated with a reduction in the number of awakenings during the night and an increase in total sleep time. The drug is generally well-tolerated, with side effects such as dizziness, headache, and fatigue being common but usually mild and transient.\n\nGiven the evidence from clinical trials, it is reasonable to conclude that daridorexant is effective for insomnia.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "64041dae201352f04a00001d", "messages": [{"role": "user", "content": "Is deucravacitinib effective for psoriasis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nDeucravacitinib is a novel oral Janus kinase (JAK) inhibitor that is approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. It works by inhibiting the JAK1, JAK2, and TYK2 enzymes, which are involved in the signaling pathways that lead to inflammation and the overproduction of skin cells in psoriasis.\n\nThe efficacy of deucravacitinib for psoriasis has been demonstrated in clinical trials. In a phase 3 trial, deucravacitinib was found to be superior to placebo in improving the signs and symptoms of psoriasis, as measured by the Psoriasis Area and Severity Index (PASI) 90 response rate at week 16. Additionally, it was found to be non-inferior to adalimumab, a biologic therapy, in terms of PASI 90 response rate at week 16.\n\nGiven the evidence from clinical trials, we can conclude that deucravacitinib is effective for the treatment of psoriasis.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6428da47690f196b51000051", "messages": [{"role": "user", "content": "Can the epigenetic status of introns affect gene expression?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nEpigenetics is the study of heritable changes in gene expression that do not involve changes in the DNA sequence. One of the most well-known examples of epigenetic regulation is the methylation of cytosine residues in the DNA, which can lead to changes in gene expression without altering the DNA sequence.\n\nIntrons are the non-coding regions of DNA that are spliced out of the primary RNA transcript before it is translated into a protein. While introns themselves do not code for proteins, they can contain regulatory elements that can affect gene expression. These regulatory elements can include binding sites for transcription factors, which can influence the rate of transcription of the gene.\n\nEpigenetic modifications such as DNA methylation can occur in introns and can affect the binding of transcription factors, which in turn can affect the expression of the gene. For example, methylation of intronic regulatory elements can prevent the binding of transcription factors, which can lead to reduced gene expression.\n\nSo, the answer is A. Yes, the epigenetic status of introns can affect gene expression. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "642d4c9b57b1c7a315000013", "messages": [{"role": "user", "content": "Are Luminopsins a fusion proteins of luminol and Rhodopsin ?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": ".maybe\n<|assistant|>\nLuminopsins are a class of proteins that are used in optogenetics, which is a technique that uses light to control cells in living tissue, typically neurons, that have been genetically modified to express light-sensitive ion channels or other proteins. Luminopsins are a type of light-sensitive protein that can be used to control the activity of neurons when exposed to light.\n\nNow, let's analyze the question:\n\nA. yes - This is incorrect because luminopsins are not a fusion of luminol and Rhodopsin. Luminol is a chemical used in chemiluminescence, and Rhodopsin is a light-sensitive protein found in the retina that is responsible for vision in dim light. Luminopsins are a different type of light-sensitive protein that is used in optogenetics.\n\nB. no - This is incorrect because luminopsins are not a fusion of luminol and Rhodopsin.\n\nC. maybe - This is incorrect because luminopsins are not a fusion of luminol and Rhodopsin.\n\nSo, the answer is B. no. Luminopsins are not a fusion of luminol and Rhodopsin. They are a class of light-sensitive proteins that are used in optogenetics, but they are not a fusion of luminol and Rhodopsin.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6428da98690f196b51000053", "messages": [{"role": "user", "content": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nCOVID-19, caused by the SARS-CoV-2 virus, is a respiratory illness that can present with a wide range of symptoms, from mild to severe. The clinical presentation of COVID-19 can overlap with other respiratory illnesses, such as influenza, making it difficult to distinguish between the two without testing.\n\nHowever, there are some key differences that can be considered when making a clinical diagnosis:\n\n1. Fever: Both COVID-19 and influenza can present with fever, but COVID-19 is more likely to cause a high fever (above 38\u00b0C or 100.4\u00b0F) than influenza.\n2. Cough: A cough is a common symptom of both COVID-19 and influenza, but COVID-19 is more likely to cause a dry cough, while influenza is more likely to cause a productive cough.\n3. Shortness of breath: COVID-19 is more likely to cause shortness of breath, especially in severe cases, while influenza is less likely to cause this symptom.\n4. Loss of taste or smell: COVID-19 is more commonly associated with loss of taste or smell, which is not typically a symptom of influenza.\n5. Gastrointestinal symptoms: While both COVID-19 and influenza can cause gastrointestinal symptoms, COVID-19 is more likely to cause diarrhea and vomiting.\n\nGiven these differences, it is possible to distinguish COVID-19 from influenza clinically, but it is not always straightforward, and testing is often necessary for a definitive diagnosis.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6428d7da690f196b51000050", "messages": [{"role": "user", "content": "Can untranslated regions (UTRs) regulate gene expression?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nUntranslated regions (UTRs) are the parts of a gene that are not translated into protein. They are located at the 5' end (5' UTR) and 3' end (3' UTR) of the mRNA. While the coding regions of genes are responsible for the production of proteins, the UTRs can play a role in regulating gene expression.\n\nThe 5' UTR can contain regulatory elements that affect the efficiency of translation initiation, such as ribosome binding sites and secondary structures that can affect the stability of the mRNA. The 3' UTR can contain regulatory elements that affect the stability of the mRNA, such as microRNA binding sites, and can also influence the efficiency of translation termination.\n\nTherefore, untranslated regions can indeed regulate gene expression by affecting the stability and translation efficiency of the mRNA.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "63f9cbb433942b094c00000c", "messages": [{"role": "user", "content": "Is alternative splicing associated with heart disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nAlternative splicing is a process that occurs during gene expression, where a single gene can produce multiple mRNA transcripts and, subsequently, different protein products. This process is important for the diversity of proteins in the cell and can contribute to the complexity of the human genome.\n\nHeart disease is a broad term that encompasses a variety of conditions affecting the heart. While alternative splicing is not directly associated with heart disease, it can play a role in the development of certain heart conditions. For example, alternative splicing of the cardiac troponin T gene has been implicated in the development of hypertrophic cardiomyopathy, a condition characterized by the thickening of the heart muscle.\n\nSo, the answer is C. Maybe. Alternative splicing is not directly associated with heart disease, but it can be associated with specific conditions that fall under the umbrella of heart disease. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "61fa941ec9dfcb9c09000005", "messages": [{"role": "user", "content": "Should Intepirdine be used for Alzheimer's disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nIntepirdine is a drug that was being investigated for the treatment of Alzheimer's disease. It works by inhibiting the reuptake of serotonin and norepinephrine, which are neurotransmitters that are thought to be involved in cognitive function. However, clinical trials of intepirdine for Alzheimer's disease have not shown a significant benefit in cognitive function or behavior.\n\nThe largest trial, the INT-2000 study, was a phase 3 trial that compared intepirdine to placebo in patients with mild to moderate Alzheimer's disease. The results showed no significant difference between the intepirdine and placebo groups in terms of cognitive function or behavior. Given the lack of evidence of efficacy, intepirdine is not currently recommended for the treatment of Alzheimer's disease.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "61f7cb37882a024a10000029", "messages": [{"role": "user", "content": "Is rilonacept effective for pericarditis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nRilonacept is a biologic drug that is used to treat cryopyrin-associated periodic syndromes (CAPS), which include familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease (NOMID). These conditions are characterized by recurrent episodes of fever, rash, and joint pain, often triggered by cold exposure.\n\nPericarditis is an inflammation of the pericardium, the sac-like membrane that surrounds the heart. It can be caused by a variety of conditions, including infections, autoimmune diseases, and trauma. Pericarditis is not typically associated with CAPS or the conditions for which rilonacept is indicated.\n\nWhile rilonacept may be effective for treating the symptoms of CAPS, there is no evidence to suggest that it is effective for pericarditis. Therefore, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "64041f38201352f04a00001f", "messages": [{"role": "user", "content": "Is tebentafusp effective for uveal melanoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nUveal melanoma is a rare form of melanoma that affects the eye. It is the most common primary intraocular malignancy in adults. The standard treatment for uveal melanoma is enucleation (removal of the eye), which is often curative but can lead to significant visual and cosmetic impairment. There is a need for alternative treatments that can preserve vision and quality of life.\n\nTebentafusp is a novel immunotherapy that has shown promising results in the treatment of uveal melanoma. It is a bispecific T-cell engager (BiTE) that targets the melanoma-associated antigen 1 (MAGE-A1) and the T-cell receptor, which allows it to activate the immune system to attack the cancer cells. Clinical trials have shown that tebentafusp can prolong progression-free survival in patients with uveal melanoma, and it is currently being evaluated in a phase 3 clinical trial.\n\nGiven the current evidence, tebentafusp appears to be an effective treatment for uveal melanoma, as it has shown to be able to prolong progression-free survival in patients with this disease.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "63f73f1b33942b094c000008", "messages": [{"role": "user", "content": "Is erenumab effective for trigeminal neuralgia?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nErenumab is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. CGRP is a neuropeptide that is involved in the pathophysiology of migraine. Trigeminal neuralgia is a chronic pain condition that is characterized by severe, electric shock-like pains in the areas of the face where the trigeminal nerve is distributed. While there is some evidence that CGRP may be involved in the pathophysiology of trigeminal neuralgia, there is no clear evidence that erenumab is effective for this condition.\n\nThe primary indication for erenumab is the prevention of migraine headaches. There is no specific evidence that it is effective for trigeminal neuralgia. In fact, the FDA has not approved erenumab for the treatment of trigeminal neuralgia.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "643c88a257b1c7a315000030", "messages": [{"role": "user", "content": "Can other vaccines be given with COVID-19 vaccine?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be given\nD.may not be given\n<|assistant|>\nThe COVID-19 vaccine is a new vaccine that has been developed to protect against the SARS-CoV-2 virus, which causes COVID-19. Like any other vaccine, it is important to follow the recommended schedule for administering other vaccines alongside the COVID-19 vaccine.\n\nThe Centers for Disease Control and Prevention (CDC) has provided guidance on the administration of other vaccines with the COVID-19 vaccine. The CDC recommends that other vaccines can be administered without regard to timing with COVID-19 vaccines, with the exception of live vaccines, which should be deferred for at least 14 days before and after COVID-19 vaccination.\n\nSo, the answer is C. Other vaccines may be given with COVID-19 vaccine, with the exception of live vaccines. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6441302d57b1c7a315000056", "messages": [{"role": "user", "content": "Is music therapy effective for pain management in neonates?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unproven\n<|assistant|>\nMusic therapy is a form of therapy that uses music to achieve specific goals. In the context of pain management in neonates, music therapy has been studied for its potential to reduce pain and stress in infants undergoing medical procedures.\n\nStudies have shown that music therapy can be effective in reducing pain and stress in neonates. For example, one study found that music therapy reduced pain in neonates undergoing heel lance procedures. Another study found that music therapy reduced stress in neonates undergoing surgery.\n\nHowever, it's important to note that not all studies have shown a significant effect of music therapy on pain management in neonates. Some studies have found no significant difference between music therapy and standard care in reducing pain in neonates.\n\nGiven the mixed results of the research, it's difficult to definitively say that music therapy is effective for pain management in neonates. However, there is some evidence to suggest that it may be beneficial in certain contexts.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "63f02b50f36125a426000014", "messages": [{"role": "user", "content": "Is there any association between Tripe palms and cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nTripe palms, also known as cutis tricolor, is a rare skin condition characterized by the presence of three distinct colors on the palms of the hands and soles of the feet. The colors are typically red, white, and brown, and they can be arranged in a variety of patterns.\n\nThere is no direct association between tripe palms and cancer. However, some skin conditions that are associated with internal malignancies, such as acanthosis nigricans, are not directly associated with cancer but are more commonly seen in patients with certain types of cancer. This is because cancer can cause changes in the body that affect the skin, including the production of hormones that can lead to skin changes.\n\nWhile tripe palms is not a known marker for cancer, it is important to note that any unexplained skin changes should be evaluated by a healthcare professional to rule out underlying conditions, including cancer.\n\nSo, the answer is B. no. There is no direct association between tripe palms and cancer. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "641c516d690f196b5100003f", "messages": [{"role": "user", "content": "Can Amyotrophic Lateral Sclerosis (ALS) be associated with a mutation of the Super Oxide Dismutase 1 (SOD) gene?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nAmyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. It is characterized by the death of motor neurons, which are responsible for controlling voluntary muscle movement.\n\nA mutation in the Super Oxide Dismutase 1 (SOD1) gene is one of the known genetic causes of familial ALS. This mutation leads to the production of a misfolded SOD1 protein that accumulates in the motor neurons, causing them to die. This mutation is responsible for about 20% of familial ALS cases.\n\nGiven this information, the answer is A. Yes, ALS can be associated with a mutation of the SOD1 gene. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "643c396457b1c7a31500002d", "messages": [{"role": "user", "content": "Are any medications available to prevent COVID-19 following exposure?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nThe prevention of COVID-19 following exposure is a critical aspect of public health efforts to control the spread of the disease. While there is no vaccine currently available to prevent COVID-19, there are medications that can be used to reduce the risk of infection after exposure.\n\nOne such medication is monoclonal antibodies. Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens. They can be used to prevent infection in individuals who have been exposed to the virus but have not yet developed symptoms.\n\nAnother option is post-exposure prophylaxis with antiviral medications. These medications can be used to prevent infection in individuals who have been exposed to the virus and are at high risk for developing severe disease.\n\nSo, the answer is A. yes. There are medications available to prevent COVID-19 following exposure. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6440092d57b1c7a315000040", "messages": [{"role": "user", "content": "Has RTA 408 received FDA approval?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.under review\n<|assistant|>\nRTA 408 is a drug that is being developed for the treatment of a rare genetic disorder called X-linked adrenoleukodystrophy (X-ALD). This disorder is characterized by the accumulation of very long chain fatty acids in the brain and adrenal glands, leading to neurological and endocrine symptoms.\n\nThe FDA approval process for new drugs is a rigorous one, involving multiple stages of clinical trials to assess safety and efficacy. The FDA has not yet approved RTA 408 for the treatment of X-ALD, as it is still in the clinical trial phase. However, the drug has shown promising results in early clinical trials, and it is currently being evaluated in larger, more advanced trials.\n\nSo, the answer is B. no. RTA 408 has not yet received FDA approval. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "643c446357b1c7a31500002f", "messages": [{"role": "user", "content": "Can reinfection occur after SARS-CoV-2 infection?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nSARS-CoV-2, the virus that causes COVID-19, is a novel coronavirus that has not been previously identified in humans. Like other coronaviruses, it is possible for a person to be infected with SARS-CoV-2, recover from the illness, and then be reinfected with the same virus at a later date.\n\nReinfection with SARS-CoV-2 has been reported in a few cases, but it is still a relatively rare occurrence. Most people who have been infected with SARS-CoV-2 develop antibodies that can provide some level of protection against future infections. However, the duration of this protection is not yet fully understood, and it is possible that some people may not develop a strong enough immune response to prevent reinfection.\n\nGiven the current state of knowledge, it is not possible to definitively say that reinfection with SARS-CoV-2 is impossible. However, it is less likely than reinfection with other coronaviruses, such as those that cause the common cold, because the immune response to SARS-CoV-2 is typically stronger.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "63ee5eeaf36125a426000002", "messages": [{"role": "user", "content": "Does mutation of ARTEMIS gene causes severe combined immunodeficiency?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nSevere combined immunodeficiency (SCID) is a group of disorders characterized by a severe deficiency in the body's immune system. SCID is a rare but life-threatening condition that can lead to recurrent and life-threatening infections.\n\nThe ARTEMIS gene is involved in the repair of DNA double-strand breaks, which are critical for the development and function of the immune system. Mutations in the ARTEMIS gene can lead to a condition known as ARTEMIS deficiency, which is a form of SCID. Individuals with ARTEMIS deficiency have a defective DNA repair mechanism, which leads to a variety of immune system defects.\n\nGiven this information, it is correct to say that mutation of the ARTEMIS gene can cause severe combined immunodeficiency.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "640c821c201352f04a000023", "messages": [{"role": "user", "content": "Is Wilson's disease described as an iron storage disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nWilson's disease is a genetic disorder that affects copper metabolism. It is characterized by the accumulation of copper in various tissues, including the liver, brain, and eyes. The disease is caused by mutations in the ATP7B gene, which encodes a copper-transporting ATPase. This enzyme is responsible for the excretion of copper into the bile, and when it is defective, copper accumulates in the body.\n\nIron storage diseases, on the other hand, are conditions where there is an excessive accumulation of iron in the body. These diseases are typically caused by genetic mutations that affect the body's ability to regulate iron levels. Examples include hemochromatosis and atransferrinemia.\n\nWilson's disease is not an iron storage disease because it involves the accumulation of copper, not iron. Therefore, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6440084357b1c7a31500003e", "messages": [{"role": "user", "content": "Is omaveloxolone an activator of NFkB?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nOmaveloxolone is a drug that is being investigated for the treatment of Friedreich's ataxia, a rare genetic disorder that affects the nervous system. It is a synthetic triterpenoid that has been shown to have antioxidant and anti-inflammatory properties.\n\nOne of the mechanisms by which omaveloxolone may exert its therapeutic effects is through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. Nrf2 is a transcription factor that regulates the expression of genes involved in antioxidant defense and detoxification. When Nrf2 is activated, it can lead to the upregulation of genes that protect cells from oxidative stress and inflammation.\n\nHowever, omaveloxolone is not known to directly activate NFkB, which is a transcription factor that is involved in the regulation of immune responses and inflammation. NFkB is typically activated by various stimuli, including cytokines, free radicals, and bacterial or viral infections, and it can lead to the expression of genes involved in inflammation and immune responses.\n\nSo, the answer is B. Omaveloxolone is not an activator of NFkB. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "64040d73201352f04a000010", "messages": [{"role": "user", "content": "Can Efgartigimod be used for myasthenia gravis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nEfgartigimod is a monoclonal antibody that targets the neonatal Fc receptor (FcRn), which is responsible for the recycling of immunoglobulins in the body. By inhibiting FcRn, efgartigimod increases the clearance of immunoglobulins, including autoantibodies that are responsible for the symptoms of myasthenia gravis.\n\nMyasthenia gravis is an autoimmune disorder characterized by the production of autoantibodies against the acetylcholine receptor (AChR) at the neuromuscular junction. These autoantibodies lead to the destruction of AChR, which in turn reduces the number of functional AChRs available to bind acetylcholine, causing muscle weakness and fatigue.\n\nBy targeting the FcRn and increasing the clearance of immunoglobulins, efgartigimod can potentially reduce the levels of autoantibodies in the blood and improve the symptoms of myasthenia gravis. This has been shown in clinical trials, where efgartigimod has been found to be effective in reducing the severity of symptoms and improving quality of life in patients with myasthenia gravis.\n\nSo, the answer is A. Yes, efgartigimod can be used for myasthenia gravis. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6422e7ba690f196b51000044", "messages": [{"role": "user", "content": "Have Quercetin-biapigenin nanoparticles been shown to be effective in penetrating the blood-brain barrier\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nQuercetin-biapigenin nanoparticles are a combination of two natural compounds that have been studied for their potential to cross the blood-brain barrier (BBB). The BBB is a highly selective barrier that protects the brain from harmful substances in the blood while allowing the passage of essential nutrients and molecules. It is known that certain nanoparticles can be used to deliver drugs to the brain by overcoming the BBB.\n\nStudies have shown that nanoparticles can be engineered to have specific properties that allow them to cross the BBB. One such property is the ability to be taken up by the brain endothelial cells that form the BBB. This is often achieved by modifying the surface of the nanoparticles to include ligands that bind to receptors on the endothelial cells, which then facilitate their uptake into the brain.\n\nQuercetin-biapigenin nanoparticles have been studied for their ability to cross the BBB and deliver their cargo to the brain. However, the effectiveness of these nanoparticles in penetrating the BBB is not a simple yes or no answer. The effectiveness depends on the specific formulation of the nanoparticles, the method of delivery, and the experimental conditions. Therefore, the answer is \"maybe\" because there is not a definitive yes or no answer to this question.\n\nSo, the answer is C. maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6429eb8457b1c7a31500000a", "messages": [{"role": "user", "content": "Is adenosine methylation an epigenetic modification?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nEpigenetics is the study of heritable changes in gene expression that do not involve changes in the DNA sequence. Epigenetic modifications include DNA methylation, histone modifications, and non-coding RNA regulation.\n\nAdenosine methylation is a type of DNA methylation, which is a common epigenetic modification. DNA methylation involves the addition of a methyl group to the DNA molecule, typically at the 5th carbon of the cytosine ring, which is part of the CpG dinucleotide. This methylation can alter the accessibility of DNA to transcription factors and other proteins, thereby affecting gene expression without changing the DNA sequence.\n\nSo, the answer is A. yes. Adenosine methylation is an epigenetic modification. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "64412c2757b1c7a315000055", "messages": [{"role": "user", "content": "Can breastfeeding be used to alleviate the procedural pain in neonates?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nBreastfeeding is a natural and effective way to provide comfort and pain relief for newborns. The act of breastfeeding can help to soothe and calm a baby, which can be especially helpful during procedures that may cause discomfort or pain. The sucking motion and the warmth and closeness of the mother's body can help to distract the baby from the pain and provide a sense of security.\n\nStudies have shown that breastfeeding can help to reduce the pain response in newborns during procedures such as heel sticks, immunizations, and venipuncture. For example, one study found that breastfeeding was more effective than sucrose in reducing the pain response in newborns during heel lance.\n\nSo, the answer is A. Yes, breastfeeding can be used to alleviate the procedural pain in neonates. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "64042000201352f04a000020", "messages": [{"role": "user", "content": "Can lenacapavir be used for HIV?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nLenacapavir is a novel, long-acting, injectable HIV-1 capsid inhibitor that was approved by the FDA in 2022. It is used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults with no other treatment options or who are intolerant to other antiretroviral therapies.\n\nThe capsid is a protein shell that encloses the HIV-1 genome. Lenacapavir works by inhibiting the HIV-1 capsid, which prevents the virus from entering the host cell and replicating. This mechanism of action is unique among antiretroviral drugs and provides a new option for treating HIV-1 infection.\n\nLenacapavir is administered as a subcutaneous injection every six months, which is a significant departure from the daily oral dosing of most antiretroviral medications. This long-acting formulation can help simplify the treatment regimen for patients and may improve adherence.\n\nSo, the answer is A. Yes, lenacapavir can be used for HIV. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6402c3fd201352f04a000009", "messages": [{"role": "user", "content": "Was prehospital transdermal glyceryl trinitrate effective for stroke in the RIGHT-2 trial?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.not applicable\n<|assistant|>\nThe RIGHT-2 trial was a randomized controlled trial that evaluated the effectiveness of prehospital transdermal glyceryl trinitrate (GTN) in patients with suspected stroke. The trial was conducted in the United Kingdom and included patients who were suspected of having a stroke and were transported by ambulance to the hospital. The primary outcome was the proportion of patients with a favorable outcome at 90 days, defined as a modified Rankin Scale score of 0-2.\n\nThe results of the trial showed that prehospital transdermal GTN was not effective in improving the outcome of patients with suspected stroke. The trial was stopped early due to futility, meaning that the trial was unlikely to show a benefit of the intervention. The trial did not find a significant difference in the primary outcome between the group that received prehospital transdermal GTN and the group that did not.\n\nSo, the answer is B. No, prehospital transdermal glyceryl trinitrate was not effective for stroke in the RIGHT-2 trial. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "643ff48a57b1c7a31500003d", "messages": [{"role": "user", "content": "Is omaveloxolone a suppressor of Nrf2?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nOmaveloxolone is a synthetic triterpenoid that has been studied for its potential therapeutic effects in various diseases. One of the mechanisms by which omaveloxolone may exert its effects is through the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway.\n\nNrf2 is a transcription factor that plays a critical role in the regulation of antioxidant response genes. When Nrf2 is activated, it translocates to the nucleus and binds to the antioxidant response element (ARE), which is a DNA sequence found in the promoter regions of genes that encode for antioxidant enzymes and other proteins involved in detoxification and protection against oxidative stress.\n\nOmaveloxolone has been shown to activate Nrf2 in various cell types, leading to increased expression of antioxidant enzymes and other protective proteins. This activation of Nrf2 is thought to be one of the mechanisms by which omaveloxolone may provide therapeutic benefits in conditions such as Friedreich's ataxia, where oxidative stress is a key contributor to disease pathology.\n\nSo, the answer is A. Yes, omaveloxolone is a suppressor of Nrf2. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "64410f8057b1c7a315000054", "messages": [{"role": "user", "content": "Can salivary cortisol be used to evaluate pain in neonates?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nSalivary cortisol is a measure of the body's stress response. It is a hormone that is released by the adrenal glands in response to stress, including pain. In adults and older children, salivary cortisol levels can be used to assess pain because it is a reliable indicator of the body's stress response.\n\nHowever, in neonates, the use of salivary cortisol to evaluate pain is not as straightforward. Neonates have immature adrenal glands and their stress response systems are not fully developed. Additionally, the collection of saliva in neonates can be challenging and may not be as accurate as in older children and adults.\n\nTherefore, while salivary cortisol can be used to evaluate pain in older children and adults, it is not a reliable measure in neonates due to their physiological differences.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6402c0d5201352f04a000008", "messages": [{"role": "user", "content": "Does nintedanib improve response rate in patients with bladder cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.cannot be determined\n<|assistant|>\nNintedanib is a tyrosine kinase inhibitor that is used to treat various types of cancer, including non-small cell lung cancer and hepatocellular carcinoma. It works by inhibiting the growth of new blood vessels that tumors need to grow and spread.\n\nBladder cancer is a different type of cancer, and the standard treatment for bladder cancer includes surgery, chemotherapy, and immunotherapy. There is no evidence that nintedanib is effective in treating bladder cancer.\n\nGiven the lack of evidence, we cannot say that nintedanib improves response rate in patients with bladder cancer. Therefore, the answer is D. cannot be determined. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "63f9ee5c33942b094c000014", "messages": [{"role": "user", "content": "Does SRRM4 regulate neuronal-specific microexon splicing of TAF1 mRNA?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nSRRM4 is a serine/arginine-rich (SR) protein that is known to be involved in the regulation of alternative splicing. It is particularly important in the splicing of neuronal-specific microexons, which are small exons that are often found in genes that are expressed in the nervous system.\n\nTAF1 (transcriptional activator factor 1) is a gene that is involved in transcriptional regulation and is expressed in a variety of tissues, including the brain. The TAF1 gene has a number of alternative splicing events, including the inclusion of neuronal-specific microexons.\n\nGiven that SRRM4 is known to regulate neuronal-specific microexon splicing and TAF1 is a gene that has neuronal-specific microexons, it is likely that SRRM4 does regulate the splicing of TAF1 mRNA.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6431f71057b1c7a315000019", "messages": [{"role": "user", "content": "In twin-twin transfusion syndrome, are the twins identical?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nTwin-twin transfusion syndrome (TTTS) is a condition that occurs in monochorionic twin pregnancies, where there is an imbalance in the blood flow between the two fetuses. One twin (the donor) receives more blood than it needs, while the other twin (the recipient) receives less blood than it needs. This can lead to complications such as anemia in the donor and heart failure in the recipient.\n\nThe twins in TTTS are identical because they are monochorionic, which means they share a single placenta. Monochorionic twins are always identical because they develop from a single fertilized egg that splits into two embryos. This is different from dichorionic twins, which are fraternal and develop from two separate eggs that are fertilized at the same time.\n\nSo, the answer is A. yes, the twins in TTTS are identical. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6415b7b8690f196b5100000c", "messages": [{"role": "user", "content": "Optogenetics refers to the study of gene expression optimization\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nOptogenetics is a technique that uses light to control cells in living tissue, typically neurons, that have been genetically modified to express light-sensitive ion channels. This technique allows for precise control of neuronal activity and has been used to study the function of specific neurons in the brain and to treat neurological disorders.\n\nThe term \"optogenetics\" combines the words \"optical\" and \"genetics,\" which refers to the use of light to control genetically modified cells. The technique involves the use of light-sensitive proteins, such as channelrhodopsin, which are introduced into cells using genetic engineering techniques. When light is shone on these cells, the proteins open ion channels, which can lead to changes in the electrical activity of the cell.\n\nSo, the answer is A. yes. Optogenetics does involve the study of gene expression optimization, as it relies on the genetic modification of cells to express light-sensitive proteins. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "63f03155f36125a426000019", "messages": [{"role": "user", "content": "Was DNX-2401 tested for treatment of Diffuse Intrinsic Pontine Glioma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.not sure\n<|assistant|>\nDNX-2401 is a drug that was being investigated for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG), a type of brain tumor that affects children. DIPG is a particularly aggressive and difficult-to-treat form of cancer, and there is a great need for new treatments.\n\nThe drug DNX-2401 is a virus that has been genetically modified to target and kill cancer cells. It is designed to infect and replicate within tumor cells, causing them to die. The virus is injected directly into the tumor, which is a common approach for treating brain tumors.\n\nThe drug was tested in a clinical trial for the treatment of DIPG. The trial was conducted at several sites in the United States and Europe, and it included children with newly diagnosed DIPG. The results of the trial were published in 2017, showing that the drug was well-tolerated and had a modest effect on survival.\n\nSo, the answer is A. Yes, DNX-2401 was tested for the treatment of Diffuse Intrinsic Pontine Glioma. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6436953757b1c7a315000028", "messages": [{"role": "user", "content": "Is Functional Neurological Disorder (FND) classified as a psychosomatic disorder?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nFunctional Neurological Disorder (FND) is a condition where neurological symptoms are not caused by a structural or biochemical problem in the nervous system. Instead, the symptoms are believed to be caused by a problem in the way the brain processes information. This can lead to symptoms that mimic neurological disorders, such as seizures, paralysis, or loss of sensation.\n\nFND is not classified as a psychosomatic disorder. Psychosomatic disorders are those where psychological factors are thought to be the primary cause of a physical symptom. In FND, the symptoms are not caused by psychological factors alone, but rather by a problem in the way the brain processes information.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "645004fa57b1c7a31500008b", "messages": [{"role": "user", "content": "Are accessible enhancers necessarily active?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nAccessible enhancers are DNA sequences that can be bound by transcription factors and other regulatory proteins, which can then influence the expression of nearby genes. However, just because a DNA sequence is accessible to regulatory proteins does not necessarily mean that it is active. The activity of an enhancer depends on the presence of specific transcription factors and other regulatory elements that can interact with the enhancer to activate gene expression.\n\nFor example, an enhancer may be accessible to transcription factors but may not be active if the necessary transcription factors are not present or if the enhancer is not in the correct orientation or distance from the gene it is supposed to regulate. Conversely, an enhancer may be active even if it is not accessible to all transcription factors, if the necessary factors are present and can interact with the enhancer.\n\nSo, the answer is D. It depends. The activity of an enhancer depends on the presence of the correct transcription factors and other regulatory elements, as well as the accessibility of the enhancer to these factors. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "63eef9b6f36125a426000011", "messages": [{"role": "user", "content": "Is Prasinezumab effective for Parkinson\u2019s Disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nPrasinezumab is a monoclonal antibody that targets alpha-synuclein, a protein that accumulates in the brains of people with Parkinson's disease. The accumulation of alpha-synuclein is thought to be a key pathogenic event in the development of Parkinson's disease.\n\nA clinical trial (APOLLO) was conducted to evaluate the efficacy and safety of prasinezumab in patients with early Parkinson's disease. The results of the trial were published in the New England Journal of Medicine in 2022. The study found that prasinezumab did not significantly slow the progression of Parkinson's disease compared to placebo. However, the study did not meet its primary endpoint of slowing the rate of clinical decline in Parkinson's disease.\n\nGiven the results of the APOLLO trial, it is not possible to conclude that prasinezumab is effective for Parkinson's disease. While the trial did not show a significant benefit, it is important to note that the study was not designed to definitively prove or disprove the efficacy of prasinezumab. Further research and clinical trials are needed to fully assess the potential benefits and risks of this treatment.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "63f02e1bf36125a426000016", "messages": [{"role": "user", "content": "Was AAVS3 developed for hemophilia A?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nAAVS3 is a gene therapy approach for hemophilia A, a genetic disorder characterized by a deficiency in clotting factor VIII (FVIII). The AAVS3 gene is a safe and effective vector for delivering the FVIII gene to the liver cells, where it can be expressed and secreted into the bloodstream. This approach has been shown to be effective in clinical trials, with patients experiencing a significant reduction in bleeding episodes and an improvement in their quality of life.\n\nSo, the answer is A. Yes, AAVS3 was developed for hemophilia A. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6419d79c690f196b5100003b", "messages": [{"role": "user", "content": "Does iron regulate oligodendrocyte maturation?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nIron is an essential element for many cellular processes, including myelination. Oligodendrocytes are the cells responsible for myelinating the axons of neurons in the central nervous system. Myelination is a process that requires a lot of energy, and iron is a key component of the enzymes involved in energy production.\n\nIron is also important for the synthesis of myelin proteins and lipids, which are the building blocks of the myelin sheath. Without sufficient iron, oligodendrocytes may not be able to produce the necessary components for myelination, which could affect their maturation.\n\nGiven the critical role of iron in energy metabolism and myelin synthesis, it is reasonable to conclude that iron does regulate oligodendrocyte maturation.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "644efd5157b1c7a315000086", "messages": [{"role": "user", "content": "Are epigenetic changes heritable?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nEpigenetics refers to the study of heritable changes in gene expression that do not involve changes in the DNA sequence. These changes can be caused by chemical modifications to the DNA or to the proteins that package the DNA, such as histones. One of the most well-known examples of epigenetic inheritance is the phenomenon of paramutation, where a gene can be altered by the presence of a different allele at the same locus.\n\nEpigenetic changes can be heritable because they can be passed on to daughter cells during cell division and to future generations through the process of gametogenesis. However, the extent to which epigenetic changes are heritable can vary depending on the type of modification and the organism in question. For example, some epigenetic changes are more stable and can be passed on for multiple generations, while others may be more transient and may not be inherited.\n\nSo, the answer is D. It depends. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "644efd2c57b1c7a315000085", "messages": [{"role": "user", "content": "Do epigenetic changes change the DNA sequence?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nEpigenetics is the study of heritable changes in gene expression that do not involve changes in the DNA sequence. These changes can be caused by chemical modifications to the DNA or to the proteins that package the DNA, such as histones. These modifications can affect the way the DNA is packaged and how accessible it is to the transcriptional machinery, which can in turn affect gene expression.\n\nSo, the answer is B. No, epigenetic changes do not change the DNA sequence. They alter the way the DNA is packaged and expressed, but they do not alter the actual sequence of the DNA. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6414c5ba690f196b51000007", "messages": [{"role": "user", "content": "Can skin picking phenotype present following methylphenidate treatment?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nSkin picking disorder (SPD) is a body-focused repetitive behavior characterized by the recurrent picking of one's own skin which results in skin lesions. SPD is often associated with other psychiatric disorders, such as obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), and trichotillomania (hair pulling disorder).\n\nMethylphenidate is a stimulant medication commonly used to treat attention-deficit/hyperactivity disorder (ADHD). While it is generally well-tolerated, it can have side effects, including psychiatric side effects such as anxiety, irritability, and mood swings. However, there is no direct evidence that methylphenidate treatment can cause skin picking.\n\nGiven the lack of evidence that methylphenidate treatment directly causes skin picking, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "644f0fd257b1c7a31500008a", "messages": [{"role": "user", "content": "Do enhancers have to be close to their gene targets?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.it depends\nD.it is unknown\n<|assistant|>\nEnhancers are DNA sequences that can regulate the expression of genes. They are often located far away from the genes they regulate, and they can be hundreds of thousands of base pairs away. The distance between an enhancer and its target gene is not a limiting factor for enhancer function. Instead, enhancers can communicate with their target genes through the 3D structure of the DNA, which is organized into chromatin loops. These loops bring the enhancer and the gene together, allowing for the regulation of gene expression.\n\nSo, the answer is C. It depends. The distance between an enhancer and its target gene is not a fixed requirement, but rather, the 3D structure of the DNA allows for communication between the two even if they are not physically close. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "64463f9357b1c7a31500006a", "messages": [{"role": "user", "content": "Are there any other types of Spinal Muscular Atrophy except for types 1-4?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nSpinal muscular atrophy (SMA) is a genetic disorder that affects the motor neurons in the spinal cord. It is characterized by progressive muscle weakness and atrophy, leading to muscle wasting and difficulty with movement. There are several types of SMA, which are classified based on the age of onset and severity of symptoms.\n\nThe most common types of SMA are types 1, 2, 3, and 4. Type 1 is the most severe form, with symptoms typically appearing within the first few months of life and leading to death by the age of 2. Type 2 is less severe and symptoms usually appear between 6 and 18 months of age. Type 3 is the most common form and symptoms typically appear between 18 months and 3 years of age. Type 4 is the mildest form and symptoms usually appear after the age of 35.\n\nHowever, there are other types of SMA that are less common and are not typically classified as types 1-4. These include SMA type 0, which is the most severe form and presents in the newborn period, and SMA type 5, which is the mildest form and symptoms may not appear until adulthood. There are also other subtypes of SMA that are not classified as types 1-4, such as SMA with respiratory distress, which is a severe form that can present in the neonatal period with respiratory failure.\n\nSo, the answer is A. Yes, there are other types of Spinal Muscular Atrophy except for types 1-4. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "640418af201352f04a000018", "messages": [{"role": "user", "content": "Is Tilavonemab effective for progressive supranuclear palsy?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nTilavonemab is a monoclonal antibody that targets the protein tau, which is implicated in the pathogenesis of tauopathies such as progressive supranuclear palsy (PSP). Tauopathies are a group of neurodegenerative disorders characterized by the accumulation of tau protein in the brain.\n\nThe efficacy of tilavonemab in PSP has not been established in clinical trials. While there is some evidence that targeting tau may be beneficial in PSP, the results of clinical trials are not yet conclusive. Therefore, it is not possible to say with certainty whether tilavonemab is effective for progressive supranuclear palsy.\n\nGiven the current state of research, the most accurate answer is \"unsure\" as there is not enough evidence to definitively say that tilavonemab is effective for PSP.\n\nSo, the answer is D. unsure. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "641791ed690f196b51000032", "messages": [{"role": "user", "content": "Is SARS-CoV-2 transmitted through breast milk?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nSARS-CoV-2, the virus that causes COVID-19, is primarily transmitted through respiratory droplets and contact with contaminated surfaces. There is no evidence that the virus is transmitted through breast milk. The World Health Organization (WHO) and the American Academy of Pediatrics (AAP) recommend that mothers with COVID-19 continue to breastfeed their infants, as the benefits of breastfeeding outweigh any potential risks of transmission.\n\nThe virus has not been detected in breast milk samples from mothers with COVID-19, and there is no evidence that infants who are breastfed by mothers with COVID-19 are at an increased risk of infection. In fact, breast milk may provide protection against COVID-19 infection in infants, as it contains antibodies and other immune factors that can help protect the infant from infection.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "644284a957b1c7a31500005c", "messages": [{"role": "user", "content": "Is there any treatment for the Facioscapulohumeral Muscular Dystrophy?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nFacioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder that affects the muscles of the face, shoulders, and upper arms. It is caused by a mutation in the D4Z4 region on chromosome 4, which leads to the abnormal expression of a protein called DUX4. This protein is toxic to muscle cells, leading to muscle weakness and atrophy.\n\nCurrently, there is no cure for FSHD. Treatment is focused on managing symptoms and preserving muscle function. This may include physical therapy, occupational therapy, and the use of assistive devices to help with activities of daily living. Some patients may also benefit from medications that can help with muscle cramps, pain, and fatigue.\n\nHowever, there is ongoing research into potential treatments for FSHD. One approach is to develop drugs that can inhibit the activity of DUX4 or prevent its expression. Another approach is to use gene therapy to correct the genetic mutation that causes FSHD.\n\nSo, the answer is A. yes, there is treatment for FSHD, but it is not a cure. The treatment is focused on managing symptoms and preserving muscle function. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "644e642a57b1c7a315000075", "messages": [{"role": "user", "content": "Do all proteins start with methionine?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nThe answer to this question depends on the context. In general, the answer is no, not all proteins start with methionine. Methionine is the first amino acid in the genetic code, and it is the start codon for most proteins. However, there are exceptions to this rule. Some proteins can start with other amino acids, such as formylmethionine (fMet) or selenocysteine (Sec), which are also start codons.\n\nIn the case of selenocysteine, it is not a true amino acid but rather a modified form of cysteine that is incorporated into specific proteins. Selenocysteine is encoded by the UGA codon, which is normally a stop codon in the genetic code. However, when the UGA codon is preceded by a specific sequence of nucleotides, it is recognized as a selenocysteine codon and is used to incorporate selenocysteine into proteins.\n\nSo, the answer is no, not all proteins start with methionine. Some proteins can start with other amino acids, depending on the genetic code and the specific protein being synthesized.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "61f80d5d882a024a1000003c", "messages": [{"role": "user", "content": "Do only changes in coding regions of MEF2C cause developmental disorders?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nMEF2C is a gene that encodes a transcription factor involved in the development of the central nervous system, heart, and skeletal muscle. Mutations in MEF2C have been associated with a variety of developmental disorders, including intellectual disability, autism spectrum disorder, and congenital heart defects.\n\nWhile it is true that mutations in coding regions of genes can lead to changes in protein function and, therefore, to developmental disorders, it is not necessarily the case that only changes in coding regions of MEF2C cause developmental disorders. Non-coding regions of genes, such as regulatory elements, can also affect gene expression and, consequently, the development of the organism.\n\nSo, the answer is D. It depends. Mutations in non-coding regions of MEF2C could potentially affect gene expression and lead to developmental disorders, even if they do not directly alter the protein sequence. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "62211c853a8413c65300006d", "messages": [{"role": "user", "content": "Is CircRNA produced by back splicing of exon, intron or both, forming exon or intron circRNA?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nCircular RNAs (circRNAs) are a class of non-coding RNAs that are covalently closed loop structures. They are formed by a backsplicing event, where the 3' end of an exon is joined to the 5' end of the same or another exon, bypassing the 5' to 3' directionality of conventional linear RNA transcripts.\n\nThe backsplicing event can occur within an exon (forming an exon circRNA), within an intron (forming an intron circRNA), or between an exon and an intron (forming a circRNA that includes both an exon and an intron). The resulting circRNA can be either an exon circRNA, an intron circRNA, or a circRNA that includes both an exon and an intron.\n\nSo, the answer is C. Maybe. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "620c27e93a8413c653000006", "messages": [{"role": "user", "content": "Is METTL1 overexpression associated with better patient survival?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nMETTL1 is a methyltransferase that is involved in the methylation of RNA. Methylation of RNA is a key step in the regulation of gene expression, and it is known to play a role in various biological processes, including cell growth, differentiation, and apoptosis.\n\nIn the context of cancer, METTL1 has been studied for its potential role in the regulation of gene expression and its impact on cancer cell behavior. However, the association between METTL1 overexpression and patient survival is not as straightforward as it might seem.\n\nOn the one hand, METTL1 has been shown to be involved in the regulation of cell proliferation and survival, and its overexpression could potentially contribute to the growth and survival of cancer cells. In some studies, METTL1 overexpression has been associated with poor prognosis in certain types of cancer, such as hepatocellular carcinoma and colorectal cancer.\n\nOn the other hand, METTL1 has also been implicated in the regulation of immune responses and the response to chemotherapy. In some cases, METTL1 overexpression has been associated with a better prognosis, as it may contribute to the immune response against cancer cells or to the sensitivity of cancer cells to certain treatments.\n\nGiven the complex and context-dependent nature of METTL1's role in cancer, it is difficult to make a general statement about whether METTL1 overexpression is always associated with better or worse patient survival. The answer depends on the specific cancer type, the role of METTL1 in that context, and the patient's response to treatment.\n\nSo, the answer is C. \"May be.\" While METTL1 overexpression may be associated with better or worse patient survival in certain contexts, it is not a universal truth and cannot be determined without considering the specific context and the patient's response to treatment. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "61f80c37882a024a1000003b", "messages": [{"role": "user", "content": "Do mutations in KCNT2 only cause phenotypes with epilepsy?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nKCNT2 is a gene that encodes a potassium channel subunit. Mutations in this gene have been associated with a variety of neurological disorders, including epilepsy. Epilepsy is a common phenotype associated with KCNT2 mutations, but it is not the only one. Other phenotypes that have been linked to KCNT2 mutations include developmental delay, intellectual disability, and autism spectrum disorder.\n\nSo, the answer is B. no. Mutations in KCNT2 can cause phenotypes other than epilepsy. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "61f593f8882a024a1000000f", "messages": [{"role": "user", "content": "Is there an association between pyostomatitis vegetans and Crohn's disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.uncertain\n<|assistant|>\nPyostomatitis vegetans is a rare oral mucosal disease characterized by the presence of multiple, small, yellowish-white papules that are often surrounded by a halo of erythema. It is typically associated with inflammatory bowel disease (IBD), most commonly Crohn's disease. The association between pyostomatitis vegetans and Crohn's disease is well-established, and the condition is considered a cutaneous marker of Crohn's disease.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6217e1ac3a8413c653000031", "messages": [{"role": "user", "content": "Is serotonin transported by platelets?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nSerotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter and hormone that plays a role in various physiological processes, including mood regulation, sleep, appetite, and gastrointestinal motility. It is synthesized from the amino acid tryptophan and is stored in the central nervous system and in the enterochromaffin cells of the gastrointestinal tract.\n\nPlatelets are small blood cells that are involved in the clotting process. They do not contain nuclei and are not considered to be true cells. However, they do have a limited capacity for protein synthesis and can store and release various substances, including serotonin.\n\nSerotonin is stored in platelets in the form of dense granules. When platelets are activated, they release serotonin into the bloodstream, which can contribute to vasoconstriction and the formation of blood clots. This is particularly important in the context of hemostasis, where platelets play a crucial role in stopping bleeding.\n\nSo, the answer is A. Yes, serotonin is transported by platelets. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "61f59592882a024a10000010", "messages": [{"role": "user", "content": "Is Sotrovimab effective for COVID-19?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nSotrovimab is a monoclonal antibody that is used to treat COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.\n\nThe FDA has authorized the emergency use of Sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.\n\nThe FDA has determined that it is reasonable to believe that Sotrovimab may be effective in treating COVID-19 due to its mechanism of action and in vitro data demonstrating activity against the SARS-CoV-2 virus. Additionally, the FDA has determined that the known and potential benefits of Sotrovimab outweigh the known and potential risks for the authorized use.\n\nSo, the answer is A. yes. Sotrovimab is effective for COVID-19, as it has been authorized by the FDA for emergency use in certain high-risk patients. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "621b5bcc3a8413c65300003d", "messages": [{"role": "user", "content": "Is Otolin-1 a matrix protein?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nOtolin-1 is a protein that is found in the inner ear and is involved in the formation of the tectorial membrane, which is a structure that helps to transmit sound waves to the hair cells in the cochlea. The tectorial membrane is a part of the inner ear's sensory apparatus, and it is essential for hearing.\n\nThe tectorial membrane is a complex structure that is composed of several different types of proteins, including Otolin-1. Otolin-1 is a matrix protein because it is part of the extracellular matrix, which is a network of proteins and other molecules that provide structural support to cells and tissues. The extracellular matrix is a key component of many tissues in the body, including the inner ear.\n\nSo, the answer is A. yes. Otolin-1 is a matrix protein. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "620aedee3a8413c653000001", "messages": [{"role": "user", "content": "Is AGO2 related to cytokinesis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nAGO2 is a protein that is part of the RNA-induced silencing complex (RISC), which is involved in the RNA interference (RNAi) pathway. RNAi is a mechanism for gene silencing that is triggered by double-stranded RNA (dsRNA). The RISC complex uses the dsRNA as a guide to identify and degrade complementary mRNA molecules, thereby silencing the gene that encodes the mRNA.\n\nAGO2 is a key component of the RISC complex and is responsible for the cleavage of the target mRNA. However, AGO2 is not directly involved in the process of cytokinesis, which is the division of the cytoplasm that occurs during cell division. Cytokinesis is a process that involves the formation of the cleavage furrow and the subsequent separation of the cytoplasm into two daughter cells.\n\nSo, the answer is B. no. AGO2 is not related to cytokinesis. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "621b61833a8413c65300003e", "messages": [{"role": "user", "content": "Is the protein HOXA11 associated with endometrial disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nHOXA11 is a homeobox gene that is involved in the development of the female reproductive system. It is expressed in the endometrium and plays a role in the differentiation and function of endometrial cells. Mutations in the HOXA11 gene have been associated with Mayer-Rokitansky-K\u00fcster-Hauser syndrome, which is characterized by the absence of the uterus and the upper part of the vagina.\n\nGiven the role of HOXA11 in the development and function of the endometrium, it is not surprising that mutations or alterations in this gene could be associated with endometrial disease. However, the question does not specify the type of endometrial disease, and the answer would depend on the context. For example, mutations in HOXA11 could potentially lead to endometrial cancer or other endometrial pathologies.\n\nSo, the answer is not straightforward, but it is reasonable to assume that HOXA11 could be associated with endometrial disease, given its role in endometrial development and function.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "621ed10f3a8413c653000062", "messages": [{"role": "user", "content": "Are Tregs CD4(+)CD25(+) regulatory T cells a positive regulator of the immune response?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nTregs, or CD4(+)CD25(+) regulatory T cells, are a subset of T cells that play a critical role in maintaining immune homeostasis. They are known for their ability to suppress the activation and proliferation of other immune cells, including T cells, B cells, and macrophages. This suppression is achieved through various mechanisms, including the production of anti-inflammatory cytokines such as IL-10 and TGF-\u03b2, and the expression of inhibitory receptors like CTLA-4.\n\nThe primary function of Tregs is to prevent the immune system from overreacting to harmless antigens or from attacking the body's own tissues. They do this by dampening the immune response, which helps to maintain a state of tolerance to self-antigens and prevents autoimmune diseases. However, if Tregs are not functioning properly, the immune system can become hyperactive, leading to autoimmune diseases or allergies.\n\nSo, the answer is A. Yes, Tregs are a positive regulator of the immune response because they help to maintain a balance between immune activation and suppression, which is crucial for the proper functioning of the immune system. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5fdb4100a43ad31278000015", "messages": [{"role": "user", "content": "Is Mediator present at super enhancers?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nSuper enhancers are regions of the genome that are highly active in transcription and are associated with the expression of key genes. They are characterized by the presence of multiple transcription factor binding sites and are often associated with the regulation of genes involved in important biological processes.\n\nMediator is a large protein complex that plays a key role in the regulation of transcription by RNA polymerase II. It acts as a bridge between transcription factors and the RNA polymerase II complex, facilitating the recruitment of the polymerase to the promoter region of genes and enhancing the rate of transcription.\n\nGiven the role of Mediator in the regulation of transcription, it is likely that it would be present at super enhancers, as these regions are known to be highly active in transcription and require the coordinated action of multiple transcription factors and the RNA polymerase II complex.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "62057b35c9dfcb9c0900002d", "messages": [{"role": "user", "content": "Does atemoya juice inhibit the CYP1A2 enzyme?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nAtemoya juice is a fruit juice made from the atemoya fruit, which is a hybrid of two species of fruit trees, Annona cherimola and Annona squamosa. The atemoya fruit is native to the tropical regions of South America and is known for its sweet, custard-like pulp.\n\nThe CYP1A2 enzyme is a member of the cytochrome P450 family of enzymes and is involved in the metabolism of various drugs and other xenobiotics. It is particularly important in the metabolism of certain medications, including some antidepressants, antipsychotics, and anti-epileptics.\n\nThere is no direct evidence that atemoya juice inhibits the CYP1A2 enzyme. However, some fruits and juices have been shown to affect the activity of certain enzymes, including the cytochrome P450 enzymes. For example, grapefruit juice is known to inhibit the CYP3A4 enzyme, which can lead to increased levels of certain drugs in the body.\n\nGiven the lack of specific information on the effects of atemoya juice on the CYP1A2 enzyme, it is difficult to say with certainty whether it inhibits this enzyme. However, it is not a common practice to consume large amounts of atemoya juice with the intention of altering drug metabolism, and there is no clear evidence that it has this effect.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6217dc9d3a8413c65300002d", "messages": [{"role": "user", "content": "Is NfL (neurofilament light chain) a biomarker of neurodegeneration?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nNeurofilament light chain (NfL) is a protein that is found in the central nervous system and is a component of the neurofilament, which is a structural protein that helps maintain the integrity of neurons. NfL levels are typically low in the blood and cerebrospinal fluid (CSF) of healthy individuals, but they can increase in various neurological conditions that involve neuronal damage or death.\n\nNfL has been studied as a potential biomarker for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Elevated levels of NfL in the CSF or blood have been associated with these conditions, suggesting that NfL may be a marker of neurodegeneration.\n\nHowever, it's important to note that NfL is not a specific biomarker for any one disease. It can be elevated in a variety of neurological conditions, including traumatic brain injury, stroke, and other forms of brain injury. Additionally, NfL levels can fluctuate over time, and there is still a need for more research to fully understand its role in different neurological conditions.\n\nSo, the answer is C. Maybe. While NfL is a biomarker that can be indicative of neurodegeneration, it is not specific to any one disease and can be elevated in a variety of neurological conditions. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "621ebec63a8413c65300005d", "messages": [{"role": "user", "content": "Is Epistaxis associated with dental implant placement?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.unlikely\n<|assistant|>\nEpistaxis, or nosebleeds, can be a common occurrence in the general population. However, there is no direct association between epistaxis and dental implant placement. Dental implants are surgically placed into the jawbone to support artificial teeth. The procedure involves making an incision in the gum tissue to expose the bone, drilling into the bone to create a hole for the implant, and then inserting the implant into the bone. There is no direct connection between the nasal cavity and the jawbone, so there is no reason to believe that dental implant placement would cause epistaxis.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "61f58a1a882a024a10000009", "messages": [{"role": "user", "content": "Is Daprodustat effective for anemia?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nDaprodustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that is being investigated as a treatment for anemia. HIF-PHIs work by inhibiting the degradation of hypoxia-inducible factor (HIF), which is a transcription factor that regulates the expression of genes involved in the response to low oxygen levels. By inhibiting the degradation of HIF, HIF-PHIs can increase the production of erythropoietin, which is a hormone that stimulates the production of red blood cells.\n\nClinical trials have shown that daprodustat can effectively increase hemoglobin levels in patients with anemia, including those with chronic kidney disease and those undergoing dialysis. However, the long-term safety and efficacy of daprodustat are still being evaluated, and it is not yet approved for use in the treatment of anemia.\n\nGiven the current state of research, it is not possible to definitively say that daprodustat is effective for anemia. While it does show promise in clinical trials, more data is needed to fully assess its safety and efficacy.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "621218353a8413c653000013", "messages": [{"role": "user", "content": "Is REGN5458 a single-targeted antibody?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nREGN5458 is a monoclonal antibody that is used to treat a specific type of cancer. Monoclonal antibodies are designed to target a specific antigen on the surface of cells. They are often used in cancer treatment because they can be engineered to recognize and bind to cancer cells, which can then be targeted for destruction by the immune system.\n\nREGN5458 is a single-targeted antibody because it is designed to bind to a single antigen on the surface of cancer cells. This specificity allows the antibody to selectively target the cancer cells without affecting healthy cells. Single-targeted antibodies are a common type of monoclonal antibody used in cancer treatment.\n\nSo, the answer is A. yes. REGN5458 is a single-targeted antibody. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6020a7391cb411341a00007e", "messages": [{"role": "user", "content": "Is Benralizumab effective for Chronic Spontaneous Urticaria?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nChronic spontaneous urticaria (CSU) is a condition characterized by the presence of hives for more than 6 weeks without an obvious cause. It is a chronic and often debilitating condition that can significantly impact a person's quality of life.\n\nBenralizumab is a monoclonal antibody that targets the interleukin-5 receptor alpha subunit (IL-5R\u03b1), which is expressed on the surface of eosinophils. Eosinophils are a type of white blood cell that are thought to play a role in the pathogenesis of CSU. By binding to IL-5R\u03b1, benralizumab prevents the activation and survival of eosinophils, which are believed to contribute to the allergic response in CSU.\n\nSeveral clinical trials have shown that benralizumab is effective in reducing the symptoms of CSU, including the frequency and severity of hives, and the need for antihistamines. In one study, patients treated with benralizumab had a significant reduction in the number of hives and itch compared to placebo, and the effect was sustained over time.\n\nGiven the evidence from clinical trials, it is reasonable to conclude that benralizumab is effective for the treatment of Chronic Spontaneous Urticaria.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6217dd013a8413c65300002f", "messages": [{"role": "user", "content": "Do the proteins Talin and Amot interact?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nTalin and Amot are both proteins that play important roles in cell adhesion and migration. Talin is a protein that binds to integrins, which are cell surface receptors that mediate cell adhesion to the extracellular matrix. Amot is a protein that interacts with integrins and also with the Hippo signaling pathway, which is involved in regulating cell proliferation, apoptosis, and organ size.\n\nWhile both Talin and Amot are involved in cell adhesion and migration, they do not directly interact with each other. Talin interacts with integrins, and Amot interacts with integrins and the Hippo pathway. There is no evidence that Talin and Amot physically interact with each other.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6220cbf83a8413c653000067", "messages": [{"role": "user", "content": "Do RNA binding Proteins  that bind to adenine uridine (AU)-rich elements (AREs) in the 5' untranslated region (UTR) of mRNAs (AU-RBPs) regulate the DNA Damage Response?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nThe DNA Damage Response (DDR) is a complex set of cellular processes that are activated in response to DNA damage. One of the key mechanisms in the DDR is the regulation of gene expression, which is crucial for the repair of damaged DNA and the prevention of further damage.\n\nRNA binding proteins (RBPs) are known to play a role in the regulation of gene expression by binding to specific sequences in the RNA. One type of RBP that is particularly relevant to the DDR is the AU-rich element (ARE) binding protein (AU-RBP). AREs are found in the 3' untranslated regions (UTRs) of many mRNAs and are recognized by AU-RBPs. These proteins can regulate mRNA stability and translation, which can affect the levels of proteins involved in the DDR.\n\nFor example, the AU-RBP HuR (also known as ELAVL1) has been shown to bind to AREs in the 3' UTR of mRNAs encoding proteins involved in the DDR, such as p53 and DNA polymerase beta. By binding to these mRNAs, HuR can stabilize them and increase their translation, leading to an increase in the levels of these proteins and a more robust DDR.\n\nSo, the answer is A. yes. RNA binding Proteins that bind to adenine uridine (AU)-rich elements (AREs) in the 5' untranslated region (UTR) of mRNAs (AU-RBPs) do regulate the DNA Damage Response. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6211566a3a8413c653000010", "messages": [{"role": "user", "content": "Has CPX-351 been approved by the FDA and the EMA?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.both\nD.neither\n<|assistant|>\nCPX-351 is a combination chemotherapy regimen that includes cytarabine and daunorubicin. It is used to treat acute myeloid leukemia (AML), a type of blood cancer. The FDA approved CPX-351 in 2017 for the treatment of adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. The EMA (European Medicines Agency) has not yet approved CPX-351 for use in the European Union.\n\nSo, the answer is B. no. The EMA has not approved CPX-351. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6217dc173a8413c65300002b", "messages": [{"role": "user", "content": "Do we find bacteriophages in the gut?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nBacteriophages, also known as phages, are viruses that infect bacteria. They are the most abundant biological entities on the planet and are found in a wide range of environments, including the human gut. The human gut microbiome is a complex ecosystem that includes a diverse community of bacteria, and bacteriophages are known to play a significant role in the regulation of this community.\n\nBacteriophages can infect and lyse bacterial cells, which can have a profound impact on the composition of the gut microbiome. They can also transfer genetic material between bacteria, which can lead to the evolution of new bacterial strains. The presence of bacteriophages in the gut is important for maintaining the balance of the microbiome and for the survival of the host.\n\nSo, the answer is A. Yes, we do find bacteriophages in the gut. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "601d6fe11cb411341a000033", "messages": [{"role": "user", "content": "Is tirabrutinib effective for lymphoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nTirabrutinib is a novel, selective Bruton's tyrosine kinase (BTK) inhibitor that is being investigated for the treatment of various hematologic malignancies, including lymphoma. BTK is a key enzyme in the B-cell receptor signaling pathway, and its inhibition can lead to the death of malignant B cells.\n\nIn clinical trials, tirabrutinib has shown promising results in the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). In a phase 2 trial, tirabrutinib was found to be effective in treating patients with relapsed or refractory CLL, with a response rate of 80% and a complete response rate of 30%. In another phase 2 trial, tirabrutinib was found to be effective in treating patients with relapsed or refractory MCL, with a response rate of 60% and a complete response rate of 20%.\n\nGiven the positive results from clinical trials, it is reasonable to conclude that tirabrutinib is effective for lymphoma, particularly in the treatment of CLL and MCL.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "621ea5a53a8413c653000055", "messages": [{"role": "user", "content": "Are Epoxyeicosatrienoic acids (EETs) synthesized by cytochrome P450 epoxygenases from arachidonic acid?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nEpoxyeicosatrienoic acids (EETs) are a class of eicosanoids that are synthesized from arachidonic acid by the action of cytochrome P450 epoxygenases. Arachidonic acid is a polyunsaturated fatty acid that is a precursor to many eicosanoids, including prostaglandins, leukotrienes, and EETs. The cytochrome P450 epoxygenases are a family of enzymes that catalyze the epoxidation of arachidonic acid, leading to the formation of EETs.\n\nSo, the answer is A. yes. EETs are synthesized by cytochrome P450 epoxygenases from arachidonic acid. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6027446d1cb411341a0000dd", "messages": [{"role": "user", "content": "Does trimetazidine protect from myocardial injury after percutaneous coronary intervention?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nTrimetazidine is a metabolic modulator that is used in the treatment of angina pectoris. It works by inhibiting fatty acid oxidation in the heart, which helps to preserve glucose metabolism and improve myocardial energy supply. This effect is thought to be beneficial in the setting of ischemia, as it can help to reduce the oxygen demand of the heart muscle.\n\nPercutaneous coronary intervention (PCI) is a procedure used to open blocked coronary arteries and restore blood flow to the heart. During PCI, the heart muscle is subjected to ischemia and reperfusion, which can lead to myocardial injury. The use of trimetazidine during PCI is thought to help protect the heart from this injury by preserving energy metabolism and reducing the risk of ischemia-reperfusion injury.\n\nSeveral studies have shown that trimetazidine can reduce the incidence of myocardial infarction and the need for repeat revascularization procedures after PCI. It has also been shown to improve clinical outcomes, such as reducing the risk of death and hospitalization for heart failure.\n\nGiven the evidence, it is reasonable to conclude that trimetazidine does protect from myocardial injury after percutaneous coronary intervention.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "62211d6f3a8413c65300006f", "messages": [{"role": "user", "content": "Are circRNAs susceptible to degradation by RNase R?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nCircRNAs, or circular RNAs, are a class of non-coding RNAs that are covalently closed loops without free ends. They are resistant to degradation by exonucleases because they lack the 5' cap and 3' poly(A) tail that are typically targeted by these enzymes. RNase R is an exonuclease that degrades RNA from the 3' end, and since circRNAs do not have a 3' poly(A) tail, they are not susceptible to degradation by RNase R.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "62057f1ec9dfcb9c0900002e", "messages": [{"role": "user", "content": "Does atemoya juice inhibit tye CYP3A4 enzyme?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nAtemoya juice is a fruit juice made from the atemoya fruit, which is a hybrid of two species of fruit trees, Annona cherimola and Annona squamosa. The atemoya fruit is native to the tropical regions of South America and is known for its sweet, custard-like pulp.\n\nWhen it comes to the effect of fruit juices on the CYP3A4 enzyme, there is limited research specifically on atemoya juice. However, in general, it is known that certain fruits and their juices can affect the activity of the CYP3A4 enzyme. For example, grapefruit juice is well-known for its ability to inhibit the CYP3A4 enzyme, which can lead to increased levels of certain drugs in the body.\n\nGiven the lack of specific research on atemoya juice and the CYP3A4 enzyme, it is difficult to say with certainty whether atemoya juice inhibits this enzyme. However, given the general knowledge about the effects of fruit juices on drug metabolism, it is possible that atemoya juice could have an inhibitory effect on the CYP3A4 enzyme.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6217db763a8413c653000028", "messages": [{"role": "user", "content": "Is Mycobacterium abscessus a human pathogen?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nMycobacterium abscessus is a species of nontuberculous mycobacteria (NTM) that can cause infections in humans. NTM are a group of bacteria that are related to the bacteria that cause tuberculosis, but they do not cause the same type of disease. Instead, NTM can cause a variety of infections, including lung infections, skin infections, and infections of the lymph nodes.\n\nMycobacterium abscessus is known to cause a variety of infections in humans, including pulmonary infections, skin and soft tissue infections, and disseminated infections. It is particularly known for causing chronic lung infections in patients with cystic fibrosis and other chronic lung diseases. It can also cause infections in immunocompromised individuals and those with underlying lung conditions.\n\nGiven that Mycobacterium abscessus is a known human pathogen that can cause a variety of infections, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "62121c583a8413c653000016", "messages": [{"role": "user", "content": "Is MEDI2228 a bispecific antibody?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nA bispecific antibody is an antibody that is engineered to bind to two different antigens. This can be achieved by either linking two different monoclonal antibodies together or by creating a single antibody that has two different antigen-binding sites.\n\nMEDI2228 is a monoclonal antibody that is used in the treatment of non-small cell lung cancer. It is a humanized IgG1 monoclonal antibody that targets the PD-L1 and PD-1 pathways. PD-L1 is a protein that is expressed on the surface of tumor cells and can bind to PD-1 on T cells, inhibiting their activation and function. By targeting both PD-L1 and PD-1, MEDI2228 can potentially overcome the immune evasion mechanisms used by cancer cells.\n\nHowever, MEDI2228 is not a bispecific antibody because it is not engineered to bind to two different antigens. It is a single monoclonal antibody that targets a single antigen (PD-L1) and its receptor (PD-1).\n\nSo, the answer is B. no. MEDI2228 is not a bispecific antibody. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "601c4ff61cb411341a000022", "messages": [{"role": "user", "content": "Is proton beam therapy used for treatment of craniopharyngioma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nCraniopharyngioma is a type of brain tumor that arises from the remnants of Rathke's pouch, which is a structure in the developing brain that gives rise to the pituitary gland. These tumors are typically benign but can be locally aggressive and can cause significant symptoms due to their location near critical structures in the brain.\n\nProton beam therapy is a type of radiation therapy that uses protons rather than x-rays to deliver radiation to the tumor. It is often used for tumors that are located near critical structures in the brain or spine, as it can precisely target the tumor while minimizing damage to surrounding healthy tissue.\n\nGiven the location of craniopharyngiomas near critical structures in the brain, proton beam therapy is often considered a treatment option for these tumors. It can be particularly useful in cases where the tumor is close to the optic chiasm or other sensitive areas, as it can help to reduce the risk of damage to these structures.\n\nSo, the answer is A. yes. Proton beam therapy is used for treatment of craniopharyngioma. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "601d73261cb411341a00003a", "messages": [{"role": "user", "content": "Is there a genetic cause of craniostenosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nCraniostenosis is a condition where the skull is abnormally small or misshapen. It can be caused by a variety of factors, including genetic disorders, environmental factors, or a combination of both.\n\nSome genetic disorders that can cause craniostenosis include:\n- Apert syndrome\n- Crouzon syndrome\n- Pfeiffer syndrome\n- Saethre-Chotzen syndrome\n- Muenke syndrome\n\nThese syndromes are characterized by craniosynostosis, which is the premature fusion of one or more of the cranial sutures. This can lead to abnormal head shape and other symptoms.\n\nSo, the answer is A. Yes, there is a genetic cause of craniostenosis. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "620586a8c9dfcb9c09000032", "messages": [{"role": "user", "content": "Can bergapten cross the blood-brain barrier?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nBergapten is a furocoumarin compound that is found in citrus fruits and is responsible for the photosensitizing effects of these fruits. It is used in some sunscreens and is known to cause phototoxic reactions when exposed to ultraviolet light.\n\nThe blood-brain barrier (BBB) is a highly selective barrier that protects the central nervous system from harmful substances in the blood. It is composed of endothelial cells that are tightly joined together and have specialized transport mechanisms to control the passage of substances into the brain.\n\nGiven the nature of the blood-brain barrier, it is unlikely that bergapten would be able to cross it in significant amounts. This is because the BBB is designed to prevent the entry of substances that could be harmful to the brain, and bergapten is known to cause phototoxic reactions when exposed to light.\n\nSo, the answer is B. No, bergapten does not cross the blood-brain barrier. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "620be4fd3a8413c653000002", "messages": [{"role": "user", "content": "Does TIMELESS-TIPIN participate in replisome disassembly?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nTIMELESS-TIPIN is a complex of two proteins, TIMELESS and TIPIN, that is involved in the regulation of DNA replication. During DNA replication, the replisome, which is the complex of proteins that carry out DNA synthesis, must be disassembled after the replication fork has passed. This disassembly is necessary to prevent the replication machinery from continuing to replicate the same DNA strand over and over again.\n\nTIMELESS-TIPIN is known to be involved in the initiation of DNA replication, but its role in replisome disassembly is less clear. Some studies suggest that TIMELESS-TIPIN may be involved in the disassembly of the replisome, while others suggest that it may not be directly involved in this process. However, the consensus is that TIMELESS-TIPIN is not the primary factor responsible for replisome disassembly.\n\nSo, the answer is B. no. TIMELESS-TIPIN does not participate in replisome disassembly. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "60570fe494d57fd879000026", "messages": [{"role": "user", "content": "Is hemoglobin antimicrobial?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nHemoglobin is a protein that is found in red blood cells and is responsible for carrying oxygen from the lungs to the tissues of the body. It is composed of four subunits, each of which contains a heme group that binds to oxygen. The heme group is a porphyrin ring with an iron atom at its center, which is responsible for the oxygen-binding properties of hemoglobin.\n\nWhile hemoglobin is not typically considered to be antimicrobial, it does have some properties that could potentially be beneficial in the context of infection. For example, the iron in the heme group can be used by certain bacteria as a source of iron, which is an essential nutrient for their growth. However, the body has mechanisms to limit the availability of iron to bacteria, such as the production of lactoferrin, which binds to iron and makes it less accessible to pathogens.\n\nAdditionally, hemoglobin can be a source of free radicals, which can damage bacterial cells. However, this is not a primary mechanism of defense against infection.\n\nSo, while hemoglobin does have some properties that could be considered antimicrobial, it is not a primary defense mechanism against infection.\n\nSo, the answer is B. no. Hemoglobin is not antimicrobial in the sense of being a direct defense against infection. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "620588f9c9dfcb9c09000033", "messages": [{"role": "user", "content": "Can bergapten cause phototoxicity?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nBergapten is a furocoumarin compound that is found in citrus fruits and their peels. It is known to cause photosensitivity reactions when exposed to sunlight. When bergapten is absorbed into the skin and then exposed to ultraviolet (UV) light, it can cause a phototoxic reaction. This reaction can lead to erythema (redness), edema (swelling), and even blistering of the skin. The reaction is due to the activation of bergapten by UV light, which leads to the formation of reactive oxygen species that damage the skin cells.\n\nSo, the answer is A. Yes, bergapten can cause phototoxicity. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6217d9bf3a8413c653000024", "messages": [{"role": "user", "content": "Can IFNg induce the expression of IDO?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nInterferon-gamma (IFNg) is a cytokine that is known to have a variety of effects on immune cells and other cell types. One of the effects of IFNg is to induce the expression of indoleamine 2,3-dioxygenase (IDO), which is an enzyme that catabolizes the amino acid tryptophan. IDO is important in the regulation of immune responses, particularly in the context of the immune system's response to pathogens and tumors.\n\nWhen IFNg binds to its receptor on cells, it activates a signaling pathway that leads to the transcription of genes that are responsive to IFNg. One of these genes is IDO. Therefore, IFNg can induce the expression of IDO.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "602c2ade1cb411341a000124", "messages": [{"role": "user", "content": "Are TAMs good anticancer therapeutic targets?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nTumor-associated macrophages (TAMs) are immune cells that are often found in the tumor microenvironment. They can have both pro-tumorigenic and anti-tumorigenic effects, depending on their activation state and the context in which they are found.\n\nOn the one hand, TAMs can promote tumor growth and progression by secreting cytokines that stimulate angiogenesis, tumor cell proliferation, and metastasis. They can also suppress the immune response by secreting immunosuppressive factors and by phagocytosing and degrading immune cells.\n\nOn the other hand, TAMs can also have anti-tumorigenic effects. For example, they can produce cytokines that activate cytotoxic T cells and natural killer cells, which can kill tumor cells. They can also phagocytose tumor cells and present tumor antigens to T cells, which can lead to an anti-tumor immune response.\n\nGiven the dual role of TAMs, it is difficult to say that they are unequivocally good or bad anticancer therapeutic targets. However, there is a growing interest in targeting TAMs to modulate their activity in the tumor microenvironment, with the goal of shifting the balance towards an anti-tumor immune response.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6027434c1cb411341a0000dc", "messages": [{"role": "user", "content": "Is gabapentin effective for chronic pelvic pain?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nGabapentin is an anticonvulsant medication that is sometimes used off-label to treat chronic pain conditions. It is known to have analgesic properties and is sometimes used to treat neuropathic pain, which is a type of chronic pain that is caused by damage to the nerves.\n\nChronic pelvic pain is a condition that can have various causes, including pelvic inflammatory disease, endometriosis, interstitial cystitis, and other conditions. While gabapentin may be effective for some types of chronic pelvic pain that have a neuropathic component, it is not a first-line treatment for all types of chronic pelvic pain.\n\nGiven the information, the answer is C. Maybe. Gabapentin may be effective for some types of chronic pelvic pain, but it is not a universal treatment for all types of chronic pelvic pain.\n\nSo, the answer is C. maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6056fbfc94d57fd87900001d", "messages": [{"role": "user", "content": "Does the royal jelly contain proteins?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nRoyal jelly is a substance produced by worker honey bees to feed the larvae of the colony. It is a complex mixture of proteins, sugars, fats, vitamins, and minerals. The proteins in royal jelly are particularly interesting because they are responsible for the development of the queen bee, which is fed royal jelly exclusively during her larval stage. These proteins are thought to be responsible for the queen bee's larger size, longer lifespan, and reproductive capabilities.\n\nSo, the answer is A. Yes, royal jelly does contain proteins. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6217c0b63a8413c65300001e", "messages": [{"role": "user", "content": "Does UBE4B promote renal cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nUBE4B is a gene that encodes a protein involved in the ubiquitin-proteasome system, which is a major pathway for the degradation of proteins in cells. Mutations in this gene have been associated with several types of cancer, including renal cell carcinoma (RCC).\n\nRCC is a type of kidney cancer that can be hereditary or sporadic. Hereditary RCC is often associated with mutations in genes involved in the von Hippel-Lindau (VHL) pathway, which is a key regulator of the ubiquitin-proteasome system. Mutations in UBE4B have been found in some cases of hereditary RCC, particularly in families with a predisposition to RCC and pheochromocytoma (a type of tumor that arises from the adrenal glands).\n\nSo, the answer is A. yes. UBE4B has been implicated in the development of renal cancer, particularly in hereditary cases. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6025d9e41cb411341a0000b7", "messages": [{"role": "user", "content": "Does addition of valproic acid improve survival of patients with diffuse intrinsic pontine glioma?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nDiffuse intrinsic pontine glioma (DIPG) is a highly aggressive brainstem tumor that primarily affects children. The prognosis for DIPG is very poor, with a median survival of less than 1 year and a 5-year survival rate of less than 10%. Despite advances in neurosurgery, radiation therapy, and chemotherapy, there is no cure for DIPG.\n\nValproic acid is an antiepileptic drug that has been studied for its potential to inhibit histone deacetylases (HDACs), which are enzymes that can regulate gene expression. Inhibition of HDACs by valproic acid has been shown to have anti-tumor effects in some types of cancer, including gliomas.\n\nHowever, the addition of valproic acid to standard treatment for DIPG has not been shown to improve survival. In fact, a randomized controlled trial (RCT) conducted by the Children's Oncology Group (COG) found that the addition of valproic acid to radiation therapy did not improve overall survival in children with DIPG. The trial was stopped early due to futility, meaning that the addition of valproic acid did not appear to be beneficial.\n\nSo, the answer is B. No, the addition of valproic acid does not improve survival in patients with diffuse intrinsic pontine glioma. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "621b950f3a8413c653000044", "messages": [{"role": "user", "content": "Is SMOC2 expressed during wound healing?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.uncertain\n<|assistant|>\nSMOC2, also known as SPARC-related modular calcium-binding protein 2, is a protein that is involved in the regulation of cell growth and differentiation. It is a member of the SPARC family of proteins, which are known to be involved in various cellular processes, including cell adhesion, migration, and differentiation.\n\nWound healing is a complex process that involves a series of events, including inflammation, proliferation, and remodeling. During the inflammatory phase, cells such as neutrophils and macrophages are recruited to the site of injury to clear debris and initiate the healing process. During the proliferative phase, fibroblasts and endothelial cells migrate to the wound site and begin to produce new extracellular matrix components. Finally, in the remodeling phase, the extracellular matrix is remodeled to restore the tissue to its original structure and function.\n\nSMOC2 has been shown to be involved in the regulation of cell adhesion and migration, which are critical processes during wound healing. It has been found to be expressed in various cell types, including fibroblasts, endothelial cells, and epithelial cells, which are all involved in the wound healing process. Therefore, it is likely that SMOC2 is expressed during wound healing.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "620580afc9dfcb9c0900002f", "messages": [{"role": "user", "content": "Does daily atemoya juice intake change the pharmacokinetics of CYP1A2 substrates?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nAtemoya juice is known to contain compounds that can induce the activity of the CYP1A2 enzyme. CYP1A2 is a cytochrome P450 enzyme that is involved in the metabolism of many drugs, including caffeine, theophylline, and clozapine. When the activity of CYP1A2 is induced, it can lead to a decrease in the plasma concentration of drugs that are metabolized by this enzyme, as the drugs are metabolized more quickly.\n\nTherefore, daily intake of atemoya juice could potentially change the pharmacokinetics of CYP1A2 substrates by inducing the activity of the enzyme, which could lead to a decrease in the plasma concentration of these drugs.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "61f602a3882a024a1000001f", "messages": [{"role": "user", "content": "Is Cabotegravir effective for HIV prevention?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nCabotegravir is a long-acting injectable antiretroviral medication that is used for the treatment and prevention of HIV infection. It is part of a class of drugs called integrase strand transfer inhibitors (INSTIs) and is used in combination with other antiretroviral medications.\n\nFor the prevention of HIV, cabotegravir is used as a pre-exposure prophylaxis (PrEP) in individuals who are at high risk of acquiring HIV. The medication is administered as a long-acting injection every 8 weeks, which makes it a convenient option for those who may have difficulty adhering to daily oral PrEP regimens.\n\nStudies have shown that cabotegravir is effective for HIV prevention when used as PrEP. In a clinical trial, the drug was found to be 89% effective in preventing HIV infection among men who have sex with men and transgender women who have sex with men. This is comparable to the efficacy of daily oral PrEP with tenofovir disoproxil fumarate/emtricitabine.\n\nSo, the answer is A. Yes, cabotegravir is effective for HIV prevention when used as PrEP. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "62211b973a8413c65300006c", "messages": [{"role": "user", "content": "Are G-quadruplexes(G4) possible drug targets for glioblastoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nGlioblastoma is a highly aggressive and malignant brain tumor that is notoriously difficult to treat. One of the challenges in treating glioblastoma is the resistance of the tumor cells to chemotherapy and radiation therapy. This resistance is often due to the ability of the tumor cells to repair DNA damage and to evade apoptosis.\n\nG-quadruplexes (G4) are non-canonical structures that can form in the DNA of certain regions, particularly in the telomeres and in the promoter regions of certain genes. These structures can affect the transcription of genes and the stability of the DNA. They have been implicated in various biological processes, including telomere maintenance, gene regulation, and DNA repair.\n\nGiven the role of G4 in DNA repair and gene regulation, it is possible that targeting G4 structures could be a novel approach to treating glioblastoma. By inhibiting the formation of G4 structures or by stabilizing them, it may be possible to disrupt the normal function of the tumor cells, leading to their death or to a reduction in their ability to repair DNA damage.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "622608ea3a8413c653000079", "messages": [{"role": "user", "content": "Is RUNX1T1 associate with obesity?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nRUNX1T1 is a gene that is associated with a chromosomal translocation that is characteristic of acute myeloid leukemia (AML). This translocation, t(8;21), involves the fusion of the RUNX1 gene on chromosome 21 with the RUNX1T1 gene on chromosome 8. The resulting fusion protein, RUNX1-RUNX1T1, is thought to contribute to the development of AML by promoting the proliferation and survival of leukemic cells.\n\nObesity is a complex condition that is influenced by a variety of genetic and environmental factors. There is no direct evidence that RUNX1T1 is associated with obesity. While some genetic variants have been linked to obesity, RUNX1T1 is not one of them.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "61f9cb19c9dfcb9c09000002", "messages": [{"role": "user", "content": "Is Adamts18 deficiency associated with cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nAdamts18 is a gene that encodes for a protein called a disintegrin and metalloproteinase with thrombospondin motifs 18. This protein is involved in the development of the nervous system and the cardiovascular system. It is also known to play a role in the regulation of cell adhesion, migration, and proliferation.\n\nWhile there is no direct evidence that Adamts18 deficiency is associated with cancer, it is important to note that mutations in genes that encode for proteins involved in cell adhesion, migration, and proliferation can potentially lead to uncontrolled cell growth, which is a hallmark of cancer.\n\nGiven the role of Adamts18 in these processes, it is possible that mutations in this gene could contribute to the development of cancer. However, there is currently no strong evidence to support a direct link between Adamts18 deficiency and cancer.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "61f5f89b882a024a10000019", "messages": [{"role": "user", "content": "Is Ozanimod effective for Ulcerative Colitis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nOzanimod is a sphingosine 1-phosphate receptor modulator that is approved for the treatment of multiple sclerosis. It is not currently approved for the treatment of ulcerative colitis. However, there is ongoing research into the potential use of sphingosine 1-phosphate receptor modulators for inflammatory bowel diseases, including ulcerative colitis.\n\nWhile there is some evidence that suggests that sphingosine 1-phosphate receptor modulators may have a role in the treatment of inflammatory bowel diseases, the specific efficacy of ozanimod for ulcerative colitis has not been established. Therefore, it is not yet possible to say with certainty whether ozanimod is effective for ulcerative colitis.\n\nGiven the current state of research, it is not accurate to say that ozanimod is effective for ulcerative colitis. However, it is also not accurate to say that it is not effective, as there is ongoing research that may lead to a different conclusion in the future.\n\nSo, the answer is C. maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "621bd38d3a8413c653000046", "messages": [{"role": "user", "content": "Is esophageal adenocarcinoma associated with aberrant glycosylation?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nEsophageal adenocarcinoma is a type of cancer that develops in the cells lining the esophagus. It is a relatively rare form of cancer, but its incidence has been increasing in recent years, particularly in Western countries.\n\nAberrant glycosylation refers to the modification of proteins and lipids by the addition of sugar molecules. This process is important for the structure and function of many proteins and lipids, and it can be altered in various diseases, including cancer.\n\nThere is evidence that aberrant glycosylation is associated with the development and progression of several types of cancer, including esophageal adenocarcinoma. Studies have shown that the expression of certain glycosyltransferases, which are enzymes involved in the addition of sugar molecules to proteins and lipids, is altered in esophageal adenocarcinoma. These changes can lead to the production of abnormal glycoproteins and glycolipids, which can contribute to the malignant phenotype of the cancer cells.\n\nGiven this evidence, it is reasonable to conclude that esophageal adenocarcinoma is associated with aberrant glycosylation.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "622629d13a8413c65300007e", "messages": [{"role": "user", "content": "Can FTO promote pancreatic cancer development?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nThe FTO gene (fat mass and obesity-associated) is a gene that has been associated with obesity and type 2 diabetes. Obesity is a known risk factor for several types of cancer, including pancreatic cancer. However, the direct role of FTO in promoting pancreatic cancer development is not well established.\n\nWhile there is some evidence that FTO may be involved in the development of certain cancers, including pancreatic cancer, the specific mechanisms by which FTO might promote cancer are not fully understood. Some studies have suggested that FTO may play a role in regulating energy metabolism and insulin signaling, which could potentially contribute to the development of cancer. However, the exact role of FTO in pancreatic cancer development is not yet clear.\n\nGiven the current state of knowledge, it is difficult to definitively say that FTO promotes pancreatic cancer development. While there is some evidence to suggest a potential role, the mechanisms are not well characterized, and more research is needed to fully understand the relationship between FTO and pancreatic cancer.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "621b8dee3a8413c653000042", "messages": [{"role": "user", "content": "Is Lysozyme abundant in human tears?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.uncertain\n<|assistant|>\nLysozyme is an enzyme that is found in many bodily fluids, including tears. It is known for its antibacterial properties, as it can break down the cell walls of certain bacteria. This makes it an important component of the immune system, particularly in the eyes, where it helps to protect against bacterial infections.\n\nHuman tears contain a variety of proteins, including lysozyme. Lysozyme is present in the lacrimal glands, which produce tears, and it is also found in the tears themselves. Its presence in tears is crucial for the maintenance of ocular health and the prevention of bacterial infections of the eye.\n\nSo, the answer is A. yes. Lysozyme is abundant in human tears. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6052715494d57fd87900000e", "messages": [{"role": "user", "content": "Is FTY720 FDA approved?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nFTY720, also known as fingolimod, is a medication used to treat multiple sclerosis (MS). It is a sphingosine 1-phosphate receptor modulator that works by reducing the number of immune cells that can enter the central nervous system, thereby reducing the inflammatory response that can damage the nerves in MS.\n\nThe FDA approved FTY720 for the treatment of relapsing forms of multiple sclerosis in 2010. It is available under the brand name Gilenya.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "621d19cc3a8413c65300004a", "messages": [{"role": "user", "content": "Is cytokeratin a tumor marker?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nCytokeratins are intermediate filaments found in the cytoplasm of epithelial cells. They are a family of proteins that are important for the structure and function of epithelial cells. Cytokeratins are not specific to cancer cells, as they are also found in normal epithelial cells. However, they are often used as markers in the diagnosis of certain types of cancer because they are more abundant in cancer cells than in normal cells.\n\nIn the context of cancer, cytokeratins can be used to identify the origin of a tumor. For example, if a tumor expresses cytokeratin 7 and 20, it is likely to be of gastrointestinal origin. This is because these cytokeratins are commonly found in the gastrointestinal tract.\n\nSo, the answer is A. yes, cytokeratin is a tumor marker. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "602596691cb411341a0000ad", "messages": [{"role": "user", "content": "Is tofacitinib a JAK inhibitor?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nTofacitinib is a Janus kinase (JAK) inhibitor. JAK inhibitors are a class of drugs that block the activity of Janus kinases, which are a family of enzymes involved in signaling pathways that regulate immune responses. Tofacitinib is used to treat rheumatoid arthritis and ulcerative colitis by inhibiting the activity of JAK enzymes, which are important in the signaling pathways that lead to inflammation.\n\nSo, the answer is A. yes. Tofacitinib is a JAK inhibitor. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "60292dc61cb411341a000110", "messages": [{"role": "user", "content": "\u0391re plants from the genus Strychnos the original source of curare?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nCurare is a group of toxins found in various plants, particularly in the families Menispermaceae and Strychnaceae. The genus Strychnos includes plants such as Strychnos toxifera, Strychnos nux-vomica, and Strychnos ignatii, which are known to contain strychnine, a potent neurotoxin. However, the original source of curare is not from the genus Strychnos.\n\nCurare is a mixture of alkaloids that are found in various plants, including Chondrodendron tomentosum, which is a member of the Menispermaceae family. The alkaloids in curare are primarily tubocurarine and d-tubocurarine, which are not found in the genus Strychnos.\n\nSo, the answer is B. No, plants from the genus Strychnos are not the original source of curare. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "61f9605f882a024a1000004f", "messages": [{"role": "user", "content": "Are variants in FHF2 (also known as FGF13) associated with encephalopathy?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nFHF2, also known as FGF13, is a gene that encodes a protein that is involved in the development and function of the central nervous system. Mutations in this gene have been associated with a variety of neurological disorders, including benign familial infantile epilepsy, benign familial neonatal convulsions, and infantile convulsions and choreoathetosis syndrome.\n\nOne of the conditions associated with FHF2 mutations is infantile convulsions and choreoathetosis syndrome (ICCA), which is characterized by early-onset seizures and movement disorders. The syndrome is often associated with mutations in the FGF13 gene, which encodes the FHF2 protein.\n\nSo, the answer is A. yes. Variants in FHF2 are associated with encephalopathy, which is a broad term for brain dysfunction, including seizures and movement disorders. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "602c26171cb411341a000122", "messages": [{"role": "user", "content": "Is AZD9668 a VEGF mRNA drug?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nAZD9668 is a drug that is used to treat various conditions, including diabetic retinopathy. It is a selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), which is a receptor for vascular endothelial growth factor (VEGF). VEGF is a protein that is involved in the growth of new blood vessels, and its receptors are important for angiogenesis, which is the process by which new blood vessels form from pre-existing vessels.\n\nThe action of AZD9668 is to inhibit the binding of VEGF to its receptor, thereby preventing the activation of the signaling pathways that lead to angiogenesis. This inhibition can be useful in conditions where excessive angiogenesis is a problem, such as in diabetic retinopathy, where new blood vessels can form in the retina, leading to vision loss.\n\nHowever, AZD9668 does not directly target VEGF mRNA. It is a small molecule that binds to the receptor and inhibits its activity, not the mRNA itself. Therefore, the answer is B. AZD9668 is not a VEGF mRNA drug. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "603400051cb411341a00014e", "messages": [{"role": "user", "content": "Is histone variant H3.3K27M associated with gliomas?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nHistone variants are proteins that replace the canonical histones in chromatin. One of the most well-known histone variants is H3.3, which is involved in the maintenance of chromatin structure and is particularly important for the incorporation of histones into nucleosomes during DNA replication and repair.\n\nThe K27M mutation in H3.3 is a specific mutation that is associated with certain types of brain tumors, particularly gliomas. This mutation is found in a subset of pediatric gliomas, including diffuse intrinsic pontine gliomas (DIPGs) and high-grade gliomas. The K27M mutation is known to be associated with a poor prognosis and is thought to contribute to the aggressive behavior of these tumors.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6081a83f4e6a4cf630000007", "messages": [{"role": "user", "content": "Is FKBP52 encoding a chaperone ?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "|assistant|>\nFKBP52 (FK506-binding protein 52) is a member of the FKBP family of proteins, which are known as immunophilins. Immunophilins are a class of proteins that bind to immunosuppressive drugs such as FK506 and cyclosporine. However, FKBP52 has a unique function beyond its role as a drug-binding protein.\n\nFKBP52 is a co-chaperone of the heat shock protein Hsp90. Hsp90 is a molecular chaperone that assists in the folding and stability of various proteins, including steroid hormone receptors and signaling proteins. FKBP52 helps to stabilize the Hsp90 complex and is involved in the maturation and activation of steroid hormone receptors.\n\nSo, the answer is A. yes. FKBP52 is a chaperone because it assists in the folding and stabilization of proteins, particularly steroid hormone receptors, in conjunction with the Hsp90 chaperone system. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "62004357c9dfcb9c09000015", "messages": [{"role": "user", "content": "Does \u03b1CGRP have amyloidogenic properties?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\n\u03b1CGRP (alpha calcitonin gene-related peptide) is a neuropeptide that is known to have various physiological effects, including vasodilation and pain modulation. It is not typically associated with amyloidogenic properties, which are properties that promote the formation of amyloid plaques, a hallmark of Alzheimer's disease and other neurodegenerative conditions.\n\nAmyloidogenic proteins are those that have a tendency to aggregate into insoluble fibrils, which can then deposit in the brain and form plaques. While some proteins, such as amyloid-beta (A\u03b2) and tau, are known to be amyloidogenic, \u03b1CGRP is not one of them.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "60282c3f1cb411341a0000fe", "messages": [{"role": "user", "content": "Is istiratumab effective for pancreatic cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nIstradefylline is a drug that is used to treat Parkinson's disease by inhibiting adenosine A2A receptors. It is not used for the treatment of pancreatic cancer. The treatment of pancreatic cancer typically involves a combination of surgery, chemotherapy, and radiation therapy, depending on the stage of the disease. There is no evidence that istiratumab is effective for pancreatic cancer.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "601efda31cb411341a000069", "messages": [{"role": "user", "content": "Does bleomycin cause lung toxicity?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nBleomycin is an antineoplastic agent that is used in the treatment of various types of cancer, including testicular cancer, Hodgkin's lymphoma, and squamous cell carcinoma of the skin. One of the known side effects of bleomycin is pulmonary toxicity, which can range from mild to severe. The pulmonary toxicity can manifest as cough, shortness of breath, and chest pain, and in severe cases, can lead to pulmonary fibrosis, which is a scarring of the lung tissue.\n\nThe mechanism of bleomycin-induced lung toxicity is thought to involve the generation of reactive oxygen species, which can damage the lung tissue. This damage can lead to inflammation and fibrosis, which can impair lung function and potentially be fatal.\n\nGiven this information, the answer is A. Yes, bleomycin does cause lung toxicity. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6082f4374e6a4cf63000000f", "messages": [{"role": "user", "content": "Is Keutel syndrome a common genetic disorder?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nKeutel syndrome is a rare genetic disorder characterized by skeletal abnormalities, particularly affecting the ribs, and by other features such as hearing loss, heart defects, and distinctive facial features. It is caused by mutations in the FKBP10 gene, which encodes a protein that is involved in the formation of collagen. The prevalence of Keutel syndrome is not well established, but it is considered to be very rare, with only a few dozen cases reported in the literature.\n\nGiven that Keutel syndrome is a rare disorder, the answer is no, it is not a common genetic disorder.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "601d724a1cb411341a000035", "messages": [{"role": "user", "content": "Is fusobacterium associated with Lemierre's syndrome?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nLemierre's syndrome, also known as postanginal sepsis, is a rare but serious condition that typically affects young, otherwise healthy individuals. It is characterized by thrombophlebitis of the internal jugular vein, which can lead to septic emboli and systemic infection. The most common causative organism is Fusobacterium necrophorum, a gram-negative anaerobic rod.\n\nFusobacterium is a normal part of the oral flora and can be found in the throat and nasopharynx. It is not typically associated with Lemierre's syndrome unless there is a preceding oropharyngeal infection, such as tonsillitis or pharyngitis. When Fusobacterium enters the bloodstream, it can cause septicemia and lead to the formation of thrombi in the internal jugular vein, which can then break off and travel to other parts of the body, leading to septic emboli.\n\nSo, the answer is A. yes. Fusobacterium is associated with Lemierre's syndrome. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "621fd6083a8413c653000066", "messages": [{"role": "user", "content": "Unlike DNA, RNA is not methylated, yes or no?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nDNA is known to be methylated at certain positions, particularly at the 5-methylcytosine (5-mC) position. This methylation is important for various functions, including gene regulation and protection from damage. RNA, on the other hand, is not typically methylated. While there are some exceptions, such as the 5-methyluridine (m5U) found in tRNA, RNA is generally not methylated to the same extent as DNA.\n\nSo, the answer is B. no. RNA is not typically methylated to the same extent as DNA. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "620155b6c9dfcb9c09000024", "messages": [{"role": "user", "content": "Is covid-19 induced anosmia caused by disruption of nuclear architecture?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nAnosmia, or the loss of the sense of smell, is a common symptom of COVID-19. While the exact mechanism by which COVID-19 causes anosmia is not fully understood, it is known that the virus can infect cells in the nasal cavity and olfactory epithelium, which are responsible for the sense of smell.\n\nOne theory that has been proposed is that the disruption of the nuclear architecture of cells in the olfactory epithelium could be a contributing factor to anosmia. The nuclear architecture refers to the organization of the nucleus within a cell, including the arrangement of chromatin, nucleoli, and other nuclear components. It is believed that the disruption of this architecture could affect the function of the cells, including their ability to produce the proteins necessary for normal olfactory function.\n\nHowever, this theory is not yet conclusive, and there is still much research to be done to fully understand the mechanisms behind COVID-19-induced anosmia. Therefore, while it is possible that disruption of nuclear architecture could play a role, it is not yet certain.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "622dd1433a8413c6530000a5", "messages": [{"role": "user", "content": "Is taxilin a cancer marker?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nTaxilin is a protein that is involved in the regulation of cell division and is essential for the proper functioning of the mitotic spindle. It is a component of the spindle assembly checkpoint (SAC), which ensures that chromosomes are properly aligned on the metaphase plate before the cell can enter anaphase. The SAC is a critical mechanism for preventing aneuploidy, which is a hallmark of cancer.\n\nIn cancer cells, the SAC is often compromised, leading to the premature entry into anaphase and the production of cells with an abnormal number of chromosomes. This is a key step in the development of cancer, as aneuploidy can lead to the accumulation of genetic mutations that drive the uncontrolled growth of cancer cells.\n\nGiven this role in the regulation of cell division and its importance in preventing aneuploidy, taxilin is not a cancer marker per se, but rather a protein that is involved in the prevention of cancer by ensuring proper chromosome segregation during cell division.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "622668313a8413c653000087", "messages": [{"role": "user", "content": "Is PCAT6 a microRNA?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nPCAT6 is a microRNA (miRNA) that is associated with prostate cancer. MicroRNAs are small, non-coding RNAs that regulate gene expression by binding to complementary sequences on target messenger RNAs (mRNAs), leading to their degradation or translational repression. The discovery of PCAT6 as a miRNA was a significant finding in the field of prostate cancer research because it was found to be overexpressed in prostate cancer cells and was associated with poor prognosis.\n\nSo, the answer is A. yes. PCAT6 is a microRNA. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6201a4edc9dfcb9c09000028", "messages": [{"role": "user", "content": "Is HDAC1 required for GATA-1 transcriptional activity?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.cannot be determined\n<|assistant|>\nHDAC1 is a histone deacetylase, which is an enzyme that removes acetyl groups from histones, leading to a more compacted chromatin structure and reduced transcriptional activity. GATA-1 is a transcription factor that is important for the development and function of erythroid cells. It binds to specific DNA sequences and activates the transcription of genes involved in erythropoiesis.\n\nThe relationship between HDAC1 and GATA-1 is not straightforward. While HDAC1 can indeed repress transcription by deacetylating histones, it is not clear whether it directly affects the transcriptional activity of GATA-1. GATA-1 is known to interact with other proteins, such as FOG-1, which can modulate its activity, and it is possible that HDAC1 could affect GATA-1 indirectly through these interactions.\n\nGiven the complexity of the interactions involved and the lack of direct evidence, it is difficult to say with certainty whether HDAC1 is required for GATA-1 transcriptional activity. Therefore, the answer is D. cannot be determined. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "623a24d6f0baec9a1b000002", "messages": [{"role": "user", "content": "Is telomestatin, a novel statin drug used to treat high cholesterol?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nTelomestatin is a natural product isolated from the fungus Streptomyces anulatus. It is known for its ability to inhibit telomerase, an enzyme that is essential for the maintenance of telomere length. Telomerase is often overexpressed in cancer cells, which allows them to maintain their telomeres and become immortalized. Therefore, telomestatin has been investigated as a potential anticancer agent.\n\nHowever, telomestatin is not a statin drug. Statins are a class of drugs that are used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which is involved in the synthesis of cholesterol. Telomestatin does not have this mechanism of action.\n\nSo, the answer is B. Telomestatin is not a statin drug. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "61f7d4da882a024a10000033", "messages": [{"role": "user", "content": "Is there an association between Guillain\u2013Barr\u00e9 syndrome and covid vaccine?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nGuillain\u2013Barr\u00e9 syndrome (GBS) is a rare neurological disorder that can cause muscle weakness and paralysis. It is often triggered by an infection, such as Campylobacter jejuni, which can lead to an autoimmune response that attacks the peripheral nerves.\n\nThere have been reports of GBS following vaccination, but the incidence is very low. The most common vaccines associated with GBS are the influenza vaccine and the hepatitis B vaccine. However, the risk of GBS following vaccination is much lower than the risk of GBS following an infection.\n\nThe COVID-19 vaccines have been extensively studied and have not been found to be associated with an increased risk of GBS. In fact, the incidence of GBS following COVID-19 infection is much higher than following vaccination. This is because the COVID-19 vaccines are based on mRNA technology, which does not contain any viral components that could trigger an autoimmune response.\n\nSo, the answer is B. no. There is no association between Guillain\u2013Barr\u00e9 syndrome and covid vaccine. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "61fa904fc9dfcb9c09000004", "messages": [{"role": "user", "content": "Is Erythropoietin effective for neuroprotection of Preterm Infants.\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.unlikely\n<|assistant|>\nErythropoietin (EPO) is a hormone that is naturally produced by the kidneys and is primarily known for its role in the production of red blood cells. However, in recent years, EPO has been investigated for its potential neuroprotective effects in preterm infants.\n\nPreterm infants are at high risk for brain injury due to their immature brains and the stressors they experience during the neonatal period. EPO has been shown to have neuroprotective properties in animal models of brain injury, and there is some evidence that it may have similar effects in preterm infants.\n\nA study published in 2005 found that EPO administration to preterm infants reduced the risk of severe intraventricular hemorrhage (IVH), a type of brain bleeding that can occur in preterm infants. Another study from 2010 showed that EPO treatment was associated with improved neurodevelopmental outcomes at 2 years of age in preterm infants.\n\nWhile more research is needed to fully understand the role of EPO in neuroprotection, the available evidence suggests that it may have a beneficial effect on the developing brain of preterm infants.\n\nSo, the answer is C. may be. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6226317a3a8413c653000080", "messages": [{"role": "user", "content": "Is Ameloblastoma (AB) a common benign tumor occurring in the brain?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nAmeloblastoma is a benign tumor that arises from the cells that form the enamel of teeth. It is a common tumor of the jaw, particularly the mandible, but it is not a tumor that occurs in the brain. The brain is not composed of enamel-forming cells, and therefore, ameloblastoma would not be a common benign tumor in the brain.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "622901d23a8413c65300008c", "messages": [{"role": "user", "content": "Is Ameloblastoma (AB) a benign tumor that never metastasizes?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may metastasize\nD.may not metastasize\n<|assistant|>\nAmeloblastoma is a benign tumor that arises from the cells that form the enamel of teeth. It is a common odontogenic tumor that can occur in any part of the jaw, but it is most commonly found in the mandible. The tumor is characterized by its slow growth and the tendency to recur after surgical removal.\n\nWhile ameloblastoma is considered a benign tumor, it can be locally aggressive and can cause significant damage to surrounding tissues. It can also recur if not completely removed, which is why it is important to ensure that all of the tumor is removed during surgery.\n\nAmeloblastoma does not typically metastasize to other parts of the body, but it can invade surrounding tissues and cause significant damage. Therefore, the answer is that ameloblastoma is a benign tumor that does not metastasize, but it can be locally aggressive and can cause significant damage if not treated properly.\n\nSo, the answer is A. yes. Ameloblastoma is a benign tumor that never metastasizes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "620157bec9dfcb9c09000025", "messages": [{"role": "user", "content": "Is there any role of the 'Greek islands' in olfactory receptor choice?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nThe 'Greek islands' are a reference to the olfactory receptor gene family, which is the largest gene family in the human genome. The Greek islands are a metaphor for the diversity of olfactory receptors, as there are over 400 different types of olfactory receptors in the human genome, each with its own unique specificity for different odorant molecules.\n\nOlfactory receptors are responsible for detecting and transducing odorant molecules into electrical signals that the brain can interpret as smells. Each receptor has a specific binding site that recognizes a particular odorant molecule. The diversity of olfactory receptors allows us to detect a wide range of odors, which is crucial for our survival and ability to navigate the world.\n\nSo, the answer is A. Yes, there is a role of the 'Greek islands' in olfactory receptor choice, as they represent the diversity of olfactory receptors and their specificities for different odorants. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "622dc4b63a8413c6530000a4", "messages": [{"role": "user", "content": "Is paxillin affected by RANKL?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nPaxillin is a protein that is involved in cell adhesion and signaling. It is a key component of focal adhesions, which are structures that anchor cells to the extracellular matrix and transmit signals from the extracellular environment to the cell interior.\n\nRANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) is a protein that is known to be involved in the regulation of bone metabolism and the immune system. It is primarily associated with the activation of osteoclasts, which are cells responsible for bone resorption.\n\nWhile paxillin is involved in cell adhesion and signaling, there is no direct evidence that it is affected by RANKL. RANKL primarily acts through its receptor, RANK, to activate osteoclasts and their precursors. Paxillin is not a known target of RANKL.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "622b95dc3a8413c653000092", "messages": [{"role": "user", "content": "Is retinol binding protein 4 an adipokine?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nRetinol binding protein 4 (RBP4) is a protein that binds to vitamin A (retinol) in the blood and transports it to tissues. It is produced primarily by the liver and is found in high concentrations in the blood.\n\nRBP4 has been implicated in the regulation of glucose and lipid metabolism, and it has been suggested that it may be an adipokine, a hormone produced by adipose tissue. However, the evidence for RBP4 being an adipokine is not as strong as for other adipokines like leptin or adiponectin.\n\nWhile RBP4 is produced by adipocytes, its primary function is not to regulate metabolism, and its role in glucose and lipid metabolism is not as well established as for other adipokines. Therefore, while RBP4 is associated with adipose tissue, it is not considered a classic adipokine.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "622ce21d3a8413c65300009c", "messages": [{"role": "user", "content": "Is HYDIN (Hydrocephalus-inducing protein homolog) an axonemal protein?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nHYDIN is a protein that is involved in the development of the central nervous system, particularly in the formation of the cerebral cortex and the development of the cerebellum. It is also known to be involved in the development of the brain ventricles, which are the fluid-filled spaces within the brain.\n\nThe axoneme is a structure found in cilia and flagella, which are hair-like projections that extend from the surface of some cells. The axoneme is composed of microtubules and other proteins that are essential for the motility of cilia and flagella. HYDIN is not typically associated with the axoneme or the function of cilia and flagella.\n\nGiven this information, HYDIN is not an axonemal protein.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "621e62c33a8413c653000050", "messages": [{"role": "user", "content": "Are there any R packages that help with visualizing data on spirals?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nThere are several R packages that can be used to visualize data on spirals. Here are a few examples:\n\n1. The `spirals` package provides functions for generating and visualizing spirals, including the Archimedean spiral, the logarithmic spiral, and the Fibonacci spiral.\n\n2. The `spiral` package provides functions for generating and visualizing spirals, including the Archimedean spiral, the logarithmic spiral, and the Fibonacci spiral. It also includes functions for fitting spirals to data.\n\n3. The `spiralize` package provides functions for generating and visualizing spirals, including the Archimedean spiral, the logarithmic spiral, and the Fibonacci spiral. It also includes functions for fitting spirals to data.\n\nSo, the answer is A. yes. There are R packages that help with visualizing data on spirals. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "61faa3bac9dfcb9c0900000b", "messages": [{"role": "user", "content": "Was ALVAC-HIV effective for HIV prevention in the HVTN 702 trial?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.not enough data\n<|assistant|>\nThe HVTN 702 trial was a phase 3 clinical trial that evaluated the efficacy of the ALVAC-HIV and AIDSVAX B/E vaccines in preventing HIV infection in men and women at high risk of HIV infection in South Africa. The trial enrolled 5400 participants and was conducted from 2015 to 2020.\n\nThe primary endpoint of the trial was to determine whether the vaccine regimen could reduce the risk of HIV infection by at least 25% compared to placebo. The results of the trial were published in 2021 and showed that the vaccine regimen did not reduce the risk of HIV infection. In fact, the vaccine regimen was associated with a 29% increased risk of HIV infection compared to placebo.\n\nGiven these results, we can conclude that the ALVAC-HIV and AIDSVAX B/E vaccines were not effective for HIV prevention in the HVTN 702 trial.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "622baf3f3a8413c653000099", "messages": [{"role": "user", "content": "Do Afamin bind Vitamin E?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.both\nD.none of the above\n<|assistant|>\nAfamin is a protein that is part of the vitamin-binding protein family. It is known to bind vitamin A, specifically retinol, which is the form of vitamin A that is found in the blood and is used by the body. Vitamin E is another fat-soluble vitamin that is important for human health. However, Afamin does not bind vitamin E. Instead, vitamin E is bound by other proteins such as alpha-tocopherol transfer protein (\u03b1-TTP) and lipoproteins.\n\nSo, the answer is B. no. Afamin does not bind vitamin E. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "622632483a8413c653000081", "messages": [{"role": "user", "content": "Is disruption of immune regulation mechanisms associated with adverse pregnancy outcomes, including preeclampsia (PE)?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nPreeclampsia (PE) is a pregnancy-specific syndrome characterized by new-onset hypertension and proteinuria after 20 weeks of gestation. It is a serious condition that can lead to maternal and fetal complications. While the exact cause of PE is not fully understood, there is evidence to suggest that it may be related to abnormal immune regulation during pregnancy.\n\nOne theory is that PE is associated with an abnormal immune response to the placenta. The placenta is a unique organ that develops during pregnancy and is responsible for the exchange of nutrients and waste between the mother and the fetus. During normal pregnancy, the maternal immune system is tolerant of the placenta, which is considered a \"semi-allograft\" because it is genetically different from the mother. However, in PE, there may be an overactive immune response to the placenta, leading to inflammation and damage.\n\nStudies have shown that women with PE have higher levels of certain inflammatory markers, such as cytokines and chemokines, which are involved in the immune response. Additionally, there is evidence that certain genetic variants associated with immune regulation may be linked to an increased risk of PE.\n\nGiven this information, it is reasonable to conclude that disruption of immune regulation mechanisms is associated with adverse pregnancy outcomes, including preeclampsia.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "62266c353a8413c65300008a", "messages": [{"role": "user", "content": "Can autophagy related lncRNAs be used for colorectal cancer prognosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nAutophagy is a process by which cells break down and recycle their contents. It is a crucial mechanism for maintaining cellular homeostasis and is involved in various cellular processes, including cell death, survival, and differentiation. Long non-coding RNAs (lncRNAs) are a class of RNA molecules that are longer than 200 nucleotides and do not code for proteins. They have been implicated in various biological processes, including autophagy.\n\nIn the context of colorectal cancer, lncRNAs have been studied for their potential role in the regulation of autophagy. For example, the lncRNA HOTAIR has been shown to regulate autophagy in colorectal cancer cells by interacting with the autophagy-related protein ATG5. Other lncRNAs, such as MALAT1, have also been implicated in the regulation of autophagy in colorectal cancer.\n\nGiven the evidence that lncRNAs can regulate autophagy in colorectal cancer, it is reasonable to suggest that autophagy-related lncRNAs could be used for colorectal cancer prognosis. However, the field is still relatively new, and more research is needed to fully understand the role of lncRNAs in the prognosis of colorectal cancer.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "621e9aa13a8413c653000053", "messages": [{"role": "user", "content": "Are there roles for cohesin mutations in AML?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nCohesin is a protein complex that plays a critical role in the proper segregation of chromosomes during cell division. Mutations in cohesin genes have been associated with a variety of genetic disorders, including Cornelia de Lange syndrome and Roberts syndrome. In recent years, there has been increasing evidence that mutations in cohesin genes can also contribute to the development of certain types of cancer, including acute myeloid leukemia (AML).\n\nIn AML, cohesin mutations are most commonly found in patients with a specific subtype of the disease, known as core binding factor (CBF) AML. CBF AML is characterized by chromosomal translocations involving the RUNX1 and CBFB genes, which encode components of the CBF transcription factor complex. These translocations lead to the production of fusion proteins that disrupt normal cohesin function, which can contribute to the development of AML.\n\nSo, the answer is A. Yes, there are roles for cohesin mutations in AML, particularly in the context of CBF AML. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "622d0aa63a8413c6530000a0", "messages": [{"role": "user", "content": "Is ASF1 phopshorylated by  the Tousled-like kinases?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nASF1 (Acetyltransferase of Sir2-related proteins 1) is a histone chaperone that plays a crucial role in the regulation of chromatin structure and DNA replication. It is known to be phosphorylated by several kinases, including the Tousled-like kinases (TLKs).\n\nTLKs are a family of serine/threonine kinases that are involved in various cellular processes, including DNA replication, DNA repair, and chromatin remodeling. One of the functions of TLKs is to phosphorylate ASF1, which is essential for the proper function of ASF1 in DNA replication and chromatin assembly.\n\nSo, the answer is A. yes. ASF1 is phosphorylated by the Tousled-like kinases. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6237a6e93a8413c6530000b1", "messages": [{"role": "user", "content": "Does sphingosine-1 phosphoate suppress epiregulin?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nSphingosine-1-phosphate (S1P) is a bioactive lipid that is known to have various effects on cell signaling and function. One of the effects of S1P is to suppress the production of epiregulin, a growth factor that is involved in the regulation of cell proliferation and differentiation.\n\nEpiregulin is a member of the epidermal growth factor (EGF) family and is known to promote cell proliferation and differentiation. S1P has been shown to inhibit the production of epiregulin by various cell types, including cancer cells. This inhibition is thought to be due to the activation of the S1P receptor, which leads to the suppression of epiregulin transcription.\n\nSo, the answer is A. yes. Sphingosine-1 phosphoate does suppress epiregulin. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "62068e67c9dfcb9c09000038", "messages": [{"role": "user", "content": "Can whole genome sequencing be used for diagnosis of mitochondrial disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nMitochondrial diseases are a group of disorders caused by genetic mutations that affect the mitochondria, the energy-producing units of cells. These diseases can be difficult to diagnose because they can present with a wide range of symptoms and can be caused by mutations in either the nuclear DNA or the mitochondrial DNA.\n\nWhole genome sequencing (WGS) is a technique that can be used to sequence all of the DNA in an individual's genome, including both nuclear and mitochondrial DNA. This makes it a powerful tool for identifying genetic mutations that could be causing mitochondrial disease.\n\nHowever, WGS is not always the first step in the diagnostic process for mitochondrial disease. In some cases, less expensive and less invasive tests, such as biochemical tests or genetic testing for specific mutations, may be used first. WGS is typically reserved for cases where the diagnosis is unclear or when there is a suspicion of a novel mutation.\n\nSo, the answer is A. yes, whole genome sequencing can be used for diagnosis of mitochondrial disease. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "622662e13a8413c653000085", "messages": [{"role": "user", "content": "Can METTL3 methylate long noncoding RNAs?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nMETTL3 is a methyltransferase that is part of the methyltransferase-like (METTL) family. This family of enzymes is involved in the methylation of RNA, specifically the N6-methyladenosine (m6A) modification. m6A is the most common internal modification in eukaryotic mRNA and is known to play a role in various aspects of RNA metabolism, including mRNA splicing, stability, and translation.\n\nLong noncoding RNAs (lncRNAs) are a class of RNA molecules that are longer than 200 nucleotides but do not code for proteins. They are involved in various cellular processes, including transcriptional regulation, chromatin remodeling, and epigenetic regulation. While m6A modification has been studied extensively in mRNA, there is growing evidence that lncRNAs can also be methylated by METTL3 and other members of the METTL family.\n\nFor example, a study published in 2017 found that METTL3 can methylate lncRNAs in human cells, and that this methylation is important for the stability and function of these lncRNAs. The study showed that METTL3 knockdown led to a decrease in the levels of certain lncRNAs, suggesting that METTL3 is involved in their methylation and stability.\n\nSo, the answer is A. yes, METTL3 can methylate long noncoding RNAs. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "622f6ad13a8413c6530000aa", "messages": [{"role": "user", "content": "Can parasite infections by Schistosoma japonicum prevent or improve asthma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.may be\n<|assistant|>\nSchistosomiasis, also known as bilharzia, is a parasitic disease caused by the blood flukes of the genus Schistosoma. There are several species of Schistosoma that can infect humans, including Schistosoma japonicum, which is endemic to East Asia.\n\nThere is some evidence that suggests that Schistosoma japonicum infection may be associated with a reduced risk of asthma. This is because the immune response to the parasite can lead to the production of certain cytokines that may have an anti-inflammatory effect, which could potentially reduce the symptoms of asthma.\n\nHowever, this is a complex issue and the relationship between Schistosoma japonicum infection and asthma is not fully understood. Some studies have found a protective effect, while others have not. Additionally, the long-term effects of schistosomiasis on the immune system and the potential for the development of other diseases or complications are also important considerations.\n\nGiven the current state of research, it is difficult to definitively say that Schistosoma japonicum infection prevents or improves asthma. While there is some evidence to suggest a protective effect, more research is needed to fully understand the relationship between these two conditions.\n\nSo, the answer is C. may be. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6212c25c3a8413c653000019", "messages": [{"role": "user", "content": "Is there a role for CADM1 in Myelodysplastic syndrome (MDS)?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nMyelodysplastic syndrome (MDS) is a group of hematopoietic stem cell disorders characterized by the production of abnormal blood cells. The pathogenesis of MDS is complex and involves a combination of genetic and epigenetic factors. One of the genes that has been implicated in the development of MDS is CADM1, which encodes a cell adhesion molecule that is involved in the regulation of cell-cell interactions.\n\nStudies have shown that mutations in CADM1 can lead to the development of MDS. Specifically, mutations in the CADM1 gene can cause a loss of function, which can disrupt the normal cell adhesion and signaling processes, leading to the production of abnormal blood cells. These mutations are particularly common in a subtype of MDS called refractory anemia with ring sideroblasts (RARS), where they are found in up to 30% of cases.\n\nGiven the evidence that mutations in CADM1 can contribute to the pathogenesis of MDS, it is reasonable to conclude that CADM1 does have a role in the development of this disease.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "625374a8e764a53204000027", "messages": [{"role": "user", "content": "Is periampullary carcinoma (PAC) a relatively rare genitourinary malignancy\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nPeriampullary carcinoma (PAC) is a type of cancer that occurs in the area around the ampulla of Vater, which is where the bile duct and pancreatic duct join to form the duodenum. It includes cancers of the ampulla of Vater, the distal bile duct, and the duodenum near the ampulla.\n\nPAC is not a genitourinary malignancy. The genitourinary system includes the kidneys, ureters, bladder, and urethra. PAC is a gastrointestinal malignancy, specifically affecting the pancreas and bile ducts.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "62015485c9dfcb9c09000023", "messages": [{"role": "user", "content": "Do SETD1A mutations predispose to schizophrenia?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nSETD1A is a gene that encodes a protein involved in the regulation of histone methylation, which is a key epigenetic modification that affects gene expression. Mutations in this gene have been associated with intellectual disability, developmental delay, and autism spectrum disorder. However, there is no strong evidence to suggest that mutations in SETD1A directly predispose to schizophrenia.\n\nSchizophrenia is a complex disorder with a strong genetic component, but the specific genes involved are not well understood. While there are some genetic associations with schizophrenia, such as with the neuregulin 1 gene, the role of SETD1A mutations in the development of schizophrenia is not well established.\n\nGiven the current state of knowledge, it is unlikely that SETD1A mutations are a direct cause of schizophrenia. However, as our understanding of the genetic basis of psychiatric disorders continues to evolve, it is possible that mutations in this gene or other epigenetic regulators could be associated with increased risk for schizophrenia or other psychiatric conditions.\n\nSo, the answer is D. Unlikely. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "61f7cca7882a024a1000002b", "messages": [{"role": "user", "content": "Is Sotatercept effective for Pulmonary Arterial Hypertension?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nSotatercept is a novel drug that is being investigated for the treatment of pulmonary arterial hypertension (PAH). It is a recombinant fusion protein that binds to both activin A and activin B, which are members of the transforming growth factor-beta (TGF-\u03b2) superfamily. Activins are known to play a role in the pathogenesis of PAH by promoting smooth muscle cell proliferation and fibrosis in the pulmonary vasculature.\n\nIn clinical trials, sotatercept has shown promising results in reducing pulmonary vascular resistance and improving exercise capacity in patients with PAH. However, the drug is not yet approved for the treatment of PAH. The FDA has granted sotatercept an orphan drug designation for the treatment of PAH, which provides incentives for the development of drugs for rare diseases.\n\nGiven the current state of research, it is not possible to definitively say that sotatercept is effective for PAH. However, the preliminary data from clinical trials suggest that it may be a promising treatment option.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "624f2355e764a5320400000b", "messages": [{"role": "user", "content": "Is the 22-item sino-nasal outcome test (SNOT-22) a widely used measure for Health-Related Quality-of-Life (HRQOL) associated with chronic rhinosinusitis (CRS)?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nThe Sino-Nasal Outcome Test (SNOT) is a validated questionnaire used to assess the impact of chronic rhinosinusitis (CRS) on a patient's quality of life. The SNOT-22 is a 22-item version of the SNOT-20, which was developed to provide a more comprehensive assessment of the impact of CRS on HRQOL. The SNOT-22 includes items related to nasal obstruction, nasal discharge, facial pain/pressure, sense of smell, sleep disturbance, and emotional consequences of CRS, among others.\n\nThe SNOT-22 is widely used in clinical practice and research to assess the impact of CRS on HRQOL. It is a reliable and valid measure that has been used in numerous studies to evaluate the effectiveness of treatments for CRS and to compare the quality of life between patients with CRS and healthy controls.\n\nSo, the answer is A. yes. The Sino-Nasal Outcome Test (SNOT-22) is a widely used measure for Health-Related Quality-of-Life (HRQOL) associated with chronic rhinosinusitis (CRS). Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "626aa563e764a53204000036", "messages": [{"role": "user", "content": "Is pRETRO-SUPER an adenoviral vector?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nPRETRO-SUPER is a type of adenoviral vector used in gene therapy. Adenoviruses are a group of viruses that can cause respiratory illnesses, but they are also commonly used as vectors in gene therapy because they can infect a wide range of cells and are relatively easy to manipulate in the laboratory.\n\nAdenoviral vectors are engineered to remove the viral genes that cause disease and to insert the desired gene into the vector. The resulting vector can then be used to deliver the gene to target cells, where it can be expressed and potentially provide a therapeutic benefit.\n\nSo, the answer is A. yes. PRETRO-SUPER is an adenoviral vector. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6201a85cc9dfcb9c0900002a", "messages": [{"role": "user", "content": "Is there a dependence between chromatin organization and dorsoventral gene expression in Drosophila?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nIn Drosophila, the dorsoventral axis is established early in development, and the genes that are expressed along this axis are regulated by a series of signaling pathways. One of the key features of the dorsoventral axis is the presence of the dorsal-ventral gradient of gene expression, where genes are expressed at different levels depending on their position along the axis.\n\nChromatin organization refers to the structure of DNA and its associated proteins within the nucleus. It is known that chromatin organization can affect gene expression, as the structure of chromatin can influence the accessibility of DNA to transcription factors and other regulatory proteins.\n\nGiven this information, it is reasonable to assume that there could be a dependence between chromatin organization and dorsoventral gene expression in Drosophila. Chromatin organization could potentially influence the accessibility of genes to the transcriptional machinery, which in turn could affect the levels of gene expression along the dorsoventral axis.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "61faa1fcc9dfcb9c0900000a", "messages": [{"role": "user", "content": "Is vocimagene amiretrorepvec effective for recurrent high-grade glioma?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nVocimagene amiretrorepvec (also known as talimogene laherparepvec, or T-VEC) is a genetically modified herpes simplex virus type 1 (HSV-1) that has been engineered to selectively replicate in and kill cancer cells. It is used in the treatment of melanoma and is currently being investigated for the treatment of other solid tumors, including glioblastoma, a type of high-grade glioma.\n\nIn a phase 3 clinical trial, T-VEC was found to be effective in the treatment of patients with unresectable stage IIIB, IIIC, or IV melanoma. The trial showed that T-VEC significantly improved progression-free survival and overall survival compared to granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with unresectable stage IIIB, IIIC, or IV melanoma.\n\nHowever, there is currently no evidence that T-VEC is effective for recurrent high-grade glioma. While it is being investigated for this indication, the results of clinical trials are not yet available. Therefore, it is not possible to say with certainty whether T-VEC is effective for recurrent high-grade glioma at this time.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "61f93e68882a024a1000004d", "messages": [{"role": "user", "content": "Should perampanel be used for amyotrophic lateral sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nPerampanel is an antiepileptic drug that works by blocking AMPA receptors, which are involved in the transmission of signals between neurons in the brain. It is approved for the treatment of partial-onset seizures in adults with epilepsy.\n\nAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord. While there is no cure for ALS, treatments can help manage symptoms and slow the progression of the disease.\n\nThere is currently no evidence that perampanel is effective in treating ALS. In fact, a study published in 2017 found that perampanel did not improve survival or slow the progression of ALS in patients with the disease. Therefore, perampanel is not recommended for the treatment of ALS.\n\nSo, the answer is B. no. Perampanel should not be used for amyotrophic lateral sclerosis. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "624c88a1e764a53204000002", "messages": [{"role": "user", "content": "Is Satb1 a transcription factor?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nSatb1 is a protein that is known to bind to DNA and regulate gene expression. It is a member of the SATB family of proteins, which are known to be involved in chromatin remodeling and transcriptional regulation. Specifically, Satb1 is known to bind to the matrix attachment regions (MARs) of the genome, which are regions that are important for the organization of chromatin and the regulation of gene expression. It is also known to interact with other transcription factors and co-regulate gene expression.\n\nGiven this information, Satb1 is indeed a transcription factor because it binds to DNA and regulates gene expression. It is not a simple protein that binds to DNA, but rather a protein that has a specific function in the regulation of gene expression.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6228b3553a8413c65300008b", "messages": [{"role": "user", "content": "Are circular RNAs implicated in diseases of the eye?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nCircular RNAs (circRNAs) are a class of non-coding RNAs that are covalently closed loops without a 5' to 3' polarity. They are generated by a backsplicing mechanism, where the 3' end of the RNA is joined to the 5' end, forming a continuous loop.\n\nWhile circRNAs have been studied in various tissues and cell types, their role in diseases of the eye is not as well established. However, there is some evidence that circRNAs may be involved in ocular diseases. For example, a study found that circRNA_100782 is upregulated in the aqueous humor of patients with primary open-angle glaucoma, suggesting a potential role in the pathogenesis of this disease.\n\nGiven the limited research on the role of circRNAs in eye diseases, it is difficult to say with certainty whether they are implicated in such diseases. However, there is some evidence that suggests they may be involved in certain ocular conditions.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "626aaaa8e764a5320400003a", "messages": [{"role": "user", "content": "Can epigenetic modifications be heritable?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nEpigenetic modifications are chemical changes that occur in DNA or histone proteins that do not alter the nucleotide sequence, but can affect gene expression and function. These modifications can be inherited through cell division and can be passed on to future generations.\n\nFor example, in mammals, the process of imprinting involves the selective silencing of one of the two copies of a gene inherited from either the mother or the father. This silencing is maintained through cell division and can be passed on to future generations.\n\nSo, the answer is A. yes. Epigenetic modifications can be heritable. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "61f7d2a5882a024a10000032", "messages": [{"role": "user", "content": "Is Belimumab used for lupus nephritis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nBelimumab is a monoclonal antibody that is used to treat systemic lupus erythematosus (SLE). It is not specifically used for lupus nephritis, which is a complication of SLE that involves inflammation and damage to the kidneys. Instead, belimumab is used to treat the systemic symptoms of SLE, such as fatigue, joint pain, and skin rashes.\n\nLupus nephritis is typically treated with immunosuppressive medications, such as mycophenolate mofetil, cyclophosphamide, or rituximab, depending on the severity of the disease. These medications are used to reduce inflammation and prevent further damage to the kidneys.\n\nSo, the answer is B. No, belimumab is not used for lupus nephritis. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "62507ca3e764a5320400000f", "messages": [{"role": "user", "content": "Is SOX10 expressed in melanoma cells?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nSOX10 is a transcription factor that is known to be expressed in melanocytes, the cells that give rise to melanoma. Melanocytes are neural crest-derived cells that are responsible for the production of melanin, the pigment that gives skin its color. Melanoma is a type of skin cancer that arises from melanocytes.\n\nSOX10 is a marker that is often used to identify melanoma cells, as it is specifically expressed in melanocytes and their derivatives, including melanoma cells. Therefore, the answer is that SOX10 is expressed in melanoma cells.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "61f939a5882a024a1000004a", "messages": [{"role": "user", "content": "Is tivantinib effective for MET-high hepatocellular carcinoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nTivantinib is a tyrosine kinase inhibitor that targets the MET receptor. MET is a receptor tyrosine kinase that is involved in cell growth, survival, and migration. Overexpression of MET has been associated with poor prognosis in several types of cancer, including hepatocellular carcinoma (HCC).\n\nIn a phase III clinical trial, tivantinib was evaluated in patients with MET-high HCC. The trial was stopped early due to futility, meaning that the trial did not show a significant benefit of tivantinib over placebo. The study did not demonstrate a significant improvement in overall survival or progression-free survival in patients with MET-high HCC.\n\nGiven this information, we can conclude that tivantinib is not effective for MET-high hepatocellular carcinoma, as the clinical trial did not show a significant benefit.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6250a545e764a53204000012", "messages": [{"role": "user", "content": "Is EuroQol 5-Dimension Health Assessment (EQ-5D) [a widely used, simple instrument that monitors the general health-related quality of life (HRQoL) in chronic disease] a 5 question assessment?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nThe EuroQol 5-Dimension Health Assessment (EQ-5D) is a standardized instrument for use as a measure of health-related quality of life (HRQoL). It is designed to be a generic measure of health status for clinical and economic appraisal, and it is widely used in clinical trials and health economic evaluations.\n\nThe EQ-5D consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three levels: no problems, some problems, and extreme problems. The respondent is asked to rate his or her health state by choosing the most appropriate level for each of the five dimensions. This generates a profile of the respondent's health state. The EQ-5D also includes a visual analog scale (VAS) that allows the respondent to rate their overall health on a scale from 0 to 100, where 0 is the worst imaginable health state and 100 is the best imaginable health state.\n\nSo, the answer is no, the EQ-5D is not a 5-question assessment. It is a 5-dimensional assessment with 3 levels per dimension, plus a VAS, which makes it a total of 15 questions.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "61f608d4882a024a10000023", "messages": [{"role": "user", "content": "Is sacituzumab govitecan effective for breast cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nSacituzumab govitecan is a targeted therapy that is used to treat metastatic triple-negative breast cancer (TNBC). TNBC is a type of breast cancer that does not express the receptors for estrogen, progesterone, or HER2. Sacituzumab govitecan is a combination of an antibody and a chemotherapy drug that is specifically designed to target and kill cancer cells that express the Trop-2 protein, which is often overexpressed in TNBC.\n\nClinical trials have shown that sacituzumab govitecan is effective in treating metastatic TNBC that has progressed after at least two prior therapies for metastatic disease. The drug has been approved by the FDA for this indication. It is important to note that sacituzumab govitecan is not effective for all types of breast cancer, but it is specifically designed to target TNBC.\n\nSo, the answer is A. yes. Sacituzumab govitecan is effective for breast cancer, specifically for metastatic triple-negative breast cancer. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "622905043a8413c65300008e", "messages": [{"role": "user", "content": "Is Acute Necrotizing Encephalopathy (ANE) which typically affects young, healthy children usually triggered by exposure to air pollution?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nAcute necrotizing encephalopathy (ANE) is a rare neurological disorder that typically affects young, healthy children. It is characterized by the sudden onset of neurological symptoms, such as seizures, altered consciousness, and focal neurological deficits, often following a viral infection or other stressor.\n\nWhile the exact cause of ANE is not fully understood, it is believed to be a result of a hypercoagulable state that leads to microvascular thrombosis and subsequent brain tissue necrosis. There is no direct evidence that air pollution triggers ANE. However, air pollution can be a risk factor for various respiratory and cardiovascular diseases, and it is possible that it could contribute to the development of ANE by exacerbating underlying conditions or by causing systemic inflammation.\n\nGiven the lack of direct evidence linking air pollution to ANE, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6251465ae764a53204000017", "messages": [{"role": "user", "content": "Is Phospholemman a membrane protein?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nPhospholemman (PLM) is a protein that is found in the plasma membrane of cells. It is a member of the FXYD protein family, which are regulatory proteins that associate with sodium-potassium pumps (Na+/K+-ATPase). PLM is known to regulate the activity of the Na+/K+-ATPase, which is a key enzyme in maintaining the proper balance of sodium and potassium ions across cell membranes.\n\nThe FXYD proteins are known to be membrane proteins because they are integral components of the plasma membrane, where they interact with the Na+/K+-ATPase. They are not soluble proteins that are found in the cytosol or other cellular compartments.\n\nSo, the answer is A. yes. Phospholemman is a membrane protein. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "61f93c38882a024a1000004b", "messages": [{"role": "user", "content": "Can Isradipine slow progression of Early Parkinson Disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.may be not\n<|assistant|>\nIsradipine is a calcium channel blocker that is used to treat hypertension. It has been studied for its potential to slow the progression of Parkinson's disease (PD), as it has been shown to have neuroprotective effects in animal models of PD. However, the evidence for its efficacy in humans is not conclusive.\n\nA 2019 study by the Parkinson Study Group found that long-term treatment with isradipine did not slow the progression of PD in patients with early disease. The study was a randomized, double-blind, placebo-controlled trial that followed patients for 5 years. The results showed that isradipine did not significantly slow the progression of PD as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) or the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).\n\nWhile isradipine may have neuroprotective properties in animal models, the evidence in humans is not strong enough to support its use as a disease-modifying therapy for PD. Therefore, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "625144c9e764a53204000016", "messages": [{"role": "user", "content": "Is neurofilament light marker for disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nNeurofilaments are a type of intermediate filament protein found in neurons. They are important for the structural support and maintenance of neurons. Neurofilament light (NFL) is one of the three subunits of neurofilaments, along with neurofilament medium (NFM) and neurofilament heavy (NFH).\n\nNeurofilaments are often used as biomarkers for neurodegenerative diseases because they are released into the cerebrospinal fluid (CSF) when neurons are damaged or dying. The levels of NFL in the CSF can be measured and are often elevated in conditions where there is neuronal damage or loss, such as in multiple sclerosis, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.\n\nSo, the answer is A. yes. Neurofilament light is a marker for disease because it is released into the CSF when neurons are damaged or dying, and its levels can be used as a biomarker for neurodegenerative diseases. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "62532d42e764a53204000022", "messages": [{"role": "user", "content": "Is resistance training usually associated with increasing muscle hypertrophy?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nResistance training, also known as weight training or strength training, is a type of exercise that involves the use of resistance to increase muscular strength and endurance. It is a common form of exercise used by athletes and bodybuilders to improve their performance and build muscle mass.\n\nWhen it comes to muscle hypertrophy, which is the increase in the size of a muscle, resistance training is indeed associated with it. By lifting weights or using resistance bands, the muscles are subjected to stress that causes microscopic tears in the muscle fibers. The body then repairs these tears, leading to an increase in muscle size and strength.\n\nSo, the answer is A. Yes, resistance training is usually associated with increasing muscle hypertrophy. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "61f93cc7882a024a1000004c", "messages": [{"role": "user", "content": "Is nerinetide effective for ischaemic stroke?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nNerinetide is a drug that is being investigated for the treatment of acute ischaemic stroke. It is a neuroprotective agent that works by inhibiting the NMDA receptor, which is involved in the pathophysiology of ischaemic stroke. The NMDA receptor is a glutamate receptor that, when activated, can lead to excitotoxicity, which is a major contributor to the damage caused by ischaemic stroke.\n\nClinical trials have been conducted to evaluate the efficacy of nerinetide in the treatment of ischaemic stroke. One such trial, the NEST-3 trial, was a phase 3 randomized controlled trial that compared nerinetide to placebo in patients with acute ischaemic stroke. The results of this trial showed that nerinetide did not significantly improve the primary outcome of functional independence at 90 days compared to placebo. However, the trial did show a trend towards a benefit in the nerinetide group, and further analysis is ongoing.\n\nGiven the current state of research, it is not yet clear whether nerinetide is effective for ischaemic stroke. While the NEST-3 trial did not show a significant benefit, the trend towards a benefit and the ongoing analysis suggest that there may be a potential role for nerinetide in the treatment of ischaemic stroke. However, the final verdict on its efficacy will likely come from further clinical trials and analysis of the data.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "61f938e7882a024a10000049", "messages": [{"role": "user", "content": "Is Algenpantucel-L effective for pancreatic cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nAlgenpantucel-L is a vaccine that is being studied for the treatment of pancreatic cancer. It is a combination of two types of pancreatic cancer cells that have been genetically modified to express a protein that stimulates the immune system. The vaccine is designed to help the immune system recognize and attack pancreatic cancer cells.\n\nThe vaccine has been tested in clinical trials, and while the results are not yet conclusive, there is some evidence that it may be effective in prolonging survival in patients with pancreatic cancer. However, the vaccine is not yet approved for use in the treatment of pancreatic cancer, and more research is needed to determine its efficacy.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "62515021e764a53204000018", "messages": [{"role": "user", "content": "Is Mical an oxidoreductase?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nMical is a protein that is involved in the regulation of the actin cytoskeleton. It is a member of the Wiskott-Aldrich syndrome protein (WASP) family of proteins, which are known to play a role in actin polymerization and the organization of the cytoskeleton. WASP proteins are known to be involved in the activation of the Arp2/3 complex, which is a key regulator of actin polymerization.\n\nThe Arp2/3 complex is a multi-subunit protein complex that is responsible for the nucleation of new actin filaments. It is activated by a variety of proteins, including WASP proteins. WASP proteins are activated by guanine nucleotide exchange factors (GEFs), which exchange GDP for GTP on the WASP protein. This GTP-bound form of WASP is then able to interact with the Arp2/3 complex and activate it.\n\nThe activation of the Arp2/3 complex by WASP proteins is a key step in the regulation of actin polymerization and the organization of the cytoskeleton. This process is essential for many cellular functions, including cell motility, cell division, and endocytosis.\n\nGiven this information, we can conclude that Mical is an oxidoreductase because it is a protein that catalyzes the transfer of electrons from one molecule to another. In the context of the WASP family of proteins, Mical is known to be a guanine nucleotide exchange factor (GEF) that activates WASP proteins by exchanging GDP for GTP. This process involves the transfer of electrons, which is a characteristic of oxidoreductase enzymes.\n\nSo, the answer is A. yes. Mical is an oxidoreductase because it is a protein that catalyzes the transfer of electrons from one molecule to another. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "61fa9a60c9dfcb9c09000007", "messages": [{"role": "user", "content": "Should istiratumab be used for Pancreatic Cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nIstradefylline is a drug that is used to treat Parkinson's disease by inhibiting adenosine A2A receptors. It is not used for the treatment of pancreatic cancer. Pancreatic cancer is typically treated with a combination of surgery, chemotherapy, and radiation therapy, depending on the stage of the disease. Istradefylline is not a standard treatment for pancreatic cancer.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "605b9c2a94d57fd879000035", "messages": [{"role": "user", "content": "Does Amblyopia affect the eye?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nAmblyopia, also known as lazy eye, is a condition where one eye does not develop normal vision during early childhood. It is the most common cause of monocular visual impairment in children. Amblyopia is not a disease of the eye itself but rather a disorder of the visual system, which can affect the eye's ability to see clearly.\n\nAmblyopia is caused by a lack of use or stimulation of the vision in one eye during early childhood, typically before the age of 8. This can be due to several factors, including strabismus (misalignment of the eyes), anisometropia (unequal refractive errors between the eyes), or a cataract in one eye. The brain learns to favor the stronger eye and suppresses the vision from the weaker eye, leading to a permanent reduction in vision in the affected eye.\n\nSo, the answer is A. Yes, Amblyopia can affect the eye by causing a permanent reduction in vision. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "603bc2b61cb411341a00015b", "messages": [{"role": "user", "content": "Is autism thought to be related to the  Arginine Vasopressin Peptide (AVP)?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nAutism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by difficulties in social interaction, verbal and nonverbal communication, and restricted and repetitive behaviors. The exact cause of ASD is not fully understood, but it is believed to involve a combination of genetic and environmental factors.\n\nArginine vasopressin (AVP) is a peptide hormone that is known to play a role in social behavior. It is involved in the regulation of water balance, blood pressure, and social bonding. Studies have shown that individuals with ASD often have altered levels of AVP in their blood and cerebrospinal fluid, which could be related to the social deficits seen in the disorder.\n\nHowever, the relationship between AVP and ASD is not yet fully understood. While there is evidence that AVP may be involved in the social deficits seen in ASD, it is not the only factor considered in the diagnosis or treatment of the disorder. ASD is a complex condition with multiple contributing factors, and AVP is just one of the many areas of research that are being explored to better understand the underlying mechanisms of the disorder.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6278da4456bf9aee6f00000f", "messages": [{"role": "user", "content": "Is thalidomide used as an immunomodulatory drug nowadays?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nThalidomide is a drug that was originally developed as a sedative and antiemetic but was later found to have teratogenic effects, meaning it could cause severe birth defects when taken by pregnant women. It was withdrawn from the market in the 1960s due to these risks.\n\nHowever, in the 1990s, thalidomide was found to have immunomodulatory properties and was used to treat certain conditions such as multiple myeloma and erythema nodosum leprosum. It is also used off-label for other conditions such as Crohn's disease and graft-versus-host disease.\n\nSo, the answer is A. Yes, thalidomide is used as an immunomodulatory drug nowadays. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6278d0a756bf9aee6f00000e", "messages": [{"role": "user", "content": "Does p85\u03b1 homodimerize?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.uncertain\n<|assistant|>\np85\u03b1 is a regulatory subunit of phosphoinositide 3-kinase (PI3K), which is a key enzyme in the PI3K/AKT signaling pathway. PI3K is a heterodimeric enzyme composed of a p110 catalytic subunit and a p85 regulatory subunit. The p85 subunit can exist as a monomer or as a homodimer, which is formed by the association of two p85 subunits. The p85 homodimer is thought to be important for the regulation of PI3K activity and for its interaction with other proteins.\n\nSo, the answer is A. yes. p85\u03b1 can homodimerize. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6276d2d956bf9aee6f000002", "messages": [{"role": "user", "content": "Do angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) increase the likelihood of severe COVID-19?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nThe use of ACE inhibitors and ARBs in patients with COVID-19 has been a topic of debate due to the potential for these medications to affect the renin-angiotensin-aldosterone system (RAAS). The RAAS is involved in the body's response to viral infections, and it is possible that ACE inhibitors and ARBs could alter this response, potentially increasing the risk of severe COVID-19.\n\nHowever, the evidence to support this hypothesis is not conclusive. While some studies have suggested that ACE inhibitors and ARBs may be associated with a higher risk of severe COVID-19, other studies have not found a significant association. Additionally, the ACE2 receptor, which is the target of these medications, is also the receptor that SARS-CoV-2 uses to enter cells, but the exact role of ACE inhibitors and ARBs in this process is not fully understood.\n\nGiven the current state of research, it is difficult to definitively say that ACE inhibitors and ARBs increase the likelihood of severe COVID-19. Some studies suggest a possible association, but the evidence is not conclusive, and further research is needed to fully understand the role of these medications in the context of COVID-19.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6278ddfe56bf9aee6f000013", "messages": [{"role": "user", "content": "Are functional tests a good biomarker for Duchenne Muscular Dystrophy?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nDuchenne Muscular Dystrophy (DMD) is a genetic disorder caused by mutations in the dystrophin gene, which leads to the absence of dystrophin protein. Dystrophin is a protein that helps maintain the integrity of muscle fibers. Without dystrophin, muscle fibers are more susceptible to damage and degeneration.\n\nFunctional tests, such as muscle strength tests, are important in the diagnosis and management of DMD. These tests can help to assess the progression of the disease and the response to treatment. However, they are not a definitive biomarker for DMD because they can be affected by other factors such as age, muscle mass, and overall health.\n\nWhile functional tests are useful in monitoring the disease, they are not a definitive biomarker because they can be influenced by other factors and can change over time. A definitive biomarker would be a test that directly measures the absence of dystrophin or the presence of a specific mutation in the dystrophin gene.\n\nSo, the answer is B. no. Functional tests are not a good biomarker for Duchenne Muscular Dystrophy because they can be influenced by other factors and do not directly measure the underlying genetic defect. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "627926bc56bf9aee6f00001a", "messages": [{"role": "user", "content": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, particularly influenza?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nThe clinical presentation of COVID-19 can overlap with other respiratory illnesses, including influenza. Both COVID-19 and influenza are respiratory illnesses that can cause symptoms such as fever, cough, and shortness of breath. However, there are some key differences that can help distinguish between the two.\n\nOne of the main differences is the incubation period. Influenza typically has a shorter incubation period, usually 1-4 days, while COVID-19 has a longer incubation period, which can range from 2-14 days. This can be helpful in differentiating between the two illnesses, especially in the early stages when symptoms may be similar.\n\nAnother difference is the prevalence of certain symptoms. Influenza is more commonly associated with sudden onset of symptoms, such as fever, chills, and body aches, while COVID-19 can have a more gradual onset and may present with a wider range of symptoms, including gastrointestinal symptoms like diarrhea and loss of taste or smell.\n\nCOVID-19 is also more likely to cause severe respiratory distress and can lead to acute respiratory distress syndrome (ARDS), which is less common in influenza. Additionally, COVID-19 can cause more severe complications, such as multi-organ failure and death, especially in older adults and those with underlying medical conditions.\n\nSo, the answer is yes, there are ways to distinguish COVID-19 from other respiratory illnesses, particularly influenza, but it can be challenging in the early stages when symptoms may be similar. However, the incubation period, symptom presentation, and severity of illness can help guide the diagnosis.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "627a6ef856bf9aee6f000020", "messages": [{"role": "user", "content": "Is lumbar puncture the first test that should be performed on a patient with increased intracranial pressure?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nLumbar puncture (LP) is a procedure that involves inserting a needle into the spinal canal to withdraw cerebrospinal fluid (CSF) for diagnostic purposes. One of the indications for performing an LP is to measure the opening pressure of the CSF, which can provide information about the intracranial pressure (ICP).\n\nWhen a patient presents with symptoms suggestive of increased intracranial pressure, such as headache, nausea, vomiting, and altered mental status, an LP can be used to measure the opening pressure. This can help to confirm the diagnosis and guide further management.\n\nHowever, in some cases, an LP may not be the first test performed. For example, if the patient is unstable or has a contraindication to LP, such as a coagulopathy or a history of spinal surgery, other tests may be performed first. Additionally, in cases where the diagnosis is not immediately clear, other diagnostic tests such as imaging studies (CT or MRI) may be performed before an LP.\n\nSo, the answer is C. Maybe. It depends on the clinical context and the patient's presentation. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "60258ebe1cb411341a0000a8", "messages": [{"role": "user", "content": "Has tocilizumab been assessed against Covid-19?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nTocilizumab is an interleukin-6 (IL-6) receptor antagonist that is used to treat certain autoimmune diseases such as rheumatoid arthritis and systemic juvenile idiopathic arthritis. IL-6 is a cytokine that plays a role in the immune response and is known to be elevated in patients with severe COVID-19. Therefore, there has been interest in using tocilizumab to treat COVID-19, particularly in patients with severe disease.\n\nSeveral studies have been conducted to assess the efficacy of tocilizumab in the treatment of COVID-19. One of the largest studies, the REMAP-CAP trial, found that tocilizumab did not improve survival or reduce the need for mechanical ventilation in patients with severe COVID-19. However, other studies have shown some benefit in reducing the need for mechanical ventilation and improving clinical outcomes in certain patient populations.\n\nGiven the mixed results from the studies, it is difficult to say with certainty whether tocilizumab has been assessed against COVID-19. However, there is a body of evidence that suggests it may have some benefit in certain patient populations, particularly those with severe disease and high levels of IL-6.\n\nSo, the answer is A. yes. Tocilizumab has been assessed against COVID-19, and while the results are not conclusive, there is evidence that it may have some benefit in certain patient populations. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5fdb2e60a43ad3127800000c", "messages": [{"role": "user", "content": "Is the TFR1 gene dispensable for erythropoiesis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nThe TFR1 gene encodes for the transferrin receptor 1, which is a protein that plays a crucial role in iron metabolism. It is expressed on the surface of cells, including erythroblasts, and is responsible for the uptake of iron from transferrin, a protein that transports iron in the blood.\n\nWithout the TFR1 gene, erythroblasts would not be able to take up iron from transferrin, which is essential for the synthesis of hemoglobin. Hemoglobin is the oxygen-carrying protein in red blood cells, and its synthesis requires iron. Therefore, the TFR1 gene is not dispensable for erythropoiesis, as it is crucial for the proper function of erythroblasts and the production of red blood cells.\n\nSo, the answer is B. no. The TFR1 gene is not dispensable for erythropoiesis. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e94aadf0d431b5f73000002", "messages": [{"role": "user", "content": "Is Bcl-2-like protein 1 an pro apoptotic protein?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nBcl-2-like protein 1 (Bcl-xL) is a member of the Bcl-2 family of proteins, which are involved in the regulation of apoptosis (programmed cell death). The Bcl-2 family includes both pro-apoptotic and anti-apoptotic proteins. Bcl-xL is an anti-apoptotic protein, meaning that it inhibits the process of apoptosis. It does this by preventing the release of cytochrome c from the mitochondria, which is a key step in the activation of the caspase cascade and the initiation of apoptosis.\n\nSo, the answer is B. Bcl-2-like protein 1 is not a pro-apoptotic protein. It is an anti-apoptotic protein. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e52c96b6d0a27794100004f", "messages": [{"role": "user", "content": "Glucoraphanin from broccoli can help reduce obesity , yes or no?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "|assistant|>\nGlucoraphanin is a glucosinolate found in cruciferous vegetables like broccoli. When broccoli is chewed or digested, glucoraphanin is converted into sulforaphane, which has been studied for its potential health benefits. One of the areas of interest is its role in weight management.\n\nSulforaphane has been shown to have anti-obesity effects in animal studies. It can increase energy expenditure, reduce fat accumulation, and improve insulin sensitivity. However, the evidence in humans is not as strong. While some studies have shown positive effects on body weight and composition, others have not. The results are mixed, and more research is needed to fully understand the role of sulforaphane in weight management in humans.\n\nGiven the current state of research, it is difficult to say with certainty that glucoraphanin from broccoli can help reduce obesity in humans. While there is some evidence to suggest that sulforaphane may have anti-obesity effects, the results are not conclusive, and more research is needed to determine the full extent of its potential benefits.\n\nSo, the answer is B. no. While glucoraphanin from broccoli may have some potential health benefits, there is not enough evidence to say definitively that it can help reduce obesity in humans. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e6f774ec6a8763d23000009", "messages": [{"role": "user", "content": "Are bacteria in the genus Clostridium facultative anaerobes?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nClostridium is a genus of bacteria that are commonly found in the environment and are known for their ability to produce endospores. These bacteria are often associated with anaerobic conditions, as they can survive and grow in the absence of oxygen. However, some species of Clostridium are also capable of growing in the presence of oxygen, albeit less efficiently.\n\nFacultative anaerobes are organisms that can grow with or without oxygen. They can switch between aerobic and anaerobic respiration depending on the availability of oxygen. While some species of Clostridium are obligate anaerobes, meaning they cannot survive in the presence of oxygen, others are facultative anaerobes, meaning they can survive in both aerobic and anaerobic conditions.\n\nGiven this information, we can conclude that some species of Clostridium are facultative anaerobes, as they can grow in the presence of oxygen, although they may not do so as efficiently as in anaerobic conditions.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5fdb4253a43ad31278000022", "messages": [{"role": "user", "content": "Do nematodes contain architectural proteins like CTCF?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nNematodes are a type of roundworm that can be found in various environments, including soil, water, and even the human body. They are known for their simple body plan and lack of a true body cavity. Nematodes are also known for their small size, with some species being less than 1 millimeter in length.\n\nCTCF (CCCTC-binding factor) is a protein that is known for its role in the organization of chromatin and the regulation of gene expression. It is involved in the formation of topologically associating domains (TADs), which are regions of the genome that are more likely to interact with each other than with other regions. CTCF is also involved in the regulation of gene expression by binding to specific DNA sequences and recruiting other proteins to form transcriptional regulatory complexes.\n\nGiven the complexity of the functions of CTCF and its role in the organization of chromatin and gene regulation, it is unlikely that nematodes would have a protein with the same level of complexity and functionality as CTCF. Nematodes have a relatively simple genome and do not have the same level of gene regulation and chromatin organization as more complex organisms.\n\nSo, the answer is B. no. Nematodes do not contain architectural proteins like CTCF. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6025912a1cb411341a0000aa", "messages": [{"role": "user", "content": "Is tocilizumab a tumor necrosis factor inhibitor?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nTocilizumab is a monoclonal antibody that targets the interleukin-6 receptor (IL-6R), which is involved in the inflammatory response. It is used to treat conditions such as rheumatoid arthritis, giant cell arteritis, and Castleman's disease. Tocilizumab does not directly inhibit tumor necrosis factor (TNF), which is a cytokine that plays a role in inflammation and is targeted by TNF inhibitors like etanercept, adalimumab, and infliximab.\n\nSo, the answer is B. Tocilizumab is not a tumor necrosis factor inhibitor. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e43ee1f48dab47f26000012", "messages": [{"role": "user", "content": "Do circular exons increase gene expression?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nCircular exons are a type of exon that is not linearly arranged along the DNA strand. Instead, they form a closed loop, which can be transcribed into RNA and translated into protein. The presence of circular exons does not necessarily increase gene expression. In fact, circular exons can be challenging to transcribe and translate, as they may not be recognized by the transcription machinery or the ribosome.\n\nHowever, some circular exons may be more efficiently transcribed and translated than linear exons, depending on the specific sequence and structure of the exon. For example, if the circular exon has a sequence that is more easily recognized by the transcription machinery or the ribosome, it could potentially increase gene expression.\n\nSo, the answer is D. It depends. The presence of circular exons can increase or decrease gene expression, depending on the specific sequence and structure of the exon. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e4d6e446d0a27794100002f", "messages": [{"role": "user", "content": "Is MAGE-A3 immunotherapeutic effective for non-small-cell lung cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.uncertain\n<|assistant|>\nMAGE-A3 is a cancer/testis antigen that is expressed in a variety of cancers, including non-small-cell lung cancer (NSCLC). Immunotherapies that target cancer/testis antigens have been explored as potential treatments for various cancers.\n\nA clinical trial (MAGRIT) was conducted to evaluate the efficacy of MAGE-A3 immunotherapeutic in patients with resected stage IB, II, or IIIA NSCLC and no evidence of disease. The trial was designed to assess the ability of the vaccine to prevent recurrence of the disease. However, the trial was stopped early due to futility, meaning that the vaccine did not show a significant benefit in preventing recurrence.\n\nGiven this information, we can conclude that MAGE-A3 immunotherapeutic is not effective for non-small-cell lung cancer, as the clinical trial did not demonstrate a significant benefit.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e94a8250d431b5f73000001", "messages": [{"role": "user", "content": "Does protein ALEX1 contain armadillo repeats?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nProtein ALEX1 is a protein that is involved in the regulation of cell proliferation and differentiation. It is known to interact with other proteins through its N-terminal domain, which contains a series of repeats that are similar to the armadillo repeats found in proteins such as beta-catenin and plakoglobin.\n\nArmadillo repeats are a type of protein domain that is characterized by a specific sequence of amino acids that form a beta-sheet structure. These repeats are often found in proteins that are involved in protein-protein interactions, such as those that mediate cell adhesion or signal transduction.\n\nGiven that ALEX1 is known to interact with other proteins and that it contains a domain with a similar structure to armadillo repeats, it is likely that ALEX1 does contain armadillo repeats.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e3390fafbd6abf43b000060", "messages": [{"role": "user", "content": "Does radiotherapy for cervical cancer increases risk of colon cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nCervical cancer is a type of cancer that affects the cervix, which is the lower part of the uterus that connects to the vagina. Radiotherapy is a common treatment for cervical cancer, and it involves the use of high-energy radiation to kill cancer cells.\n\nThere is a potential risk of secondary cancers, including colon cancer, associated with radiotherapy. This is because radiation can damage DNA and lead to mutations that can cause cancer. However, the risk of developing a secondary cancer after radiotherapy for cervical cancer is relatively low compared to the risk of the primary cancer itself.\n\nThe risk of developing colon cancer after radiotherapy for cervical cancer is estimated to be about 1-2% over a 20-year period. This risk is higher than the general population's risk of developing colon cancer, but it is still relatively low compared to the risk of the primary cancer.\n\nSo, the answer is C. May be. While radiotherapy for cervical cancer does increase the risk of colon cancer, the risk is relatively low and must be weighed against the benefits of treating the primary cancer. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5fe31321a43ad3127800004b", "messages": [{"role": "user", "content": "Is yeast fbp1 affected by glucose starvation stress?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nYeast fbp1 is a gene that encodes for fructose-1,6-bisphosphatase, an enzyme that catalyzes the conversion of fructose-1,6-bisphosphate to fructose-6-phosphate in the gluconeogenesis pathway. This enzyme is important for the production of glucose from non-carbohydrate sources.\n\nWhen yeast cells are subjected to glucose starvation stress, they enter a state of metabolic adaptation known as the diauxic shift. During this shift, yeast cells switch from a fermentative metabolism to a respiratory metabolism. This switch is necessary to allow the cells to survive in the absence of glucose, which is their primary carbon source.\n\nDuring the diauxic shift, yeast cells downregulate the expression of genes involved in glucose metabolism and upregulate the expression of genes involved in the utilization of alternative carbon sources. This includes the upregulation of genes involved in gluconeogenesis, which is the pathway that allows the cells to produce glucose from non-carbohydrate sources.\n\nGiven this information, we can conclude that yeast fbp1 is indeed affected by glucose starvation stress. The expression of fbp1 is increased during the diauxic shift to support the production of glucose from non-carbohydrate sources.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e4b64516d0a277941000029", "messages": [{"role": "user", "content": "Is Semagacestat effective for Alzheimer's Disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nSemagacestat is a gamma-secretase inhibitor that was being investigated as a potential treatment for Alzheimer's disease. Gamma-secretase is an enzyme that is involved in the production of amyloid beta peptides, which are thought to be a key contributor to the pathology of Alzheimer's disease. By inhibiting gamma-secretase, the hope was that the production of amyloid beta peptides would be reduced, thereby slowing the progression of the disease.\n\nHowever, clinical trials of semagacestat were discontinued in 2010 due to the finding that the drug actually increased the risk of developing skin cancer and did not show any significant benefit in slowing cognitive decline in patients with Alzheimer's disease. In fact, the drug seemed to worsen the symptoms of the disease in some patients.\n\nSo, the answer is B. Semagacestat is not effective for Alzheimer's Disease. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e9eba150d431b5f73000005", "messages": [{"role": "user", "content": "Do nematodes contain a CTCF gene?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nCTCF (CCCTC-binding factor) is a protein that plays a crucial role in the regulation of gene expression and chromatin organization. It is known to bind to specific DNA sequences and can influence the three-dimensional structure of the genome. CTCF is involved in the formation of topologically associating domains (TADs), which are regions of the genome that are more likely to interact with each other than with other regions.\n\nNematodes, also known as roundworms, are a diverse group of invertebrate animals that include free-living and parasitic species. They are characterized by a long, cylindrical body and a simple digestive system. While nematodes have been studied extensively for their role in parasitic diseases and as model organisms for developmental biology, there is no direct evidence that they contain a CTCF gene.\n\nThe CTCF gene is well-studied in mammals, where it is known to play a critical role in the regulation of gene expression and chromatin organization. However, there is no clear evidence that nematodes have a homologous gene with the same function. While nematodes do have genes that are involved in chromatin organization and gene regulation, the specific role of CTCF in nematodes has not been established.\n\nSo, the answer is B. no. There is no direct evidence that nematodes contain a CTCF gene. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "60259fe91cb411341a0000b3", "messages": [{"role": "user", "content": "Is tocilizumab a csDMARD?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nTocilizumab is a biologic drug that is used to treat rheumatoid arthritis (RA). It is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, which is involved in the inflammatory process in RA. It is not a conventional synthetic disease-modifying antirheumatic drug (csDMARD) because it is a biologic agent, not a synthetic drug.\n\ncsDMARDs are a class of medications that are used to treat inflammatory arthritis, including RA. They are synthetic drugs that can modify the disease process and slow the progression of joint damage. Examples of csDMARDs include methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide.\n\nTocilizumab, on the other hand, is a biologic drug that works by blocking the action of IL-6, which is a cytokine that plays a role in the inflammatory process in RA. It is not a synthetic drug and is not considered a csDMARD.\n\nSo, the answer is B. Tocilizumab is not a csDMARD. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "601c1a271cb411341a000011", "messages": [{"role": "user", "content": "Can SMAD6 variants cause craniosynostosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nSMAD6 is a member of the SMAD family of proteins, which are involved in the TGF-beta signaling pathway. SMAD6 acts as a negative regulator of TGF-beta signaling by inhibiting the activity of SMAD2 and SMAD3, which are key mediators of TGF-beta signaling.\n\nCraniosynostosis is a condition where one or more of the fibrous joints between the bones of the skull (cranial sutures) close prematurely, causing an abnormal head shape. It is often associated with mutations in genes that are involved in the TGF-beta signaling pathway, including genes that encode for proteins that are part of the pathway.\n\nGiven that SMAD6 is a negative regulator of TGF-beta signaling, mutations in SMAD6 could potentially lead to increased TGF-beta signaling, which could in turn lead to premature closure of cranial sutures. Therefore, SMAD6 variants could potentially cause craniosynostosis.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5fdb4124a43ad31278000017", "messages": [{"role": "user", "content": "Is Tcf3 associated with the Wnt pathway?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.uncertain\n<|assistant|>\nTcf3 is a transcription factor that is part of the Wnt signaling pathway. The Wnt pathway is a complex signaling cascade that is involved in various processes during development and in the maintenance of adult tissues. Tcf3 is a key component of the Wnt pathway, as it acts as a transcriptional repressor when the Wnt pathway is inactive and as a transcriptional activator when the Wnt pathway is active.\n\nWhen the Wnt pathway is inactive, Tcf3 binds to \u03b2-catenin, which is also a key component of the pathway. This binding prevents \u03b2-catenin from entering the nucleus and activating target genes. However, when the Wnt pathway is activated, \u03b2-catenin accumulates in the cytoplasm and then translocates to the nucleus, where it binds to Tcf3 and other transcription factors to activate target genes.\n\nSo, the answer is A. yes. Tcf3 is associated with the Wnt pathway. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e766256835f4e4777000003", "messages": [{"role": "user", "content": "Have the rotavirus vaccines changed the predominant rotavirus genotypes?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nRotavirus vaccines have been in use since the 2000s, and they have had a significant impact on the epidemiology of rotavirus infections. Before the introduction of rotavirus vaccines, rotavirus was the leading cause of severe diarrhea in children worldwide. The vaccines have been shown to be effective in reducing the burden of rotavirus disease, particularly in high-income countries where they are widely used.\n\nOne of the changes that has occurred since the introduction of rotavirus vaccines is a shift in the predominant rotavirus genotypes. Before the vaccines, the most common genotypes were G1, G2, G3, and G4. After the introduction of vaccines, there has been a decrease in the prevalence of these genotypes and an increase in the prevalence of other genotypes, such as G9 and G12. This is because the vaccines are designed to target specific genotypes, and as the vaccines become more widespread, the less common genotypes become more prevalent.\n\nSo, the answer is A. Yes, the rotavirus vaccines have changed the predominant rotavirus genotypes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e323e93fbd6abf43b000059", "messages": [{"role": "user", "content": "Does head ct increase brain tumor risk?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nThe question asks whether head CT (computed tomography) increases the risk of brain tumors. CT scans use ionizing radiation to create images of the body, and ionizing radiation is known to be a carcinogen, meaning it can cause cancer. However, the amount of radiation exposure from a single CT scan is relatively low, and the risk of developing cancer from a single scan is considered to be very small.\n\nThe risk of developing a brain tumor from a single head CT scan is even lower because the brain is relatively protected from radiation by the skull. Additionally, the brain is a relatively radiosensitive organ, so the risk of developing a brain tumor from a single CT scan is lower than the risk of developing a tumor in other parts of the body.\n\nSo, the answer is B. No, head CT does not increase the risk of brain tumors. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e764732c6a8763d23000017", "messages": [{"role": "user", "content": "Can AGY be used as antidiuretic replacement therapy?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.uncertain\n<|assistant|>\nAGY, or arginine vasopressin, is a hormone that is naturally produced by the pituitary gland and is responsible for regulating the body's water balance. It works by increasing the permeability of the kidney's collecting ducts to water, which leads to the reabsorption of water back into the bloodstream, thereby reducing the amount of urine produced.\n\nAntidiuretic replacement therapy is used to treat conditions such as central diabetes insipidus, where the body does not produce enough vasopressin. The synthetic form of vasopressin, desmopressin, is often used for this purpose because it is more selective for the antidiuretic effects and has a longer duration of action compared to AGY.\n\nGiven this information, AGY can be used as antidiuretic replacement therapy, but it is not the preferred choice due to its shorter duration of action and potential for side effects such as vasoconstriction and increased blood pressure.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e323d79fbd6abf43b000058", "messages": [{"role": "user", "content": "Can secondary glioblastoma be caused by brain irradiation?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nSecondary glioblastoma is a type of brain tumor that can develop in patients who have received radiation therapy to the brain. This is because radiation can damage DNA and lead to mutations that can cause cancer. However, the development of secondary glioblastoma is not a certainty after brain irradiation. It is a risk factor, but not a guarantee.\n\nThe risk of developing secondary glioblastoma after brain irradiation is higher in patients who have received a higher dose of radiation, those who have had a longer period of time since the radiation treatment, and those who have a history of certain genetic mutations that can predispose them to cancer.\n\nSo, the answer is C. Maybe. While brain irradiation can increase the risk of secondary glioblastoma, it is not a certainty that it will cause the tumor. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e94902f2d3121100d000012", "messages": [{"role": "user", "content": "Is aggrephagy a variant of autophagy?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nAggrephagy is a process by which cells degrade and recycle aggregated proteins. It is a form of autophagy, which is a process by which cells break down and recycle their own components. Autophagy is a normal process that occurs in all cells and is important for maintaining cellular homeostasis. Aggrephagy is a specific type of autophagy that targets aggregated proteins for degradation.\n\nSo, the answer is A. yes. Aggrephagy is a variant of autophagy. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "601d75281cb411341a000043", "messages": [{"role": "user", "content": "Is there any role of genotoxic pks + E. coli in cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nGenotoxic pks (polyketide synthases) are enzymes that are involved in the synthesis of complex molecules, including many natural products with antibiotic, antifungal, and anticancer properties. These enzymes are found in bacteria, fungi, and plants, and they are responsible for the production of a wide range of secondary metabolites.\n\nOne of the most well-known examples of a genotoxic pks is the enzyme responsible for the production of doxorubicin, a chemotherapy drug used to treat various types of cancer. Doxorubicin is a member of the anthracycline class of antibiotics, which are known for their ability to intercalate into DNA and cause DNA damage, leading to cell death.\n\nWhile genotoxic pks are not directly responsible for causing cancer, they can be used to produce compounds that are used in cancer treatment. These compounds can target and damage cancer cells by interfering with their DNA, which is a common strategy in chemotherapy.\n\nSo, the answer is A. yes. Genotoxic pks do have a role in cancer treatment, as they are involved in the production of drugs that are used to treat cancer. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e44c59848dab47f26000021", "messages": [{"role": "user", "content": "Should tirilazad be used for treatment of ischemic stroke?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.uncertain\n<|assistant|>\nTirilazad is a 21-aminosteroid that was developed as a neuroprotective agent for the treatment of ischemic stroke. It was thought to work by scavenging free radicals and reducing oxidative stress in the brain. However, clinical trials of tirilazad in the treatment of acute ischemic stroke did not show a significant benefit in terms of reducing disability or improving functional outcomes. In fact, the largest trial, the International Stroke Trial, showed a trend towards worse outcomes in patients treated with tirilazad compared to placebo.\n\nGiven the lack of evidence for efficacy and the potential for harm, tirilazad is not recommended for the treatment of ischemic stroke.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e64f11a1af46fc130000017", "messages": [{"role": "user", "content": "Is the Paramyxovirus geneome segmented, negative-sense RNA?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nParamyxoviruses are a family of viruses that includes several important human pathogens, such as measles virus, mumps virus, and respiratory syncytial virus (RSV). They are enveloped viruses with a negative-sense, single-stranded RNA genome. The genome is not segmented, meaning it is a single piece of RNA.\n\nThe genome of paramyxoviruses is negative-sense because it is complementary to the mRNA that is transcribed from it. This means that the genome is not directly translated into proteins; instead, it must be transcribed into mRNA, which is then translated into proteins.\n\nSo, the answer is B. no. The Paramyxovirus genome is not segmented, but it is negative-sense RNA. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "602599251cb411341a0000b1", "messages": [{"role": "user", "content": "Does the use of bDMARDs during pregnancy impact neonatal development?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.may be not\n<|assistant|>\nBiologic disease-modifying antirheumatic drugs (bDMARDs) are a class of medications used to treat autoimmune diseases such as rheumatoid arthritis. These drugs can be used during pregnancy, but there is a risk that they may affect the developing fetus.\n\nThe use of bDMARDs during pregnancy can be associated with an increased risk of congenital malformations, particularly in the first trimester. However, the risk of these drugs to the fetus is not as high as the risk of uncontrolled maternal disease, which can lead to complications such as preterm birth, low birth weight, and other adverse outcomes.\n\nIt is important to weigh the risks and benefits of using bDMARDs during pregnancy, and the decision should be made in consultation with a rheumatologist and a maternal-fetal medicine specialist. The risks and benefits of continuing or discontinuing bDMARDs during pregnancy should be carefully considered, taking into account the severity of the maternal disease and the potential risks to the fetus.\n\nSo, the answer is C. may be. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "601d46d61cb411341a000030", "messages": [{"role": "user", "content": "Do exon 38 or 39 KMT2D missense variants cause Kabuki syndrome type 1 (KS1)?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nKabuki syndrome type 1 (KS1) is a rare genetic disorder characterized by a distinctive facial appearance, intellectual disability, and various other physical abnormalities. The syndrome is caused by mutations in the KMT2D gene, which encodes a histone methyltransferase involved in the regulation of gene expression.\n\nThe KMT2D gene has 50 exons, and mutations in different exons can lead to different phenotypes. However, the majority of mutations associated with KS1 are found in exons 38 and 39. These exons encode a region of the protein that is critical for its function.\n\nGiven that the majority of mutations associated with KS1 are found in exons 38 and 39, it is reasonable to conclude that variants in these exons are likely to cause the syndrome.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "601c4e5e1cb411341a000021", "messages": [{"role": "user", "content": "Is cabergoline used for treatment of the Nelson's syndrome ?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": ".may be used\nD.uncertain\n<|assistant|>\nNelson's syndrome is a condition that occurs after the removal of the pituitary gland or parts of it. It is characterized by the overproduction of adrenocorticotropic hormone (ACTH) by the remaining pituitary tissue, leading to the enlargement of the adrenal glands and the production of excessive amounts of cortisol.\n\nCabergoline is a dopamine agonist that is primarily used to treat hyperprolactinemia, a condition where the body produces too much prolactin, a hormone that stimulates the production of breast milk. It is not typically used for the treatment of Nelson's syndrome.\n\nThe treatment of Nelson's syndrome involves surgical removal of the remaining pituitary tissue or radiation therapy to the pituitary gland. Medical therapy with drugs like cabergoline is not the primary treatment for Nelson's syndrome.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "604903551cb411341a000162", "messages": [{"role": "user", "content": "Are mucins glycosylated proteins?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nMucins are a family of high-molecular-weight glycoproteins that are found in mucous secretions and on the surface of epithelial cells. They are characterized by a highly glycosylated region that is rich in serine, threonine, and proline residues, which serve as attachment sites for O-linked glycans. These glycans are important for the lubricating and protective properties of mucins, as well as for cell-cell and cell-matrix interactions.\n\nGiven this information, the answer is yes, mucins are glycosylated proteins. The glycosylation of mucins is crucial for their function and structure.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "601d73ee1cb411341a00003f", "messages": [{"role": "user", "content": "Is carpal tunnel syndrome a type of nerve entrapment?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nCarpal tunnel syndrome is a condition that affects the median nerve in the wrist. The median nerve provides sensation to the thumb, index finger, middle finger, and part of the ring finger. It also provides motor function to the muscles that control the thumb.\n\nThe carpal tunnel is a narrow passageway in the wrist that protects the median nerve and the tendons that bend the fingers. When the median nerve is compressed or irritated within the carpal tunnel, it can cause symptoms such as numbness, tingling, and weakness in the hand and fingers.\n\nNerve entrapment is a condition where a nerve is compressed or irritated as it passes through a narrow space or is surrounded by tissues that are not normal. Carpal tunnel syndrome is a classic example of nerve entrapment, as the median nerve is compressed within the carpal tunnel.\n\nSo, the answer is A. yes. Carpal tunnel syndrome is a type of nerve entrapment. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "602905e81cb411341a000108", "messages": [{"role": "user", "content": "Is there a link between rare variants in PPARG and type 1 diabetes?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nType 1 diabetes is an autoimmune disease where the body's immune system attacks and destroys the insulin-producing beta cells of the pancreas. This leads to the body's inability to produce insulin, which is necessary to regulate blood sugar levels.\n\nPPARG is a gene that encodes the peroxisome proliferator-activated receptor gamma (PPAR-\u03b3), a nuclear receptor that plays a role in the regulation of glucose and lipid metabolism. Mutations in PPARG are known to cause a condition called familial partial lipodystrophy (FPLD), which is characterized by a loss of adipose tissue and insulin resistance.\n\nWhile there is a link between PPARG mutations and FPLD, there is no direct link between rare variants in PPARG and type 1 diabetes. Type 1 diabetes is primarily an autoimmune disease, and while there are genetic components to it, the mutations that cause type 1 diabetes are not in PPARG.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5fd78702a43ad31278000005", "messages": [{"role": "user", "content": "Does steroid 5A-Reductase deficiency lead to hermaphroditism?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nSteroid 5A-Reductase deficiency is a condition where the enzyme 5A-reductase is not functioning properly. This enzyme is responsible for converting testosterone to dihydrotestosterone (DHT), which is a more potent androgen. In males, DHT is important for the development of the external genitalia during fetal development.\n\nWithout the conversion of testosterone to DHT, the external genitalia of a male fetus may not develop properly. This can lead to a condition known as 5A-Reductase Deficiency Syndrome, which is characterized by ambiguous genitalia at birth. The affected individuals may have a female-appearing external genitalia, but with a small penis and scrotum, and the testes may be located in the inguinal canal or labia majora.\n\nSo, the answer is A. yes. Steroid 5A-Reductase deficiency can lead to hermaphroditism, which is a condition where an individual has both male and female sexual characteristics. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6026db1f1cb411341a0000cf", "messages": [{"role": "user", "content": "Has ubrogepant entered clinical phase III trials?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.not sure\n<|assistant|>\nUbrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that is being developed for the acute treatment of migraine. It is a small molecule that is administered orally and has a rapid onset of action.\n\nThe clinical development of ubrogepant began with phase I trials to assess its safety and pharmacokinetics. Phase II trials were conducted to evaluate its efficacy and safety in the treatment of migraine. Phase III trials are the final stage of clinical trials before a drug is submitted for regulatory approval.\n\nGiven that ubrogepant has already completed phase II trials and is currently in phase III trials, the answer is A. Yes, ubrogepant has entered clinical phase III trials. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6031002d1cb411341a000129", "messages": [{"role": "user", "content": "Are PDXK mutations linked to polyneuropathy?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nPDXK, or pyridoxine (vitamin B6) kinase, is an enzyme that is involved in the metabolism of vitamin B6. Mutations in the PDXK gene can lead to pyridoxine-dependent epilepsy (PDE), a rare genetic disorder characterized by seizures that are controlled by high doses of vitamin B6. However, there is no direct link between PDXK mutations and polyneuropathy, which is a condition affecting the peripheral nerves.\n\nPolyneuropathy can be caused by a variety of conditions, including diabetes, alcoholism, and certain medications. It is not typically associated with PDXK mutations. While vitamin B6 deficiency can lead to neuropathy, this is not due to mutations in the PDXK gene but rather due to a lack of vitamin B6 in the diet or other metabolic issues.\n\nSo, the answer is B. no. PDXK mutations are not linked to polyneuropathy. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "601d76131cb411341a000044", "messages": [{"role": "user", "content": "Is avelumab effective for urothelial carcinoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nAvelumab is a monoclonal antibody that targets the programmed death ligand-1 (PD-L1), which is a protein that helps cancer cells evade the immune system. By blocking PD-L1, avelumab can potentially enhance the immune response against cancer cells.\n\nUrothelial carcinoma, also known as transitional cell carcinoma, is a type of cancer that affects the cells lining the urinary tract. It can occur in the bladder, ureters, or renal pelvis.\n\nAvelumab has been studied in clinical trials for the treatment of urothelial carcinoma, both as a monotherapy and in combination with other treatments. The results of these trials have shown that avelumab can be effective in certain subgroups of patients with urothelial carcinoma, particularly those with high levels of PD-L1 expression on their tumor cells.\n\nSo, the answer is A. Yes, avelumab can be effective for urothelial carcinoma in certain patients. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "601dc46c1cb411341a000050", "messages": [{"role": "user", "content": "Is MIS-C or Multisystem  Inflammatory syndrome in children a complication of Covid-19?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nMultisystem Inflammatory Syndrome in Children (MIS-C) is a condition that has been associated with COVID-19. MIS-C is a rare but serious condition that can occur in children after they have been infected with the virus that causes COVID-19. It is characterized by inflammation of multiple organ systems, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs.\n\nThe symptoms of MIS-C can include fever, abdominal pain, vomiting, diarrhea, neck pain, rash, bloodshot eyes, and feeling very tired. Some children may also have symptoms that are similar to Kawasaki disease, such as changes in their lips and tongue, and swollen glands in their neck.\n\nWhile MIS-C is not a direct complication of COVID-19, it is believed to be associated with the body's immune response to the virus. Children who have had COVID-19 or been exposed to someone with COVID-19 are at an increased risk of developing MIS-C. However, not all children who have had COVID-19 will develop MIS-C, and not all cases of MIS-C are linked to COVID-19.\n\nGiven the information, the answer is C. MIS-C may be a complication of COVID-19, but it is not a direct complication. It is a condition that can occur after a child has been infected with the virus that causes COVID-19, but it is not a direct result of the infection itself. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6020010a1cb411341a00007c", "messages": [{"role": "user", "content": "Is co-loss of BRCA2-RB1 associated with better prognosis for prostate cancer patients?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nBRCA2 and RB1 are both tumor suppressor genes. BRCA2 is known to be involved in DNA repair, particularly in homologous recombination, and RB1 is involved in cell cycle regulation. The loss of both of these genes in the same individual could potentially lead to a more aggressive form of cancer due to the combined effects of the loss of DNA repair and cell cycle control.\n\nIn the context of prostate cancer, the loss of BRCA2-RB1 could lead to a more aggressive form of the disease because the loss of BRCA2 would impair DNA repair, and the loss of RB1 would lead to uncontrolled cell division. This combination could result in a more rapid progression of the cancer and a worse prognosis.\n\nHowever, it's important to note that this is a complex issue and the exact impact of co-loss of BRCA2-RB1 on prostate cancer prognosis is not well established. There may be other factors that influence the prognosis of prostate cancer in individuals with this genetic profile.\n\nSo, the answer is C. May be. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6028ffae1cb411341a000106", "messages": [{"role": "user", "content": "Does erenumab target the calcitonin gene-related peptide?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nErenumab is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. CGRP is a neuropeptide that is involved in the pathophysiology of migraine. By targeting the CGRP receptor, erenumab can prevent the activation of the receptor and thus reduce the symptoms of migraine.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "601c44ab1cb411341a00001c", "messages": [{"role": "user", "content": "Can radiosurgery be used for the DNET tumors?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nDNET (dysembryoplastic neuroepithelial tumor) is a type of brain tumor that typically occurs in children and young adults. It is characterized by seizures and can be associated with cognitive and behavioral problems. The treatment for DNETs often involves surgical resection, which is the preferred treatment option when possible.\n\nRadiosurgery is a form of radiation therapy that delivers a high dose of radiation to a small area of the brain. It is often used for brain tumors that are inoperable or for tumors that cannot be completely removed surgically. However, DNETs are typically benign and can often be treated with surgery alone, making radiosurgery less common for this type of tumor.\n\nGiven that DNETs are often benign and can be treated with surgery alone, radiosurgery is not typically the first-line treatment for these tumors. However, in cases where surgery is not feasible or when there is a high risk of recurrence, radiosurgery may be considered as an adjunctive treatment.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6026754f1cb411341a0000c8", "messages": [{"role": "user", "content": "Should minocycline be used for mild Alzheimer disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nMinocycline is an antibiotic that has been studied for its potential to reduce inflammation and oxidative stress, which are thought to be involved in the pathogenesis of Alzheimer's disease (AD). However, the evidence for its use in AD is not conclusive.\n\nA 2018 meta-analysis of randomized controlled trials found that minocycline did not significantly improve cognitive function in patients with mild to moderate AD. While some studies have shown promising results, the overall evidence is not strong enough to recommend minocycline as a treatment for AD.\n\nGiven the current state of research, it is unlikely that minocycline should be used for mild Alzheimer disease.\n\nSo, the answer is D. unlikely. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "60290a131cb411341a000109", "messages": [{"role": "user", "content": "Is there an association of alterations in ADCY7 and ulcerative colitis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nUlcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that affects the colon and rectum. It is characterized by inflammation and ulceration of the mucosal lining of the colon. The pathogenesis of UC is complex and involves both genetic and environmental factors.\n\nThe ADCY7 gene encodes for adenylate cyclase 7, which is involved in the regulation of intracellular cyclic AMP levels. Cyclic AMP is a second messenger that plays a role in various cellular processes, including cell proliferation and differentiation. Alterations in the ADCY7 gene have been associated with several diseases, including congenital heart defects, obesity, and cancer.\n\nWhile there is some evidence that genetic factors may contribute to the development of UC, the specific role of ADCY7 in the pathogenesis of UC is not well established. There is no strong evidence to suggest a direct association between alterations in ADCY7 and ulcerative colitis.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "604906ed1cb411341a000163", "messages": [{"role": "user", "content": "Are mucin overexpression associated with disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nMucins are a family of glycoproteins that are found in the mucus that lines the surfaces of many organs in the body. They are important for protecting the epithelial surfaces from mechanical and chemical damage, as well as for lubrication and protection against pathogens.\n\nIn the context of disease, mucin overexpression can be associated with certain conditions. For example, in some cancers, such as colorectal cancer, mucin overexpression can be a marker of malignancy and can be used as a diagnostic tool. In other cases, such as in chronic obstructive pulmonary disease (COPD), mucin overexpression can be a sign of inflammation and can contribute to the pathophysiology of the disease.\n\nSo, the answer is A. yes. Mucin overexpression is associated with disease in certain contexts. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6025fdf41cb411341a0000c0", "messages": [{"role": "user", "content": "Should nerinetide be used for treatment of ischaemic stroke?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nNerinetide is a recombinant form of the naturally occurring peptide neuromedin N. It is a neuroprotective agent that has been studied for the treatment of acute ischaemic stroke. The rationale behind its use is that it can protect the brain from the effects of ischaemia by inhibiting the release of glutamate, a neurotransmitter that can be toxic to neurons when released in excess.\n\nHowever, the results of clinical trials have been mixed. While some studies have shown a benefit in terms of improved neurological outcomes, others have not. The largest trial, the NINDS tPA Stroke Study, which included 1,000 patients, found that nerinetide did not improve outcomes compared to placebo when given within 6 hours of stroke onset.\n\nGiven the current evidence, it is not clear whether nerinetide should be used for the treatment of ischaemic stroke. While it may have some neuroprotective effects, the lack of consistent positive results in clinical trials makes it difficult to recommend its use as a standard treatment.\n\nSo, the answer is B. No, nerinetide should not be used for the treatment of ischaemic stroke based on the current evidence. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6026de661cb411341a0000d1", "messages": [{"role": "user", "content": "Are there small molecule CGRPs under development for the treatment of migraine?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.not sure\n<|assistant|>\nCGRP (calcitonin gene-related peptide) is a neuropeptide that is involved in the pathophysiology of migraine. CGRP is released from trigeminal nerve endings during a migraine attack and contributes to the pain and other symptoms associated with migraine. In recent years, there has been a significant focus on developing CGRP receptor antagonists as a treatment for migraine.\n\nSeveral small molecule CGRP receptor antagonists have been developed and are currently in various stages of clinical trials. These include rimegepant, ubrogepant, and atogepant, among others. These drugs work by blocking the CGRP receptor, which reduces the inflammatory response and pain associated with migraine.\n\nSo, the answer is A. Yes, there are small molecule CGRP receptor antagonists under development for the treatment of migraine. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6026ee821cb411341a0000d3", "messages": [{"role": "user", "content": "Is eptinezumab a small molecule?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nEptinezumab is a monoclonal antibody that is used to prevent migraine headaches. It works by inhibiting the calcitonin gene-related peptide (CGRP) receptor, which is involved in the pathophysiology of migraine. Monoclonal antibodies are large molecules that are produced by a single clone of cells and are not considered small molecules.\n\nSmall molecules are typically less than 1,000 daltons in size and are often used in drug development because they can be easily absorbed and distributed throughout the body. They are also more stable and can be administered orally, which is not the case for monoclonal antibodies.\n\nSo, the answer is B. Eptinezumab is not a small molecule. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "60324b771cb411341a000139", "messages": [{"role": "user", "content": "Is the apilimod inhibitor effective against SARS-CoV-2?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nApilimod is an inhibitor of the enzyme phosphatidylinositol 3-kinase (PI3K), which is involved in the activation of the immune system. It is used to treat autoimmune diseases such as lupus and rheumatoid arthritis.\n\nSARS-CoV-2, the virus that causes COVID-19, does not directly infect immune cells. Instead, it primarily infects epithelial cells in the respiratory tract. The immune response to the virus is critical for controlling the infection and preventing severe disease.\n\nApilimod is not known to have a direct antiviral effect against SARS-CoV-2. It is not a drug that is used to treat COVID-19. Therefore, the answer is no, apilimod is not effective against SARS-CoV-2.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "602673e91cb411341a0000c7", "messages": [{"role": "user", "content": "Is Lanabecestat effective for Alzheimer's disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nLanabecestat is a beta-secretase inhibitor that was being developed as a potential treatment for Alzheimer's disease. Beta-secretase is an enzyme that is involved in the production of amyloid beta peptides, which are thought to be a key contributor to the pathology of Alzheimer's disease. By inhibiting beta-secretase, lanabecestat was hoped to reduce the production of amyloid beta peptides and thus slow the progression of the disease.\n\nHowever, in 2018, the clinical trials for lanabecestat were discontinued due to a lack of efficacy. The trials showed that lanabecestat did not slow the progression of Alzheimer's disease and did not improve cognitive function in patients. This means that lanabecestat is not effective for the treatment of Alzheimer's disease.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "601c46f61cb411341a00001d", "messages": [{"role": "user", "content": "Was golimumab tested for diabetes?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nGolimumab is a biologic medication used to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is a tumor necrosis factor (TNF) inhibitor, which works by blocking the action of TNF, a protein that is involved in the inflammatory response.\n\nDiabetes is not a known side effect of golimumab. In fact, golimumab is not typically associated with the development of diabetes. However, it is important to note that TNF inhibitors, including golimumab, have been associated with the development of new-onset diabetes in patients with rheumatoid arthritis. This is a rare side effect, and the risk is generally considered to be low.\n\nGiven that golimumab is a TNF inhibitor, it is possible that it could have been tested for diabetes as a potential side effect. However, the primary focus of golimumab's clinical trials and subsequent use has been on its efficacy in treating inflammatory conditions, not on its potential to cause diabetes.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "604fc22894d57fd879000008", "messages": [{"role": "user", "content": "Is G3BP1 found in stress granules?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nG3BP1, also known as Ras-GAP SH3 domain-binding protein 1, is a protein that is involved in the regulation of the Ras signaling pathway. It is also known to be a component of stress granules, which are cytoplasmic aggregates that form in response to cellular stress.\n\nStress granules are dynamic structures that form in response to various types of cellular stress, including heat shock, oxidative stress, and viral infection. They are composed of untranslated messenger RNAs (mRNAs) and proteins that are involved in mRNA metabolism, translation, and stress response. G3BP1 is one of the proteins that is found in stress granules, where it plays a role in the assembly and disassembly of these structures.\n\nSo, the answer is A. yes. G3BP1 is found in stress granules. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5fdb4290a43ad31278000024", "messages": [{"role": "user", "content": "Do polycomb group proteins (PcG) mediate the formation of chromatin loops?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nPolycomb group proteins (PcG) are a family of proteins that are involved in the regulation of gene expression by modifying chromatin structure. They are known to be involved in the maintenance of gene silencing and the repression of developmental genes.\n\nOne of the mechanisms by which PcG proteins are thought to function is by forming chromatin loops. Chromatin loops are structures that bring together distant regions of DNA, allowing for the regulation of gene expression. PcG proteins are known to bind to specific DNA sequences and recruit other proteins that can modify chromatin structure, including histone modifications that can lead to the formation of chromatin loops.\n\nSo, the answer is A. yes. PcG proteins are known to mediate the formation of chromatin loops. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5fe31319a43ad31278000046", "messages": [{"role": "user", "content": "Can ATAC-Seq be employed in single-cell mode?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nATAC-Seq (Assay for Transposase-Accessible Chromatin using Sequencing) is a technique used to identify regions of open chromatin in cells. It involves transposase enzymes that randomly cut the DNA at accessible sites, followed by sequencing to identify the locations of these cuts. This technique is typically used to study the epigenetic landscape of cells, including the identification of enhancer regions and other regulatory elements.\n\nATAC-Seq can be performed on single cells, which is a powerful approach for studying the heterogeneity of chromatin accessibility within a population of cells. This is particularly useful for studying cell types that are difficult to isolate or for which there is a limited amount of starting material.\n\nSo, the answer is A. yes. ATAC-Seq can be employed in single-cell mode. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5fdb42fba43ad31278000027", "messages": [{"role": "user", "content": "Are there negative enhancers?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nNegative enhancers are DNA sequences that can inhibit the expression of a gene or a group of genes. They can do this by binding to transcription factors or other regulatory proteins that would normally activate gene expression, but instead, they prevent the activation of the gene. This can be achieved through various mechanisms, such as blocking the binding of transcription factors to their target sites or by recruiting proteins that repress transcription.\n\nNegative enhancers are important in the regulation of gene expression, as they can help to fine-tune the expression of genes in response to different cellular conditions. For example, in the case of a gene that is normally expressed at a high level, a negative enhancer can be used to reduce its expression in certain contexts, such as when the cell is under stress or in a different developmental stage.\n\nSo, the answer is A. Yes, there are negative enhancers. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5fdb42b7a43ad31278000025", "messages": [{"role": "user", "content": "Are super enhancers structurally insulated in chromatin loops?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nSuper enhancers are regions of the genome that are particularly important for gene regulation. They are characterized by the presence of multiple transcription factor binding sites that work together to enhance the expression of nearby genes. These regions are often associated with genes that are critical for cell identity and function.\n\nOne of the key features of super enhancers is that they are often located in regions of open chromatin, which is more accessible to transcription factors and other regulatory proteins. This accessibility is important for the binding of transcription factors and the subsequent activation of gene expression.\n\nHowever, super enhancers are not necessarily insulated from the rest of the genome. In fact, they are often located in regions of the genome that are highly active and accessible, which means that they can interact with other regions of the genome through chromatin loops. These loops can bring distal regulatory elements into close proximity with their target genes, allowing for the coordinated regulation of gene expression.\n\nSo, the answer is C. Maybe. Super enhancers are not structurally insulated in the sense that they are completely isolated from the rest of the genome. Instead, they are often part of a larger chromatin landscape that allows for interactions with other regions of the genome through chromatin loops. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6060e1a094d57fd879000049", "messages": [{"role": "user", "content": "Does IL18 signaling have a role in thymus?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nIL18 (interleukin 18) is a pro-inflammatory cytokine that plays a role in the immune response. It is known to be involved in the activation of T cells, natural killer cells, and macrophages. IL18 is also involved in the production of interferon-gamma (IFN-gamma), which is a key cytokine in the immune response.\n\nThe thymus is a primary lymphoid organ where T cells mature and differentiate. T cells are crucial for the adaptive immune response, and their development and function are tightly regulated. While IL18 is known to be involved in the activation of T cells, it is not directly involved in the development of T cells in the thymus. Instead, IL18 is more involved in the activation of mature T cells and their effector functions.\n\nSo, the answer is B. No, IL18 signaling does not have a direct role in the development of the thymus. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "601c18921cb411341a00000f", "messages": [{"role": "user", "content": "Does an antiphlogistic promotes inflammation?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.unlikely\n<|assistant|>\nAn antiphlogistic is a substance that reduces inflammation. Inflammation is a natural response of the body to injury or infection, and it is characterized by redness, swelling, pain, and sometimes loss of function. Antiphlogistics are often used to treat inflammatory conditions such as arthritis, gout, and other musculoskeletal disorders.\n\nHowever, it is important to note that not all substances that reduce inflammation are antiphlogistics. For example, nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of medications that reduce inflammation, but they are not antiphlogistics because they do not directly promote inflammation.\n\nSo, the answer is B. no. An antiphlogistic does not promote inflammation. It reduces inflammation. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6020ad161cb411341a000082", "messages": [{"role": "user", "content": "Is liraglutide effective for weight reduction?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nLiraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that is used for the treatment of type 2 diabetes. It is also approved for weight management in adults with a body mass index (BMI) of 30 kg/m^2 or greater, or a BMI of 27 kg/m^2 or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia.\n\nLiraglutide has been shown to be effective for weight reduction in clinical trials. In one study, participants who received liraglutide lost an average of 8.5% of their body weight compared to 2.6% in the placebo group. The drug is also associated with a reduction in waist circumference and an improvement in other metabolic parameters such as blood pressure and lipid levels.\n\nSo, the answer is A. yes. Liraglutide is effective for weight reduction. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6020b0e21cb411341a000085", "messages": [{"role": "user", "content": "Is Eflornithine and Sulindac are effective for prevention of progression in Familial Adenomatous Polyposis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nFamilial Adenomatous Polyposis (FAP) is a genetic condition characterized by the development of hundreds to thousands of adenomatous polyps in the colon and rectum, which can lead to colorectal cancer if not treated. The goal of treatment in FAP is to prevent the development of colorectal cancer.\n\nEflornithine is an antiparasitic drug that has been studied for its potential role in the prevention of colorectal cancer in FAP. It works by inhibiting ornithine decarboxylase, an enzyme involved in polyamine synthesis, which is thought to be important in the growth of polyps. However, the results of clinical trials have been mixed, and the drug is not currently recommended for the prevention of colorectal cancer in FAP.\n\nSulindac is a nonsteroidal anti-inflammatory drug (NSAID) that has also been studied for its potential role in the prevention of colorectal cancer in FAP. It works by inhibiting cyclooxygenase enzymes, which are involved in the production of prostaglandins, which are thought to promote the growth of polyps. Sulindac has shown some promise in reducing the number of polyps in FAP patients, but it is not a cure and is not recommended as a sole treatment for FAP due to the risk of side effects and the need for long-term use.\n\nGiven the current state of research, it is not clear that either eflornithine or sulindac are effective for the prevention of progression in Familial Adenomatous Polyposis. While they may have some potential, they are not considered standard treatments and are not widely recommended for this purpose.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "602498cb1cb411341a00009e", "messages": [{"role": "user", "content": "Is Olaparib effective for prostate cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nOlaparib is a PARP inhibitor, which is a class of drugs that are used to treat certain types of cancer. PARP inhibitors work by blocking the activity of an enzyme called poly(ADP-ribose) polymerase, which is involved in the repair of DNA damage. When PARP is inhibited, cells with DNA damage accumulate and eventually die.\n\nProstate cancer is not typically treated with PARP inhibitors. PARP inhibitors are more commonly used in the treatment of ovarian, breast, and other cancers that have BRCA mutations or other DNA repair deficiencies. These cancers are more sensitive to PARP inhibitors because they rely heavily on the PARP pathway for DNA repair.\n\nSo, the answer is B. Olaparib is not effective for prostate cancer. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6025fd261cb411341a0000bf", "messages": [{"role": "user", "content": "Is isradipine effective for Parkinson's disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nIsradipine is a calcium channel blocker that is used to treat high blood pressure and angina. It works by relaxing the blood vessels, which helps to lower blood pressure and improve blood flow.\n\nParkinson's disease is a neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra, leading to motor symptoms such as tremor, rigidity, and bradykinesia. There is no cure for Parkinson's disease, and the treatment is focused on managing symptoms.\n\nWhile calcium channel blockers like isradipine can be used to treat hypertension, there is no evidence that they are effective for the treatment of Parkinson's disease. In fact, some studies have suggested that calcium channel blockers may worsen Parkinson's disease symptoms by reducing the amount of dopamine available in the brain.\n\nSo, the answer is B. no. Isradipine is not effective for Parkinson's disease. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6026c1071cb411341a0000cb", "messages": [{"role": "user", "content": "Is MK-1602 a CGRP antagonist?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nMK-1602 is a drug that has been studied for its potential to treat migraine headaches. It is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP), which is a neuropeptide that is thought to play a role in the pathophysiology of migraine. By binding to CGRP, MK-1602 is believed to prevent the activation of CGRP receptors, thereby reducing the symptoms of migraine.\n\nGiven this information, we can conclude that MK-1602 is indeed a CGRP antagonist. It works by blocking the activity of CGRP, which is consistent with the definition of an antagonist.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6027dc011cb411341a0000eb", "messages": [{"role": "user", "content": "Does inactivation of CYLD help in colorectal cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.unlikely\n<|assistant|>\nColorectal cancer is a common type of cancer that affects the colon or rectum. The development of colorectal cancer is a complex process that involves the accumulation of genetic mutations in cells that lead to uncontrolled cell growth and division. One of the genes that has been implicated in the development of colorectal cancer is CYLD.\n\nCYLD is a tumor suppressor gene that encodes a protein that functions as a deubiquitinating enzyme. It is involved in the regulation of the NF-\u03baB signaling pathway, which is important for the immune response and inflammation. Mutations in CYLD can lead to the activation of the NF-\u03baB pathway, which can promote the growth of tumors.\n\nInactivation of CYLD, therefore, could potentially contribute to the development of colorectal cancer by allowing the NF-\u03baB pathway to remain active and promote tumor growth. However, the exact role of CYLD inactivation in colorectal cancer is not fully understood, and there is not yet conclusive evidence that inactivation of CYLD is a primary driver of colorectal cancer.\n\nGiven the current state of knowledge, we can say that inactivation of CYLD may help in colorectal cancer, but the evidence is not definitive.\n\nSo, the answer is C. may be. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "60290c2b1cb411341a00010a", "messages": [{"role": "user", "content": "Is there high nucleotide diversity in the Drosophila suzukii species?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nNucleotide diversity is a measure of the genetic variation within a population. It is calculated by comparing the DNA sequences of individuals within a species and measuring the number of nucleotide differences between them. The more nucleotide diversity there is, the greater the genetic variation within the population.\n\nDrosophila suzukii is a species of fruit fly that has become a significant pest in recent years due to its ability to infest a wide range of fruits. It is native to Asia but has spread to other parts of the world, including North America and Europe. Given that it is a relatively new invasive species, it is likely that there is a high degree of genetic variation within the population, as it has not had as much time to adapt to its new environments and may still be in the process of adapting.\n\nSo, the answer is A. Yes, there is high nucleotide diversity in the Drosophila suzukii species. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "60327e541cb411341a00013e", "messages": [{"role": "user", "content": "Is Hunter's disease is associated with the X Chromosome?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.uncertain\n<|assistant|>\nHunter's disease, also known as mucopolysaccharidosis type II (MPS II), is a lysosomal storage disease caused by a deficiency in the enzyme iduronate-2-sulfatase. This enzyme is responsible for breaking down glycosaminoglycans (GAGs), which are long chains of sugar molecules that are found in the extracellular matrix and on the surfaces of cells.\n\nThe gene that encodes for iduronate-2-sulfatase is located on the X chromosome. Since males have only one X chromosome, they are more likely to develop Hunter's disease if they inherit a defective copy of the gene. Females, on the other hand, have two X chromosomes, so they can be carriers of the disease without showing symptoms themselves.\n\nGiven this information, we can conclude that Hunter's disease is associated with the X chromosome because the gene responsible for the disease is located on that chromosome.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "60328f351cb411341a000145", "messages": [{"role": "user", "content": "Can Freund's complete adjuvant induce arthritis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nFreund's complete adjuvant (FCA) is a mixture of mineral oil and an emulsifier, usually used to enhance the immune response to antigens. It is commonly used in research to induce an immune response in animals, such as in the development of vaccines.\n\nOne of the well-known effects of FCA is its ability to induce arthritis in animals. This is due to the presence of mycobacterial components in the adjuvant, which can trigger an autoimmune response leading to the development of arthritis. This is a common model used to study the pathogenesis of rheumatoid arthritis in animals.\n\nSo, the answer is A. Yes, Freund's complete adjuvant can induce arthritis. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "603291f21cb411341a000146", "messages": [{"role": "user", "content": "Can saponins be used as adjuvant?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nSaponins are a class of natural compounds found in many plants, including some that are used in traditional medicine. They are known for their foaming properties and are often used as detergents or surfactants. In the context of medicine, saponins have been studied for their potential as adjuvants, which are substances that enhance the immune response to a vaccine.\n\nSaponins have been shown to have immunostimulatory properties, which could potentially make them useful as adjuvants. They have been used in some vaccines, such as the inactivated polio vaccine, and have been shown to enhance the immune response to the vaccine.\n\nHowever, the use of saponins as adjuvants is not without controversy. Some studies have raised concerns about their safety, particularly when used in high doses or in combination with other adjuvants. Additionally, the use of saponins as adjuvants is not as widespread as other adjuvants like aluminum salts or oil emulsions.\n\nSo, the answer is A. Yes, saponins can be used as adjuvants, but their use is not without potential risks and is not as common as other adjuvants. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "603bc16b1cb411341a000158", "messages": [{"role": "user", "content": "Is erabutoxin b usually found in plants?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nErabutoxin b is a toxin found in the venom of the sea snake Erabuena. It is a neurotoxin that binds to the acetylcholine receptor and inhibits its function, leading to muscle paralysis. It is not typically found in plants, as plants do not produce toxins that target the acetylcholine receptor.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "603285861cb411341a000141", "messages": [{"role": "user", "content": "Are Toll-like receptors (TLRs) induced by microbes?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nTLRs are a family of proteins that play a critical role in the innate immune response. They are found on the surface of immune cells and recognize pathogen-associated molecular patterns (PAMPs), which are molecular structures that are unique to pathogens and not found in the host. When a TLR binds to a PAMP, it triggers a signaling cascade that leads to the activation of immune cells and the production of inflammatory mediators.\n\nTLRs are not induced by microbes themselves; rather, they are present on immune cells and are ready to recognize and respond to microbial molecules. The induction of TLRs is a process that occurs during the development of the immune system and is not directly related to the presence of microbes.\n\nSo, the answer is B. no. TLRs are not induced by microbes; they are already present on immune cells and are ready to recognize and respond to microbial molecules. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "603e43d51cb411341a00015e", "messages": [{"role": "user", "content": "Is Ixodes a species of tick?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nIxodes is a genus of ticks, which are arachnids that feed on the blood of mammals, birds, and sometimes reptiles. Ticks are known for transmitting diseases to their hosts, including Lyme disease, Rocky Mountain spotted fever, and tick-borne encephalitis. The genus Ixodes includes several species that are important vectors of these diseases.\n\nSo, the answer is A. yes. Ixodes is a species of tick. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "60367f5e1cb411341a000157", "messages": [{"role": "user", "content": "Is HbA1c an ideal biomarker of well-controlled diabetes?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nHbA1c (glycated hemoglobin) is a measure of the average blood glucose concentration over the previous 2-3 months. It is used as a biomarker to assess long-term glycemic control in individuals with diabetes. A well-controlled diabetes is typically defined as an HbA1c level below 7% (53 mmol/mol) for most adults with type 1 or type 2 diabetes.\n\nHowever, HbA1c has some limitations as a biomarker. It does not provide information about short-term glucose control, which can be important for managing acute complications of diabetes. Additionally, HbA1c can be affected by factors such as hemoglobinopathies, anemia, and certain medications, which can lead to inaccurate readings.\n\nDespite these limitations, HbA1c is still considered a valuable biomarker for assessing long-term glycemic control in diabetes. It is a simple and reliable test that can be used to monitor the effectiveness of treatment and to adjust therapy as needed.\n\nSo, the answer is A. yes. HbA1c is an ideal biomarker of well-controlled diabetes because it provides a long-term average of blood glucose levels and is a standard measure used to assess diabetes management. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6057003594d57fd879000020", "messages": [{"role": "user", "content": "Are the major royal jelly proteins similar to the yellow proteins?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nRoyal jelly is a substance produced by worker honey bees to feed the larvae and the queen bee. It is rich in proteins, vitamins, minerals, and sugars. The major royal jelly proteins (MRJPs) are a group of proteins that make up a significant portion of royal jelly.\n\nThe yellow proteins are a group of proteins found in the venom of bees and wasps. They are responsible for the pain and swelling associated with bee and wasp stings. These proteins are not the same as the major royal jelly proteins.\n\nSo, the answer is B. The major royal jelly proteins are not similar to the yellow proteins. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6057014c94d57fd879000022", "messages": [{"role": "user", "content": "Is the Apis mellifera genome available?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nApis mellifera, commonly known as the honey bee, is a species of bee that is well-studied due to its economic and scientific importance. The honey bee is a social insect that lives in colonies with a complex social structure and division of labor. It is also a model organism for studying the evolution of eusociality and the genetics of social behavior.\n\nThe genome of Apis mellifera was sequenced in 2006 by an international consortium of scientists. The genome is available to researchers and can be accessed through various databases, such as the National Center for Biotechnology Information (NCBI) and the European Nucleotide Archive (ENA). The genome sequence is a valuable resource for studying the biology of honey bees and other social insects.\n\nSo, the answer is A. yes. The Apis mellifera genome is available. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "60570af094d57fd879000025", "messages": [{"role": "user", "content": "Has the olive tree pollen proteome been studied?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nOlive trees are known for their high pollen production, which can cause allergic reactions in some individuals. The pollen of olive trees contains a variety of proteins that can be allergenic. However, the specific proteome of olive tree pollen has not been extensively studied.\n\nWhile there have been some studies that have analyzed the proteins present in olive pollen, they are not as comprehensive as the proteome studies that have been conducted for other allergenic plants such as ragweed or birch. The proteome of a plant refers to the entire set of proteins that are produced by the plant, and it is a complex and dynamic system that can change depending on various factors such as the plant's growth stage, environmental conditions, and the presence of pathogens or pests.\n\nGiven the importance of olive pollen as an allergen and the potential for new allergens to be discovered, it would be beneficial to have a more complete understanding of the proteome of olive tree pollen. This would allow for a more comprehensive analysis of the allergenic potential of olive pollen and could lead to the development of better diagnostic tools and treatments for those who suffer from olive pollen allergies.\n\nSo, the answer is B. no. The olive tree pollen proteome has not been studied in a comprehensive manner. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6060c7c094d57fd879000046", "messages": [{"role": "user", "content": "Is cadherin a plasma membrane marker?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nCadherins are a family of calcium-dependent cell adhesion proteins that are found in the plasma membrane of cells. They are involved in the formation of cell-cell adhesion and are important for maintaining tissue structure and function. Cadherins are transmembrane proteins, which means they have a portion that is embedded in the plasma membrane and a portion that extends into the cytoplasm of the cell. The extracellular domain of cadherins is responsible for binding to other cadherins on adjacent cells, while the intracellular domain interacts with the cytoskeleton and signaling molecules within the cell.\n\nGiven this information, it is clear that cadherins are indeed plasma membrane markers. They are integral membrane proteins that are located in the plasma membrane and play a crucial role in cell-cell adhesion.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5fe31304a43ad3127800003a", "messages": [{"role": "user", "content": "Is methotrexate used for the treatment of Rheumatoid Arthritis (RA)?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nMethotrexate is a disease-modifying antirheumatic drug (DMARD) commonly used in the treatment of rheumatoid arthritis (RA). It is one of the first-line treatments for RA and is often used in combination with other DMARDs or biologic agents. Methotrexate works by reducing the activity of the immune system, which helps to slow the progression of RA and reduce symptoms such as joint pain and swelling.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "605e3c8294d57fd879000037", "messages": [{"role": "user", "content": "Is atenolol metabolized by CYP2D6?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.uncertain\n<|assistant|>\nAtenolol is a beta-blocker that is used to treat high blood pressure and other heart conditions. It is a substrate of the cytochrome P450 (CYP) enzyme system, specifically CYP2D6. CYP2D6 is a major enzyme involved in the metabolism of many drugs, including atenolol.\n\nWhen a drug is metabolized by CYP2D6, it means that the drug is broken down into smaller, more water-soluble compounds that can be excreted from the body. This process is important because it helps to eliminate the drug from the body and prevents it from accumulating to toxic levels.\n\nGiven that atenolol is metabolized by CYP2D6, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "606b3b6794d57fd879000064", "messages": [{"role": "user", "content": "Is the glucocorticoid receptor a transcription factor?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nGlucocorticoids are a class of steroid hormones that are known to have a wide range of effects on the body, including anti-inflammatory, immunosuppressive, and metabolic effects. The glucocorticoid receptor (GR) is a protein that is found in the cytoplasm of cells and is activated by glucocorticoids. Once activated, the GR translocates to the nucleus, where it binds to specific DNA sequences called glucocorticoid response elements (GREs) and regulates the expression of genes involved in various physiological processes.\n\nThe GR is a transcription factor because it binds to DNA and regulates the expression of genes. It does this by either activating or repressing the transcription of specific genes, depending on the context. This is a classic example of a transcription factor, which is a protein that binds to DNA and regulates the expression of genes.\n\nSo, the answer is A. yes. The glucocorticoid receptor is a transcription factor. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "601fff6a1cb411341a00007b", "messages": [{"role": "user", "content": "Are there sex differences in oncogenic mutational processes?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nThe question asks about sex differences in oncogenic mutational processes, which refers to the genetic changes that occur in cells that lead to the development of cancer. These mutations can be caused by various factors, including environmental exposures, lifestyle choices, and genetic predisposition.\n\nWhile there is some evidence that certain types of cancer may have a higher incidence in one sex compared to the other, the underlying genetic mechanisms that drive these cancers are not necessarily sex-specific. For example, breast cancer is more common in women, but the genetic mutations that lead to its development are not unique to women.\n\nHowever, there are some sex-specific differences in the risk factors for certain cancers. For example, prostate cancer is more common in men, and the risk factors for this cancer include age, family history, and certain genetic mutations. Similarly, ovarian cancer is more common in women, and the risk factors include age, family history, and certain genetic mutations.\n\nSo, while there are sex differences in the incidence of certain cancers, the underlying oncogenic mutational processes are not necessarily sex-specific. Therefore, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "606a232a94d57fd87900004c", "messages": [{"role": "user", "content": "Is metoprolol metabolized by CYP2D6?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nMetoprolol is a beta-blocker used to treat high blood pressure, heart failure, and certain heart rhythm disorders. It works by blocking the action of certain natural chemicals in the body, such as epinephrine, on the heart and blood vessels. This action results in the lowering of blood pressure, heart rate, and strain on the heart.\n\nNow, let's consider the metabolism of metoprolol. Metoprolol is primarily metabolized by the cytochrome P450 (CYP) enzyme system, specifically by CYP2D6. This enzyme is responsible for the metabolism of many drugs, including metoprolol. The metabolism of metoprolol by CYP2D6 can lead to the formation of two active metabolites, which contribute to the overall pharmacological effect of the drug.\n\nGiven this information, we can conclude that metoprolol is metabolized by CYP2D6.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "60292e1b1cb411341a000111", "messages": [{"role": "user", "content": "Does Curare function by stimulating the acetylcholine receptor?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nCurare is a plant-derived compound that is a potent neuromuscular blocking agent. It is used in medicine as a muscle relaxant and in research to study the neuromuscular junction. Curare works by binding to the acetylcholine receptor on the postsynaptic muscle membrane, preventing the binding of acetylcholine and thus blocking the transmission of nerve impulses to the muscle.\n\nThe acetylcholine receptor is a ligand-gated ion channel that opens when acetylcholine binds to it. Curare does not stimulate the acetylcholine receptor; instead, it blocks the receptor, preventing the binding of acetylcholine and thereby inhibiting the muscle contraction that would normally occur when acetylcholine is released at the neuromuscular junction.\n\nSo, the answer is B. Curare does not function by stimulating the acetylcholine receptor; it functions by blocking it. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5fdb2ee4a43ad3127800000f", "messages": [{"role": "user", "content": "Are somatic mutations positioned towards the nuclear periphery?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nSomatic mutations are genetic changes that occur in cells after conception. These mutations can affect the function of genes and can lead to the development of diseases such as cancer. One of the key features of cancer cells is their ability to proliferate uncontrollably, which is often due to mutations in genes that regulate cell growth and division.\n\nNow, let's consider the question of whether somatic mutations are positioned towards the nuclear periphery. The nuclear periphery refers to the area of the nucleus that is closest to the nuclear envelope. The nuclear envelope is a double membrane that surrounds the nucleus and separates it from the cytoplasm. The nuclear periphery is known to be a region where certain types of chromatin are found, including heterochromatin, which is a highly condensed form of DNA that is typically associated with gene silencing.\n\nThere is some evidence that suggests that certain types of somatic mutations, particularly those that occur in cancer cells, may be more likely to occur in the nuclear periphery. This is because the nuclear periphery is a region where the chromatin is more compact and less accessible to DNA repair mechanisms. This can lead to a higher rate of mutations in this area.\n\nHowever, it's important to note that this is not a universal phenomenon and that somatic mutations can occur throughout the genome, not just at the nuclear periphery.\n\nSo, the answer is A. yes, somatic mutations can be positioned towards the nuclear periphery, but this is not a universal characteristic of all somatic mutations. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6020ab801cb411341a000081", "messages": [{"role": "user", "content": "Is belimumab effective for the lupus nephritis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nBelimumab is a monoclonal antibody that targets the B lymphocyte stimulator (BLyS), which is a protein that plays a role in the activation and survival of B cells. Belimumab is approved for the treatment of systemic lupus erythematosus (SLE), including lupus nephritis, which is a common and serious complication of SLE that involves inflammation of the kidneys.\n\nStudies have shown that belimumab can reduce disease activity and improve kidney function in patients with lupus nephritis. In a randomized controlled trial, belimumab was found to be effective in reducing the risk of renal flare and improving renal response in patients with active lupus nephritis. Additionally, belimumab has been shown to reduce the need for dialysis and kidney transplants in patients with lupus nephritis.\n\nSo, the answer is A. Yes, belimumab is effective for the lupus nephritis. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5fdb4311a43ad31278000028", "messages": [{"role": "user", "content": "Are enhancers directional in their targeting of gene promoters?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nEnhancers are regulatory DNA sequences that can be found upstream or downstream of a gene, or even within the gene itself. They are typically involved in the regulation of gene expression, often by binding to transcription factors that can then activate or repress the transcription of the gene.\n\nThe directionality of enhancer action is a matter of debate. Some studies suggest that enhancers can act in a directional manner, meaning that they can only influence the expression of a gene in one direction, either upstream or downstream. This is because enhancers can be oriented in a specific direction relative to the gene they regulate, and they may only be able to influence the expression of the gene in the direction they are facing.\n\nHowever, other studies suggest that enhancers can act in a non-directional manner, meaning that they can influence the expression of a gene in both directions, upstream and downstream. This is because enhancers can interact with the promoter of a gene in either direction, and they can also influence the expression of genes that are located further away from them.\n\nGiven the conflicting evidence, it is difficult to say with certainty whether enhancers are directional in their targeting of gene promoters. Some studies suggest that they can be directional, while others suggest that they can be non-directional. Therefore, the answer is \"maybe.\" Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "606b718994d57fd87900006b", "messages": [{"role": "user", "content": "Has dupilumab been FDA approved for atopic dermatitis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nDupilumab is a monoclonal antibody that targets the interleukin-4 (IL-4) receptor alpha subunit. It is used to treat atopic dermatitis (AD), also known as eczema, in adults and adolescents aged 12 years and older. The FDA approved dupilumab for the treatment of moderate-to-severe AD in 2017.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6025dd0c1cb411341a0000b9", "messages": [{"role": "user", "content": "Should cerebrolysin be used for aneurysmal subarachnoid hemorrhage?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nCerebrolysin is a drug that is derived from pig brain and is used as a neuroprotective agent. It is thought to have neurotrophic and neuroprotective effects, and it is used in the treatment of various neurological conditions, including stroke, traumatic brain injury, and Alzheimer's disease.\n\nHowever, there is no clear evidence that cerebrolysin is effective in the treatment of aneurysmal subarachnoid hemorrhage (aSAH). In fact, a randomized controlled trial (RCT) conducted in 2010 found that cerebrolysin did not improve outcomes in patients with aSAH. The trial was stopped early due to futility, meaning that the drug was not shown to be effective.\n\nGiven the lack of evidence for the efficacy of cerebrolysin in aSAH, it is not recommended for use in this condition.\n\nSo, the answer is B. No, cerebrolysin should not be used for aneurysmal subarachnoid hemorrhage. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "603213ea1cb411341a000131", "messages": [{"role": "user", "content": "Do bacteria release extracellular vesicles?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nExtracellular vesicles (EVs) are small membrane-bound structures that are released by cells into the extracellular space. They can be found in various bodily fluids and are known to carry a variety of molecules, including proteins, lipids, and nucleic acids. While EVs are commonly associated with eukaryotic cells, they can also be released by prokaryotic cells, including bacteria.\n\nBacteria have been shown to release extracellular vesicles, which are often referred to as outer membrane vesicles (OMVs) in the context of bacterial cells. These vesicles are thought to play a role in intercellular communication, the transfer of virulence factors, and the delivery of toxins to host cells. They can also be used as a means of horizontal gene transfer between bacteria.\n\nSo, the answer is A. Yes, bacteria release extracellular vesicles. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6025ddde1cb411341a0000ba", "messages": [{"role": "user", "content": "Is Tranexamic acid effective for intracerebral haemorrhage?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.unsure\n<|assistant|>\nTranexamic acid is an antifibrinolytic agent that is commonly used to reduce bleeding in various clinical settings. It works by inhibiting the breakdown of fibrin clots, which can help to stabilize bleeding.\n\nIntracerebral hemorrhage (ICH) is a type of stroke caused by bleeding into the brain tissue. The primary treatment for ICH is to control the bleeding and reduce the risk of further hemorrhage. While there is no specific treatment that can reverse the effects of ICH, controlling the bleeding is crucial to prevent further damage to the brain.\n\nTranexamic acid has been studied in the context of ICH, and while the results are not conclusive, there is some evidence to suggest that it may be beneficial. A randomized controlled trial (RESTART) found that tranexamic acid was associated with a reduction in death or disability at 6 months in patients with ICH. However, other studies have not shown a significant benefit.\n\nGiven the current state of research, it is difficult to definitively say that tranexamic acid is effective for ICH. However, there is some evidence to suggest that it may be beneficial, and further research is ongoing to determine its true efficacy.\n\nSo, the answer is C. may be. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "60490dc71cb411341a000167", "messages": [{"role": "user", "content": "Are interferons defensive proteins?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nInterferons are a group of signaling proteins produced by cells in response to the presence of several viruses, bacteria, parasites, and other pathogens. They are part of the innate immune system and are involved in the antiviral state of cells, which helps to protect the body from viral infections.\n\nInterferons are not considered defensive proteins in the same way that antibodies or complement proteins are. They are not directly involved in the destruction of pathogens or the neutralization of toxins. Instead, they act as messengers between cells, alerting them to the presence of a pathogen and triggering a cascade of events that lead to the activation of the immune system.\n\nSo, the answer is B. Interferons are not defensive proteins. They are signaling proteins that help to coordinate the immune response. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "60354a7b1cb411341a000154", "messages": [{"role": "user", "content": "Do honey contain diastases/amylases?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nHoney is a natural sweetener made by bees from the nectar of flowers. It is a complex mixture of sugars, including glucose, fructose, and sucrose, as well as other compounds such as enzymes, minerals, and amino acids. However, honey does not contain diastases or amylases, which are enzymes that break down starch into sugars.\n\nDiastases are enzymes that are found in malt and are used in the brewing industry to convert starch into fermentable sugars. Amylases are enzymes that break down starch into sugars, and they are commonly used in the food industry to convert starch into glucose for use in various products.\n\nSince honey is not made from starch, it does not contain diastases or amylases. Instead, honey contains enzymes that are naturally present in the nectar and are responsible for the transformation of nectar into honey, such as invertase, which converts sucrose into glucose and fructose.\n\nSo, the answer is B. No, honey does not contain diastases or amylases. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "601ecab41cb411341a000065", "messages": [{"role": "user", "content": "Is adenosine signaling prognostic for cancer outcome?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nAdenosine is a signaling molecule that plays a role in various physiological processes, including the immune response. In the context of cancer, adenosine can be produced by tumor cells and can have both pro-tumorigenic and anti-tumorigenic effects.\n\nOn the one hand, adenosine can promote tumor growth and metastasis by inhibiting the immune response. It does this by binding to adenosine receptors on immune cells, which can lead to the suppression of T-cell activity and the promotion of tumor cell survival and proliferation.\n\nOn the other hand, adenosine can also have anti-tumorigenic effects by inhibiting angiogenesis and promoting apoptosis in tumor cells. This is because adenosine can bind to receptors on endothelial cells, which can lead to the inhibition of blood vessel growth, and it can also bind to receptors on tumor cells, which can induce cell death.\n\nGiven these dual effects, it is difficult to say that adenosine signaling is prognostic for cancer outcome in general. The effects of adenosine signaling on cancer progression can vary depending on the specific tumor type, the adenosine receptor expression profile, and the local microenvironment.\n\nSo, the answer is D. It depends. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e67cd6b1af46fc13000001e", "messages": [{"role": "user", "content": "Does AZD3759 cross the blood brain barrier?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nAZD3759 is a drug that is being developed as a potential treatment for glioblastoma, a type of brain cancer. The effectiveness of a drug in treating brain cancer depends on its ability to cross the blood-brain barrier (BBB), which is a protective barrier that prevents most substances from entering the brain. The BBB is composed of endothelial cells that form tight junctions and are highly selective in what they allow to pass through.\n\nTo be effective in treating brain cancer, a drug must be able to cross the BBB. AZD3759 is a small molecule inhibitor of the epidermal growth factor receptor (EGFR), which is overexpressed in many glioblastoma tumors. In order for AZD3759 to reach the tumor cells in the brain, it must be able to cross the BBB.\n\nThere is no definitive answer to the question of whether AZD3759 crosses the BBB, as this information is not publicly available. However, given that AZD3759 is being developed as a treatment for brain cancer, it is likely that the drug has been tested for its ability to cross the BBB and that it does, at least to some extent, in order to be effective.\n\nSo, the answer is A. yes. AZD3759 is likely to cross the blood-brain barrier to some extent in order to be effective in treating glioblastoma. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5fe0c141a43ad31278000035", "messages": [{"role": "user", "content": "Is the zelda transcription factor a chromatin remodeller?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nThe Zelda transcription factor is a key regulator of the maternal-to-zygotic transition (MZT) in Drosophila melanogaster. During the MZT, the maternal transcripts are degraded and the zygotic genome is activated. Zelda is known to bind to the promoters of zygotic genes and activate their transcription.\n\nZelda is a member of the high mobility group (HMG) family of DNA-binding proteins. It contains an HMG box domain that is involved in DNA binding and bending. This domain is also found in other chromatin remodelling factors, such as the SWI/SNF complex, which is known to remodel chromatin structure to facilitate transcription.\n\nHowever, the primary function of Zelda is not to directly remodel chromatin. Instead, it acts as a transcription factor that binds to specific DNA sequences and recruits other factors that can remodel chromatin. For example, Zelda recruits the Brahma complex, which is a chromatin remodelling complex, to the promoters of zygotic genes.\n\nSo, while Zelda is not a direct chromatin remodeller, it does play a critical role in the activation of zygotic genes by recruiting chromatin remodelling complexes.\n\nSo, the answer is B. no. Zelda is not a chromatin remodeller itself, but it does recruit chromatin remodelling complexes to the promoters of zygotic genes. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6025db0e1cb411341a0000b8", "messages": [{"role": "user", "content": "Is capmatinib effective for glioblastoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nCapmatinib is a tyrosine kinase inhibitor that is used to treat non-small cell lung cancer. It is not typically used for the treatment of glioblastoma, which is a type of brain cancer. Glioblastoma is often treated with chemotherapy, radiation therapy, and surgery, and targeted therapies like capmatinib are not commonly used in this context.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6057151094d57fd879000027", "messages": [{"role": "user", "content": "Are there antimicrobial proteins in royal jelly?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nRoyal jelly is a substance produced by worker honey bees to feed the larvae and the queen bee. It is known for its nutritional and medicinal properties, and it has been used in traditional medicine for various purposes, including as an anti-inflammatory, antioxidant, and antimicrobial agent.\n\nThere are several studies that have investigated the antimicrobial properties of royal jelly. One study found that royal jelly has a broad spectrum of antimicrobial activity against various bacteria, including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Another study showed that royal jelly has antifungal activity against Candida albicans, a common cause of fungal infections.\n\nGiven this evidence, it is reasonable to conclude that royal jelly does contain antimicrobial proteins that can help protect against various pathogens.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6025e2641cb411341a0000bb", "messages": [{"role": "user", "content": "Can thiotepa be recommended for treatment of osteosarcoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nThiotepa is an alkylating agent that is used in the treatment of various types of cancer, including osteosarcoma. It is often used in combination with other chemotherapy drugs as part of a multi-agent chemotherapy regimen for osteosarcoma.\n\nOsteosarcoma is a type of bone cancer that typically affects children and young adults. The standard treatment for osteosarcoma includes surgery to remove the tumor and chemotherapy to kill any remaining cancer cells. Chemotherapy regimens for osteosarcoma often include multiple drugs, and thiotepa is one of the agents that may be used.\n\nSo, the answer is A. yes. Thiotepa can be recommended for treatment of osteosarcoma as it is a standard part of the chemotherapy regimen for this type of cancer. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "601db7fb1cb411341a00004a", "messages": [{"role": "user", "content": "Does a comet assay measure radiation induced mutations?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nA comet assay, also known as the single-cell gel electrophoresis assay, is a technique used to measure DNA damage in individual cells. It is often used to assess the effects of genotoxic agents, including radiation, on DNA. The assay involves embedding cells in agarose gel, lysing the cells to release the DNA, and then subjecting the DNA to an electric field. The DNA is then visualized under a microscope, and the extent of damage can be quantified by measuring the length of the \"comet tail,\" which is the DNA that has been broken and has migrated away from the nucleus.\n\nWhen cells are exposed to radiation, it can cause DNA damage, including single- and double-strand breaks, which are detectable by the comet assay. Therefore, the comet assay can be used to measure radiation-induced mutations, as mutations are often the result of DNA damage that is not repaired properly.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "606c017294d57fd879000076", "messages": [{"role": "user", "content": "Has the companion diagnostic HercepTest received FDA approval?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C. pending\n<|assistant|>\nThe HercepTest is a companion diagnostic test that is used to determine the presence of the HER2 protein in breast cancer cells. This protein is a target for certain types of breast cancer treatments, such as Herceptin (trastuzumab), which is a monoclonal antibody that targets the HER2 protein.\n\nThe FDA has approved the use of the HercepTest as a companion diagnostic for breast cancer. The test is used to determine whether a patient's breast cancer cells overexpress the HER2 protein, which is a marker for certain types of breast cancer that are more likely to respond to HER2-targeted therapies.\n\nSo, the answer is A. yes. The HercepTest has received FDA approval as a companion diagnostic for breast cancer. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6033f5541cb411341a00014c", "messages": [{"role": "user", "content": "Is phosphoenolpyruvate carboxykinase 1 (PCK1) the rate-limiting enzyme in gluconeogenesis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nGluconeogenesis is the process by which glucose is synthesized from non-carbohydrate precursors in the liver and kidneys. This process is important for maintaining blood glucose levels during periods of fasting or starvation, when glycogen stores are depleted.\n\nPhosphoenolpyruvate carboxykinase (PCK1) is a key enzyme in gluconeogenesis. It catalyzes the conversion of oxaloacetate to phosphoenolpyruvate, which is a precursor for glucose synthesis. However, the rate-limiting step in gluconeogenesis is not always the same.\n\nIn the liver, the rate-limiting step in gluconeogenesis is often considered to be the conversion of pyruvate to phosphoenolpyruvate, which is catalyzed by pyruvate carboxylase. This is because pyruvate carboxylase is the first enzyme in the pathway that is not also part of glycolysis, and it is the step that commits pyruvate to the gluconeogenic pathway rather than glycolysis.\n\nHowever, in the kidneys, the rate-limiting step may be different. In the kidneys, the conversion of oxaloacetate to phosphoenolpyruvate by PCK1 may be the rate-limiting step, as the kidney has a lower activity of pyruvate carboxylase compared to the liver.\n\nSo, the answer is that PCK1 is not always the rate-limiting enzyme in gluconeogenesis, but it can be in certain tissues or under certain conditions.\n\nSo, the answer is C. maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "605265ee94d57fd87900000d", "messages": [{"role": "user", "content": "Has FTY720  been considered for the treatment of stroke?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nFTY720, also known as fingolimod, is a medication used to treat multiple sclerosis (MS). It works by modulating the immune system, which is believed to be involved in the pathogenesis of MS. FTY720 is a sphingosine 1-phosphate receptor modulator that acts as an agonist at S1P1 receptors, which are involved in the egress of lymphocytes from lymph nodes and other secondary lymphoid organs. By binding to these receptors, FTY720 reduces the number of circulating lymphocytes, which is thought to be beneficial in the treatment of MS.\n\nWhile FTY720 has not been specifically studied for the treatment of stroke, it is not typically considered for this purpose. Stroke is a neurological event caused by a disruption in the blood supply to the brain, leading to the death of brain cells. FTY720 is not a treatment for stroke, as it does not address the underlying cause of stroke, which is a vascular event.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6081af3c4e6a4cf630000008", "messages": [{"role": "user", "content": "Is colistin an antibiotic?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nColistin is an antibiotic. It is a polymyxin antibiotic that is used to treat infections caused by gram-negative bacteria. It works by binding to the bacterial cell membrane, causing it to become more permeable and allowing the contents of the cell to leak out. This leads to the death of the bacteria.\n\nColistin is particularly useful in treating infections caused by multidrug-resistant (MDR) bacteria, including those that are resistant to other antibiotics. It is often used as a last resort when other antibiotics have failed.\n\nSo, the answer is A. yes. Colistin is an antibiotic. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "602e84e61cb411341a000126", "messages": [{"role": "user", "content": "Is Tocilizumab (Actemra) used to block/antagonize the  IL-6 receptor?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nTocilizumab is a monoclonal antibody that binds to the interleukin-6 (IL-6) receptor and inhibits its activity. IL-6 is a cytokine that plays a role in inflammation and is involved in the pathogenesis of various autoimmune diseases. By blocking the IL-6 receptor, tocilizumab can reduce inflammation and improve symptoms in conditions such as rheumatoid arthritis, giant cell arteritis, and Castleman's disease.\n\nSo, the answer is A. yes. Tocilizumab is used to block the IL-6 receptor. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5cebe41ea49efeb44c000006", "messages": [{"role": "user", "content": "Is the process of DNA loop-extrusion independent of ATP?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nDNA loop-extrusion is a process by which DNA is extruded from the nucleus into the cytoplasm. This process is thought to be important for the regulation of gene expression and the organization of chromatin. It is believed to be mediated by a class of proteins called chromatin remodelers, which use the energy from ATP hydrolysis to alter the structure of chromatin.\n\nATP is a key source of energy for many cellular processes, including DNA replication, transcription, and chromatin remodeling. Chromatin remodelers, such as the SWI/SNF complex, use the energy from ATP hydrolysis to move DNA strands and alter the structure of chromatin. This process is essential for the proper regulation of gene expression and the maintenance of chromatin structure.\n\nGiven this information, it is clear that the process of DNA loop-extrusion is not independent of ATP. ATP is required for the energy-dependent activity of chromatin remodelers, which are necessary for the extrusion of DNA from the nucleus.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6060df1e94d57fd879000047", "messages": [{"role": "user", "content": "Is there an upper limit on the functional fraction of the human genome?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nThe human genome is the complete set of genetic material in a human cell. It is estimated that the human genome contains approximately 3 billion base pairs of DNA, which encode the genetic information necessary for the development and functioning of the human body. However, not all of this DNA is functional; some of it is non-coding, meaning it does not directly code for proteins or other functional products.\n\nThe functional fraction of the human genome is the portion of the genome that is actively transcribed into RNA and/or translated into proteins. This fraction is estimated to be around 1.5% to 2% of the total genome. This means that the vast majority of the human genome is not actively transcribed or translated, and therefore is not directly involved in the production of proteins or other functional products.\n\nSo, the answer is A. Yes, there is an upper limit on the functional fraction of the human genome. The upper limit is around 2% of the total genome, which is the portion that is actively transcribed and translated. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "601ec5661cb411341a000063", "messages": [{"role": "user", "content": "Is SLIC-CAGE used for quantification of translation?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nSLIC-CAGE (Serial Analysis of Gene Expression) is a technique used to quantify gene expression levels in a sample. It involves the isolation of mRNA from cells, followed by reverse transcription to cDNA, and then amplification of the cDNA using PCR. The amplified cDNA is then sequenced, and the resulting data is analyzed to determine the relative abundance of different transcripts in the sample.\n\nThe technique is not specifically used for quantification of translation, which is the process by which mRNA is converted into protein. Translation is typically quantified using methods such as ribosome profiling or polysome profiling, which measure the amount of ribosomes bound to mRNA, or the amount of protein produced, respectively.\n\nSo, the answer is B. SLIC-CAGE is not used for quantification of translation. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "6025fa371cb411341a0000be", "messages": [{"role": "user", "content": "Does hypofractionated radiotherapy offers any benefit for DIPG?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.unlikely\n<|assistant|>\nDiffuse intrinsic pontine glioma (DIPG) is a highly aggressive brainstem tumor that primarily affects children. The standard treatment for DIPG is radiation therapy, which is typically given in a fractionated manner over several weeks. Hypofractionated radiotherapy is a form of radiation therapy that delivers a higher dose of radiation in fewer fractions, compared to conventional fractionated radiotherapy.\n\nThe rationale for using hypofractionated radiotherapy in DIPG is to potentially improve the efficacy of radiation therapy by delivering a higher dose of radiation in a shorter time frame. This approach is based on the idea that DIPG cells may be more sensitive to a higher dose of radiation delivered in a shorter time period, which could lead to improved tumor control.\n\nHowever, there is limited evidence to support the use of hypofractionated radiotherapy in DIPG. While some studies have shown promising results, the data is not conclusive, and further research is needed to determine the optimal radiation therapy regimen for DIPG.\n\nGiven the current state of knowledge, it is not possible to definitively say that hypofractionated radiotherapy offers a benefit for DIPG. While it may be a promising approach, more research is needed to confirm its efficacy.\n\nSo, the answer is C. may be. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "601d72e61cb411341a000039", "messages": [{"role": "user", "content": "Is progeria caused by an autosomal recessive gene?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.uncertain\n<|assistant|>\nProgeria, also known as Hutchinson-Gilford Progeria Syndrome (HGPS), is a rare genetic disorder that causes children to age rapidly. The condition is characterized by a premature aging process that begins in childhood and leads to the appearance of aging features such as baldness, wrinkled skin, and atherosclerosis (hardening of the arteries) at a very young age.\n\nThe genetic mutation responsible for HGPS is a point mutation in the LMNA gene, which encodes for lamin A, a protein that helps maintain the structure of the cell nucleus. This mutation leads to the production of a truncated form of lamin A, called progerin, which is toxic to cells and causes the symptoms of progeria.\n\nThe mutation is not inherited in an autosomal recessive pattern. Instead, it is a de novo mutation, which means it occurs spontaneously in the affected individual and is not inherited from either parent. This is because the mutation is not located on a sex chromosome and is not inherited in a recessive manner.\n\nSo, the answer is B. No, progeria is not caused by an autosomal recessive gene. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "601d73c71cb411341a00003e", "messages": [{"role": "user", "content": "Is acupotomy used to treat muscle stiffness?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nAcupotomy is a form of acupuncture that involves the use of a needle to cut through connective tissue and muscle fibers. The goal of acupotomy is to release adhesions and scar tissue, which can lead to muscle stiffness and pain. By cutting through these adhesions, the acupuncturist aims to improve the range of motion and reduce pain.\n\nSo, the answer is A. Yes, acupotomy is used to treat muscle stiffness. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "60234bd51cb411341a000093", "messages": [{"role": "user", "content": "Is ofatumumab effective for multiple sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nOfatumumab is a monoclonal antibody that targets CD20, a protein found on the surface of B cells. It is used to treat certain types of leukemia and lymphoma. However, it is not typically used for the treatment of multiple sclerosis (MS).\n\nMS is an autoimmune disease where the immune system attacks the central nervous system, leading to inflammation and damage to the myelin sheath that protects nerve fibers. The primary treatment for MS is to manage the symptoms and slow the progression of the disease. This is typically done with disease-modifying therapies, which include medications that can reduce the frequency of relapses and slow the progression of disability.\n\nOfatumumab is not one of the approved disease-modifying therapies for MS. The medications that are approved for the treatment of MS include interferons, glatiramer acetate, natalizumab, dimethyl fumarate, teriflunomide, and others. These medications work by different mechanisms to reduce the immune system's attack on the central nervous system.\n\nSo, the answer is B. no. Ofatumumab is not effective for multiple sclerosis. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "60206bae1cb411341a00007d", "messages": [{"role": "user", "content": "Is there a role for Dickkopf-1 (DKK1) in prostate cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nDickkopf-1 (DKK1) is a protein that is known to play a role in the Wnt signaling pathway. The Wnt signaling pathway is involved in various cellular processes, including cell proliferation, differentiation, and apoptosis. In the context of cancer, the Wnt pathway can be dysregulated, leading to uncontrolled cell growth and tumor formation.\n\nIn prostate cancer, the Wnt pathway is often hyperactivated, which can contribute to the growth and progression of the disease. DKK1 is a negative regulator of the Wnt pathway, meaning that it inhibits the signaling pathway. Therefore, in prostate cancer, where the Wnt pathway is already hyperactive, DKK1 could potentially act as a tumor suppressor by inhibiting the Wnt pathway further.\n\nHowever, there is some evidence that DKK1 may also have pro-tumorigenic effects in certain contexts. For example, in some studies, DKK1 has been shown to promote the growth of prostate cancer cells by inhibiting the production of osteoprotegerin, which is a protein that can inhibit tumor growth.\n\nGiven the conflicting evidence, it is difficult to say definitively whether DKK1 has a role in prostate cancer. Some studies suggest that it may have a tumor suppressive role, while others suggest it may have a pro-tumorigenic role. Therefore, the answer is \"maybe.\"\n\nSo, the answer is C. maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "602c28551cb411341a000123", "messages": [{"role": "user", "content": "Has AZD9668 been tested in clinical trials?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.uncertain\n<|assistant|>\nAZD9668 is a drug that was developed by AstraZeneca as a potential treatment for asthma and chronic obstructive pulmonary disease (COPD). It is a selective phosphodiesterase 4 (PDE4) inhibitor, which means it works by inhibiting the enzyme PDE4, which is involved in the breakdown of cyclic adenosine monophosphate (cAMP). By inhibiting PDE4, AZD9668 increases the levels of cAMP in the airways, which can help to relax smooth muscle and reduce inflammation.\n\nClinical trials for AZD9668 were conducted in the early 2000s, but the drug was discontinued due to safety concerns. In particular, there were reports of serious liver toxicity in patients taking AZD9668. This led to the termination of the clinical trials and the drug's development was halted.\n\nSo, the answer is B. no. AZD9668 has not been tested in clinical trials since the safety concerns were raised. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5fdb415ba43ad31278000019", "messages": [{"role": "user", "content": "Is Nanog repressed in pluripotent stem cells?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nNanog is a transcription factor that is essential for the maintenance of pluripotency in embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). It is part of a regulatory network that includes Oct4 and Sox2, which together form the core transcription factors that define the pluripotent state.\n\nIn pluripotent stem cells, Nanog is not repressed. In fact, it is highly expressed and plays a critical role in maintaining the undifferentiated state. It helps to regulate the expression of genes that are important for self-renewal and pluripotency, and it also helps to repress genes that are associated with differentiation.\n\nSo, the answer is A. Yes, Nanog is not repressed in pluripotent stem cells. It is highly expressed and plays a key role in maintaining the pluripotent state. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6060e03394d57fd879000048", "messages": [{"role": "user", "content": "Are synonymous sites in primates and rodents functionally constrained?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nSynonymous sites are those that do not change the amino acid sequence of a protein because they are located in non-coding regions of the DNA or in regions that do not affect the protein's function. In evolutionary terms, synonymous sites are considered to be \"neutral\" because they do not affect the fitness of an organism.\n\nIn primates and rodents, synonymous sites are often thought to be functionally constrained because they are subject to natural selection. This is because even though they do not directly affect the protein's function, they can still be under selection if they affect other aspects of the gene's expression or regulation, such as splicing, mRNA stability, or translation efficiency.\n\nSo, the answer is A. Yes, synonymous sites in primates and rodents are functionally constrained. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6027f7171cb411341a0000ec", "messages": [{"role": "user", "content": "Is there a role for TFII-I in megakaryopoiesis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nTFII-I is a transcription factor that is known to play a role in the regulation of gene expression in various cell types. It is involved in the transcription of genes that are important for cell growth, differentiation, and survival.\n\nIn the context of megakaryopoiesis, which is the process of megakaryocyte development and maturation, TFII-I has been shown to be essential for the proliferation and differentiation of megakaryocyte progenitors. It is known to regulate the expression of genes that are critical for megakaryocyte development, such as those involved in platelet production and function.\n\nGiven the importance of TFII-I in the regulation of megakaryocyte development, it is reasonable to conclude that it does have a role in megakaryopoiesis.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "604915581cb411341a00016a", "messages": [{"role": "user", "content": "Is YKL-40 used as a biomarker for Alzheimer's disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nYKL-40, also known as chitinase-3-like protein 1 (CHI3L1), is a glycoprotein that is produced by a variety of cells, including macrophages, fibroblasts, and endothelial cells. It has been implicated in various inflammatory and fibrotic processes.\n\nIn the context of Alzheimer's disease (AD), YKL-40 has been studied as a potential biomarker. Some studies have shown that YKL-40 levels are elevated in the cerebrospinal fluid (CSF) of patients with AD compared to healthy controls. However, other studies have not found a significant difference in YKL-40 levels between AD patients and controls. Additionally, YKL-40 levels do not seem to correlate well with the severity of AD or with the presence of amyloid plaques or neurofibrillary tangles, which are the hallmark pathological features of AD.\n\nGiven the mixed results and the lack of strong correlation with AD pathology, YKL-40 is not currently used as a biomarker for Alzheimer's disease.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "601c3f041cb411341a000018", "messages": [{"role": "user", "content": "Can propofol cause green urine?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nPropofol is a commonly used intravenous anesthetic agent. One of its side effects is the formation of green urine, which is due to the breakdown of the drug by the liver. Propofol is metabolized by the liver, and one of the metabolites is a green-colored compound called propofol glucuronide. This metabolite is excreted in the urine, giving it a greenish color.\n\nSo, the answer is A. Yes, propofol can cause green urine. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6032187e1cb411341a000132", "messages": [{"role": "user", "content": "Are Gram positive bacteria able to release extracellular vesicles?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nGram-positive bacteria are a group of bacteria that have a thick peptidoglycan layer in their cell walls, which is the main difference between them and Gram-negative bacteria. This thick peptidoglycan layer is responsible for the Gram-positive bacteria's characteristic Gram-positive staining.\n\nExtracellular vesicles (EVs) are small membrane-bound structures that are released by a variety of cells, including bacteria. They can carry various molecules, including proteins, lipids, and nucleic acids, and can be involved in intercellular communication and the transfer of genetic material.\n\nWhile the exact mechanisms of EV release in bacteria are not fully understood, it is known that both Gram-positive and Gram-negative bacteria can release EVs. In fact, EVs have been identified in a wide range of bacteria, including both Gram-positive and Gram-negative species.\n\nSo, the answer is A. Yes, Gram-positive bacteria are able to release extracellular vesicles. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "6025d88c1cb411341a0000b6", "messages": [{"role": "user", "content": "Is vocimagene amiretrorepvec effective for glioblastoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nVocimagene amiretrorepvec (also known as talimogene laherparepvec, or T-VEC) is a genetically modified herpes simplex virus type 1 (HSV-1) that has been engineered to selectively replicate in and kill cancer cells. It is used in the treatment of melanoma, a type of skin cancer.\n\nGlioblastoma is a type of brain cancer, and while there are many treatments available for glioblastoma, including surgery, radiation therapy, and chemotherapy, there is no specific treatment that is effective for all patients. T-VEC is not currently approved for the treatment of glioblastoma.\n\nGiven that T-VEC is not approved for glioblastoma and there is no evidence that it is effective for this type of cancer, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "601cb7a61cb411341a000026", "messages": [{"role": "user", "content": "Can Panitumumab cause trichomegaly?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.unlikely\n<|assistant|>\nPanitumumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is used in the treatment of metastatic colorectal cancer. It is known to cause a variety of side effects, including skin reactions, diarrhea, and fatigue. However, one of the less common side effects of Panitumumab is trichomegaly, which is the excessive growth of eyelashes.\n\nTrichomegaly is a rare side effect of Panitumumab, but it has been reported in clinical trials and case reports. The mechanism by which Panitumumab causes trichomegaly is not fully understood, but it is thought to be related to the inhibition of EGFR signaling, which is involved in the growth and differentiation of hair follicles.\n\nGiven the information above, the answer is A. Yes, Panitumumab can cause trichomegaly. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e48e0e0f8b2df0d49000001", "messages": [{"role": "user", "content": "Are gut microbiota profiles altered by irradiation?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nIrradiation is a form of radiation therapy used to treat cancer and other diseases. It involves exposing the body to high-energy radiation, which can damage cells and tissues. While the primary goal of irradiation is to kill cancer cells, it can also have effects on the surrounding healthy tissues, including the gut microbiota.\n\nThe gut microbiota is a complex community of microorganisms that live in the digestive tract. These microorganisms play a crucial role in various aspects of human health, including metabolism, immune function, and protection against pathogens. Irradiation can alter the composition of the gut microbiota by killing off certain species and allowing others to flourish. This can lead to changes in the balance of the microbiome, which can have both positive and negative effects on health.\n\nFor example, irradiation can lead to a decrease in beneficial bacteria such as Lactobacillus and Bifidobacterium, which are known for their probiotic effects. However, it can also lead to an increase in potentially pathogenic bacteria, such as Clostridium difficile, which can cause diarrhea and other gastrointestinal issues.\n\nGiven the potential for irradiation to alter the gut microbiota, the answer is C. Maybe. While the effects of irradiation on the gut microbiota are well-documented, the specific changes and their implications for health are complex and can vary depending on the dose and type of radiation, as well as the individual's baseline microbiome composition.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c7a4c35d774d04240000007", "messages": [{"role": "user", "content": "Is TIM-3 a target for cancer immunotherapy in NSCLC?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nTIM-3 (T-cell immunoglobulin and mucin domain-containing protein 3) is a protein that is expressed on the surface of T cells and is involved in the regulation of immune responses. It is known to play a role in the suppression of T cell function, particularly in the context of chronic viral infections and cancer.\n\nIn non-small cell lung cancer (NSCLC), TIM-3 has been shown to be expressed on tumor-infiltrating lymphocytes (TILs), and its expression is associated with a poor prognosis. This suggests that TIM-3 may be involved in the immune evasion of NSCLC cells.\n\nGiven this information, it is reasonable to consider TIM-3 as a potential target for cancer immunotherapy in NSCLC. There are currently clinical trials investigating the use of TIM-3 inhibitors in various types of cancer, including NSCLC, to enhance the anti-tumor immune response.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c7019557c78d6947100005f", "messages": [{"role": "user", "content": "Does an interferon (IFN) signature exist for SLE patients?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nSystemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of autoantibodies against various cellular components. The pathogenesis of SLE is complex and involves both genetic and environmental factors. One of the hallmarks of SLE is the production of type I interferons (IFNs), which are a group of cytokines that play a role in the immune response to viral infections.\n\nStudies have shown that SLE patients have elevated levels of IFN-alpha and IFN-beta in their serum and tissues, which is indicative of a chronic IFN signature. This signature is thought to be a result of the activation of the innate immune system, which is a key component of the pathogenesis of SLE.\n\nSo, the answer is A. Yes, an interferon signature exists for SLE patients. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e36d924b5b409ea5300000b", "messages": [{"role": "user", "content": "Is AND-1/Ctf4 essential for proliferation?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.uncertain\n<|assistant|>\nAND-1 (also known as Ctf4) is a protein that is involved in DNA replication and repair. It is a component of the CMG (Cdc45-Mcm2-7-GINS) complex, which is essential for the initiation of DNA replication. The CMG complex is responsible for loading the replicative helicase onto the DNA, which is a crucial step in the process of DNA replication.\n\nAND-1/Ctf4 is not essential for the survival of cells in the absence of DNA replication, as it is not required for the basic functions of the cell. However, it is essential for the proper functioning of the CMG complex and for the initiation of DNA replication. Without AND-1/Ctf4, the CMG complex cannot form properly, and DNA replication cannot occur.\n\nSo, the answer is A. yes. AND-1/Ctf4 is essential for proliferation because it is required for the initiation of DNA replication, which is a necessary step for cell division and proliferation. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e4adcbe6d0a277941000017", "messages": [{"role": "user", "content": "Does the BRAFV600E mutation have an effect on clinical response to radioiodine therapy?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nThe BRAFV600E mutation is a common genetic alteration found in papillary thyroid cancer. This mutation leads to the constitutive activation of the BRAF protein, which is a member of the RAF family of serine/threonine protein kinases. The BRAFV600E mutation is associated with more aggressive forms of thyroid cancer and is often associated with a poorer prognosis.\n\nRadioiodine therapy, also known as radioactive iodine ablation (RAI), is a common treatment for differentiated thyroid cancer, including papillary and follicular thyroid cancers. The effectiveness of RAI therapy is based on the ability of the thyroid cells to concentrate iodine, which is then destroyed by the radiation. The BRAFV600E mutation does not directly affect the ability of thyroid cells to concentrate iodine, so it does not have a direct effect on the clinical response to radioiodine therapy.\n\nHowever, the BRAFV600E mutation is associated with a higher risk of recurrence and a poorer prognosis, which may indirectly affect the clinical response to radioiodine therapy. Patients with the BRAFV600E mutation may be more likely to have residual disease after RAI therapy, which could lead to a higher risk of recurrence and a poorer clinical response.\n\nSo, the answer is B. no. The BRAFV600E mutation does not directly affect the clinical response to radioiodine therapy, but it may indirectly affect the outcome due to its association with more aggressive disease. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e30b56efbd6abf43b000037", "messages": [{"role": "user", "content": "Is the BAGEL algorithm used for arrayed CRISPR screens?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nThe BAGEL algorithm is a computational tool used to analyze and interpret the results of CRISPR screens. A CRISPR screen is a high-throughput genetic screening method that uses CRISPR/Cas9 technology to identify genes that are essential for cell growth or survival. The BAGEL algorithm is used to analyze the data from these screens and to identify the genes that are most likely to be essential for the growth or survival of the cells being studied.\n\nThe algorithm takes into account the frequency of guide RNA (gRNA) hits in the screen and uses a statistical model to identify genes that are likely to be essential. It also accounts for the possibility of off-target effects and other sources of error in the data.\n\nSo, the answer is A. yes, the BAGEL algorithm is used for arrayed CRISPR screens. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e2b253ffbd6abf43b000006", "messages": [{"role": "user", "content": "Is AZD5153 active in prostate cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nAZD5153 is a drug that is being investigated for the treatment of prostate cancer. It is a small molecule inhibitor of the androgen receptor (AR), which is a key driver of prostate cancer growth and progression. By inhibiting the AR, AZD5153 is thought to reduce the growth and spread of prostate cancer cells.\n\nThe clinical trials for AZD5153 have shown promising results in patients with advanced prostate cancer who have failed standard treatments. In these trials, AZD5153 has demonstrated a significant reduction in prostate-specific antigen (PSA) levels, which is a marker of prostate cancer activity. Additionally, there have been reports of tumor shrinkage and prolonged progression-free survival in patients treated with AZD5153.\n\nGiven the evidence from clinical trials, it is reasonable to conclude that AZD5153 is active in prostate cancer, as it has shown efficacy in reducing tumor growth and progression in patients with advanced disease.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e2b3784fbd6abf43b000009", "messages": [{"role": "user", "content": "Is GRG5 involved only in late embryonic mouse development?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nGRG5 is a gene that encodes a protein that is involved in the development of the gastrointestinal tract in mice. The protein is expressed in the developing gut and is thought to play a role in the formation of the intestinal villi and crypts. These structures are important for the absorption of nutrients and the secretion of digestive enzymes.\n\nThe expression of GRG5 is not limited to late embryonic development. It is expressed throughout the development of the gastrointestinal tract, from early embryonic stages to adulthood. However, the specific role of GRG5 in late embryonic development may be more pronounced, as this is a critical period for the formation of the gut structures that are essential for the function of the digestive system.\n\nSo, the answer is B. no. GRG5 is involved in the development of the gastrointestinal tract throughout development, not just in late embryonic stages. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e480909d14c9f295d000003", "messages": [{"role": "user", "content": "Are astronauts in higher risk for developing cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nAstronauts are exposed to a variety of environmental factors that can potentially increase their risk of developing cancer. These factors include cosmic radiation, which is a form of ionizing radiation that can damage DNA and lead to mutations that can cause cancer. Additionally, astronauts are exposed to microgravity, which can alter the immune system and potentially increase the risk of cancer.\n\nHowever, the risk of cancer in astronauts is difficult to quantify because it is a long-term risk and the number of astronauts is relatively small. Furthermore, the data on the health of astronauts is limited due to the relatively short duration of most space missions and the fact that many astronauts are carefully selected for their health and fitness.\n\nGiven the potential risks and the limited data, it is difficult to definitively state that astronauts are in higher risk for developing cancer. However, the exposure to cosmic radiation and the altered immune system environment in space could potentially increase their risk.\n\nSo, the answer is C. may be. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e2906948b3851296d00000a", "messages": [{"role": "user", "content": "Is Niraparib effective for ovarian cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nNiraparib is a PARP inhibitor that is used in the treatment of ovarian cancer. PARP inhibitors are a class of drugs that are particularly effective in treating ovarian cancer that is caused by mutations in the BRCA genes. These mutations lead to a deficiency in the repair of DNA damage, which makes the cancer cells more sensitive to PARP inhibitors.\n\nThe PARP inhibitors are used in the treatment of ovarian cancer that has progressed after other treatments, such as platinum-based chemotherapy. Niraparib is one of the PARP inhibitors that has been approved by the FDA for this indication.\n\nSo, the answer is A. Yes, Niraparib is effective for ovarian cancer. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c72768a7c78d6947100006c", "messages": [{"role": "user", "content": "Are genes that escape X-chromosome inactivation related to mental impairment?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nX-chromosome inactivation (XCI) is a process that occurs in female mammals to ensure that each cell has only one active copy of the X chromosome. This is necessary because females have two X chromosomes, while males have one X and one Y chromosome. During XCI, one of the two X chromosomes in each cell is inactivated, leaving the other X chromosome active.\n\nGenes that escape X-chromosome inactivation are those that are expressed from both the active and inactive X chromosomes. These genes are important because they provide a backup copy of the gene in case the active copy is mutated or lost. This is particularly important for genes that are essential for normal development or function.\n\nMental impairment can be caused by a variety of genetic and environmental factors. However, genes that escape X-chromosome inactivation are not typically associated with mental impairment. Instead, they are more likely to be associated with conditions that affect the development of the brain or nervous system, such as certain types of epilepsy or autism spectrum disorders.\n\nSo, the answer is B. no. Genes that escape X-chromosome inactivation are not typically related to mental impairment. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e29fe76aa19d74431000007", "messages": [{"role": "user", "content": "Has LB-100 been tested in clinical trials?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.uncertain\n<|assistant|>\nLB-100 is a drug that is being developed for the treatment of various conditions, including cancer. It is a small molecule that inhibits the activity of the enzyme dihydrofolate reductase (DHFR), which is involved in the synthesis of DNA and RNA. By inhibiting DHFR, LB-100 can potentially kill cancer cells that are rapidly dividing.\n\nClinical trials are a crucial part of the drug development process. They are designed to evaluate the safety and efficacy of a new drug in humans. Before a drug can be approved for use in the general population, it must go through a series of clinical trials to ensure that it is safe and effective.\n\nGiven that LB-100 is a drug that is being developed for the treatment of cancer, it is likely that it has been tested in clinical trials. Clinical trials are typically conducted in phases, with each phase designed to answer specific questions about the drug's safety and efficacy. The first phase of clinical trials is usually focused on safety, while later phases are focused on efficacy.\n\nSo, the answer is A. yes. LB-100 has likely been tested in clinical trials, as it is a drug that is being developed for the treatment of cancer. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e290a268b3851296d00000d", "messages": [{"role": "user", "content": "Is palbociclib effective for glioblastoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nPalbociclib is a CDK4/6 inhibitor that is used in the treatment of certain types of cancer, including breast cancer. It works by inhibiting the activity of cyclin-dependent kinases (CDKs), which are enzymes that control the cell cycle. By inhibiting CDK4/6, palbociclib prevents the cell from progressing through the G1 phase of the cell cycle into the S phase, which is where DNA replication occurs. This effectively halts the cell's growth and division.\n\nGlioblastoma is a type of brain cancer that is highly aggressive and difficult to treat. While there are a variety of treatments available, including surgery, radiation therapy, and chemotherapy, the prognosis for glioblastoma is generally poor, with a median survival of about 15 months.\n\nThere is currently no evidence that palbociclib is effective for the treatment of glioblastoma. In fact, a clinical trial (NCT02523014) that evaluated the use of palbociclib in combination with temozolomide in patients with glioblastoma was terminated early due to lack of efficacy.\n\nSo, the answer is B. no. Palbociclib is not effective for glioblastoma. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e36d807b5b409ea5300000a", "messages": [{"role": "user", "content": "Does the Mcm2-Ctf4-Pol\u03b1 axis play a role in transfer of histones to leading strand DNA at the replication forks?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nThe Mcm2-Ctf4-Pol\u03b1 axis is a complex of proteins that plays a crucial role in DNA replication. Mcm2 is a subunit of the DNA helicase, which unwinds the DNA double helix to allow for replication. Ctf4 (also known as Cdc6) is a protein that helps to load the Mcm2-7 complex onto the DNA. Pol\u03b1 is a DNA polymerase that synthesizes the leading strand of DNA during replication.\n\nDuring DNA replication, the leading strand is synthesized continuously by DNA polymerase, while the lagging strand is synthesized discontinuously in short segments called Okazaki fragments. These fragments are then joined together by DNA ligase. The Mcm2-Ctf4-Pol\u03b1 axis is involved in the transfer of histones to the leading strand DNA at the replication forks. Histones are the proteins that package DNA into nucleosomes, which are the basic units of chromatin. The Mcm2-Ctf4-Pol\u03b1 axis is responsible for the transfer of histones to the leading strand DNA to ensure that the newly synthesized DNA is properly packaged and protected.\n\nSo, the answer is A. yes. The Mcm2-Ctf4-Pol\u03b1 axis does play a role in transfer of histones to leading strand DNA at the replication forks. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e2b0d71fbd6abf43b000001", "messages": [{"role": "user", "content": "Can discharge destinations be accurately predicted using the Risk Assessment and Prediction Tool (RAPT)?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nThe Risk Assessment and Prediction Tool (RAPT) is a tool used in healthcare to predict the likelihood of a patient being discharged to a specific destination, such as home, a skilled nursing facility, or a rehabilitation facility. The tool uses a combination of clinical and demographic data to generate a score that indicates the probability of discharge to a particular destination.\n\nThe accuracy of the RAPT in predicting discharge destinations can vary depending on the quality of the data used and the specific population being assessed. However, in general, the tool has been shown to be a useful tool for predicting discharge destinations, especially when used in conjunction with clinical judgment and other factors.\n\nSo, the answer is A. yes. The RAPT can accurately predict discharge destinations, but it is not foolproof and should be used in conjunction with clinical judgment. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e2db15cfbd6abf43b000014", "messages": [{"role": "user", "content": "Has amantadine ER been approved by the FDA?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.preliminary\nD.not yet\n<|assistant|>\nAmantadine is an antiviral medication that is used to treat influenza A and Parkinson's disease. It is available in both immediate-release and extended-release (ER) formulations. The immediate-release form is used to treat influenza A, while the extended-release form is used to treat Parkinson's disease.\n\nThe FDA has approved the use of amantadine ER for the treatment of Parkinson's disease. It is not approved for the treatment of influenza A, as the immediate-release form is more commonly used for this purpose.\n\nSo, the answer is B. no. Amantadine ER has not been approved by the FDA for the treatment of influenza A. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e2a0eb1aa19d7443100000c", "messages": [{"role": "user", "content": "Can PRL3-zumab inhibit PRL3+ cancer cells in vitro and in vivo?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nPRL3-zumab is a monoclonal antibody that targets the protein tyrosine phosphatase PRL3. PRL3 is overexpressed in many cancers, including colorectal cancer, hepatocellular carcinoma, and breast cancer, and is associated with tumor progression and metastasis. By inhibiting PRL3, PRL3-zumab could potentially block the signaling pathways that PRL3 is involved in, which could lead to the inhibition of cancer cell growth and proliferation.\n\nIn vitro studies have shown that PRL3-zumab can inhibit the growth of PRL3+ cancer cells by blocking the PRL3-mediated signaling pathways. In vivo studies have also demonstrated that PRL3-zumab can inhibit the growth of PRL3+ tumors in animal models.\n\nGiven the evidence from both in vitro and in vivo studies, it is reasonable to conclude that PRL3-zumab can inhibit PRL3+ cancer cells in vitro and in vivo.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5ca61b14ecadf2e73f00004f", "messages": [{"role": "user", "content": "Does Estrogen lead to forkhead FoxA1 activation?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nEstrogen is a hormone that plays a crucial role in the development and maintenance of female reproductive tissues. It is known to have a significant impact on gene expression in these tissues, including the activation of certain genes.\n\nForkhead box A1 (FoxA1) is a transcription factor that is involved in the regulation of gene expression during development and in adult tissues. It is particularly important in the liver, where it plays a role in the regulation of lipid metabolism and the expression of genes involved in bile acid synthesis.\n\nThere is evidence that estrogen can indeed lead to the activation of FoxA1. For example, in a study by Zhang et al. (2013), it was shown that estrogen treatment in mice led to the activation of FoxA1 in the liver, which in turn led to the upregulation of genes involved in lipid metabolism and bile acid synthesis.\n\nSo, the answer is A. Yes, estrogen can lead to the activation of forkhead FoxA1. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5cc011e2a49efeb44c000001", "messages": [{"role": "user", "content": "Does association with the nuclear pore promote gene silencing?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nThe nuclear pore complex (NPC) is a large structure that spans the nuclear envelope and allows for the transport of molecules between the nucleus and the cytoplasm. The NPC is not typically associated with gene silencing, which is a process that involves the regulation of gene expression, often leading to the inactivation of genes.\n\nGene silencing can occur through various mechanisms, including epigenetic modifications, such as DNA methylation and histone modifications, which can lead to the inactivation of genes without altering the DNA sequence. These modifications are not directly related to the function of the NPC.\n\nThe NPC is more involved in the transport of molecules, including proteins and RNA, between the nucleus and the cytoplasm. It does not actively participate in the regulation of gene expression or gene silencing.\n\nSo, the answer is B. No, association with the nuclear pore does not promote gene silencing. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e29f959aa19d74431000004", "messages": [{"role": "user", "content": "Can LB-100 sensitize ovarian carcinoma to cisplatin?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nLB-100 is a small molecule that has been studied for its potential to sensitize cancer cells to chemotherapy. It works by inhibiting the expression of the multidrug resistance protein 1 (MDR1), which is a transporter that pumps chemotherapeutic drugs out of cells, thereby reducing their effectiveness. By inhibiting MDR1, LB-100 can potentially increase the intracellular concentration of chemotherapeutic drugs, making the cells more sensitive to them.\n\nOvarian carcinoma is known to be resistant to many chemotherapeutic agents, including cisplatin. One of the mechanisms of resistance is the overexpression of MDR1, which can lead to the efflux of cisplatin from the cells, reducing its cytotoxic effect. By inhibiting MDR1, LB-100 could potentially increase the sensitivity of ovarian carcinoma cells to cisplatin.\n\nGiven this information, the answer is A. Yes, LB-100 can sensitize ovarian carcinoma to cisplatin by inhibiting the MDR1 transporter. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e2dac4efbd6abf43b00000f", "messages": [{"role": "user", "content": "Has istadefylline been considered as a treatment for Parkinson's disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nIstodax (istodifene) is a drug that is used to treat multiple myeloma, a type of blood cancer. It is not used to treat Parkinson's disease. Parkinson's disease is a neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra, which leads to the symptoms of the disease. Istodax is a histone deacetylase inhibitor that is used to treat certain types of cancer, not Parkinson's disease.\n\nSo, the answer is B. No, istodifene has not been considered as a treatment for Parkinson's disease. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e2dad57fbd6abf43b000010", "messages": [{"role": "user", "content": "Is amantadine ER the first approved treatment for akinesia?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unclear\n<|assistant|>\nAmantadine is an antiviral medication that is also used as a treatment for Parkinson's disease. It is known to have anticholinergic and dopamine agonist properties, which can help improve symptoms of Parkinson's disease, such as akinesia (lack of movement).\n\nAmantadine was first approved by the FDA in 1966 for the treatment of influenza A. In the 1970s, it was found to have beneficial effects on Parkinson's disease symptoms, and it was approved for this use in 1993. However, it is not the first approved treatment for akinesia specifically. Levodopa, which is converted to dopamine in the brain, was the first medication approved for the treatment of Parkinson's disease, including akinesia, in 1970.\n\nSo, the answer is B. No, amantadine ER is not the first approved treatment for akinesia. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e480ccfd14c9f295d000005", "messages": [{"role": "user", "content": "Is g-H2AX a marker for double strand breaks?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\ng-H2AX is a phosphorylated form of the histone H2AX protein. It is a marker for DNA double-strand breaks (DSBs) because it is rapidly phosphorylated at the sites of DSBs. This phosphorylation is mediated by the ATM (ataxia telangiectasia mutated) and ATR (ataxia telangiectasia and Rad3-related) protein kinases, which are activated in response to DNA damage.\n\nThe phosphorylation of H2AX at serine 139 (S139) creates a site for the recruitment of repair proteins to the damaged DNA. This process is known as the \"guardian of the genome\" because it helps to ensure the integrity of the genome by rapidly signaling the presence of DNA damage and initiating the repair process.\n\nSo, the answer is A. yes. g-H2AX is a marker for double strand breaks. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c7f806d617e120c34000001", "messages": [{"role": "user", "content": "Are tumour specific antigens originating from known protein coding genes?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nTumor-specific antigens are proteins or peptides that are expressed by cancer cells but not by normal cells. These antigens can be recognized by the immune system and can potentially be targeted by immunotherapy.\n\nThe origin of tumor-specific antigens can be from various sources. Some of them may be derived from mutations in known protein coding genes, such as oncogenes or tumor suppressor genes. These mutations can lead to the production of proteins that are not normally found in healthy cells, which can then be recognized as foreign by the immune system.\n\nHowever, not all tumor-specific antigens are derived from known protein coding genes. Some may be due to epigenetic changes or other mechanisms that do not involve mutations in the DNA sequence.\n\nSo, the answer is C. May be. Tumor-specific antigens may or may not originate from known protein coding genes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e2a04feaa19d74431000009", "messages": [{"role": "user", "content": "Can LB-100 downregulate miR-33?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nLB-100 is a drug that is used to treat certain types of cancer. It is known to inhibit the activity of the enzyme HMG-CoA reductase, which is involved in the synthesis of cholesterol. However, LB-100 is not directly related to microRNA (miRNA) regulation.\n\nmiR-33 is a microRNA that is involved in the regulation of cholesterol metabolism. It is known to target genes involved in cholesterol efflux and reverse cholesterol transport, which are important for maintaining cholesterol homeostasis. miR-33 is also involved in the regulation of other cellular processes, such as inflammation and lipid metabolism.\n\nThe question asks if LB-100 can downregulate miR-33. While LB-100 does affect cholesterol metabolism, it does so by inhibiting the enzyme HMG-CoA reductase, which is upstream of miR-33's targets. Therefore, LB-100 does not directly affect miR-33 expression or activity.\n\nSo, the answer is B. no. LB-100 does not downregulate miR-33. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e30f638fbd6abf43b000045", "messages": [{"role": "user", "content": "Does teplizumab hold promise for diabetes prevention?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nTeplizumab is a humanized monoclonal antibody that targets CD3, a protein found on the surface of T cells. It is used in the treatment of type 1 diabetes (T1D), which is an autoimmune disease where the immune system attacks and destroys the insulin-producing beta cells in the pancreas. The goal of teplizumab is to prevent the immune system from attacking the beta cells, thereby preserving insulin production and delaying the onset of T1D.\n\nThe PREVENT T1D trial, which was published in 2020, showed that teplizumab can delay the onset of T1D in individuals at high risk for developing the disease. The trial followed 76 participants who had a first-degree relative with T1D and were at high risk for developing the disease themselves. Participants were randomized to receive either teplizumab or placebo. The results showed that those who received teplizumab had a significantly lower risk of developing T1D over the next 3 years compared to those who received placebo.\n\nGiven these findings, teplizumab does hold promise for diabetes prevention in individuals at high risk for developing T1D. However, it is important to note that the trial was small and further research is needed to confirm these results and to determine the long-term benefits and risks of teplizumab.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e2dfab2fbd6abf43b00001d", "messages": [{"role": "user", "content": "Does ProSavin use an adenoviral vector?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nProSavin is a gene therapy treatment for Parkinson's disease. It is a recombinant adeno-associated virus (rAAV) vector that is used to deliver the genes for dopamine synthesis to the brain. The vector is designed to integrate into the host genome and provide a sustained expression of the therapeutic genes.\n\nAdenoviral vectors are commonly used in gene therapy, but they are not the only type of vector used. Adeno-associated viruses (AAVs) are a type of parvovirus that are often used in gene therapy because they can integrate into the host genome and provide long-term expression of the therapeutic genes. However, they are not adenoviruses, which are a different type of virus.\n\nSo, the answer is B. ProSavin does not use an adenoviral vector. It uses an adeno-associated viral vector. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e3238bcfbd6abf43b000056", "messages": [{"role": "user", "content": "Does radiation for tinea capitis increases brain tumor risk?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.unlikely\n<|assistant|>\nTinea capitis is a fungal infection of the scalp that is common in children. The treatment for tinea capitis typically involves the use of antifungal medications, which are often administered orally. However, in some cases, especially when the infection is severe or does not respond to oral medications, radiation therapy may be considered.\n\nRadiation therapy is a treatment that uses high-energy waves or particles to kill cancer cells. It is not typically used for tinea capitis, which is not a cancerous condition. Instead, it is used to treat conditions like cancer or benign tumors.\n\nThere is no evidence to suggest that radiation therapy for tinea capitis increases the risk of brain tumors. In fact, the doses of radiation used for tinea capitis are very low and are not known to cause long-term side effects like brain tumors.\n\nSo, the answer is B. no. Radiation therapy for tinea capitis does not increase the risk of brain tumors. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e2dbd0afbd6abf43b000017", "messages": [{"role": "user", "content": "Is pimavanserin a typical antipsychotic?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nPimavanserin is a medication used to treat hallucinations and delusions associated with Parkinson's disease psychosis. It is not a typical antipsychotic. Typical antipsychotics are a class of medications that are used to treat schizophrenia and other psychotic disorders. They work by blocking dopamine receptors in the brain, which helps to reduce the symptoms of psychosis.\n\nPimavanserin, on the other hand, is a selective serotonin inverse agonist/antagonist. It works by blocking serotonin receptors in the brain, which helps to reduce the hallucinations and delusions associated with Parkinson's disease psychosis. It is not used to treat schizophrenia or other psychotic disorders.\n\nSo, the answer is B. no. Pimavanserin is not a typical antipsychotic. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e5b93a2752ebcdc7a000003", "messages": [{"role": "user", "content": "Can Flotillin be used as exosomal marker?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\n<|assistant|>\nFlotillin is a protein that is associated with lipid rafts, which are microdomains within the plasma membrane that are enriched in cholesterol and sphingolipids. Lipid rafts are known to be involved in the formation of exosomes, which are small vesicles that are released from cells and can carry cargo such as proteins, lipids, and nucleic acids.\n\nWhile flotillin is not exclusively associated with exosomes, it is often used as a marker for lipid rafts and can be found in exosomes. However, it is not the only marker for exosomes, and other proteins and lipids are also commonly used to identify exosomes.\n\nSo, the answer is C. Flotillin may be used as an exosomal marker, but it is not the only marker and is not exclusively associated with exosomes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e30f417fbd6abf43b000043", "messages": [{"role": "user", "content": "Is Apremilast effective for Beh\u00e7et\u2019s Syndrome?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nBeh\u00e7et's syndrome is a chronic inflammatory disease that can affect multiple systems of the body, including the skin, eyes, mouth, joints, and central nervous system. It is characterized by recurrent oral ulcers, genital ulcers, and uveitis (inflammation of the eye).\n\nApremilast is a phosphodiesterase 4 (PDE4) inhibitor that is used to treat psoriasis and psoriatic arthritis. It works by inhibiting the activity of PDE4, which is involved in the breakdown of cyclic adenosine monophosphate (cAMP). This leads to an increase in cAMP levels, which can reduce inflammation.\n\nWhile there is some evidence that apremilast may be effective for Beh\u00e7et's syndrome, the data is not as robust as for other indications. A small study found that apremilast was effective in reducing the number of oral ulcers in patients with Beh\u00e7et's syndrome, but the study was not randomized or placebo-controlled. A larger, randomized, placebo-controlled trial is needed to confirm the efficacy of apremilast in Beh\u00e7et's syndrome.\n\nGiven the current state of the evidence, it is not possible to definitively say that apremilast is effective for Beh\u00e7et's syndrome. However, there is some preliminary evidence that suggests it may be beneficial for certain symptoms.\n\nSo, the answer is C. maybe. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e46ece93f5415952900000e", "messages": [{"role": "user", "content": "Is Rad4/XPC a DNA damage sensing protein?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nRad4/XPC is a protein that is part of the nucleotide excision repair (NER) pathway. NER is a DNA repair mechanism that recognizes and removes various types of DNA damage, including UV-induced lesions, intrastrand crosslinks, and bulky adducts. The NER pathway is initiated by the recognition of DNA damage by the XPC protein, which is a DNA damage sensing protein.\n\nXPC is a DNA damage sensor because it is the first protein in the NER pathway that directly interacts with DNA damage. It has a high affinity for damaged DNA, particularly for lesions that are not easily repaired by other DNA repair pathways. Once XPC binds to the damaged DNA, it recruits other proteins to the site of the damage, initiating the repair process.\n\nSo, the answer is A. yes. Rad4/XPC is a DNA damage sensing protein. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e5b60adb761aafe0900000b", "messages": [{"role": "user", "content": "Is the protein ABCG2 transmembrane?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nABCG2 is a member of the ATP-binding cassette (ABC) transporter superfamily. ABC transporters are transmembrane proteins that use the energy of ATP hydrolysis to transport various substances across membranes. ABCG2 is a half-transporter, meaning it has only one transmembrane domain and one nucleotide-binding domain. However, it is still considered a transmembrane protein because it spans the membrane and is involved in the transport of substances across the membrane.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e3247f1fbd6abf43b00005b", "messages": [{"role": "user", "content": "Can radiotherapy cause radiation induced osteosarcoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nRadiotherapy, also known as radiation therapy, is a common treatment for various types of cancer. It involves the use of high-energy radiation to kill cancer cells and shrink tumors. While radiotherapy is generally a safe and effective treatment, there are potential side effects, including the risk of developing secondary cancers.\n\nOne of the concerns with radiotherapy is the potential for radiation-induced cancers. This is particularly true for cancers that are sensitive to radiation, such as leukemia and thyroid cancer. However, the risk of developing radiation-induced osteosarcoma, a type of bone cancer, is relatively low.\n\nThe risk of radiation-induced osteosarcoma is highest in children and young adults who have received radiation therapy to the bones, especially the long bones of the arms and legs. The risk is also higher in those who have received a high dose of radiation or who have been exposed to radiation at a young age.\n\nHowever, the overall risk of developing osteosarcoma after radiotherapy is relatively low compared to other types of cancer. The risk is also lower than the risk of developing other types of secondary cancers that are more common after radiotherapy, such as leukemia or breast cancer.\n\nSo, the answer is B. No, radiotherapy does not typically cause radiation-induced osteosarcoma. While there is a small risk, it is not the most common type of secondary cancer to develop after radiotherapy. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5cf4dec0a49efeb44c00000c", "messages": [{"role": "user", "content": "Are lamina-associated domains (LADs) associated with transcriptional activation?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nLamina-associated domains (LADs) are regions of the genome that are bound by proteins in the nuclear lamina, a meshwork of proteins that lines the inner surface of the nuclear envelope. These domains are typically associated with transcriptionally inactive regions of the genome, such as heterochromatin, which is characterized by a compacted, low-activity state.\n\nHowever, it is important to note that the association with the nuclear lamina does not necessarily mean that the DNA within LADs is transcriptionally inactive. In fact, some studies have shown that LADs can be associated with active transcription, particularly in the context of gene activation. For example, during the early stages of development, genes that are normally repressed in somatic cells can be activated in the context of embryonic stem cells, and these genes are often found in LADs.\n\nSo, the answer is C. Maybe. While LADs are generally associated with transcriptional repression, there are exceptions where they can be associated with transcriptional activation, particularly in specific contexts such as development. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e31cc22fbd6abf43b000050", "messages": [{"role": "user", "content": "Is Hemochromatosis type 4 is caused by a mutation in a recessive gene?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.uncertain\n<|assistant|>\nHemochromatosis is a genetic disorder that leads to the accumulation of iron in various organs of the body. There are several types of hemochromatosis, and each type is associated with a different genetic mutation.\n\nType 1 hemochromatosis, also known as hereditary hemochromatosis, is the most common form and is caused by mutations in the HFE gene. This is an autosomal recessive disorder, meaning that two copies of the mutated gene are required for the disease to manifest.\n\nType 2 hemochromatosis is caused by mutations in the HJV gene, which is also autosomal recessive.\n\nType 3 hemochromatosis is caused by mutations in the TFR2 gene, which is also autosomal recessive.\n\nType 4 hemochromatosis, also known as juvenile hemochromatosis, is caused by mutations in the HAMP gene. This form of hemochromatosis typically presents at a younger age and is also autosomal recessive.\n\nGiven that all types of hemochromatosis are caused by mutations in recessive genes, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e371a1db5b409ea53000015", "messages": [{"role": "user", "content": "Can Patient-derived organoids (PDOs) recapitulate patient responses in the clinic?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nPatient-derived organoids (PDOs) are three-dimensional cell cultures that are derived from human tissues and can be used to study the behavior of cells in a more physiologically relevant context compared to traditional cell culture models. They are often used to study diseases and to test the efficacy of potential treatments.\n\nOne of the key advantages of PDOs is that they can be derived from a patient's own cells, which means that they can potentially mimic the patient's own biology and response to treatments. This can be particularly useful in personalized medicine, where treatments are tailored to the individual patient's genetic makeup and disease characteristics.\n\nHowever, it's important to note that PDOs are not perfect replicas of the patient's body and may not always accurately predict the patient's response to treatments. There can be variability in the culture conditions and the ability to maintain the organoid's characteristics over time. Additionally, the organoids may not fully recapitulate the complex interactions that occur in the body.\n\nSo, the answer is D. It depends. While PDOs can be useful in predicting patient responses, they are not a perfect substitute for the patient's body and may not always accurately predict the response to treatments. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e49c5336d0a277941000011", "messages": [{"role": "user", "content": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nLY6K is a member of the Ly6/uPAR family of proteins, which are involved in cell adhesion, migration, and differentiation. Overexpression of LY6K has been associated with various types of cancer, including non-small cell lung cancer (NSCLC). However, the prognostic significance of LY6K overexpression in NSCLC is not clear-cut.\n\nSome studies have found that LY6K overexpression is associated with a worse prognosis in NSCLC patients, as it is associated with increased tumor cell proliferation, migration, and invasion. Other studies have found that LY6K overexpression is associated with a better prognosis, as it may be a marker of a more differentiated and less aggressive tumor phenotype.\n\nGiven the conflicting results, it is difficult to definitively state that overexpression of LY6K is associated with better prognosis for non-small cell lung cancer patients. Therefore, the answer is D. cannot be determined. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5d31daacb3a6380763000003", "messages": [{"role": "user", "content": "Are the members of the KRAB-ZNF  gene family promoting gene repression?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nThe KRAB-ZNF (Kruppel-associated box zinc finger) gene family is a large group of transcription factors that play a role in gene regulation. These proteins contain a KRAB domain, which is a transcriptional repression domain, and multiple zinc finger motifs that are responsible for DNA binding. The KRAB domain is known to recruit histone deacetylases and other repressive complexes to the DNA, leading to the formation of heterochromatin and the silencing of nearby genes.\n\nGiven this information, it is clear that the members of the KRAB-ZNF gene family are indeed promoting gene repression. They do this by recruiting repressive complexes to the DNA, which leads to the silencing of nearby genes.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e5b5c6fb761aafe0900000a", "messages": [{"role": "user", "content": "Is the protein ABCG2 (ATP-Binding Cassette, subfamily G, member 2, transporter) excreting uric acid?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nABCG2 is a member of the ATP-binding cassette (ABC) transporter family, which is known for its role in transporting various substances across cell membranes. ABCG2 is particularly important in the excretion of certain drugs and toxins from the body, as well as in the protection of the body from harmful substances.\n\nUric acid is a waste product that is produced by the breakdown of purines. In humans, uric acid is primarily excreted by the kidneys into the urine. However, there is some evidence that ABCG2 may also play a role in the excretion of uric acid. Studies have shown that ABCG2 can transport uric acid out of cells, and it has been suggested that this transporter may be involved in the renal excretion of uric acid.\n\nGiven the available evidence, it is possible that ABCG2 does contribute to the excretion of uric acid, but the exact role of this transporter in uric acid excretion is not fully understood. Therefore, the answer is \"maybe.\"\n\nSo, the answer is C. maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e30f23cfbd6abf43b000042", "messages": [{"role": "user", "content": "Is modified vaccinia Ankara effective for smallpox?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nModified vaccinia Ankara (MVA) is a strain of the vaccinia virus that has been genetically modified to be less virulent and more attenuated. It is used as a vaccine against smallpox, which is caused by the variola virus. The modified strain was developed to reduce the risk of serious side effects associated with the original vaccinia virus, which is the same virus used in the smallpox vaccine but is more virulent.\n\nThe modified vaccinia Ankara strain has been shown to be effective in inducing an immune response against smallpox, and it is considered safe for use as a vaccine. It is not as effective as the original vaccinia virus in terms of inducing a strong immune response, but it is still effective and is used in the event of a smallpox outbreak or as a precautionary measure.\n\nSo, the answer is A. yes. Modified vaccinia Ankara is effective for smallpox. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e30f76afbd6abf43b000046", "messages": [{"role": "user", "content": "Does nintedanib hold promise for lung disease associated with systemic sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nNintedanib is a tyrosine kinase inhibitor that is used to treat idiopathic pulmonary fibrosis (IPF) and is also being investigated for the treatment of interstitial lung disease (ILD) associated with systemic sclerosis (SSc). SSc is a chronic autoimmune disease that can lead to the development of ILD, which is a common and serious complication of the disease.\n\nIn clinical trials, nintedanib has shown some promise in the treatment of ILD associated with SSc. A phase 3 trial (INBUILD) found that nintedanib significantly reduced the risk of disease progression in patients with SSc-ILD, as measured by the change in forced vital capacity (FVC) over 52 weeks. This was the first trial to demonstrate a significant benefit of a drug in the treatment of SSc-ILD.\n\nHowever, it's important to note that nintedanib is not currently approved for the treatment of SSc-ILD by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). The FDA has granted nintedanib an orphan drug designation for the treatment of SSc-ILD, which provides incentives to develop drugs for rare diseases, but it is not yet approved for this indication.\n\nGiven the promising results from clinical trials and the need for effective treatments for SSc-ILD, nintedanib does hold promise for the treatment of lung disease associated with systemic sclerosis. However, it is not yet approved for this use, and further research is needed to confirm its efficacy and safety in this patient population.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e49a1196d0a27794100000d", "messages": [{"role": "user", "content": "Is PF-05190457 an inverse agonist of the ghrelin receptor?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nPF-05190457 is a drug that was developed as a potential treatment for obesity. It is a small molecule that acts as an antagonist at the ghrelin receptor, which is a G protein-coupled receptor (GPCR) that is primarily activated by the hormone ghrelin. Ghrelin is known to stimulate appetite and increase food intake, and antagonists at the ghrelin receptor are thought to be useful for weight loss.\n\nAn inverse agonist is a type of drug that binds to a receptor and stabilizes the receptor in its inactive state, thereby reducing the activity of the receptor. In the case of the ghrelin receptor, an inverse agonist would be expected to reduce the activity of the receptor, which would lead to a decrease in appetite and food intake.\n\nGiven that PF-05190457 is an antagonist at the ghrelin receptor, it is not an inverse agonist. Antagonists block the receptor from being activated by its natural ligand, but they do not necessarily stabilize the receptor in an inactive state. Therefore, the answer is B. PF-05190457 is not an inverse agonist of the ghrelin receptor. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e30e9e3fbd6abf43b00003c", "messages": [{"role": "user", "content": "Is Ubrogepant effective for migraine?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nUbrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that is approved for the acute treatment of migraine with or without aura in adults. It works by blocking the action of CGRP, which is a key player in the pathophysiology of migraine. By inhibiting CGRP, ubrogepant can help to reduce the symptoms of migraine, such as headache pain, nausea, and sensitivity to light and sound.\n\nThe efficacy of ubrogepant has been studied in clinical trials, and it has been shown to be effective in reducing the pain of migraine attacks. In a phase 3 trial, ubrogepant was found to be more effective than placebo in reducing the pain of migraine attacks at 2 hours after treatment. Additionally, it was well-tolerated and had a favorable safety profile.\n\nSo, the answer is A. Yes, ubrogepant is effective for migraine. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e30f494fbd6abf43b000044", "messages": [{"role": "user", "content": "Is Selinexor effective for multiple myeloma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nSelinexor is a selective inhibitor of nuclear export (SINE) compound that has been studied for the treatment of multiple myeloma. It works by inhibiting the export of proteins from the nucleus, which can lead to the accumulation of tumor suppressor proteins and the activation of apoptosis in cancer cells.\n\nIn clinical trials, Selinexor has shown promising results in the treatment of multiple myeloma, particularly in patients who have relapsed or are refractory to other treatments. It has been shown to have a significant impact on progression-free survival and overall survival in these patients.\n\nGiven the evidence from clinical trials, it is reasonable to conclude that Selinexor is effective for multiple myeloma, especially in patients who have failed other treatments.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e447f2448dab47f26000013", "messages": [{"role": "user", "content": "Are there lncRNAs that control the extent of neuronal outgrowth?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nLong non-coding RNAs (lncRNAs) are a class of RNA molecules that are longer than 200 nucleotides but do not code for proteins. They are known to play important roles in various biological processes, including gene regulation, cell differentiation, and development.\n\nIn the context of neuronal outgrowth, lncRNAs have been implicated in the regulation of neuronal development and plasticity. For example, lncRNA HOTAIR has been shown to be involved in the regulation of neuronal differentiation and axon guidance. Another lncRNA, MALAT1, has been linked to the regulation of neuronal differentiation and synaptic plasticity.\n\nGiven the evidence that lncRNAs can influence various aspects of neuronal development and function, it is reasonable to conclude that they can also control the extent of neuronal outgrowth.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e4af1d86d0a277941000018", "messages": [{"role": "user", "content": "Does metformin has as an antitumor effect?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nMetformin is a medication commonly used to treat type 2 diabetes. It works by reducing the amount of glucose produced by the liver and increasing the body's sensitivity to insulin. It is also known to have other effects, including anti-inflammatory and anti-cancer properties.\n\nThere is evidence that metformin may have an antitumor effect. Studies have shown that metformin can inhibit the growth of cancer cells and may even have a protective effect against certain types of cancer. This is thought to be due to its ability to activate AMP-activated protein kinase (AMPK), which can lead to cell cycle arrest and apoptosis in cancer cells.\n\nHowever, the evidence is not conclusive, and more research is needed to fully understand the role of metformin in cancer prevention and treatment. Therefore, while metformin may have an antitumor effect, it is not yet established as a definitive treatment for cancer.\n\nSo, the answer is C. May be. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e3234e0fbd6abf43b000054", "messages": [{"role": "user", "content": "Can radiation induced meningiomas be treated with radiosurgery?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nRadiation-induced meningiomas are a type of secondary brain tumor that can occur after radiation therapy to the brain. These tumors are not the same as primary meningiomas, which are benign tumors that arise from the meninges, the membranes that cover the brain and spinal cord.\n\nRadiation-induced meningiomas are more aggressive and can be difficult to treat. They often occur in patients who have received radiation therapy for other conditions, such as brain tumors or head and neck cancers.\n\nRadiosurgery is a treatment option for primary meningiomas, but it is not typically used for radiation-induced meningiomas. This is because the radiation used in radiosurgery can actually make these tumors worse, as they are already a result of prior radiation exposure.\n\nSo, the answer is B. No, radiation-induced meningiomas cannot be treated with radiosurgery. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e3709a4b5b409ea53000012", "messages": [{"role": "user", "content": "Is there a BRCA mutation analysis in the Greek population?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nBRCA mutations are associated with an increased risk of breast and ovarian cancer. These mutations are more common in certain populations, including those with Ashkenazi Jewish ancestry, where the prevalence of BRCA1 and BRCA2 mutations is higher than in the general population.\n\nThe Greek population is not typically associated with a high prevalence of BRCA mutations. However, there have been studies that have identified BRCA mutations in the Greek population, particularly in families with a history of breast and ovarian cancer. The prevalence of BRCA mutations in the Greek population is not as high as in other populations with a known increased risk, such as Ashkenazi Jews.\n\nSo, the answer is B. no. There is not a BRCA mutation analysis that is specific to the Greek population, but there have been studies that have identified BRCA mutations in Greek families with a history of breast and ovarian cancer. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e2dbf48fbd6abf43b00001a", "messages": [{"role": "user", "content": "Has ProSavin undergone phase IV clinical trials by 2018?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.uncertain\n<|assistant|>\nProSavin is a gene therapy treatment for Parkinson's disease that is currently in clinical trials. Gene therapy is a relatively new field, and the clinical trial process can be lengthy and complex. Phase IV clinical trials are typically conducted after a drug or treatment has been approved for use in the general population. These trials are designed to monitor the long-term effects of the treatment and to gather additional safety data.\n\nAs of 2018, ProSavin had not yet been approved for use in the general population. It was still in clinical trials, which means that it had not yet completed the full set of clinical trials required for regulatory approval. Therefore, it had not yet undergone phase IV clinical trials.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5d35b9ecb3a6380763000004", "messages": [{"role": "user", "content": "Does deletion of cohesin change gene expression?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nCohesin is a protein complex that plays a crucial role in the organization of chromosomes during cell division. It helps to hold together sister chromatids and is also involved in the regulation of gene expression. Cohesin has been shown to affect gene expression by regulating the accessibility of DNA to transcription factors and other proteins that control gene activity.\n\nWhen cohesin is deleted, it can lead to changes in gene expression. For example, in yeast, the deletion of cohesin leads to the activation of genes that are normally repressed by cohesin. This suggests that cohesin plays a role in the repression of certain genes.\n\nSo, the answer is A. Yes, deletion of cohesin can change gene expression. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e2e1d6afbd6abf43b000026", "messages": [{"role": "user", "content": "Do MAIT cells have a role in multiple myeloma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nMAIT cells, or mucosal-associated invariant T cells, are a subset of T cells that are known to play a role in the immune response to certain pathogens, particularly those that are presented by the non-classical MHC class I molecule MR1. They are also known to be involved in the immune response to certain viruses and bacteria.\n\nMultiple myeloma is a type of blood cancer that affects plasma cells, which are a type of white blood cell that produce antibodies. While the role of T cells in the pathogenesis of multiple myeloma is not well understood, there is some evidence that T cells may be involved in the immune response to the disease.\n\nHowever, there is no direct evidence that MAIT cells specifically have a role in multiple myeloma. MAIT cells are known to be involved in the immune response to certain pathogens and may have a role in the immune response to cancer, but their specific role in multiple myeloma has not been established.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e3e843748dab47f26000007", "messages": [{"role": "user", "content": "Are stretch enhancers transcribed more than super-enhancers?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nA stretch enhancer is a type of regulatory element that can act over long distances to regulate gene expression. It is typically associated with the activation of genes involved in cell proliferation and differentiation. Super-enhancers, on the other hand, are a type of enhancer that is characterized by their ability to regulate the expression of genes involved in cell identity and fate.\n\nBoth stretch enhancers and super-enhancers are important for gene regulation, but they have different functions. Stretch enhancers are typically associated with the activation of genes involved in cell proliferation and differentiation, while super-enhancers are associated with the regulation of genes involved in cell identity and fate.\n\nGiven this information, it is not clear whether stretch enhancers are transcribed more than super-enhancers. The transcriptional activity of enhancers is not typically measured in terms of absolute numbers, but rather in terms of their ability to regulate gene expression. Therefore, the answer to this question is not straightforward and depends on the context and the specific genes being regulated.\n\nSo, the answer is D. It depends. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e31c4adfbd6abf43b00004d", "messages": [{"role": "user", "content": "Is mesothelioma caused by asbestos exposure?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nMesothelioma is a type of cancer that affects the mesothelium, which is the protective lining that covers many of the internal organs of the body. The most common form of mesothelioma is pleural mesothelioma, which affects the lining of the lungs.\n\nAsbestos is a mineral that was widely used in construction materials and other products due to its heat resistance and strength. However, asbestos fibers are known to be carcinogenic, meaning they can cause cancer. When asbestos fibers are inhaled or ingested, they can become lodged in the mesothelium, leading to inflammation and the potential for cancer to develop.\n\nThe link between asbestos exposure and mesothelioma is well-established. Studies have shown that people who have been exposed to asbestos, particularly those who have worked in industries where asbestos was used, have a higher risk of developing mesothelioma. The latency period for mesothelioma can be quite long, often decades after the initial exposure to asbestos.\n\nGiven this information, the answer is A. Yes, mesothelioma is caused by asbestos exposure. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e46fda33f54159529000012", "messages": [{"role": "user", "content": "Are there interactions between short and long noncoding RNAs?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nShort noncoding RNAs (sncRNAs) and long noncoding RNAs (lncRNAs) are both types of noncoding RNAs that play important roles in various biological processes. While they are both noncoding, they differ in length, with sncRNAs being shorter than 200 nucleotides and lncRNAs being longer than 200 nucleotides.\n\nThere is evidence that sncRNAs and lncRNAs can interact with each other. For example, sncRNAs can regulate the expression of lncRNAs, and lncRNAs can act as sncRNA precursors. Additionally, lncRNAs can bind to sncRNAs to form ribonucleoprotein complexes that regulate gene expression.\n\nGiven the evidence of interactions between sncRNAs and lncRNAs, the answer is yes, there are interactions between short and long noncoding RNAs.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e5b90b3752ebcdc7a000002", "messages": [{"role": "user", "content": "Can brain derived exosomes carry APP molecules?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nBrain-derived exosomes are small vesicles that are released by cells and can carry various types of molecules, including proteins, lipids, and nucleic acids. One of the proteins that can be found in brain-derived exosomes is amyloid precursor protein (APP), which is a precursor to the amyloid beta peptide (A\u03b2) that is associated with Alzheimer's disease.\n\nAPP is a transmembrane protein that is normally cleaved by alpha-secretase, which prevents the formation of A\u03b2. However, in Alzheimer's disease, APP is cleaved by beta- and gamma-secretases, leading to the production of A\u03b2. It is possible that brain-derived exosomes could carry APP molecules, as they are known to carry various types of proteins.\n\nSo, the answer is A. Yes, brain-derived exosomes can carry APP molecules. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5d38826ea1e1595105000016", "messages": [{"role": "user", "content": "Is SATB1 positioned close to AT-rich sequences?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nSATB1, also known as Special AT-rich sequence binding protein 1, is a protein that binds to AT-rich sequences in the genome. It is a chromatin-remodeling protein that plays a role in the regulation of gene expression. SATB1 is known to bind to the matrix attachment regions (MARs) of the genome, which are AT-rich sequences that are important for the organization of chromatin and the regulation of gene expression.\n\nSATB1 is a protein that specifically recognizes and binds to AT-rich sequences in the genome. It is not a general DNA-binding protein, but rather one that has a high affinity for AT-rich sequences. This is because the AT-rich sequences are often found in regions of the genome that are important for gene regulation and chromatin organization.\n\nSo, the answer is A. yes. SATB1 is positioned close to AT-rich sequences. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5d38462b7bc3fee31f000012", "messages": [{"role": "user", "content": "Does metformin alleviate atherosclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nMetformin is a medication commonly used to treat type 2 diabetes. It works by reducing the amount of glucose produced by the liver and improving the body's response to insulin. While metformin is primarily used for glycemic control, it has also been studied for its potential non-glycemic effects, including its role in cardiovascular disease.\n\nAtherosclerosis is a condition where plaque builds up in the arteries, leading to a narrowing of the arteries and reduced blood flow. This can lead to serious health problems, including heart attack and stroke. While metformin does not directly treat atherosclerosis, it has been shown to have beneficial effects on cardiovascular health.\n\nStudies have shown that metformin can reduce the risk of cardiovascular events in patients with type 2 diabetes. It has been associated with a reduction in the risk of myocardial infarction, stroke, and death from cardiovascular causes. These effects are likely due to its anti-inflammatory and anti-atherosclerotic properties, as well as its ability to improve lipid profiles and reduce blood pressure.\n\nGiven the evidence, it is reasonable to conclude that metformin does alleviate atherosclerosis, at least in the context of its effects on cardiovascular disease in patients with type 2 diabetes.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e2e1017fbd6abf43b000020", "messages": [{"role": "user", "content": "Are CD8+ (cytotoxic) T cells and  CD4+ Helper T cells generated in the thyroid and express the T-cell receptor?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nCD8+ T cells and CD4+ T cells are both types of T lymphocytes, which are a subset of white blood cells that play a critical role in the immune system. They are both generated in the thymus, not the thyroid, and they both express the T-cell receptor (TCR), which is a protein complex on the surface of T cells that recognizes specific antigens.\n\nThe TCR is what allows T cells to recognize and respond to foreign antigens. CD8+ T cells are cytotoxic, meaning they can directly kill cells that are infected with viruses or other pathogens. CD4+ T cells are helper T cells, which help coordinate the immune response by activating other immune cells and producing cytokines.\n\nSo, the answer is A. Yes, CD8+ T cells and CD4+ Helper T cells are generated in the thymus and express the T-cell receptor. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e31d181fbd6abf43b000053", "messages": [{"role": "user", "content": "Is Huntington's disease is caused by expansion of a CTG repeat in the HTT gene on Chromosome 4?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.uncertain\n<|assistant|>\nHuntington's disease (HD) is a genetic disorder that causes the progressive breakdown (degeneration) of nerve cells in the brain. It is caused by an abnormal expansion of a CAG trinucleotide repeat in the HTT gene on chromosome 4. The normal CAG repeat length is between 10 and 35, but in HD patients, the repeat length is greater than 35. The longer the repeat, the earlier the age of onset and the more severe the symptoms.\n\nThe CTG repeat is a different trinucleotide repeat than the CAG repeat associated with HD. The CTG repeat is associated with myotonic dystrophy, which is a different genetic disorder. Therefore, the answer is no, Huntington's disease is not caused by expansion of a CTG repeat in the HTT gene.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e323780fbd6abf43b000055", "messages": [{"role": "user", "content": "Is there an increased risk of meningiomas in atomic bomb survivors?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nMeningiomas are benign tumors that arise from the meninges, the membranes that cover the brain and spinal cord. They are the most common type of primary brain tumor in adults.\n\nThere is a well-established association between ionizing radiation exposure and the development of meningiomas. This is particularly relevant to the survivors of the atomic bombings in Hiroshima and Nagasaki, Japan, who were exposed to high levels of ionizing radiation.\n\nStudies have shown that the risk of developing meningiomas increases with the dose of radiation received. The risk is highest in the first 10 years after exposure, but it remains elevated for decades. The risk is also higher in those who were exposed at a younger age.\n\nGiven this information, it is reasonable to conclude that there is an increased risk of meningiomas in atomic bomb survivors.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e41620648dab47f2600000e", "messages": [{"role": "user", "content": "Is poliosis circumscripta another term for a white or unpigmented patch of hair or skin?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nPoliosis circumscripta is a term used to describe a white or unpigmented patch of hair or skin. It is a type of vitiligo, which is a condition where the skin loses its pigment cells, leading to white patches. The term \"circumscripta\" refers to the circumscribed nature of the white patches, which are well-defined and often have a border.\n\nSo, the answer is A. Yes, poliosis circumscripta is another term for a white or unpigmented patch of hair or skin. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e44bdba48dab47f2600001c", "messages": [{"role": "user", "content": "Is Selumetinib effective for low-grade glioma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nSelumetinib is a drug that inhibits the MEK1/2 protein kinase, which is part of the MAPK/ERK pathway. This pathway is involved in the growth and proliferation of cells, and its inhibition can lead to cell death. Low-grade gliomas are a type of brain tumor that can be slow-growing and less aggressive than high-grade gliomas. The treatment of low-grade gliomas often involves surgery, radiation therapy, and chemotherapy.\n\nThere is some evidence that targeting the MAPK/ERK pathway with drugs like Selumetinib may be effective in treating low-grade gliomas. A clinical trial found that Selumetinib was effective in reducing tumor size and improving progression-free survival in children with low-grade gliomas that had progressed after standard treatment. However, the drug is not approved for the treatment of low-grade gliomas in adults.\n\nGiven the current evidence, we can say that Selumetinib may be effective for low-grade glioma, but it is not yet a standard treatment and more research is needed to fully understand its efficacy and safety in this context.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5d35c227b3a6380763000007", "messages": [{"role": "user", "content": "Is SATB1 expressed in thymocytes?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.uncertain\n<|assistant|>\nSATB1 (Special AT-rich sequence-binding protein 1) is a transcription factor that plays a critical role in the development and function of the immune system. It is particularly important for the differentiation of T cells in the thymus, where it helps to regulate the expression of genes involved in T cell development and function.\n\nDuring the process of T cell development, thymocytes (immature T cells) undergo a series of stages as they mature into functional T cells. SATB1 is expressed at high levels in the thymocytes of the double-positive (DP) stage, which is a critical stage in T cell development. At this stage, the thymocytes are undergoing selection processes to determine whether they will become functional T cells or die.\n\nGiven the critical role of SATB1 in T cell development, it is reasonable to conclude that SATB1 is expressed in thymocytes, particularly during the double-positive stage.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e44c18648dab47f2600001f", "messages": [{"role": "user", "content": "Does gavestinel improve outcomes of stroke patients?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nGavestinel is a drug that was developed as a potential treatment for stroke. It is an NMDA receptor antagonist, which means it blocks the activity of NMDA receptors in the brain. The rationale behind using NMDA receptor antagonists in stroke is that they can protect brain cells from the harmful effects of glutamate, which is a neurotransmitter that can be toxic to brain cells in high concentrations.\n\nHowever, clinical trials of gavestinel and other NMDA receptor antagonists have not shown a clear benefit in improving outcomes for stroke patients. In fact, some studies have suggested that NMDA receptor antagonists may actually worsen outcomes by causing neurotoxicity or by interfering with the normal recovery process.\n\nGiven the current evidence, it is not clear that gavestinel improves outcomes of stroke patients. While it may have some neuroprotective effects, the overall benefit to patients is not well established.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e4c06d96d0a27794100002e", "messages": [{"role": "user", "content": "Can Systemic Lupus Erythematosus cause seizures?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nSystemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs and systems in the body. One of the complications of SLE can be seizures, which are a common neurological manifestation of the disease.\n\nSLE can cause seizures due to various mechanisms. One of the most common causes is cerebral vasculitis, which is inflammation of the blood vessels in the brain. This can lead to ischemic or hemorrhagic strokes, which can cause seizures. Additionally, SLE can cause a variety of other neurological symptoms, including cognitive dysfunction, psychosis, and movement disorders, which can also lead to seizures.\n\nGiven the potential for SLE to cause seizures, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e4fd4d56d0a277941000034", "messages": [{"role": "user", "content": "Is Impetigo a viral infection that affects the skin?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nImpetigo is a common bacterial skin infection that affects children and young adults. It is caused by Staphylococcus aureus or Streptococcus pyogenes bacteria. These bacteria can cause a superficial skin infection that leads to the formation of blisters or honey-colored crusts. Impetigo is not a viral infection; it is a bacterial infection.\n\nSo, the answer is B. no. Impetigo is not a viral infection. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e44caaf48dab47f26000024", "messages": [{"role": "user", "content": "Should Lubeluzole be used for treatment of ischemic stroke?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nLubeluzole is a drug that was developed as a neuroprotective agent for the treatment of ischemic stroke. It was thought to work by inhibiting glutamate release and by scavenging free radicals. However, clinical trials of lubeluzole in the treatment of acute ischemic stroke did not show a significant benefit in terms of improved neurological outcomes or reduced mortality. In fact, some studies suggested that lubeluzole might actually be harmful, as it was associated with an increased risk of intracranial hemorrhage.\n\nGiven the lack of evidence for its efficacy and the potential for harm, lubeluzole is not recommended for the treatment of ischemic stroke. Therefore, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e36994092b3349b55000002", "messages": [{"role": "user", "content": "Is there a role for TET proteins in invariant natural killer T cells (iNKT) cell fate?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nInvariant natural killer T (iNKT) cells are a unique subset of T cells that express a semi-invariant T cell receptor (TCR) and are characterized by their ability to recognize glycolipid antigens presented by the CD1d molecule. These cells play a critical role in the immune system, particularly in the regulation of immune responses.\n\nTET proteins are a family of enzymes that are involved in DNA demethylation and are known to play a role in the regulation of gene expression. They are particularly important in the context of immune cell development and function.\n\nGiven the role of TET proteins in DNA demethylation and the importance of DNA methylation in the regulation of gene expression, it is possible that TET proteins could play a role in the development and function of iNKT cells. However, there is currently limited direct evidence to support a specific role for TET proteins in iNKT cell fate.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e3c80abb5b409ea53000024", "messages": [{"role": "user", "content": "Thymoquinone is ineffective against radiation induced enteritis, yes or no?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nThymoquinone is a natural product derived from the seeds of the Nigella sativa plant, commonly known as black cumin. It has been studied for its potential anti-inflammatory, antioxidant, and anti-cancer properties. However, there is limited evidence to support its effectiveness in treating radiation-induced enteritis.\n\nRadiation-induced enteritis is a condition that occurs when the intestines are exposed to high levels of radiation, leading to inflammation and damage to the lining of the digestive tract. The symptoms can include diarrhea, abdominal pain, and nausea.\n\nWhile thymoquinone has been shown to have anti-inflammatory and antioxidant effects, there is no specific evidence that it is effective in treating radiation-induced enteritis. In fact, a study in 2017 found that thymoquinone did not reduce the severity of radiation-induced enteritis in rats.\n\nSo, the answer is B. No, thymoquinone is not effective against radiation-induced enteritis. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e5d27531af46fc130000007", "messages": [{"role": "user", "content": "Has the Spanich flu virus been reconstructed?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nThe Spanish flu, also known as the 1918 flu pandemic, was one of the deadliest pandemics in history. It is estimated to have killed between 50 and 100 million people worldwide, making it one of the most severe pandemics in recorded history. The virus that caused the Spanish flu was an influenza A virus, which is a type of virus that can cause seasonal flu outbreaks.\n\nIn the early 2000s, scientists were able to reconstruct the 1918 Spanish flu virus from preserved samples. This was done by isolating the virus from preserved lung tissue samples of victims of the pandemic. The reconstructed virus was then used to study the pathogenesis of the virus and to develop vaccines and treatments.\n\nSo, the answer is A. Yes, the Spanish flu virus has been reconstructed. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e3a6c49b5b409ea53000017", "messages": [{"role": "user", "content": "Is Verubecestat effective for Alzheimer's Disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nVerubecestat is a drug that was being developed as a potential treatment for Alzheimer's disease. It works by inhibiting the enzyme BACE1, which is involved in the production of amyloid beta peptides. These peptides are thought to be involved in the pathogenesis of Alzheimer's disease, as they can aggregate to form amyloid plaques in the brain.\n\nHowever, clinical trials of verubecestat have not shown a significant benefit in slowing the progression of Alzheimer's disease. In fact, the drug was found to be ineffective in reducing the rate of cognitive decline in patients with mild to moderate Alzheimer's disease. The drug was also associated with an increased risk of pneumonia and other infections, which led to its discontinuation in clinical trials.\n\nGiven this information, we can conclude that verubecestat is not effective for Alzheimer's disease.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e44c76f48dab47f26000022", "messages": [{"role": "user", "content": "Is Aptiganel effective for treatment of stroke?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nAptiganel, also known as 7-chlorokynurenic acid, is a non-competitive NMDA receptor antagonist. It is used as a neuroprotective agent in the treatment of stroke. NMDA receptors are involved in the pathophysiology of ischemic stroke, and blocking these receptors can potentially reduce the damage caused by the stroke.\n\nHowever, the clinical efficacy of Aptiganel in the treatment of stroke has been controversial. While some studies have shown promising results, others have not been as conclusive. The drug was tested in clinical trials, but the results were not as positive as expected, and the drug was never approved for use in stroke patients.\n\nGiven the current state of knowledge, it is difficult to say with certainty whether Aptiganel is effective for the treatment of stroke. While it may have some potential, the clinical evidence is not conclusive enough to make a definitive statement.\n\nSo, the answer is C. Maybe. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e47656935b8f0833c000004", "messages": [{"role": "user", "content": "Is indinavir effective for treatment of amyotrophic lateral sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord. It is characterized by muscle weakness, atrophy, and fasciculations, leading to paralysis and eventually death. There is no cure for ALS, and treatment is focused on managing symptoms and prolonging survival.\n\nIndinavir is an antiretroviral drug used to treat HIV infection. It is not typically used for the treatment of ALS. There is no evidence that indinavir has any effect on the progression of ALS or on the symptoms of the disease.\n\nGiven that indinavir is not used for the treatment of ALS and there is no indication that it would be effective, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e324167fbd6abf43b00005a", "messages": [{"role": "user", "content": "Is there an increased risk for meningiomas in childhood leukemia survivors?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nMeningiomas are a type of brain tumor that arises from the meninges, the membranes that cover the brain and spinal cord. Childhood leukemia is a type of cancer that affects the blood and bone marrow, and it is not directly associated with meningiomas.\n\nHowever, survivors of childhood leukemia are at an increased risk for secondary cancers, including brain tumors, due to the treatment they received. The most common secondary cancers in childhood leukemia survivors are acute myeloid leukemia (AML) and solid tumors, including brain tumors. The risk of developing a secondary brain tumor is higher in those who received cranial radiation therapy as part of their treatment.\n\nSo, the answer is A. Yes, there is an increased risk for meningiomas in childhood leukemia survivors, particularly those who received cranial radiation therapy. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e540ed36d0a277941000054", "messages": [{"role": "user", "content": "Does saracatinib promote oncogenesis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nSaracatinib is a small molecule inhibitor of the Src family of tyrosine kinases. Src kinases are involved in various cellular processes, including cell proliferation, differentiation, migration, and survival. They are often overexpressed or mutated in various cancers, making them attractive targets for cancer therapy.\n\nHowever, the inhibition of Src kinases can have both beneficial and detrimental effects. On the one hand, inhibiting Src kinases can reduce the growth and spread of cancer cells. On the other hand, Src kinases are also involved in normal cellular processes, and their inhibition can lead to side effects such as bone marrow suppression, skin rashes, and gastrointestinal issues.\n\nGiven the dual role of Src kinases in both normal and cancerous cells, it is difficult to say that saracatinib promotes oncogenesis without considering the context. In a cancer treatment setting, saracatinib might be used to inhibit the growth of cancer cells, but in a non-cancerous context, it could potentially have oncogenic effects if it disrupts normal cellular processes.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e2e0fa2fbd6abf43b00001f", "messages": [{"role": "user", "content": "Is BCL11B involved in schizophrenia?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nBCL11B is a gene that has been implicated in the development of the central nervous system, including the brain. It is known to play a role in the development of the cerebral cortex and the hippocampus, which are important for cognitive functions such as memory and learning. Mutations in the BCL11B gene have been associated with a rare genetic disorder called 3MC syndrome, which can include intellectual disability and behavioral problems.\n\nWhile there is no direct evidence that mutations in BCL11B cause schizophrenia, it is possible that variations in this gene could contribute to the risk of developing schizophrenia or other psychiatric disorders. This is because schizophrenia is a complex disorder with a strong genetic component, and many genes are likely to be involved in its etiology. Given the role of BCL11B in brain development and the fact that it is associated with a disorder that includes behavioral problems, it is plausible that BCL11B could be involved in schizophrenia.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e338cf5fbd6abf43b00005d", "messages": [{"role": "user", "content": "Are Chernobyl survivors at increased risk for breast cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nThe Chernobyl nuclear disaster in 1986 was a major event that resulted in widespread exposure to ionizing radiation. One of the concerns after such an event is the potential for increased cancer risk, including breast cancer, among those exposed.\n\nStudies have shown that there is an increased risk of breast cancer among women who were exposed to radiation during childhood or adolescence. This is because the breast tissue is particularly sensitive to the effects of radiation during these developmental stages. However, the risk of breast cancer among adults who were exposed to radiation is less clear.\n\nThe Chernobyl survivors, also known as the Chernobyl cleanup workers or liquidators, were exposed to varying levels of radiation depending on their proximity to the accident site and the duration of their exposure. While some studies have shown an increased risk of breast cancer among these individuals, others have not found a significant association.\n\nGiven the conflicting evidence and the complexity of the issue, it is difficult to definitively answer whether Chernobyl survivors are at increased risk for breast cancer. However, the available data suggests that there may be an increased risk, particularly among those who were exposed at a young age.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5d36b4817bc3fee31f000007", "messages": [{"role": "user", "content": "Is SATB1 necessary for T-cell maturation?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nSATB1 is a protein that is involved in the regulation of gene expression during T-cell development. It is known to be important for the differentiation of T cells into mature T helper cells. Specifically, SATB1 is involved in the activation of genes that are critical for T-cell function, such as cytokine production and cell proliferation.\n\nDuring T-cell maturation, SATB1 is expressed in the thymus, where it is thought to play a role in the selection of T cells that will be able to recognize foreign antigens. It is also expressed in peripheral T cells, where it is involved in the regulation of gene expression in response to antigen stimulation.\n\nGiven the role of SATB1 in the regulation of gene expression during T-cell maturation, it is necessary for T-cell maturation. Without SATB1, T cells would not be able to properly differentiate into mature T helper cells, which are essential for the immune response.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e46bf743f54159529000008", "messages": [{"role": "user", "content": "Have toll-like receptor 2 activators been found in food?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nToll-like receptors (TLRs) are a family of proteins that play a crucial role in the innate immune system. They are found on the surface of various cells, including macrophages, dendritic cells, and B cells, and are responsible for recognizing pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). When activated by these patterns, TLRs trigger an immune response to eliminate the pathogen or damaged cells.\n\nTLR2 is one of the TLRs that recognizes a variety of bacterial components, including lipoproteins, lipopeptides, and lipoteichoic acid. These components are often found on the surface of bacteria and are recognized by TLR2 as a sign of infection.\n\nWhile TLR2 activators are not typically found in food, they can be found in certain bacteria that are present in food. For example, Listeria monocytogenes, a bacterium that can contaminate food, is known to activate TLR2. However, the presence of TLR2 activators in food is not a common concern because the levels of these activators in food are usually low and are not intended to be consumed in large quantities.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e33904afbd6abf43b00005f", "messages": [{"role": "user", "content": "Does radiotherapy for Hodgkin disease increases risk for lung cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nHodgkin lymphoma (HL) is a type of lymphoma that is often treated with radiotherapy, especially in the early stages of the disease. Radiotherapy is a common treatment for HL because it can effectively target the lymph nodes and other areas where the cancer may be present, without the need for systemic chemotherapy.\n\nHowever, radiotherapy can have long-term side effects, including an increased risk of secondary cancers. One of the most common secondary cancers associated with radiotherapy for HL is lung cancer. This is because the lungs are often included in the radiation field during treatment, especially if the mediastinum (the area between the lungs) is involved.\n\nThe risk of lung cancer after radiotherapy for HL is well-documented. Studies have shown that the risk of lung cancer increases with the amount of radiation received and the age at which the radiation was given. The risk is highest in patients who received radiotherapy at a young age, as the lungs are still developing and more sensitive to the effects of radiation.\n\nSo, the answer is A. Yes, radiotherapy for Hodgkin disease increases the risk for lung cancer. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e33916afbd6abf43b000061", "messages": [{"role": "user", "content": "Does radiotherapy for prostate cancer increase bladder cancer risk?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nRadiotherapy is a common treatment for prostate cancer, and it is known to increase the risk of secondary cancers, including bladder cancer. This is because the radiation can damage the DNA of cells in the bladder, leading to mutations that can cause cancer.\n\nStudies have shown that men who have received radiotherapy for prostate cancer have a higher risk of developing bladder cancer compared to those who have not received radiotherapy. The risk is particularly high within the first 10 years after radiotherapy, but it can persist for many years.\n\nSo, the answer is A. Yes, radiotherapy for prostate cancer does increase the risk of bladder cancer. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e51a2d76d0a27794100003a", "messages": [{"role": "user", "content": "Do genes with monoallelic expression contribute proportionally to genetic diversity in humans?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nMonoallelic expression occurs when only one of the two alleles of a gene is expressed in a cell or tissue. This can be due to various mechanisms, such as genomic imprinting, X-chromosome inactivation, or other epigenetic mechanisms.\n\nThe question asks whether genes with monoallelic expression contribute proportionally to genetic diversity in humans. Genetic diversity is typically measured by the number of different alleles present in a population. Monoallelic expression does not directly contribute to genetic diversity because it does not increase the number of different alleles in a population. Instead, it can lead to phenotypic diversity by allowing for the expression of different alleles in different tissues or cells.\n\nSo, the answer is B. No, genes with monoallelic expression do not contribute proportionally to genetic diversity in humans. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e5437ffb761aafe09000002", "messages": [{"role": "user", "content": "Has MLE4901 been tested in phase III clinical trials?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.uncertain\n<|assistant|>\nMLE4901 is a novel drug being developed for the treatment of a rare genetic disorder. Phase III clinical trials are the final stage of testing before a drug is approved for use in the general population. These trials involve large numbers of patients and are designed to evaluate the safety and efficacy of the drug in a broader population.\n\nGiven that MLE4901 is a novel drug, it is likely that it has not yet been tested in phase III clinical trials. Phase III trials are typically conducted after successful completion of phase I and II trials, which are smaller in scale and focus on safety and early efficacy, respectively. If MLE4901 has not yet been tested in phase III trials, it means that it has not yet been fully evaluated in a large-scale, real-world setting.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e5508e2b761aafe09000006", "messages": [{"role": "user", "content": "Does ESN364 activate the hypothalamic-pituitary-gonadal axis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nESN364 is a synthetic estrogen that is used as a contraceptive. Estrogens, including synthetic ones like ESN364, are known to suppress the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is responsible for the production of sex hormones, including estrogen and progesterone in females and testosterone in males. By suppressing the HPG axis, ESN364 prevents the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus, which in turn inhibits the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This ultimately leads to a decrease in the production of estrogen and progesterone in the ovaries, which is the desired effect for contraception.\n\nSo, the answer is B. no. ESN364 does not activate the hypothalamic-pituitary-gonadal axis; instead, it suppresses it. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e763645c6a8763d2300000d", "messages": [{"role": "user", "content": "Has ORMD-0801 been tested in patients?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.uncertain\n<|assistant|>\nORMD-0801 is a monoclonal antibody that is being developed as a potential treatment for autoimmune diseases. It is a humanized antibody that targets the CD40 ligand, which is a protein that plays a role in the immune system's response to foreign antigens. By targeting CD40 ligand, ORMD-0801 is thought to modulate the immune response and potentially reduce inflammation in autoimmune diseases.\n\nWhile the drug has been tested in preclinical studies, it has not yet been tested in patients. Clinical trials are necessary to evaluate the safety and efficacy of a drug in humans. Therefore, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e763c3fc6a8763d23000010", "messages": [{"role": "user", "content": "Was vivotif licensed in Europe and the US at the same time?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.uncertain\n<|assistant|>\nVivotif is a vaccine against typhoid fever, which is caused by the bacterium Salmonella Typhi. The vaccine is administered orally and consists of live attenuated Salmonella Typhi Ty21a bacteria.\n\nThe vaccine was licensed in Europe in 1989 and in the United States in 1994. It is currently not available in the United States due to a lack of demand, but it is still available in Europe and other parts of the world.\n\nSo, the answer is B. no. Vivotif was not licensed in Europe and the US at the same time. It was licensed in Europe first and then in the US. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e43090d48dab47f26000011", "messages": [{"role": "user", "content": "Are stem cell transplants used to treat acute kidney injury?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nStem cell transplants, also known as hematopoietic stem cell transplants (HSCT), are a treatment option for certain types of blood cancers and other disorders of the blood and immune system. They are not typically used to treat acute kidney injury (AKI), which is a sudden loss of kidney function that can occur over a few hours or days.\n\nThe treatment of AKI involves supportive care, such as dialysis, to remove waste products and excess fluids from the blood when the kidneys are not functioning properly. Stem cell transplants are not a treatment for AKI because they do not address the immediate need to support kidney function.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e51dab06d0a27794100003d", "messages": [{"role": "user", "content": "Is deletion at 6q24.2-26 associated with shorter survival for ovarian cancer patients?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nThe deletion at 6q24.2-26 is a chromosomal abnormality that has been associated with several types of cancer, including ovarian cancer. This deletion is known to be associated with a poor prognosis in ovarian cancer patients. Studies have shown that patients with this deletion have a significantly shorter survival time compared to those without the deletion.\n\nThe deletion at 6q24.2-26 is associated with the loss of several tumor suppressor genes, including the PTEN gene, which is involved in the regulation of cell growth and apoptosis. The loss of these genes can lead to uncontrolled cell growth and proliferation, which is a hallmark of cancer.\n\nGiven the strong association between the deletion at 6q24.2-26 and a poor prognosis in ovarian cancer patients, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5d35eb01b3a638076300000f", "messages": [{"role": "user", "content": "Are there negative enhancers?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nNegative enhancers are DNA sequences that can inhibit the expression of a gene or a group of genes. They can do this by binding to transcription factors or other regulatory proteins that would normally activate gene expression, but instead, they prevent the activation of the gene. This can be achieved through various mechanisms, such as blocking the binding of transcription factors to their target sites or by recruiting proteins that repress transcription.\n\nNegative enhancers are important in the regulation of gene expression, as they can help to fine-tune the expression of genes in response to different cellular conditions. For example, in the case of a gene that is normally expressed at a high level, a negative enhancer can be used to reduce its expression in certain contexts, such as when the cell is under stress or in a different developmental stage.\n\nSo, the answer is A. Yes, there are negative enhancers. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e540db06d0a277941000053", "messages": [{"role": "user", "content": "Has saracatinib been tested in clinical trials?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.uncertain\n<|assistant|>\nSaracatinib is a small molecule tyrosine kinase inhibitor that was developed as a potential treatment for various cancers, including breast cancer, lung cancer, and chronic lymphocytic leukemia. It works by inhibiting the Src family of kinases, which are involved in cell growth and survival.\n\nSaracatinib was tested in clinical trials for various cancers. In a phase II trial, saracatinib was evaluated in patients with advanced breast cancer who had previously received chemotherapy. The results of this trial showed that saracatinib did not improve progression-free survival or overall survival compared to placebo.\n\nIn another phase II trial, saracatinib was evaluated in patients with non-small cell lung cancer. This trial also did not show a significant improvement in progression-free survival or overall survival compared to placebo.\n\nGiven these results, it is clear that saracatinib has been tested in clinical trials and has not shown a significant benefit in the treatment of cancer.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e500d8c6d0a277941000035", "messages": [{"role": "user", "content": "Is \u03b1CGRP a member of the CGRP family?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\n\u03b1CGRP is a member of the calcitonin gene-related peptide (CGRP) family. CGRP is a peptide that is produced by the central nervous system and is involved in various physiological processes, including pain perception, vasodilation, and inflammation. The CGRP family includes \u03b1CGRP, \u03b2CGRP, and CGRP-like immunoreactivity (CGLI). \u03b1CGRP is the most abundant form of CGRP in the central nervous system and is involved in the regulation of blood pressure, heart rate, and pain perception.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e44c33a48dab47f26000020", "messages": [{"role": "user", "content": "Can Enlimomab improve stroke outcomes?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nEnlimomab is a monoclonal antibody that targets the CD18 receptor on leukocytes. It is used in the treatment of ischemic stroke to prevent the secondary inflammatory response that can occur after a stroke. The inflammatory response can lead to further tissue damage and worsen the outcome of the stroke.\n\nThe use of Enlimomab in the treatment of ischemic stroke was investigated in a clinical trial, the Abciximab in Emergency Neurological Deficiency (Abciximab in Acute Ischemic Stroke) trial. The trial found that Enlimomab did not improve the outcomes of patients with ischemic stroke and may have even worsened outcomes in some patients.\n\nGiven this information, the answer is B. No, Enlimomab does not improve stroke outcomes. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5d384ce87bc3fee31f000013", "messages": [{"role": "user", "content": "Does GRHL2 over-expression lead to EMT?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nGRHL2 is a gene that encodes a transcription factor involved in the development of epithelial tissues. It is known to play a role in the maintenance of epithelial cell polarity and in the regulation of cell adhesion and migration. However, there is no direct evidence that over-expression of GRHL2 leads to epithelial-mesenchymal transition (EMT), which is a process by which epithelial cells lose their cell polarity and cell-cell adhesion properties, and acquire a mesenchymal phenotype.\n\nEMT is a complex process that involves the activation of specific transcription factors and the downregulation of epithelial markers, such as E-cadherin, and the upregulation of mesenchymal markers, such as vimentin. While GRHL2 is involved in the maintenance of epithelial cell polarity, there is no clear evidence that it is a direct driver of EMT.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e7f5cc5835f4e4777000015", "messages": [{"role": "user", "content": "Is the Fluzone intradermal and the Fluzone intradermal quadrivalent vaccine produced by different companies?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nThe Fluzone intradermal vaccine is a quadrivalent influenza vaccine that is administered intradermally, which means it is injected into the skin. It is produced by Sanofi Pasteur, a subsidiary of Sanofi, a French multinational pharmaceutical company.\n\nThe Fluzone intradermal quadrivalent vaccine is a specific formulation of the Fluzone vaccine that is designed for intradermal administration. It contains the same four influenza strains as the Fluzone intramuscular vaccine, but it is administered in a different way.\n\nSo, the answer is no, the Fluzone intradermal and the Fluzone intradermal quadrivalent vaccine are not produced by different companies. They are both produced by Sanofi Pasteur.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e821ac5835f4e4777000031", "messages": [{"role": "user", "content": "Is endotrophin derived from collagen?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nEndotrophin is a peptide fragment that is derived from the C-terminal telopeptide of type I collagen. It is released during the degradation of collagen by matrix metalloproteinases (MMPs) and other proteases. Endotrophin has been shown to have a variety of biological activities, including the ability to promote inflammation, angiogenesis, and fibrosis.\n\nThe C-terminal telopeptide of type I collagen is a specific region of the collagen molecule that is cleaved by proteases during the breakdown of collagen. This region is not part of the triple helical structure of the collagen molecule, but rather is located at the ends of the collagen fibrils.\n\nSo, the answer is A. yes. Endotrophin is derived from collagen. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e7f6090835f4e477700001a", "messages": [{"role": "user", "content": "Can Daptacel be used instead of IPOL?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nDaptacel is a vaccine used to prevent diphtheria, tetanus, and pertussis (whooping cough) in children. IPOL is a vaccine used to prevent poliomyelitis (polio). These are two different vaccines that protect against different diseases. You cannot use Daptacel instead of IPOL because they are not interchangeable. Daptacel is a combination vaccine that includes diphtheria, tetanus, and pertussis components, while IPOL is a vaccine that protects against polio.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e806ff7835f4e4777000027", "messages": [{"role": "user", "content": "Is ACE2 expressed on cell surfaces?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.both\nD.none\n<|assistant|>\nACE2 (angiotensin-converting enzyme 2) is a carboxypeptidase enzyme that is primarily known for its role in the renin-angiotensin-aldosterone system (RAAS). It is also a receptor for the SARS-CoV-2 virus, which causes COVID-19.\n\nACE2 is expressed on the cell surface of various types of cells, including epithelial cells in the lungs, kidneys, intestines, and blood vessels. The expression of ACE2 on the cell surface is crucial for the entry of the SARS-CoV-2 virus into the host cells, which is a key step in the infection process.\n\nSo, the answer is A. yes. ACE2 is expressed on cell surfaces. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e7744c3835f4e4777000005", "messages": [{"role": "user", "content": "Can leuprorelin acetate be used as androgen deprivation therapy?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.uncertain\n<|assistant|>\nLeuprorelin acetate is a synthetic analog of gonadotropin-releasing hormone (GnRH) that is used as a GnRH agonist. GnRH agonists are commonly used in androgen deprivation therapy (ADT) for prostate cancer. ADT is a treatment that reduces the production of testosterone, which is a hormone that can fuel the growth of prostate cancer cells.\n\nWhen leuprorelin acetate is administered, it initially stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. However, over time, the pituitary gland becomes desensitized to the GnRH agonist, and the release of LH and FSH is suppressed. This leads to a decrease in testosterone production by the testes, which is the primary source of testosterone in men.\n\nSo, the answer is A. Yes, leuprorelin acetate can be used as androgen deprivation therapy. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e6e35b07fc1ee872b000004", "messages": [{"role": "user", "content": "Are astrocytes part of the blood brain barrier?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nThe blood-brain barrier (BBB) is a highly selective permeability barrier that separates the circulating blood from the brain extracellular fluid in the central nervous system (CNS). It is formed by endothelial cells that line the blood vessels within the brain, which are joined together tightly by tight junctions. These tight junctions prevent the passage of many substances from the blood into the brain, including certain drugs, toxins, and pathogens.\n\nAstrocytes are a type of glial cell that are found in the brain and spinal cord. They play a critical role in the maintenance of the BBB by providing structural support to the endothelial cells and by producing factors that help regulate the permeability of the BBB. However, astrocytes are not the primary component of the BBB itself. The endothelial cells of the blood vessels are the main structural component of the BBB, and the tight junctions between these cells are what form the barrier.\n\nSo, the answer is B. No, astrocytes are not part of the blood brain barrier. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e639a8b1af46fc130000011", "messages": [{"role": "user", "content": "Is Li\u2013Fraumeni syndrome a rare, autosomal recessive, hereditary disorder that predisposes carriers to cancer development?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nLi\u2013Fraumeni syndrome is a rare genetic disorder that increases the risk of developing certain types of cancers, particularly sarcomas, breast cancer, and adrenocortical carcinoma. It is not an autosomal recessive disorder, as recessive disorders typically require two copies of the mutated gene for the phenotype to be expressed, which is not the case with Li\u2013Fraumeni syndrome.\n\nLi\u2013Fraumeni syndrome is caused by a mutation in the TP53 gene, which is located on chromosome 17. This gene is a tumor suppressor gene, and when it is mutated, it can lead to the development of various types of cancers. The mutation is inherited in an autosomal dominant pattern, which means that only one copy of the mutated gene is needed for a person to be affected by the disorder.\n\nSo, the answer is B. Li\u2013Fraumeni syndrome is not an autosomal recessive disorder. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e776c72835f4e477700000e", "messages": [{"role": "user", "content": "Has the drug Afrezza been approved by the FDA?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.potentially\nD.maybe\n<|assistant|>\nAfrezza is a rapid-acting inhaled insulin therapy for the treatment of diabetes. It was approved by the FDA in 2014 for adults with type 1 diabetes and adults with type 2 diabetes who are unable to achieve adequate glycemic control with oral antidiabetic agents and for whom metformin is inappropriate due to contraindications or intolerance.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e8220e6835f4e4777000032", "messages": [{"role": "user", "content": "Is Protoporphyrinogen oxidase localized to the mitochondrium?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nProtoporphyrinogen oxidase (PPO) is an enzyme involved in the heme biosynthesis pathway. It is responsible for the oxidation of protoporphyrinogen IX to protoporphyrin IX, which is a key step in the conversion of protoporphyrinogen to heme. The enzyme is found in the mitochondrial matrix, where it is located on the inner membrane.\n\nThe mitochondrial matrix is the site of many important metabolic processes, including the citric acid cycle, fatty acid oxidation, and the electron transport chain. The matrix is also where the enzymes involved in heme biosynthesis are located, including PPO.\n\nSo, the answer is A. Yes, Protoporphyrinogen oxidase is localized to the mitochondrium. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e36d498b5b409ea53000008", "messages": [{"role": "user", "content": "Do de novo truncating mutations in WASF1 cause cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nWASF1 (WASP family member 1) is a gene that encodes for a protein involved in the regulation of actin polymerization and cell motility. Mutations in WASF1 can lead to a condition called WASF1 deficiency, which is characterized by a variety of symptoms including developmental delay, intellectual disability, and a predisposition to certain types of cancer.\n\nWhile WASF1 mutations are not directly associated with the development of cancer, individuals with WASF1 deficiency have an increased risk of developing certain types of cancer, particularly leukemia and lymphoma. This is because WASF1 plays a role in the immune system, and mutations can lead to a weakened immune system, which can increase the risk of cancer.\n\nSo, the answer is A. Yes, de novo truncating mutations in WASF1 can cause cancer, albeit indirectly through the increased risk of cancer associated with WASF1 deficiency. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e64ed381af46fc130000015", "messages": [{"role": "user", "content": "Are ICAMS, Intracellular Adhesion Molecules, part of the immunoglobulin superfamily?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nICAMs, or Intracellular Adhesion Molecules, are a family of cell adhesion molecules that are involved in cell-to-cell interactions. They are found on the surface of various cells, including leukocytes, endothelial cells, and epithelial cells. ICAMs are known to play a role in the immune system by facilitating the adhesion of leukocytes to endothelial cells during the process of leukocyte extravasation, which is a key step in the inflammatory response.\n\nThe immunoglobulin superfamily (IgSF) is a large group of proteins that share a common structural motif, the immunoglobulin domain. This domain is found in many proteins that are involved in cell adhesion, cell signaling, and the immune system. ICAMs are indeed part of the immunoglobulin superfamily because they contain one or more immunoglobulin-like domains in their structure.\n\nSo, the answer is A. yes. ICAMs are part of the immunoglobulin superfamily. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e57fa23b761aafe09000008", "messages": [{"role": "user", "content": "Is traditional Chinese medicine associated with a decreased risk of heart failure in breast cancer patients receiving doxorubicin treatment?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.cannot be determined\n<|assistant|>\nTraditional Chinese medicine (TCM) is often used in conjunction with Western medicine to treat various conditions, including cancer. One of the main concerns with chemotherapy, such as doxorubicin, is its cardiotoxicity, which can lead to heart failure. TCM is known to have cardioprotective effects, and some studies have suggested that it may help mitigate the cardiotoxicity of chemotherapy.\n\nHowever, the evidence for the use of TCM in reducing the risk of heart failure in breast cancer patients receiving doxorubicin treatment is not conclusive. While there are some studies that suggest a potential benefit, the quality of the evidence is not high, and the results are not consistent across all studies. Some studies have shown a protective effect, while others have not found a significant difference.\n\nGiven the current state of the evidence, it is difficult to definitively say that TCM is associated with a decreased risk of heart failure in breast cancer patients receiving doxorubicin treatment. More high-quality studies are needed to draw firm conclusions.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e6df5b51af46fc130000025", "messages": [{"role": "user", "content": "Is PTEN a tumour suppressor?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nPTEN is a tumor suppressor gene that is commonly mutated in many types of cancer. It encodes a protein that is involved in the regulation of the PI3K/AKT/mTOR signaling pathway, which is important for cell growth, proliferation, and survival. When PTEN is mutated or deleted, it leads to the activation of the PI3K/AKT/mTOR pathway, which can promote tumor growth and progression.\n\nSo, the answer is A. yes. PTEN is a tumor suppressor. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5d387098a1e1595105000006", "messages": [{"role": "user", "content": "Is the tyrosine kinase BTK implicated in autoimmunity?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nBTK, or Bruton's tyrosine kinase, is a member of the Tec family of tyrosine kinases. It plays a crucial role in B-cell development and function, particularly in the activation of B cells and the downstream signaling pathways that lead to antibody production.\n\nMutations in the BTK gene can lead to a condition called X-linked agammaglobulinemia (XLA), which is characterized by a lack of mature B cells and a deficiency in antibody production. This condition is a primary immunodeficiency disorder that can increase the risk of infections due to the inability to produce antibodies.\n\nHowever, BTK is not directly implicated in autoimmune diseases. Autoimmune diseases are characterized by the body's immune system attacking its own tissues, which is not a result of BTK mutations or dysfunction. Instead, autoimmune diseases are often associated with genetic and environmental factors that lead to the misregulation of the immune system.\n\nSo, the answer is B. no. BTK is not implicated in autoimmunity. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5d387721a1e159510500000c", "messages": [{"role": "user", "content": "Is induction of interferon by TLR7 higher in males?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nInterferon (IFN) is a type of cytokine that is involved in the immune response. TLR7 (Toll-like receptor 7) is a protein that is part of the innate immune system and is known to induce the production of IFN. However, there is no direct evidence that the induction of IFN by TLR7 is higher in males compared to females.\n\nWhile there are some differences in the immune response between males and females, there is no specific evidence that the induction of IFN by TLR7 is higher in one sex over the other. The immune system is complex and involves many factors, including genetics, hormones, and environmental influences, which can all affect the immune response. However, there is no clear evidence that the induction of IFN by TLR7 is higher in males compared to females.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e64f1921af46fc130000018", "messages": [{"role": "user", "content": "Is there a vaccine for rotavirus?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nRotavirus is a common cause of severe diarrhea in infants and young children. It is a highly contagious virus that can spread quickly in daycare centers and other settings where children are in close contact. The virus is transmitted through the fecal-oral route, meaning that it is spread by contact with contaminated surfaces or objects, or by consuming contaminated food or water.\n\nA vaccine for rotavirus was first developed in the 1990s. The vaccine was initially licensed in the United States in 1998 and was recommended for routine use in infants. However, the vaccine was withdrawn from the market in 1999 due to a small but significant increase in intussusception, a type of bowel obstruction, in vaccinated infants.\n\nIn 2006, a new rotavirus vaccine was licensed in the United States. This vaccine, called RotaTeq, was found to be safe and effective in preventing rotavirus disease. It is now part of the routine childhood immunization schedule in many countries, including the United States.\n\nSo, the answer is A. Yes, there is a vaccine for rotavirus. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e2d7ceefbd6abf43b00000b", "messages": [{"role": "user", "content": "Is BNN20 involved in Parkinson's disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nBNN20 is a gene that encodes for the protein beta-naphthylamidase, which is involved in the metabolism of xenobiotics. Parkinson's disease is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor symptoms such as tremor, rigidity, and bradykinesia. The cause of Parkinson's disease is not fully understood, but genetic factors are known to play a role.\n\nWhile there is no direct evidence that BNN20 is involved in the pathogenesis of Parkinson's disease, it is possible that mutations in this gene could lead to changes in the metabolism of xenobiotics, which could potentially affect the function of dopaminergic neurons. However, there is no strong evidence to support this hypothesis at this time.\n\nGiven the current state of knowledge, it is difficult to definitively say that BNN20 is involved in Parkinson's disease. While it is possible that mutations in this gene could have an indirect effect on the disease, there is no clear evidence to support a direct role in the pathogenesis of Parkinson's disease.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e35d3c6158f994d3a000003", "messages": [{"role": "user", "content": "Is there a role for MRPL53 in cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nMRPL53 is a subunit of the mitochondrial ribosome, which is involved in the synthesis of proteins within mitochondria. Mitochondria are organelles that are critical for cellular energy production and are also involved in various other cellular processes. Alterations in mitochondrial function have been linked to various diseases, including cancer.\n\nWhile the exact role of MRPL53 in cancer is not fully understood, there is some evidence to suggest that it may be involved. For example, a study found that MRPL53 is overexpressed in several types of cancer, including breast cancer, and that its overexpression is associated with poor prognosis. Additionally, MRPL53 has been shown to interact with other proteins that are known to be involved in cancer, such as BCL2, which is a key regulator of apoptosis.\n\nGiven the evidence that MRPL53 is overexpressed in cancer and that it interacts with proteins involved in cancer, it is reasonable to conclude that MRPL53 may have a role in cancer. However, the exact nature of this role is still being investigated and is not yet fully understood.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e36a4b7b5b409ea53000003", "messages": [{"role": "user", "content": "Does Uc.63+ promote sensitivity to treatment in prostate cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nUc.63+ is a protein that is overexpressed in prostate cancer cells and is associated with a more aggressive form of the disease. It is a marker for the androgen receptor (AR) signaling pathway, which is a key driver of prostate cancer growth and progression. The AR pathway is a target for many treatments in prostate cancer, including androgen deprivation therapy (ADT) and AR-targeted therapies.\n\nOverexpression of Uc.63+ is associated with increased sensitivity to ADT and AR-targeted therapies. This is because the AR pathway is more active in cells that overexpress Uc.63+, and these cells are more responsive to treatments that target the AR pathway.\n\nSo, the answer is A. yes. Uc.63+ overexpression does promote sensitivity to treatment in prostate cancer. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e2b3d97fbd6abf43b00000a", "messages": [{"role": "user", "content": "Does BNN27 promote memory loss?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nBNN27 is a drug that is used to treat Alzheimer's disease. It works by inhibiting the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine. Acetylcholine is important for memory and learning, and its levels are often reduced in the brains of people with Alzheimer's disease. By inhibiting acetylcholinesterase, BNN27 helps to increase the levels of acetylcholine in the brain, which can potentially improve memory and cognitive function.\n\nSo, the answer is B. no. BNN27 does not promote memory loss; rather, it is designed to improve memory and cognitive function in patients with Alzheimer's disease. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e4946bf6d0a277941000005", "messages": [{"role": "user", "content": "Are genomic regulatory blocks (GRBs) any different than TADs?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nGenomic regulatory blocks (GRBs) and topologically associating domains (TADs) are both concepts used to describe the organization of the genome. However, they are not exactly the same.\n\nGRBs are regions of the genome that are thought to be regulated by a common set of transcription factors. They are often associated with the regulation of specific biological processes or pathways. GRBs are typically identified by analyzing the expression patterns of genes within a region and looking for clusters of co-regulated genes.\n\nTADs, on the other hand, are regions of the genome that are thought to be insulated from each other by the 3D structure of the chromatin. TADs are identified by analyzing the contact maps of the genome, which show the frequency of interactions between different regions of the genome. TADs are thought to be important for the proper regulation of gene expression and for the maintenance of genome stability.\n\nSo, the answer is A. Yes, GRBs are different from TADs. GRBs are identified by looking at gene expression patterns, while TADs are identified by analyzing the 3D structure of the genome. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e67bc121af46fc13000001c", "messages": [{"role": "user", "content": "Are Spinal Intradural Primary Malignant Peripheral Nerve Sheath Tumors(MPNST) rare in neurofibromatosis patients?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.cannot be determined\n<|assistant|>\nNeurofibromatosis type 1 (NF1) is a genetic disorder that can lead to the development of benign and malignant tumors, including malignant peripheral nerve sheath tumors (MPNSTs). MPNSTs are rare in the general population, but they are more common in individuals with NF1. In fact, MPNSTs are the most common malignant tumor associated with NF1, and they can occur in the central nervous system, including the spinal cord.\n\nThe risk of developing an MPNST in NF1 patients is estimated to be about 8-13% over the course of their lifetime. This risk is significantly higher than the general population, where MPNSTs are estimated to occur in less than 1% of the population.\n\nGiven this information, we can conclude that Spinal Intradural Primary Malignant Peripheral Nerve Sheath Tumors are not rare in neurofibromatosis patients, but rather are a significant concern due to the increased risk associated with the condition.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e776541835f4e4777000009", "messages": [{"role": "user", "content": "Can MVA85A confer immunity against smallpox?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nMVA85A is a vaccine candidate against tuberculosis (TB) that is being developed as a booster vaccine for the Bacille Calmette-Gu\u00e9rin (BCG) vaccine. It is a modified version of the vaccinia virus, which is the same virus used in the smallpox vaccine. However, MVA85A is not a smallpox vaccine itself. It is designed to boost the immune response to TB antigens, not to confer immunity against smallpox.\n\nSmallpox is a disease caused by the variola virus, which is a different virus from vaccinia. The smallpox vaccine, which is also made from vaccinia, does not provide immunity against other poxviruses, including vaccinia. Therefore, MVA85A, which is also derived from vaccinia, would not confer immunity against smallpox.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e6e2c1e7fc1ee872b000002", "messages": [{"role": "user", "content": "Is MLL3 part of the ASCOM complex?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nMLL3 (mixed lineage leukemia 3) is a histone methyltransferase that is part of the COMPASS (Complex Proteins Associated with Set1) complex. The COMPASS complex is a multi-subunit protein complex that is involved in the methylation of histone H3 lysine 4 (H3K4). This methylation is an important epigenetic mark associated with active transcription.\n\nThe ASCOM (Activator of Spt-Ada-Gcn5 acetyltransferase complex) complex is a different complex that is involved in the regulation of transcription. It is not directly related to the COMPASS complex or the methylation of histone H3 lysine 4.\n\nSo, the answer is B. MLL3 is not part of the ASCOM complex. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e476da1d14c9f295d000002", "messages": [{"role": "user", "content": "Is marimastat effective for small-cell lung cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nMarimastat is an inhibitor of matrix metalloproteinases (MMPs), which are enzymes involved in the breakdown of extracellular matrix components. It was initially developed as an anti-cancer agent because MMPs are involved in tumor invasion and metastasis. However, clinical trials of marimastat in various types of cancer, including small-cell lung cancer, have not shown a significant benefit in terms of survival or tumor response.\n\nIn a phase III trial of marimastat in patients with small-cell lung cancer, the drug did not improve overall survival compared to placebo. The trial was stopped early due to futility, meaning that the drug was not effective in prolonging survival. Therefore, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e4b64126d0a277941000028", "messages": [{"role": "user", "content": "Is Figitumumab effective for non-small cell lung cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nFigitumumab is a monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R). It is used in the treatment of non-small cell lung cancer (NSCLC) in combination with chemotherapy. The IGF-1R pathway is known to be involved in the growth and survival of cancer cells, and targeting this pathway with an antibody like figitumumab can potentially inhibit tumor growth.\n\nHowever, clinical trials of figitumumab in combination with chemotherapy for NSCLC have not shown a significant improvement in overall survival compared to chemotherapy alone. While the drug may have some effect on tumor growth, it does not appear to provide a significant survival benefit when used in combination with chemotherapy.\n\nGiven this information, the answer is B. no. Figitumumab is not effective for non-small cell lung cancer in terms of improving overall survival when used in combination with chemotherapy. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e3ab58db5b409ea5300001c", "messages": [{"role": "user", "content": "The LINCS L1000 data set contains gene expression data for drug treated human cells, yes or no?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nThe LINCS (Library of Integrated Network-based Cellular Signatures) L1000 data set is a large collection of gene expression data from human cells that have been treated with various drugs. The data set includes information on the expression levels of 978 genes, which are considered \"landmark genes\" because they are highly informative about the state of the cell. The data is generated using a high-throughput screening method called L1000, which measures the expression of these landmark genes in response to drug treatment.\n\nSo, the answer is A. yes. The LINCS L1000 data set does contain gene expression data for drug-treated human cells. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e46bdcd3f54159529000007", "messages": [{"role": "user", "content": "Is there a vaccine for peanut allergy?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.not yet\n<|assistant|>\nPeanut allergy is a common food allergy that can be life-threatening. It is caused by an allergic reaction to the proteins in peanuts. The only treatment for peanut allergy is avoidance of peanuts and peanut products. There is no cure or vaccine for peanut allergy.\n\nVaccines are typically used to prevent diseases by stimulating the immune system to produce antibodies against specific pathogens. In the case of peanut allergy, the immune system is already sensitized to peanut proteins, and the goal is not to prevent the allergy but to desensitize the immune system to the allergens. This is not the same as vaccination.\n\nThere are currently no vaccines approved for the treatment of peanut allergy. However, there are ongoing clinical trials investigating the use of oral immunotherapy (OIT) and sublingual immunotherapy (SLIT) to desensitize individuals to peanuts. These treatments involve gradually exposing the allergic individual to increasing amounts of peanut protein over time, with the goal of reducing the severity of allergic reactions.\n\nSo, the answer is B. no. There is no vaccine for peanut allergy. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e476b99d14c9f295d000001", "messages": [{"role": "user", "content": "Is golimumab effective for sarcoidosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nGolimumab is a biologic medication that is used to treat various inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. It is a tumor necrosis factor (TNF) inhibitor, which means it works by blocking the action of TNF, a protein that is involved in inflammation.\n\nSarcoidosis is a chronic inflammatory disease that can affect multiple organs, but it is most commonly diagnosed in the lungs. The exact cause of sarcoidosis is unknown, but it is thought to be an autoimmune disorder where the body's immune system mistakenly attacks healthy tissue. The treatment of sarcoidosis often involves corticosteroids and other immunosuppressive medications to reduce inflammation.\n\nWhile TNF inhibitors like golimumab are commonly used to treat inflammatory conditions, there is no strong evidence that they are effective for sarcoidosis. In fact, there is some concern that TNF inhibitors might worsen sarcoidosis by increasing the risk of lymphoma or other malignancies. Therefore, the use of golimumab for sarcoidosis is not recommended.\n\nSo, the answer is B. no. Golimumab is not effective for sarcoidosis. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e80675d835f4e4777000026", "messages": [{"role": "user", "content": "Is SARS virus interacting with ACE2 encoded protein?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nSARS, or severe acute respiratory syndrome, is caused by the SARS coronavirus (SARS-CoV). The virus enters the body through the respiratory tract and infects the cells lining the airways. To do so, it must bind to a receptor on the surface of these cells. The receptor that SARS-CoV binds to is angiotensin-converting enzyme 2 (ACE2).\n\nACE2 is a protein that is found on the surface of many types of cells, including those in the lungs, intestines, kidneys, and blood vessels. When the SARS-CoV binds to ACE2, it can enter the cell and begin replicating, leading to the symptoms of SARS.\n\nSo, the answer is A. Yes, the SARS virus is interacting with the ACE2 encoded protein. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e3ebaa348dab47f2600000a", "messages": [{"role": "user", "content": "Is the FIP virus thought to be a mutated strain for the Feline enteric Coronavirus?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nThe Feline Infectious Peritonitis (FIP) virus is a mutated strain of the Feline enteric Coronavirus (FECV). FECV is a common virus in cats that typically causes mild gastrointestinal symptoms. However, in some cases, the virus can mutate into a more virulent form, which is known as FIP. FIP is a serious and often fatal disease that affects multiple organ systems, particularly the gastrointestinal tract and the immune system.\n\nThe mutation that occurs in FECV to create FIP is not fully understood, but it is believed to involve a change in the virus's spike protein, which allows it to evade the cat's immune system and cause more severe disease. The mutation is thought to be random and not intentional, but once the virus mutates, it can spread and cause disease in other cats.\n\nSo, the answer is A. yes. The FIP virus is a mutated strain of the Feline enteric Coronavirus. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5d36bb777bc3fee31f00000a", "messages": [{"role": "user", "content": "Does SATB1 regulate the RAG1 and RAG2 genes?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nSATB1 is a protein that is known to bind to the regulatory regions of genes and influence their expression. It is particularly important in the regulation of genes involved in the immune system, including the RAG1 and RAG2 genes.\n\nRAG1 and RAG2 are the genes that encode the recombinase enzymes responsible for the rearrangement of immunoglobulin and T-cell receptor genes during the development of B cells and T cells. This process is crucial for the generation of a diverse immune response.\n\nSATB1 has been shown to bind to the regulatory regions of the RAG1 and RAG2 genes and to influence their expression. It is known to be involved in the activation of these genes during the early stages of T-cell development, which is necessary for the proper rearrangement of T-cell receptor genes.\n\nGiven this information, the answer is A. yes. SATB1 does regulate the RAG1 and RAG2 genes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5d371ec97bc3fee31f00000c", "messages": [{"role": "user", "content": "Is CTCF bound at nucleosome free regions?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nCTCF is a protein that is known to bind to specific sites in the genome, often at regulatory regions such as enhancers and insulators. It is involved in chromatin organization and gene regulation. One of the key features of CTCF binding sites is that they are often located at nucleosome-free regions, which are regions of DNA that are not wrapped around histone proteins.\n\nNucleosome-free regions are important for the binding of transcription factors and other proteins that regulate gene expression. CTCF is one of the proteins that preferentially binds to these regions, as it requires access to the DNA to perform its functions.\n\nSo, the answer is A. Yes, CTCF is bound at nucleosome-free regions. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e3c6850b5b409ea5300001f", "messages": [{"role": "user", "content": "Is bortezomib a Proteasome inhibitor?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nBortezomib is a proteasome inhibitor. Proteasomes are large protein complexes that are responsible for the degradation of proteins in the cell. They are particularly important in the process of ubiquitin-mediated proteolysis, which is a major mechanism for regulating the levels of proteins in the cell. Bortezomib works by inhibiting the activity of the proteasome, which leads to the accumulation of proteins that would normally be degraded by the proteasome. This accumulation can lead to the death of cancer cells, as they are unable to properly regulate their protein levels.\n\nSo, the answer is A. yes. Bortezomib is a proteasome inhibitor. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5d3856ca7bc3fee31f000016", "messages": [{"role": "user", "content": "Is PRDM9 essential for meiosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nPRDM9 is a protein that is known to play a critical role in meiosis, particularly in the process of meiotic recombination. Meiotic recombination is the exchange of genetic material between homologous chromosomes during meiosis, which is essential for the production of genetically diverse gametes. PRDM9 is involved in the initiation of meiotic recombination by binding to specific DNA sequences and recruiting other proteins to the site of recombination.\n\nWhile PRDM9 is important for meiotic recombination, it is not the only factor involved in this process. There are other proteins and mechanisms that contribute to meiotic recombination, and some organisms can undergo meiosis without PRDM9. However, in many species, including humans, PRDM9 is a key player in the initiation of meiotic recombination.\n\nSo, the answer is A. yes. PRDM9 is essential for meiosis in many species, including humans, although it is not the only factor involved. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e4b5f9a6d0a277941000021", "messages": [{"role": "user", "content": "Should Pentoxifylline be used for treatment of amyotrophic lateral sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nPentoxifylline is a medication that is primarily used to improve blood flow in the body, particularly in the peripheral circulation. It is sometimes used to treat intermittent claudication, a condition that causes pain in the legs when walking. Pentoxifylline is thought to work by reducing blood viscosity and improving red blood cell flexibility, which can help to increase blood flow.\n\nAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. It is characterized by muscle weakness and atrophy, and eventually leads to paralysis. There is no cure for ALS, and current treatments are aimed at managing symptoms and prolonging survival.\n\nWhile pentoxifylline might improve blood flow, there is no evidence that it has a direct effect on the progression of ALS or on the symptoms of the disease. In fact, a study published in the New England Journal of Medicine in 2002 found that pentoxifylline did not improve survival or slow the progression of ALS.\n\nGiven the lack of evidence that pentoxifylline is effective in treating ALS, and considering that it is not a treatment for the underlying disease process, it is not recommended for the treatment of ALS.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e52bc986d0a277941000049", "messages": [{"role": "user", "content": "Is the CADM2 gene associated with differences in information processing speed?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nCADM2, also known as SynCAM2, is a cell adhesion molecule that is involved in the formation of synapses in the brain. It is a member of the immunoglobulin superfamily and is expressed in the central nervous system, particularly in the hippocampus and cortex. SynCAM2 is thought to play a role in the formation of excitatory synapses and in the regulation of synaptic plasticity.\n\nInformation processing speed is a measure of how quickly a person can process information, such as in cognitive tasks. While there is some evidence that genetic factors can influence information processing speed, the specific role of the CADM2 gene in this context is not well established. There is no direct evidence that mutations or variations in the CADM2 gene are associated with differences in information processing speed.\n\nGiven the current state of knowledge, it is not possible to definitively say that the CADM2 gene is associated with differences in information processing speed. Therefore, the answer is \"unsure\" or \"D.unsure\".\n\nSo, the answer is D. Unsure. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e494cf96d0a277941000008", "messages": [{"role": "user", "content": "Is Nivolumab (Opdivo) a PD-L1 inhibitor?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nNivolumab is a monoclonal antibody that targets the PD-1 receptor on T cells. PD-1 is a protein that is part of the immune system and plays a role in downregulating the immune response. When PD-1 binds to its ligands, PD-L1 and PD-L2, it sends a signal to the T cell to stop attacking the body's own cells, which can lead to autoimmune diseases. By blocking the PD-1 receptor, nivolumab prevents the binding of PD-L1 and PD-L2, thereby allowing the T cells to continue attacking the body's own cells, which can lead to an immune response against cancer cells.\n\nSo, the answer is A. Yes, Nivolumab is a PD-L1 inhibitor. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e4b5fd86d0a277941000022", "messages": [{"role": "user", "content": "Does clinical trial data support the use of minocycline for amyotrophic lateral sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.not applicable\n<|assistant|>\nAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord. There is no cure for ALS, and treatment options are limited to managing symptoms and prolonging survival.\n\nMinocycline is an antibiotic that has been studied for its potential neuroprotective effects in various neurological conditions, including ALS. However, the clinical trial data on the use of minocycline for ALS is not conclusive.\n\nA 2013 meta-analysis of randomized controlled trials found that minocycline did not significantly improve survival or slow disease progression in patients with ALS. However, the authors noted that the studies included in the analysis had methodological limitations and that further research was needed.\n\nA 2017 study found that minocycline may have a modest effect on slowing disease progression in ALS, but the results were not statistically significant. The study was criticized for its small sample size and the lack of a control group.\n\nOverall, the clinical trial data does not strongly support the use of minocycline for ALS. While there may be some potential for neuroprotection, the evidence is not robust enough to recommend its use as a standard treatment for the disease.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e776a10835f4e477700000c", "messages": [{"role": "user", "content": "Is the drug Exubera currently (March 2020) available?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nExubera is an inhaled form of insulin that was approved by the FDA in 2006. It was designed to be an alternative to subcutaneous insulin injections for patients with type 1 or type 2 diabetes. However, it was withdrawn from the market in 2007 due to poor sales and safety concerns.\n\nThe drug was not available for purchase after its withdrawal from the market. While it is possible that Exubera could be reintroduced in the future, there is no indication that it is currently available.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e3c6e15b5b409ea53000023", "messages": [{"role": "user", "content": "Are breaks in double stranded DNA associated with ionizing radiation?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nIonizing radiation is a form of radiation that can cause damage to living tissue by ionizing atoms and molecules, which can lead to the formation of free radicals and other reactive species. When these high-energy particles or photons interact with biological material, they can cause damage to DNA, proteins, and other cellular components.\n\nOne of the most common types of damage caused by ionizing radiation is the formation of DNA double-strand breaks (DSBs). These breaks occur when both strands of the DNA helix are broken, which can be a particularly dangerous type of damage because it can lead to chromosomal instability and cell death if not repaired properly.\n\nSo, the answer is A. Yes, breaks in double stranded DNA are associated with ionizing radiation. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e52c0c76d0a27794100004b", "messages": [{"role": "user", "content": "Is KAT2A involved in Acute myeloid leukemia (AML)?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nKAT2A, also known as MYST3, is a histone acetyltransferase that is involved in the acetylation of histones and other proteins. It is a component of the NuA4 histone acetyltransferase complex, which is involved in the regulation of transcription and chromatin structure.\n\nAcute myeloid leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal cells that build up in the bone marrow and interfere with the production of normal blood cells. These abnormal cells are often referred to as leukemia cells.\n\nWhile KAT2A is involved in the regulation of gene expression and chromatin structure, there is no direct evidence that it is specifically involved in the pathogenesis of AML. However, it is known that chromatin remodeling and epigenetic modifications play a role in the development of AML, and KAT2A is one of the enzymes involved in these processes.\n\nGiven the lack of direct evidence linking KAT2A to AML, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e4b639c6d0a277941000027", "messages": [{"role": "user", "content": "Is NicVAX vaccine effective for smoking cessation?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nNicVAX is a vaccine that is designed to help people quit smoking by stimulating the immune system to produce antibodies against nicotine. The idea is that by exposing the body to nicotine in a controlled manner, the immune system will develop a tolerance to nicotine, making it less effective as a reward and reducing the desire to smoke.\n\nHowever, the results of clinical trials have been mixed. While some studies have shown that NicVAX can help people quit smoking, others have not found a significant benefit. The vaccine has not been approved by the FDA for use in the United States, and its effectiveness is still being debated.\n\nGiven the current state of research, it is difficult to say with certainty whether NicVAX is effective for smoking cessation. While it may have some potential, the evidence is not conclusive enough to make a definitive statement.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e48b1ddd14c9f295d000012", "messages": [{"role": "user", "content": "Does natalizumab improve disease course of secondary progressive multiple sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nNatalizumab is a monoclonal antibody that is used to treat multiple sclerosis (MS). It works by preventing the migration of immune cells into the central nervous system, which is thought to be a key mechanism in the pathogenesis of MS.\n\nThe disease course of MS is typically classified into four phases: relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), and progressive-relapsing MS. Natalizumab is approved for the treatment of RRMS and SPMS, but not for PPMS.\n\nIn patients with RRMS, natalizumab has been shown to reduce the frequency of relapses and the number of new or enlarging lesions on MRI scans. However, in patients with SPMS, the evidence for the efficacy of natalizumab is less clear. While some studies have shown a reduction in the rate of disability progression in SPMS patients treated with natalizumab, other studies have not shown a significant benefit.\n\nGiven the mixed results and the lack of a clear consensus, it is difficult to definitively state that natalizumab improves the disease course of SPMS. However, it may be considered a treatment option for some patients with SPMS, particularly those who have not responded to other therapies.\n\nSo, the answer is C. may be. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e52c9266d0a27794100004e", "messages": [{"role": "user", "content": "AhR ligands are attractive drug targets for pharmaceutical development due to their induction of Cyp1a1, yes or no?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nAhR (aryl hydrocarbon receptor) is a ligand-activated transcription factor that plays a role in the regulation of genes involved in xenobiotic metabolism, including the induction of CYP1A1. CYP1A1 is a cytochrome P450 enzyme that is involved in the metabolism of various xenobiotics, including carcinogens and environmental pollutants.\n\nWhen AhR is activated by its ligands, it translocates to the nucleus and forms a heterodimer with the AhR nuclear translocator (ARNT). This complex then binds to the xenobiotic response element (XRE) in the promoter region of genes, including CYP1A1, leading to their transcription and subsequent protein expression.\n\nTherefore, AhR ligands are indeed attractive drug targets for pharmaceutical development due to their ability to induce CYP1A1 and other genes involved in xenobiotic metabolism.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5d385f717bc3fee31f00001a", "messages": [{"role": "user", "content": "Does the chromatin remodeling complex, RSC target H2A.Z nucleosomes?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nRSC (Remodeling the Structure of Chromatin) is a chromatin remodeling complex that is involved in the regulation of gene expression by altering the structure of chromatin. One of the ways it does this is by targeting nucleosomes and modifying their structure.\n\nH2A.Z is a variant of the histone H2A protein that is found in nucleosomes. It is known to be associated with active genes and is often found at the 5' end of genes, where it is thought to play a role in transcriptional activation. RSC has been shown to target H2A.Z nucleosomes and to be involved in the exchange of H2A.Z for H2A, which can lead to changes in chromatin structure and gene expression.\n\nSo, the answer is A. yes. RSC does target H2A.Z nucleosomes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e7f69d2835f4e4777000021", "messages": [{"role": "user", "content": "Has ZP-PTH been tested in a phase II clinical trial?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.uncertain\n<|assistant|>\nZP-PTH is a synthetic parathyroid hormone (PTH) analog that is being investigated as a potential treatment for osteoporosis. Phase II clinical trials are typically conducted after a drug has shown promising results in preclinical studies and in Phase I trials. These trials are designed to evaluate the safety and efficacy of the drug in a larger group of patients.\n\nGiven that ZP-PTH is a potential treatment for osteoporosis, it is likely that it has been tested in a Phase II clinical trial. This is because Phase II trials are crucial for determining the efficacy of a drug in a larger population and for identifying any potential side effects or adverse reactions that may not have been apparent in smaller Phase I trials.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e48b9abd14c9f295d000015", "messages": [{"role": "user", "content": "Are multipotent adult progenitor cells effective for treatment of stroke?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nMultipotent adult progenitor cells (MAPCs) are a type of stem cell that has the ability to differentiate into a variety of cell types, including neurons, astrocytes, and oligodendrocytes. These cells have been studied for their potential to treat neurological conditions such as stroke, where there is a need to replace damaged brain tissue.\n\nThe idea behind using MAPCs for stroke treatment is that they can be injected into the brain and differentiate into the types of cells needed to repair the damaged tissue. However, the effectiveness of MAPCs for stroke treatment is still under investigation.\n\nWhile there have been some promising preclinical studies showing that MAPCs can improve neurological function in animal models of stroke, the results in humans are less clear. A small clinical trial in 2010 found that MAPCs did not improve neurological outcomes in patients with ischemic stroke. However, this trial was limited by its small sample size and the fact that it was not a randomized controlled trial.\n\nGiven the current state of research, it is difficult to say with certainty whether MAPCs are effective for the treatment of stroke. While there is some evidence that they may have potential, more research is needed to determine their efficacy in humans.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e3d8edf48dab47f26000003", "messages": [{"role": "user", "content": "Autophagy is the process where a virus obtains nutrients from it's host, yes or no?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nAutophagy is a process by which cells break down and recycle their own components. It is a normal physiological process that occurs in all eukaryotic cells and is important for maintaining cellular homeostasis. During autophagy, the cell engulfs parts of its own cytoplasm and organelles in a double-membrane vesicle called an autophagosome. The autophagosome then fuses with a lysosome, where the contents are degraded and the components are recycled.\n\nViruses, on the other hand, do not have the ability to perform autophagy. They are not living organisms and do not have the necessary machinery to carry out this process. Instead, viruses rely on the host cell's machinery to replicate and obtain nutrients. They can hijack the host cell's metabolic pathways to produce the proteins and other components they need to replicate.\n\nSo, the answer is B. no. Viruses do not perform autophagy. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5d387a51a1e159510500000e", "messages": [{"role": "user", "content": "Does CXorf21 escape X chromosome inactivation?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nCXorf21 is a gene located on the X chromosome. X chromosome inactivation is a process by which one of the two X chromosomes in female cells is inactivated to ensure that females do not have twice as much X-linked gene product as males. This inactivation is a random process that occurs early in development and is maintained throughout the life of the cell.\n\nThe inactivation of one of the two X chromosomes in females is a normal and necessary process to ensure that females do not have twice as much X-linked gene product as males. However, there are some genes on the X chromosome that escape this inactivation process. These genes are called X-linked genes that escape X inactivation (XES).\n\nCXorf21 is one of the genes that has been shown to escape X inactivation. This means that in female cells, both copies of the CXorf21 gene are active, unlike most other X-linked genes, which are inactivated in one of the two X chromosomes.\n\nSo, the answer is A. yes. CXorf21 does escape X chromosome inactivation. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e52ab626d0a277941000046", "messages": [{"role": "user", "content": "Does promoter shape vary across populations?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nThe shape of a promoter is important for the regulation of gene expression. Promoters are regions of DNA that are bound by transcription factors and other proteins to initiate transcription of a gene. The shape of a promoter can affect the binding of these proteins and the efficiency of transcription.\n\nHowever, the shape of a promoter can vary across populations due to several factors. For example, natural selection can favor different promoter shapes in different environments, leading to genetic variation in promoter shape across populations. Additionally, mutations can occur in the promoter region, leading to changes in its shape.\n\nSo, the answer is D. It depends. The shape of a promoter can vary across populations depending on the factors mentioned above. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e4b5ef36d0a27794100001f", "messages": [{"role": "user", "content": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord. It leads to muscle weakness and atrophy, and eventually respiratory failure. There is no cure for ALS, and treatment is focused on managing symptoms and prolonging survival.\n\nXaliproden is a drug that was investigated as a potential treatment for ALS. It is an agonist of the sigma-1 receptor, which is involved in the regulation of cell survival and stress responses. Theoretically, by activating the sigma-1 receptor, xaliproden could help protect motor neurons from damage and slow the progression of the disease.\n\nHowever, clinical trials of xaliproden in ALS have not shown a significant improvement in prognosis. In fact, one large trial (the X-SEALS study) was stopped early due to futility, meaning that the drug was not effective in improving outcomes. Therefore, the answer is B. No, xaliproden does not improve the prognosis of amyotrophic lateral sclerosis. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e8101e3835f4e477700002e", "messages": [{"role": "user", "content": "Is cathepsin L active in endosomes?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nCathepsin L is a lysosomal cysteine protease that is primarily responsible for the degradation of proteins in the lysosomes. It is synthesized in the endoplasmic reticulum and then transported to the Golgi apparatus, where it is packaged into vesicles and transported to lysosomes. Once in the lysosomes, cathepsin L is activated by the low pH environment and begins to degrade proteins.\n\nEndosomes are a type of vesicle that are involved in the internalization of extracellular material and the recycling of membrane components. They are not typically associated with the degradation of proteins, which is the primary function of lysosomes. Therefore, cathepsin L is not active in endosomes, as it is primarily active in the acidic environment of lysosomes.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e4b5f566d0a277941000020", "messages": [{"role": "user", "content": "Is celecoxib effective for amyotrophic lateral sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord. There is no cure for ALS, and treatment is focused on managing symptoms and prolonging survival.\n\nCelecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that is commonly used for pain relief and inflammation. It is not typically used for the treatment of ALS. While NSAIDs can be used to manage pain in ALS patients, there is no evidence that they have a significant impact on the progression of the disease.\n\nThere is no clear evidence that celecoxib is effective for ALS. In fact, some studies have suggested that NSAIDs may actually worsen the course of the disease by increasing oxidative stress and inflammation, which are already key components of ALS pathology.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e6e8600c6a8763d23000002", "messages": [{"role": "user", "content": "Is the protein MCL-1 anti-apoptotic?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nMCL-1 is a member of the BCL-2 family of proteins, which are known to regulate apoptosis. The BCL-2 family includes both pro-apoptotic and anti-apoptotic members. MCL-1 is considered to be an anti-apoptotic protein because it prevents the release of cytochrome c from the mitochondria, which is a key step in the activation of the caspase cascade and the initiation of apoptosis.\n\nSo, the answer is A. yes. MCL-1 is an anti-apoptotic protein. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5e48bd2ed14c9f295d000017", "messages": [{"role": "user", "content": "Is ozanezumab effective for amyotrophic lateral sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nOzanezumab is a monoclonal antibody that targets the neurotrophic receptor p75NTR. It is being investigated as a potential treatment for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord. The rationale behind using ozanezumab in ALS is that p75NTR is involved in the death of motor neurons, and by blocking its action, it may slow down the progression of the disease.\n\nHowever, the results of clinical trials have been mixed. While some studies have shown a trend towards a slower decline in function, others have not shown a significant benefit. The most recent phase 3 trial, called the SENSE trial, was stopped early due to futility, meaning that the trial did not show a significant benefit of ozanezumab over placebo.\n\nGiven the current evidence, it is not clear whether ozanezumab is effective for amyotrophic lateral sclerosis. While there is some preliminary evidence that it may have a positive effect, the results of the SENSE trial and other studies are not conclusive.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e4b62946d0a277941000024", "messages": [{"role": "user", "content": "Is Dexmecamylamine effective for depression?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nDexmecamylamine is a medication that is primarily used as an antihypertensive agent. It works by blocking the action of acetylcholine, which is a neurotransmitter that plays a role in the autonomic nervous system. While it is not typically used as a treatment for depression, it can have some effects on mood due to its action on the central nervous system.\n\nHowever, the primary use of dexmecamylamine is not for the treatment of depression. There are other medications that are specifically designed to treat depression, and dexmecamylamine is not one of them. Therefore, it is unlikely that dexmecamylamine would be effective for depression.\n\nSo, the answer is D. unlikely. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5e7f64a5835f4e477700001e", "messages": [{"role": "user", "content": "Can CMB305 be used against sarcomas?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nCMB305, also known as pembrolizumab, is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. PD-1 is a protein that acts as an immune checkpoint, inhibiting the activity of T cells. By blocking the PD-1 receptor, CMB305 can enhance the immune response against cancer cells.\n\nSarcomas are a type of cancer that arises from connective tissue, such as bone, cartilage, fat, muscle, blood vessels, or deep skin tissues. They are a diverse group of tumors that can occur in many parts of the body.\n\nWhile CMB305 is not specifically approved for the treatment of sarcomas, it has been used off-label in clinical trials and case reports for the treatment of various types of sarcomas, including soft tissue sarcomas and bone sarcomas. These trials have shown promising results, suggesting that CMB305 may be effective against sarcomas.\n\nGiven this information, the answer is A. yes, CMB305 can be used against sarcomas. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c58a74e86df2b917400000d", "messages": [{"role": "user", "content": "Is Baloxavir effective for influenza?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nBaloxavir is a novel antiviral medication that was approved by the FDA in 2018 for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours. It works by inhibiting the cap-dependent endonuclease of influenza virus RNA polymerase, which is essential for viral replication.\n\nThe effectiveness of Baloxavir in treating influenza has been studied in clinical trials. In one study, patients who received Baloxavir within 24 hours of symptom onset had a shorter time to alleviation of symptoms compared to those who received placebo. Additionally, the study showed that Baloxavir reduced the duration of influenza symptoms by 1.5 days compared to placebo.\n\nGiven the evidence from clinical trials, it can be concluded that Baloxavir is effective for the treatment of influenza when administered within 48 hours of symptom onset.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5be44bef133db5eb78000014", "messages": [{"role": "user", "content": "Are there microbes in human breast milk?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nHuman breast milk is a complex fluid that provides essential nutrients, antibodies, and other substances to the newborn. It is known to contain a variety of beneficial bacteria, including Lactobacillus species, which are important for the development of the infant's gut microbiome. These bacteria are believed to help protect the infant from pathogens and promote healthy digestion.\n\nIn addition to the beneficial bacteria, human breast milk also contains a variety of other microbes, including viruses, fungi, and protozoa. While the majority of these microbes are harmless or even beneficial, there are some that can cause infections in the infant if they are present in high numbers or if the infant has a compromised immune system.\n\nSo, the answer is A. Yes, there are microbes in human breast milk. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c61bacae842deac67000001", "messages": [{"role": "user", "content": "Is cariprazine effective for treatment of bipolar disorder?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nCariprazine is an atypical antipsychotic medication that is approved for the treatment of schizophrenia and bipolar disorder. It works by modulating dopamine and serotonin receptors in the brain, which can help to stabilize mood and reduce symptoms of bipolar disorder.\n\nIn clinical trials, cariprazine has been shown to be effective in the treatment of bipolar disorder, particularly in the manic and mixed episodes. It has been found to be effective in reducing symptoms of mania and preventing relapse, and it has a relatively good safety profile compared to other antipsychotic medications.\n\nSo, the answer is A. Yes, cariprazine is effective for the treatment of bipolar disorder. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c55d75807647bbc4b000008", "messages": [{"role": "user", "content": "Is Bobble head doll syndrome associated with hydrocephalus?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nBobble head doll syndrome, also known as Marfanoid-progeroid-lipodystrophy syndrome, is a rare genetic disorder characterized by a combination of features that include a marfanoid habitus (tall, thin, and long-limbed), premature aging, and lipodystrophy (loss of fat tissue). It is caused by mutations in the LMNA gene, which encodes the A-type lamins.\n\nHydrocephalus is a condition where there is an accumulation of cerebrospinal fluid (CSF) within the ventricles of the brain. It is not typically associated with Bobble head doll syndrome. While some genetic syndromes can be associated with hydrocephalus, such as Aicardi syndrome or Joubert syndrome, Bobble head doll syndrome is not one of them.\n\nSo, the answer is B. No, Bobble head doll syndrome is not associated with hydrocephalus. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5be44f50133db5eb78000017", "messages": [{"role": "user", "content": "Can breastfeeding confer protection from type I diabetes?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nBreastfeeding has been associated with a reduced risk of type 1 diabetes in children. This is because breast milk contains a variety of factors that can help to protect the infant's immune system. One of these factors is maternal antibodies, which can be transferred to the infant through breast milk and may help to protect against certain infections that could trigger the development of type 1 diabetes.\n\nStudies have shown that breastfeeding for at least six months can reduce the risk of type 1 diabetes in children. This is because the antibodies in breast milk can help to modulate the infant's immune system and potentially reduce the risk of autoimmune diseases like type 1 diabetes.\n\nSo, the answer is A. Yes, breastfeeding can confer protection from type 1 diabetes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5be47bff133db5eb78000018", "messages": [{"role": "user", "content": "Can pets affect infant microbiomed?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nThe microbiome of an infant is shaped by a variety of factors, including the environment, diet, and the presence of other organisms. One of the most significant influences on an infant's microbiome is the mother's microbiome, which is transferred to the infant during birth and breastfeeding. However, pets can also contribute to the infant's microbiome.\n\nPets, especially dogs and cats, can carry a variety of bacteria and other microorganisms on their fur and in their environment. When infants come into contact with these pets, they can potentially acquire some of these microorganisms. While the impact of pet exposure on the infant microbiome is not fully understood, there is some evidence that it can contribute to the diversity of the infant's microbiome.\n\nFor example, a study found that infants who had pets in the household had a more diverse gut microbiome compared to infants without pets. This diversity may be beneficial for the infant's health, as a diverse microbiome is associated with a healthier immune system and a lower risk of certain diseases.\n\nSo, the answer is A. Yes, pets can affect the infant microbiome. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5be48282133db5eb7800001b", "messages": [{"role": "user", "content": "Is there any association between the human gut microbiome and depression?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nThe human gut microbiome is a complex ecosystem of microorganisms that live in the digestive tract. It plays a crucial role in various aspects of human health, including metabolism, immune function, and even brain function. There is growing evidence that the gut microbiome can influence mental health, including depression.\n\nStudies have shown that individuals with depression often have different gut microbiome profiles compared to those without depression. For example, certain bacteria species are more abundant in the gut of people with depression, while others are less abundant. These differences in the gut microbiome may contribute to the development of depression or be a result of it.\n\nHowever, the exact nature of the relationship between the gut microbiome and depression is still being investigated. While there is a strong association, it is not yet clear if the gut microbiome is a cause or a consequence of depression. Additionally, the specific mechanisms by which the gut microbiome might influence depression are not fully understood.\n\nGiven the current state of research, it is fair to say that there is an association between the human gut microbiome and depression, but the exact nature of this relationship is still being explored.\n\nSo, the answer is A. yes. There is an association between the human gut microbiome and depression. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c2f8127133db5eb78000032", "messages": [{"role": "user", "content": "Are whole-genome duplications more divergent than small-scale duplications in yeast?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nWhole-genome duplications (WGDs) are events where an entire genome is duplicated, while small-scale duplications (SSDs) are events where only a small portion of the genome is duplicated. In yeast, WGDs are known to occur, and they can have a significant impact on the evolution of the organism.\n\nWGDs are often associated with bursts of gene innovation and the creation of new gene functions. This is because the duplicated genes can undergo neofunctionalization, where one copy of the gene evolves a new function, or subfunctionalization, where the two copies of the gene evolve to perform different parts of the original function. These processes can lead to the rapid evolution of new traits and adaptations.\n\nSSDs, on the other hand, are more likely to be retained if they are beneficial, but they are also more likely to be lost if they are not. This is because SSDs are smaller and may not contain as many genes that are essential for the organism's survival. Therefore, they may be more prone to drift and selection pressure.\n\nGiven this information, it is reasonable to assume that WGDs are more divergent than SSDs in yeast because they can lead to more rapid and significant changes in the genome, which can result in more divergent outcomes compared to SSDs.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c34794fda8336e21a000001", "messages": [{"role": "user", "content": "Do yeast LTR give rise to circular DNA?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nYeast LTRs (long terminal repeats) are a type of repetitive DNA sequence found at the ends of retrotransposons and retroviruses. They are responsible for the integration of the viral genome into the host genome during the retroviral life cycle. The LTRs are composed of regulatory sequences that are involved in the transcription and replication of the viral genome.\n\nWhen a retrovirus integrates into the host genome, the LTRs are duplicated and flanked by the host DNA. This process creates a structure that looks like a circle, with the LTRs at the ends and the host DNA in between. However, the LTRs themselves do not give rise to circular DNA. Instead, they are part of the linear viral genome that is integrated into the host genome.\n\nSo, the answer is B. No, yeast LTRs do not give rise to circular DNA. They are part of the linear viral genome that is integrated into the host genome. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c644c3de842deac67000018", "messages": [{"role": "user", "content": "Is cohesin linked to myeloid differentiation?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nCohesin is a protein complex that plays a crucial role in the condensation of chromosomes during mitosis and meiosis. It is also involved in the regulation of gene expression and the maintenance of genome stability. However, there is no direct evidence that cohesin is specifically linked to myeloid differentiation.\n\nMyeloid differentiation refers to the process by which hematopoietic stem cells differentiate into various types of blood cells, including red blood cells, platelets, and various types of white blood cells. This process is regulated by a complex network of transcription factors and signaling pathways.\n\nWhile cohesin is known to be involved in the regulation of gene expression, there is no specific evidence that it is directly involved in the differentiation of myeloid cells. Instead, other factors such as transcription factors and signaling pathways are more commonly associated with myeloid differentiation.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5be49287133db5eb7800001e", "messages": [{"role": "user", "content": "Is pembrolizumab effective against Ewing's sarcoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nPembrolizumab is an immune checkpoint inhibitor that targets the programmed cell death protein 1 (PD-1) receptor. It is used in the treatment of various cancers, including melanoma, non-small cell lung cancer, and head and neck squamous cell carcinoma. Ewing's sarcoma is a type of bone cancer that typically affects children and young adults. It is a highly aggressive tumor that is often resistant to conventional chemotherapy and radiation therapy.\n\nThere is currently no evidence to suggest that pembrolizumab is effective against Ewing's sarcoma. While immune checkpoint inhibitors have shown promise in treating other types of sarcomas, such as malignant peripheral nerve sheath tumors, there is no clinical data to support their use in Ewing's sarcoma.\n\nGiven the lack of evidence and the specific nature of Ewing's sarcoma, it is unlikely that pembrolizumab would be effective against this type of cancer.\n\nSo, the answer is D. unlikely. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5be94b87133db5eb78000020", "messages": [{"role": "user", "content": "Can gene therapy restore auditory function?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nGene therapy is a promising field in medicine that involves the transfer of genetic material into cells to treat or prevent disease. It has been used to treat a variety of conditions, including genetic disorders, cancer, and infectious diseases.\n\nIn the context of restoring auditory function, gene therapy could potentially be used to treat hearing loss. Hearing loss can be caused by a variety of factors, including genetic mutations, exposure to loud noise, and aging. In some cases of genetic hearing loss, the underlying cause is a mutation in a gene that is responsible for the production of a protein that is critical for the function of the inner ear. If the gene responsible for the protein can be identified and a functional copy of the gene can be introduced into the inner ear cells, it may be possible to restore auditory function.\n\nHowever, gene therapy for hearing loss is still in the early stages of development and has not yet been widely used in clinical practice. There are several challenges to overcome, including the delivery of the therapeutic gene to the inner ear cells and ensuring that the gene is expressed at the correct levels and in the correct cells to achieve the desired effect.\n\nSo, the answer is C. Maybe. While gene therapy has the potential to restore auditory function in certain cases of hearing loss, it is not a standard treatment and is still being researched and developed. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c58447f07647bbc4b000021", "messages": [{"role": "user", "content": "Is the PINES framework being used for the prediction of coding variants?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nThe PINES framework is a computational method for predicting the impact of coding variants on protein function. It stands for \"Predicting the Impact of Non-synonymous SNPs on Protein Function.\" The framework uses a combination of machine learning and protein structure analysis to predict the effect of a coding variant on the protein's function.\n\nThe PINES framework is specifically designed to predict the impact of coding variants, which are single nucleotide polymorphisms (SNPs) that result in a change in the amino acid sequence of a protein. It does not directly predict the impact of non-coding variants, which are changes in the DNA sequence that do not result in a change in the amino acid sequence of a protein.\n\nSo, the answer is A. yes. The PINES framework is used for the prediction of coding variants. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c647c52e842deac6700001c", "messages": [{"role": "user", "content": "Is erythropoietin effective for treatment of amyotrophic lateral sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord. It is characterized by muscle weakness and atrophy, and eventually leads to paralysis and death. There is no cure for ALS, and treatment is focused on managing symptoms and prolonging survival.\n\nErythropoietin is a hormone that stimulates the production of red blood cells. It has been studied for its potential to protect neurons from damage in various neurological conditions, including ALS. However, the evidence for its effectiveness in treating ALS is mixed. Some studies have shown that erythropoietin may slow the progression of ALS, while others have not found a significant benefit.\n\nGiven the conflicting results and the need for further research, it is difficult to say with certainty whether erythropoietin is effective for the treatment of ALS. However, it is a promising area of research, and more studies are needed to determine its true efficacy.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c6638717c78d69471000012", "messages": [{"role": "user", "content": "Is celecoxib effective for treatment of amyotrophic lateral sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord. There is no cure for ALS, and treatment is focused on managing symptoms and prolonging survival.\n\nCelecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that is commonly used for pain relief and inflammation. It is not typically used for the treatment of ALS. While NSAIDs can be used to manage pain in ALS patients, there is no evidence that they have a significant impact on the progression of the disease.\n\nThere is no clear evidence that celecoxib is effective for the treatment of ALS. In fact, some studies have suggested that NSAIDs may actually worsen the course of the disease by increasing oxidative stress and inflammation, which are already key components of ALS pathology.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c531e887e3cb0e231000018", "messages": [{"role": "user", "content": "Are ultraconserved enhancers important for normal development?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nUltraconserved enhancers are DNA sequences that are highly conserved across species, often with 100% identity between humans and other mammals. These enhancers are thought to play a critical role in the regulation of gene expression during development and in the maintenance of tissue-specific gene expression patterns.\n\nStudies have shown that mutations in ultraconserved enhancers can lead to developmental abnormalities and diseases. For example, mutations in the HoxD cluster of ultraconserved enhancers have been linked to syndactyly, a condition where two or more fingers or toes are fused together. This suggests that ultraconserved enhancers are indeed important for normal development.\n\nGiven the evidence that ultraconserved enhancers are critical for normal development, the answer is A. Yes, ultraconserved enhancers are important for normal development. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c5f12d91a4c55d80b000016", "messages": [{"role": "user", "content": "Is chlorotoxin a peptide?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nChlorotoxin is a peptide that is derived from the venom of the deathstalker scorpion (Leiurus quinquestriatus). It is a 36-amino acid peptide that is known for its ability to bind to chloride channels and inhibit their function. Chlorotoxin has been studied for its potential use in cancer therapy due to its ability to target glioma cells, which are highly invasive and difficult to treat.\n\nPeptides are short chains of amino acids linked together by peptide bonds. Chlorotoxin is a peptide because it is composed of amino acids and has a specific sequence of those amino acids. It is not a protein because proteins are typically larger and have a more complex structure than peptides.\n\nSo, the answer is A. yes. Chlorotoxin is a peptide. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c00f38e133db5eb78000023", "messages": [{"role": "user", "content": "Does vesatolimod inhibit TLR7?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nVesatolimod (formerly known as BMS-986165) is a Toll-like receptor 7 (TLR7) agonist that is being investigated for the treatment of chronic hepatitis B virus (HBV) infection. TLR7 agonists are known to stimulate the innate immune system by activating dendritic cells and natural killer cells, which can lead to the production of interferons and other cytokines that are important for the control of viral infections.\n\nThe mechanism of action of vesatolimod is to activate TLR7, which is expressed on certain immune cells, including plasmacytoid dendritic cells (pDCs). When TLR7 is activated, it leads to the production of type I interferons (IFNs), which are key mediators of the antiviral response.\n\nSo, the answer is A. yes. Vesatolimod does inhibit TLR7. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c5f21a81a4c55d80b00001c", "messages": [{"role": "user", "content": "Is selenocysteine an aminoacid?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nSelenocysteine is an amino acid that is incorporated into proteins in a process called selenocysteine insertion. It is the 21st amino acid in the standard genetic code and is encoded by the codon UGA, which is normally a stop codon. However, when the UGA codon is preceded by a specific sequence of nucleotides, it is recognized as a selenocysteine codon and is translated into selenocysteine instead of terminating the protein synthesis.\n\nSelenocysteine is found in a small number of proteins, particularly those involved in redox reactions and antioxidant defense. It is essential for the proper functioning of these proteins, and its incorporation into proteins is a unique and important aspect of protein synthesis.\n\nSo, the answer is A. yes. Selenocysteine is an amino acid. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c58923c86df2b9174000005", "messages": [{"role": "user", "content": "Is Tecovirimat effective for smallpox?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nTecovirimat, also known as ST-246, is an antiviral drug that is specifically designed to treat smallpox, which is caused by the variola virus. Smallpox is a highly contagious and deadly disease that was eradicated through a global vaccination campaign in the 1970s. However, there is a concern that the variola virus could be used as a biological weapon, and therefore, there is a need for effective treatments in case of a smallpox outbreak.\n\nTecovirimat works by inhibiting the assembly of the virus particles, which prevents the virus from spreading within the host cells. It has been shown to be effective in animal models and in vitro studies against variola virus, the causative agent of smallpox. Clinical trials in humans have not been conducted due to the ethical concerns of deliberately infecting people with smallpox, but the drug has been approved by the FDA for the treatment of smallpox.\n\nGiven the evidence from animal studies and in vitro testing, it is reasonable to conclude that Tecovirimat is effective for smallpox. Therefore, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c010e09133db5eb78000024", "messages": [{"role": "user", "content": "Can simvastatin alleviate depressive symptoms?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nSimvastatin is a statin medication that is primarily used to lower cholesterol levels and reduce the risk of cardiovascular disease. It works by inhibiting the enzyme HMG-CoA reductase, which is responsible for the production of cholesterol in the liver.\n\nHowever, there is some evidence that statins may have additional benefits beyond their cholesterol-lowering effects. One of these potential benefits is the reduction of depressive symptoms. Several studies have suggested that statins may have a positive effect on mood and cognitive function, particularly in patients with a history of depression or cognitive impairment.\n\nA meta-analysis of randomized controlled trials found that statin use was associated with a significant reduction in depressive symptoms, even after adjusting for potential confounders such as age, gender, and baseline depression severity. Another study found that statin use was associated with a lower risk of developing depression in patients with coronary artery disease.\n\nWhile the exact mechanism by which statins might alleviate depressive symptoms is not fully understood, it is possible that the anti-inflammatory and neuroprotective effects of statins may play a role. Inflammation has been linked to both cardiovascular disease and depression, and statins have been shown to reduce inflammation.\n\nSo, the answer is A. yes, simvastatin can alleviate depressive symptoms. However, it's important to note that this is an area of ongoing research and the evidence is not conclusive. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c5f2b771a4c55d80b000020", "messages": [{"role": "user", "content": "Is P. gingivalis bacteria found in brain?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nP. gingivalis is a bacterium that is commonly associated with periodontal disease, particularly chronic periodontitis. It is known to be a pathogen that can cause inflammation and tissue destruction in the gums and surrounding tissues. However, there is some evidence that suggests that P. gingivalis may also be involved in the pathogenesis of neurodegenerative diseases, such as Alzheimer's disease.\n\nStudies have shown that P. gingivalis can invade the brain and cause inflammation, which is a hallmark of Alzheimer's disease. The bacteria can also produce toxins that may contribute to the formation of amyloid plaques, which are a hallmark of Alzheimer's disease. Additionally, P. gingivalis has been found in the brains of patients with Alzheimer's disease, suggesting a potential role in the disease process.\n\nGiven this evidence, it is reasonable to conclude that P. gingivalis bacteria can be found in the brain, particularly in the context of neurodegenerative diseases like Alzheimer's disease.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c58ac2286df2b917400000f", "messages": [{"role": "user", "content": "Is ibudilast effective for multiple sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nIbudilast is a drug that has been studied for its potential to treat multiple sclerosis (MS). MS is a chronic inflammatory disease of the central nervous system that affects the brain and spinal cord. The disease is characterized by demyelination, which is the destruction of the myelin sheath that surrounds and protects nerve fibers. This can lead to a wide range of symptoms, including muscle weakness, numbness, and problems with vision, speech, and balance.\n\nIbudilast is an anti-inflammatory and neuroprotective drug that has been used in the treatment of asthma and glaucoma. It works by inhibiting the production of inflammatory mediators such as prostaglandins and leukotrienes, and by promoting the production of neurotrophic factors that support the survival of neurons.\n\nIn recent years, there has been interest in the use of ibudilast for the treatment of MS. Several clinical trials have been conducted to evaluate its efficacy in MS. One of the largest and most recent trials, the INFORMS study, found that ibudilast was not effective in reducing the number of relapses in patients with relapsing-remitting MS. However, the drug did show some promise in reducing the number of gadolinium-enhancing lesions on MRI scans, which are indicative of inflammation in the brain.\n\nGiven the current evidence, it is not clear whether ibudilast is effective for multiple sclerosis. While it may have some neuroprotective and anti-inflammatory properties, the clinical trials to date have not shown a clear benefit in reducing the number of relapses, which is a key outcome in MS treatment.\n\nSo, the answer is B. no. Ibudilast is not currently considered effective for multiple sclerosis based on the available clinical trial data. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c0114ec133db5eb78000028", "messages": [{"role": "user", "content": "Does gepotidacin activate bacterial topoisomerase?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nGepotidacin is a novel antibiotic that is currently in clinical trials for the treatment of bacterial infections. It is a quinolone derivative that works by inhibiting bacterial DNA gyrase and topoisomerase IV, which are enzymes involved in the replication and transcription of bacterial DNA.\n\nDNA gyrase and topoisomerase IV are essential for the survival of bacteria. They are responsible for the supercoiling and unknotting of DNA, which is necessary for the proper functioning of the bacterial genome. When these enzymes are inhibited by antibiotics like gepotidacin, the bacteria are unable to replicate their DNA properly, which leads to cell death.\n\nSo, the answer is A. yes, gepotidacin activates bacterial topoisomerase. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c5607aa07647bbc4b00000e", "messages": [{"role": "user", "content": "Is durvalumab used for lung cancer treatment?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nDurvalumab is a monoclonal antibody that targets the programmed death ligand-1 (PD-L1) protein. PD-L1 is a protein that is expressed on the surface of certain cells, including cancer cells, and binds to the PD-1 receptor on immune cells. This binding inhibits the immune system's ability to recognize and attack the cancer cells, which can lead to tumor growth and progression.\n\nDurvalumab is used in the treatment of certain types of lung cancer. It is approved for the treatment of non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have not progressed on platinum-based chemotherapy. It is also approved for the treatment of patients with unresectable, stage III NSCLC who have not progressed following concurrent platinum-based chemotherapy and radiation therapy.\n\nSo, the answer is A. Yes, durvalumab is used for lung cancer treatment. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c5f0c5a1a4c55d80b00000f", "messages": [{"role": "user", "content": "Is  LRP1 interacting with Urokinase receptor?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nLRP1 (low-density lipoprotein receptor-related protein 1) is a receptor that is involved in the clearance of lipoproteins and other ligands from the blood. It is also known to interact with various other proteins, including the urokinase receptor (uPAR).\n\nUrokinase receptor is a cell surface receptor that binds to urokinase-type plasminogen activator (uPA), which is an enzyme that converts plasminogen to plasmin. Plasmin is a protease that can degrade the extracellular matrix, which is important for cell migration and tissue remodeling. The interaction between LRP1 and uPAR is thought to be important for the regulation of cell migration and tissue remodeling, as well as for the clearance of uPA and its complexes from the extracellular space.\n\nGiven this information, we can conclude that LRP1 does indeed interact with the urokinase receptor.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c0e838b133db5eb7800002e", "messages": [{"role": "user", "content": "Is obesity related to cognitive decline?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nObesity is a complex condition that can have a significant impact on overall health, including cognitive function. Studies have shown that obesity is associated with a higher risk of cognitive decline and dementia, particularly Alzheimer's disease. This is likely due to the chronic inflammation and metabolic changes that occur in the body as a result of obesity, which can lead to damage to the brain and its functions.\n\nHowever, it's important to note that not all studies have found a direct link between obesity and cognitive decline. Some research suggests that the relationship may be more complex, with factors such as diet, exercise, and overall health playing a role. Additionally, the mechanisms by which obesity might lead to cognitive decline are not fully understood.\n\nGiven the current state of research, it is reasonable to conclude that obesity is related to cognitive decline, but the relationship is not yet fully established and may be influenced by other factors.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c589ddb86df2b917400000b", "messages": [{"role": "user", "content": "Is cabozantinib effective for hepatocellular carcinoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nCabozantinib is a tyrosine kinase inhibitor that is used in the treatment of several types of cancer, including hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer and is often associated with chronic liver disease, such as cirrhosis. The standard treatment for HCC is surgical resection, liver transplantation, or local ablation, but these options are not always feasible due to the advanced stage of the disease or the patient's overall health.\n\nCabozantinib has been studied in clinical trials for the treatment of HCC. In one study, patients with advanced HCC who had been previously treated with sorafenib (another tyrosine kinase inhibitor) were randomized to receive either cabozantinib or placebo. The study found that cabozantinib significantly improved overall survival compared to placebo, with a median overall survival of 10.2 months in the cabozantinib group versus 8.0 months in the placebo group.\n\nAnother study compared cabozantinib to placebo in patients with advanced HCC who had not received prior systemic therapy. This study also found that cabozantinib significantly improved overall survival compared to placebo, with a median overall survival of 10.2 months in the cabozantinib group versus 8.0 months in the placebo group.\n\nGiven these results, cabozantinib is considered an effective treatment option for hepatocellular carcinoma, particularly in patients who have been previously treated with sorafenib or who have not received prior systemic therapy.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c56033607647bbc4b00000c", "messages": [{"role": "user", "content": "Is Tisagenlecleucel effective for B-Cell Lymphoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nTisagenlecleucel is a chimeric antigen receptor (CAR) T-cell therapy that is used to treat certain types of B-cell lymphoma. It is a form of immunotherapy that involves the genetic modification of a patient's own T-cells to target and kill cancer cells. The T-cells are extracted from the patient's blood, genetically engineered to express a new receptor that recognizes a specific antigen on the surface of the cancer cells, and then infused back into the patient to attack the cancer cells.\n\nTisagenlecleucel is approved by the FDA for the treatment of two types of B-cell lymphoma: diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL). It has been shown to be effective in these types of lymphoma, particularly in patients who have not responded to other treatments or who have relapsed after treatment.\n\nSo, the answer is A. Yes, Tisagenlecleucel is effective for B-cell lymphoma. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c76cea17c78d694710000a7", "messages": [{"role": "user", "content": "Is ADP-ribosylation a PTM?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nADP-ribosylation is a post-translational modification (PTM) that involves the addition of an ADP-ribose moiety to a target protein. This modification is catalyzed by enzymes called ADP-ribosyltransferases, which transfer the ADP-ribose moiety from NAD+ to a specific amino acid residue on the target protein. ADP-ribosylation can affect protein function by altering its activity, stability, localization, or interaction with other proteins.\n\nGiven that ADP-ribosylation is a process that occurs after a protein has been synthesized, it is considered a post-translational modification. Therefore, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c56fd7407647bbc4b000013", "messages": [{"role": "user", "content": "Does epidural anesthesia for pain management during labor affect the Apgar score of the the infant?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nEpidural anesthesia is a common method of pain management during labor and delivery. It involves the injection of local anesthetics into the epidural space, which is located outside the dura mater and inside the spinal canal. The goal is to block the transmission of pain signals from the uterus and cervix to the brain.\n\nWhile epidural anesthesia can be very effective in managing labor pain, it can also have potential side effects. One of the concerns is that the local anesthetics used in epidural anesthesia can affect the baby's heart rate and breathing, which are important indicators of the baby's well-being. This is because the local anesthetics can cross the placenta and affect the baby's central nervous system.\n\nThe Apgar score is a quick assessment of a newborn's health at one and five minutes after birth. It is based on five criteria: heart rate, breathing, muscle tone, reflex irritability, and color. A low Apgar score may indicate that the baby is not getting enough oxygen, which can be a concern if the mother has received epidural anesthesia.\n\nHowever, the effects of epidural anesthesia on the Apgar score are not always consistent. Some studies have shown that epidural anesthesia can lead to lower Apgar scores, while others have not found a significant difference. The effects may also depend on the type and dose of local anesthetic used, the timing of the epidural, and the overall health of the mother and baby.\n\nGiven the potential for epidural anesthesia to affect the Apgar score, it is not possible to say with certainty that it does not affect the score. However, the effects are not always consistent, and the overall impact on the Apgar score is not always significant.\n\nSo, the answer is C. may be. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c5f22951a4c55d80b00001d", "messages": [{"role": "user", "content": "Is phospholipid hydroperoxide glutathione peroxidase a selenoprotein?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nPhospholipid hydroperoxide glutathione peroxidase (PHGPx) is an enzyme that catalyzes the reduction of hydroperoxides of phospholipids and other fatty acids. It is a member of the glutathione peroxidase family and is involved in the protection of cell membranes from oxidative damage.\n\nThe glutathione peroxidase family of enzymes contains several members, including glutathione peroxidase 1 (GPx1), glutathione peroxidase 2 (GPx2), glutathione peroxidase 3 (GPx3), glutathione peroxidase 4 (GPx4), and glutathione peroxidase 5 (GPx5). GPx1, GPx2, and GPx3 are selenium-containing selenoproteins, while GPx4 and GPx5 are not.\n\nPHGPx is a selenoprotein. It is encoded by the GPX4 gene and contains a selenocysteine residue at its active site. Selenocysteine is a unique amino acid that is incorporated into proteins in a process that is similar to the incorporation of cysteine, but it requires the presence of selenium in the diet.\n\nSo, the answer is A. yes. PHGPx is a selenoprotein. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c73aced7c78d69471000087", "messages": [{"role": "user", "content": "Is inositol effective for trichotillomania?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nTrichotillomania is a body-focused repetitive behavior characterized by the recurrent pulling out of one's hair, leading to noticeable hair loss. It is classified as an impulse control disorder. The exact cause of trichotillomania is unknown, but it is thought to be related to brain chemicals, family history, and stress.\n\nInositol is a naturally occurring substance that is found in many foods and is also available as a dietary supplement. It is a member of the vitamin B complex and is sometimes used as a treatment for various psychiatric disorders, including obsessive-compulsive disorder (OCD) and anxiety disorders. While there is some evidence that inositol may be effective for OCD, there is no specific evidence that it is effective for trichotillomania.\n\nGiven the lack of evidence specifically for the use of inositol in the treatment of trichotillomania, we can conclude that it is unlikely to be effective for this condition.\n\nSo, the answer is D. unlikely. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c640fa1e842deac67000011", "messages": [{"role": "user", "content": "Is TIAM1 favoring tumor progression in colorectal cancer (CRC)?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nTIAM1 (T-lymphoma invasion and metastasis 1) is a protein that is involved in cell adhesion, migration, and invasion. It is known to play a role in the metastasis of various types of cancer, including colorectal cancer (CRC).\n\nIn CRC, TIAM1 has been shown to promote tumor progression by enhancing the ability of cancer cells to invade and metastasize. It does this by activating the Rho GTPase signaling pathway, which is involved in the regulation of the actin cytoskeleton and cell motility. When TIAM1 is overexpressed in CRC cells, it leads to increased cell migration and invasion, which are key steps in the metastatic process.\n\nGiven this information, the answer is A. Yes, TIAM1 is favoring tumor progression in colorectal cancer. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c663afe7c78d69471000013", "messages": [{"role": "user", "content": "Is pacritinib effective for treatment of myelofibrosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.cannot be determined\n<|assistant|>\nPacritinib is a JAK2 inhibitor that was developed for the treatment of myelofibrosis, a chronic bone marrow disorder characterized by the overproduction of blood cells, bone marrow scarring, and splenomegaly. The drug was initially approved by the FDA in 2019 for the treatment of myelofibrosis in patients who have had their spleen removed or who are intolerant to other treatments.\n\nThe efficacy of pacritinib in treating myelofibrosis has been studied in clinical trials. One such trial, the PERSIST-1 trial, compared pacritinib to best supportive care in patients with myelofibrosis who had platelet counts of less than 100,000 cells per microliter. The results showed that pacritinib significantly improved spleen size and symptoms compared to best supportive care.\n\nAnother trial, the PERSIST-2 trial, compared pacritinib to ruxolitinib in patients with myelofibrosis who had platelet counts of 50,000 to 100,000 cells per microliter. The results showed that pacritinib was non-inferior to ruxolitinib in reducing spleen size and improving symptoms, and it was associated with a lower rate of thrombocytopenia (low platelet count).\n\nGiven the evidence from clinical trials, pacritinib is effective for the treatment of myelofibrosis, particularly in patients with low platelet counts.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c571f7607647bbc4b000017", "messages": [{"role": "user", "content": "Can exposure to heavy metals like lead(Pb) or cadmium(Cd) cause changes in DNA methylation patterns in Isoetes sinensis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nHeavy metals like lead and cadmium are known to be toxic to living organisms, including plants. They can accumulate in the environment and in the tissues of organisms, where they can disrupt normal cellular functions. One of the ways heavy metals can affect cellular processes is by altering DNA methylation patterns.\n\nDNA methylation is a chemical modification of DNA that can affect gene expression without changing the DNA sequence. It is an important epigenetic mechanism that can be influenced by environmental factors, including exposure to heavy metals. Heavy metals can interfere with the enzymes involved in DNA methylation, leading to changes in the methylation patterns of genes.\n\nIn the case of Isoetes sinensis, a species of quillwort, there is evidence that exposure to heavy metals can indeed cause changes in DNA methylation patterns. For example, a study found that exposure to lead and cadmium in the soil led to changes in the methylation patterns of genes involved in the response to oxidative stress in I. sinensis.\n\nSo, the answer is A. yes. Exposure to heavy metals like lead and cadmium can cause changes in DNA methylation patterns in Isoetes sinensis. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c57031107647bbc4b000014", "messages": [{"role": "user", "content": "Has Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) been reported to be a plasminogen receptor in pathogenic bacteria?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nGlyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a housekeeping enzyme that is involved in glycolysis and is found in all living cells. It is not typically known as a plasminogen receptor in pathogenic bacteria.\n\nPlasminogen receptors are proteins on the surface of bacteria that bind to plasminogen, a precursor of the enzyme plasmin. Plasmin is a serine protease that can degrade the extracellular matrix and is involved in the pathogenesis of various bacterial infections. The binding of plasminogen to these receptors allows the bacteria to activate plasminogen to plasmin, which can then contribute to the spread of the infection.\n\nWhile GAPDH is a well-known enzyme, it is not typically associated with the function of plasminogen receptor in pathogenic bacteria. Instead, other proteins such as fibronectin-binding proteins, fibrinogen-binding proteins, and plasminogen activator proteins are known to serve as plasminogen receptors in various bacteria.\n\nSo, the answer is B. No, GAPDH has not been reported to be a plasminogen receptor in pathogenic bacteria. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c6549e1e842deac67000022", "messages": [{"role": "user", "content": "Can CPX-351 be used for the treatment of tuberculosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nCPX-351 is a combination of two antifungal drugs, liposomal amphotericin B and cytarabine, used in the treatment of acute myeloid leukemia (AML). It is not approved for the treatment of tuberculosis (TB), which is caused by the bacterium Mycobacterium tuberculosis.\n\nAmphotericin B is an antifungal medication that is used to treat serious fungal infections, but it is not effective against bacteria like Mycobacterium tuberculosis. Cytarabine is a chemotherapy drug used to treat certain types of cancer, including AML, but it is not used to treat bacterial infections like TB.\n\nTherefore, CPX-351 is not used for the treatment of tuberculosis.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c654c14e842deac67000025", "messages": [{"role": "user", "content": "Does lucatumumab bind to CD140?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nLucatumumab is a monoclonal antibody that targets CD40, a protein that is expressed on the surface of B cells, macrophages, dendritic cells, and some T cells. CD40 is a member of the tumor necrosis factor receptor superfamily and plays a critical role in immune responses, including B cell activation, proliferation, and differentiation.\n\nCD140 is a different protein that is not related to CD40. CD140 is the receptor for platelet-derived growth factor (PDGF), which is involved in the regulation of cell growth and division. It is not the target of lucatumumab.\n\nSo, the answer is B. Lucatumumab does not bind to CD140. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c73ad0b7c78d69471000093", "messages": [{"role": "user", "content": "Does simvastatin improve outcomes of aneurysmal subarachnoid hemorrhage?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nSimvastatin is a statin medication that is commonly used to lower cholesterol levels. It has been studied in the context of aneurysmal subarachnoid hemorrhage (aSAH), which is a type of stroke caused by the rupture of a blood vessel in the brain. The rationale for using statins in this context is that they may have neuroprotective effects and could potentially reduce the risk of vasospasm, a common complication of aSAH that can lead to further ischemic brain injury.\n\nSeveral studies have investigated the use of simvastatin in aSAH patients. A meta-analysis of randomized controlled trials found that simvastatin treatment was associated with a significant reduction in the risk of death or dependency at 3 months after aSAH. However, the results of individual trials have been mixed, and the evidence is not conclusive.\n\nGiven the current state of the evidence, it is difficult to say with certainty that simvastatin improves outcomes of aneurysmal subarachnoid hemorrhage. While there is some evidence to suggest that it may be beneficial, more high-quality studies are needed to confirm these findings.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c72aaed7c78d6947100006f", "messages": [{"role": "user", "content": "Is pazopanib an effective treatment of glioblastoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nPazopanib is an oral tyrosine kinase inhibitor that is used to treat certain types of cancer, including renal cell carcinoma and soft tissue sarcoma. It works by inhibiting the growth of blood vessels that feed tumors, which can lead to tumor shrinkage.\n\nGlioblastoma is a type of brain cancer that is notoriously difficult to treat. While there are a variety of treatments available, including surgery, radiation therapy, and chemotherapy, the prognosis for glioblastoma is generally poor, with a median survival of around 15 months.\n\nPazopanib is not typically used as a first-line treatment for glioblastoma. It is not approved by the FDA for this indication, and there is limited evidence to support its use in this setting. While it may have some anti-angiogenic effects that could potentially be beneficial in glioblastoma, it is not a standard treatment for this type of cancer.\n\nSo, the answer is B. no. Pazopanib is not an effective treatment of glioblastoma. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c643485e842deac67000015", "messages": [{"role": "user", "content": "Are de novo mutations in regulatory elements responsible for neurodevelopmental disorders?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nNeurodevelopmental disorders are a broad category of conditions that affect brain development and can lead to a wide range of symptoms, including intellectual disability, autism spectrum disorder, and epilepsy. These disorders can have a variety of genetic causes, including mutations in genes that code for proteins involved in brain development, as well as mutations in regulatory elements that control the expression of these genes.\n\nDe novo mutations are mutations that occur in the genome of an individual and are not inherited from the parents. These mutations can occur spontaneously during the formation of gametes or early in embryonic development. De novo mutations can affect both coding regions of genes and regulatory elements.\n\nRegulatory elements are regions of DNA that control the expression of genes. They can include promoters, enhancers, and other regulatory sequences that influence the transcription of genes. Mutations in these regulatory elements can affect the expression of genes in a variety of ways, including turning them on or off at the wrong time or in the wrong place, which can lead to developmental abnormalities.\n\nGiven the importance of regulatory elements in gene expression and the fact that de novo mutations can occur in these regions, it is reasonable to conclude that de novo mutations in regulatory elements can be responsible for neurodevelopmental disorders.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c7c0e2fd774d0424000000d", "messages": [{"role": "user", "content": "Are phagosomal proteins ubiquitinated?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nPhagocytosis is a process by which cells engulf and internalize large particles or other cells. During this process, the engulfed material is contained within a phagosome, which is a membrane-bound vesicle. The phagosome then fuses with a lysosome, which contains digestive enzymes, to form a phagolysosome. This fusion is mediated by the action of Rab GTPases, which are small GTP-binding proteins that regulate vesicle trafficking.\n\nOne of the key steps in the maturation of the phagosome into a phagolysosome is the recruitment of lysosomal proteins and enzymes. This process involves the recognition of specific markers on the phagosome by the lysosomal proteins. One of the mechanisms by which lysosomal proteins are targeted to the phagosome is through the process of ubiquitination.\n\nUbiquitination is a post-translational modification where a small protein called ubiquitin is attached to other proteins. This modification is a signal for the protein to be targeted for degradation by the proteasome or for other cellular processes. In the context of phagocytosis, ubiquitination of phagosomal proteins is a key step in the recruitment of lysosomal proteins and enzymes to the phagosome.\n\nSo, the answer is A. yes. Phagosomal proteins are ubiquitinated to facilitate the recruitment of lysosomal proteins and enzymes during the maturation of the phagosome into a phagolysosome. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c73ad327c78d69471000097", "messages": [{"role": "user", "content": "Does tremelimumab improve survival of mesothelioma patients?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nTremelimumab is a monoclonal antibody that targets the immune checkpoint receptor CTLA-4. It is used in the treatment of various cancers, including mesothelioma. Mesothelioma is a rare and aggressive cancer that affects the lining of the lungs, abdomen, or heart. It is often associated with exposure to asbestos.\n\nThe use of tremelimumab in the treatment of mesothelioma has been studied in clinical trials. One such trial, the METEOR trial, compared the efficacy of tremelimumab with standard chemotherapy in patients with unresectable pleural mesothelioma. The results showed that tremelimumab did not improve overall survival compared to chemotherapy alone. However, the study did suggest that tremelimumab might be beneficial in a subset of patients with mesothelioma who have a high tumor mutational burden.\n\nGiven the current evidence, we can conclude that tremelimumab does not improve survival in the general population of mesothelioma patients. However, there may be a subgroup of patients who could benefit from this treatment, and further research is needed to identify these patients.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c6587d77c78d69471000005", "messages": [{"role": "user", "content": "Can enasidenib be used for the treatment of acute myeloid leukemia?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nEnasidenib is a drug that is used to treat acute myeloid leukemia (AML) with an IDH2 mutation. IDH2 mutations are found in about 8-10% of AML cases. Enasidenib works by inhibiting the IDH2 enzyme, which is mutated in these cases, leading to the production of abnormal molecules that promote the growth of leukemia cells. By inhibiting the IDH2 enzyme, enasidenib can help to slow the growth of leukemia cells and potentially lead to remission.\n\nSo, the answer is A. yes. Enasidenib can be used for the treatment of acute myeloid leukemia with an IDH2 mutation. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c783236d774d04240000001", "messages": [{"role": "user", "content": "Is collagen the most abundant human protein?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nCollagen is indeed the most abundant protein in the human body. It is a structural protein that provides strength and support to various tissues, including skin, bones, tendons, and ligaments. It is also found in the cornea, blood vessels, and the gut. The human body contains approximately 25-35% collagen, making it the most abundant protein in the body.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c76be617c78d694710000a5", "messages": [{"role": "user", "content": "Is the enzyme ERAP2 associated with the disease birdshot chorioretinopathy?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nBirdshot chorioretinopathy is a chronic, bilateral, multifocal, and granular chorioretinal inflammation that typically affects middle-aged women. It is a form of uveitis, which is inflammation of the uvea (the middle layer of the eye).\n\nERAP2 (Endoplasmic Reticulum Aminopeptidase 2) is a protein that is involved in the processing of peptides in the endoplasmic reticulum. It is known to be associated with the development of certain autoimmune diseases, including ankylosing spondylitis and psoriatic arthritis. However, there is no direct evidence that ERAP2 is associated with birdshot chorioretinopathy.\n\nWhile there is some overlap between the genetic associations of birdshot chorioretinopathy and other autoimmune diseases, the specific genetic associations with birdshot chorioretinopathy are not well understood. The disease is thought to be associated with HLA-A29, but the role of ERAP2 in the pathogenesis of birdshot chorioretinopathy is not established.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c73ad377c78d6947100009a", "messages": [{"role": "user", "content": "Does Panitumumab prolong survival of biliary tract cancer patients?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nPanitumumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), which is overexpressed in many cancers, including biliary tract cancer. The EGFR pathway is known to be involved in the growth and survival of cancer cells, and targeting it with an antibody like panitumumab can potentially inhibit tumor growth and prolong survival.\n\nHowever, the clinical evidence for the use of panitumumab in biliary tract cancer is limited. While there have been some studies that suggest a potential benefit, the data is not conclusive. One study found that the addition of panitumumab to gemcitabine and cisplatin did not improve overall survival in patients with advanced biliary tract cancer. Another study showed a trend towards improved progression-free survival with the addition of panitumumab to gemcitabine and cisplatin, but this was not statistically significant.\n\nGiven the current state of the evidence, it cannot be definitively stated that panitumumab prolongs survival in biliary tract cancer patients. More research is needed to determine the true impact of this treatment on patient outcomes.\n\nSo, the answer is D. cannot be determined. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c6582207c78d69471000001", "messages": [{"role": "user", "content": "Is lucatumumab a polyclonal antibody?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nLucatumumab is a monoclonal antibody, not a polyclonal antibody. Monoclonal antibodies are produced by a single clone of B cells and are highly specific for a single antigenic determinant, whereas polyclonal antibodies are a mixture of immunoglobulins produced by different clones of B cells and are less specific.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c662c507c78d6947100000d", "messages": [{"role": "user", "content": "Is lithium effective for treatment of amyotrophic lateral sclerosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord. It is characterized by muscle weakness, atrophy, and eventually paralysis. There is no cure for ALS, and treatment is focused on managing symptoms and prolonging survival.\n\nLithium is a mood stabilizer that is used to treat bipolar disorder. It has been studied for its potential neuroprotective effects in various neurological conditions, including ALS. However, the evidence for its effectiveness in ALS is limited and inconclusive.\n\nA 2017 review of lithium treatment in ALS found that while there was some evidence of a possible neuroprotective effect, the studies were small and had methodological limitations. The review concluded that further research was needed to determine the efficacy of lithium in ALS.\n\nGiven the current state of research, it is difficult to say with certainty whether lithium is effective for the treatment of ALS. While there is some evidence suggesting a possible benefit, the evidence is not strong enough to make a definitive statement.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c73acea7c78d69471000085", "messages": [{"role": "user", "content": "Should dacomitinib be used for treatment of glioblastoma patients?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nDacomitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been studied in various cancers, including glioblastoma. Glioblastoma is a type of brain cancer that is often resistant to treatment and has a poor prognosis. EGFR is overexpressed in many glioblastoma tumors, and targeting EGFR with TKIs has been explored as a potential treatment strategy.\n\nHowever, the results of clinical trials with dacomitinib in glioblastoma have been mixed. While some studies have shown a modest benefit in terms of progression-free survival, others have not shown a significant improvement in overall survival. Additionally, the side effect profile of dacomitinib can be significant, including skin reactions, diarrhea, and liver enzyme elevations.\n\nGiven the current state of research, it is not clear whether dacomitinib should be used for the treatment of glioblastoma patients. While it may have some benefits, the lack of a clear survival benefit and the potential for significant side effects make it a less attractive option compared to other treatments.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c6d7bb57c78d6947100003b", "messages": [{"role": "user", "content": "Are there ultraconserved regions in the budding yeast (Saccharomyces cerevisiae)?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nUltraconserved regions (UCRs) are DNA sequences that are highly conserved across species, often with little or no variation between them. They are typically found in non-coding regions of the genome and are thought to play important roles in gene regulation and other biological processes.\n\nBudding yeast, Saccharomyces cerevisiae, is a single-celled eukaryotic organism that is widely used in research and industry. While it is a relatively simple organism compared to humans or other complex organisms, it still has a relatively large genome for a yeast, with approximately 12 million base pairs.\n\nThere have been studies that have identified ultraconserved regions in the yeast genome. For example, a study published in 2013 identified 1,000 ultraconserved regions in the yeast genome that were conserved across 10 different yeast species. These regions were found to be enriched for regulatory elements such as transcription factor binding sites and RNA polymerase II binding sites, suggesting that they may play important roles in gene regulation.\n\nSo, the answer is A. Yes, there are ultraconserved regions in the budding yeast. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c640c2ee842deac67000010", "messages": [{"role": "user", "content": "Is there any role for HUWE1 in MYC signalling?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nHUWE1, also known as HECT, UBA, and WWE domain-containing 1, is a ubiquitin ligase that plays a role in various cellular processes, including cell cycle regulation, DNA repair, and apoptosis. It is involved in the ubiquitination of target proteins, which can lead to their degradation by the proteasome.\n\nMYC is a transcription factor that is overexpressed in many cancers and is known to play a role in cell proliferation, apoptosis, and metabolism. MYC is a well-known oncogene, and its overexpression is associated with poor prognosis in many types of cancer.\n\nWhile there is no direct evidence that HUWE1 is involved in MYC signaling, it is possible that HUWE1 could play a role in the regulation of MYC activity. For example, HUWE1 could be involved in the ubiquitination and degradation of proteins that regulate MYC activity, such as MYC itself or proteins that interact with MYC. However, there is no specific evidence that HUWE1 is directly involved in MYC signaling.\n\nGiven the lack of direct evidence, we can say that there is no definitive role for HUWE1 in MYC signaling, but it is possible that HUWE1 could play a role in the regulation of MYC activity indirectly.\n\nSo, the answer is C. maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c674aed7c78d69471000019", "messages": [{"role": "user", "content": "Do raspberries improve postprandial glucose and acute and chronic inflammation in adults with type 2 Diabetes?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nRaspberries are a type of fruit that are known to be rich in antioxidants, fiber, and other nutrients. They have been studied for their potential health benefits, including their effect on blood sugar levels and inflammation.\n\nIn the context of type 2 diabetes, postprandial glucose refers to the blood sugar levels after a meal. Acute inflammation is a short-term response to injury or infection, while chronic inflammation is a long-term condition that can contribute to the development of various diseases, including diabetes.\n\nStudies have shown that consuming raspberries can help improve postprandial glucose levels in individuals with type 2 diabetes. This is because raspberries are high in fiber, which can slow down the absorption of carbohydrates and help to regulate blood sugar levels. Additionally, raspberries contain polyphenols, which have been shown to have anti-inflammatory properties.\n\nHowever, the evidence for raspberries' ability to reduce chronic inflammation in type 2 diabetes is less clear. While some studies have shown a positive effect, others have not found a significant difference. More research is needed to fully understand the role of raspberries in chronic inflammation in the context of diabetes.\n\nGiven the available evidence, it can be concluded that raspberries do improve postprandial glucose levels in adults with type 2 diabetes. However, the effect on acute and chronic inflammation is less certain.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c7836dad774d04240000002", "messages": [{"role": "user", "content": "Are Mesenchymal stem cells (MSC) multipotent cells?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nMesenchymal stem cells (MSCs) are a type of adult stem cell that can differentiate into a variety of cell types, including bone, cartilage, fat, muscle, and connective tissue. They are found in various tissues in the body, such as bone marrow, adipose tissue, and umbilical cord blood.\n\nThe term \"multipotent\" refers to the ability of a cell to differentiate into multiple cell types, but not into all cell types. MSCs are considered multipotent because they can differentiate into a limited number of cell types, but not into all cell types in the body.\n\nSo, the answer is A. yes. MSCs are multipotent cells. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c6b198f7c78d69471000025", "messages": [{"role": "user", "content": "Is there a deep-learning algorithm for protein solubility prediction?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nProtein solubility is an important property that affects the stability, function, and purification of proteins. It is a critical factor in the success of many biotechnological and pharmaceutical applications. Deep learning is a branch of machine learning that uses artificial neural networks with multiple layers to learn complex patterns in data.\n\nThere are indeed deep-learning algorithms that have been developed for protein solubility prediction. These algorithms use various types of data, such as protein sequences, secondary structure, and tertiary structure, to predict the solubility of a protein. The goal is to identify the features that contribute to protein solubility and to develop a model that can accurately predict the solubility of a given protein.\n\nOne example of a deep-learning algorithm for protein solubility prediction is the DeepSol method, which uses a convolutional neural network to predict the solubility of proteins based on their amino acid sequences. Another example is the DeepSol2 method, which uses a combination of convolutional neural networks and recurrent neural networks to predict the solubility of proteins based on their amino acid sequences and secondary structure.\n\nSo, the answer is A. Yes, there are deep-learning algorithms for protein solubility prediction. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c5215e67e3cb0e231000004", "messages": [{"role": "user", "content": "Have machine learning methods been used to predict the severity of major depressive disorder(MDD)?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nMachine learning is a branch of artificial intelligence that involves the use of algorithms to analyze data and make predictions. It has been used in various fields, including medicine, to help diagnose and predict the outcomes of diseases.\n\nMajor depressive disorder (MDD) is a common and serious mental health condition that can have a significant impact on a person's life. While there is no single test to diagnose MDD, clinicians often use a combination of symptoms, patient history, and other factors to make a diagnosis.\n\nMachine learning methods have been used to analyze data from patients with MDD to help predict the severity of the disorder. For example, researchers have used machine learning algorithms to analyze data from patients' medical records, including symptoms, treatment history, and other factors, to predict the likelihood of a patient experiencing a relapse or a severe episode of depression.\n\nSo, the answer is A. Yes, machine learning methods have been used to predict the severity of major depressive disorder. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c6583117c78d69471000002", "messages": [{"role": "user", "content": "Can midostaurin inhibit angiogenesis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nMidostaurin is a multi-targeted kinase inhibitor that is used in the treatment of acute myeloid leukemia (AML) and systemic mastocytosis. It inhibits several kinases, including FLT3, which is a receptor tyrosine kinase that is important in the proliferation and survival of hematopoietic cells. FLT3 is also involved in angiogenesis, as it can promote the growth of new blood vessels.\n\nHowever, the primary mechanism of action of midostaurin in the treatment of AML and systemic mastocytosis is not directly related to its inhibition of angiogenesis. Instead, it is primarily used to target the FLT3 kinase, which is overexpressed or mutated in certain types of leukemia and mastocytosis, leading to uncontrolled cell growth and proliferation.\n\nSo, the answer is B. No, midostaurin does not primarily inhibit angiogenesis. Its primary mechanism of action is to inhibit the FLT3 kinase, which is involved in the proliferation and survival of hematopoietic cells, not directly in angiogenesis. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c629fffe842deac67000009", "messages": [{"role": "user", "content": "Does Groucho related gene 5 (GRG5) have a role only in late development?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nGRG5, also known as Groucho-related transcriptional repressor 5, is a protein that is involved in the regulation of gene expression. It is a member of the Groucho/TLE family of transcriptional corepressors, which are known to play a role in the development of various tissues and organs.\n\nWhile GRG5 is involved in the regulation of gene expression, it is not clear that its role is limited to late development. In fact, GRG5 has been implicated in various developmental processes, including neural crest cell migration, limb development, and the development of the central nervous system. It is also involved in the regulation of cell proliferation and differentiation, which are processes that occur throughout development.\n\nGiven the broad range of developmental processes in which GRG5 is involved, it is not accurate to say that its role is limited to late development. However, it is also not entirely correct to say that it has a role in all stages of development, as some of its functions may be more prominent at certain stages than others.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c6da11e7c78d69471000042", "messages": [{"role": "user", "content": "Are there tools for reviewing variant calls?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nVariant calling is a critical step in the analysis of genomic data, as it identifies the locations in the genome where the DNA sequence differs from a reference sequence. The accuracy of variant calling is crucial for downstream analyses such as association studies, functional studies, and clinical applications.\n\nThere are indeed tools available for reviewing variant calls. These tools can be used to assess the quality of the calls, identify potential errors, and confirm the accuracy of the calls. Some examples of tools for reviewing variant calls include:\n\n- Samtools: A suite of tools for manipulating alignments in the SAM format, including sorting, merging, indexing, and variant calling.\n- GATK: The Genome Analysis Toolkit, which includes tools for variant calling, genotyping, and other genomic analyses.\n- FreeBayes: A Bayesian genetic variant detector for next-generation sequencing data.\n- Platypus: A tool for variant calling and genotyping from next-generation sequencing data.\n- VarScan: A tool for variant detection in next-generation sequencing data.\n- BCFtools: A set of tools for manipulating VCF and BCF files.\n- VEP: The Variant Effect Predictor, which can be used to annotate variants with their potential effects on genes and transcripts.\n\nSo, the answer is A. Yes, there are tools for reviewing variant calls. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c65495be842deac67000021", "messages": [{"role": "user", "content": "Has ivosidenib been FDA approved for use against acute myeloid leukemia?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.not yet\n<|assistant|>\nIvosidenib is a targeted therapy that is used to treat certain types of acute myeloid leukemia (AML). It is specifically indicated for the treatment of adult patients with AML with a certain genetic mutation (IDH1 mutation) as detected by an FDA-approved test.\n\nThe FDA approved ivosidenib in July 2018 for the treatment of adult patients with AML with an IDH1 mutation, as detected by an FDA-approved test, who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy. The approval was based on the results of a clinical trial that showed that ivosidenib improved overall survival compared to standard chemotherapy in this patient population.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c51f44c07ef653866000004", "messages": [{"role": "user", "content": "Are Copy Number Variants (CNVs) depleted in regions of low mappability?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nCopy number variants (CNVs) are regions of the genome that have a different number of copies compared to the reference genome. They can be deletions, duplications, or insertions of DNA segments. The mappability of a region refers to the ability to map short reads from sequencing to that region.\n\nThe mappability of a region can be affected by factors such as repetitive sequences, which can make it difficult to map reads to those regions. However, CNVs are not typically associated with repetitive sequences. Instead, they are often found in regions of the genome that are relatively gene-poor and less conserved, which makes them more likely to be variable between individuals.\n\nTherefore, CNVs are not depleted in regions of low mappability. In fact, they are more likely to be found in regions that are less well-mapped due to their genomic characteristics.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c5b2f4b1a4c55d80b000001", "messages": [{"role": "user", "content": "Is Adar3 involved in learning and memory?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nAdar3 is a gene that encodes an enzyme involved in the methylation of RNA. RNA methylation is a post-transcriptional modification that can affect the stability, localization, and function of RNA molecules. It is known that RNA methylation plays a role in various cellular processes, including gene expression, protein synthesis, and RNA stability.\n\nIn the context of learning and memory, RNA methylation has been implicated in the regulation of synaptic plasticity, which is a key mechanism underlying learning and memory. For example, studies have shown that RNA methylation can affect the translation of specific mRNAs, which can influence the expression of proteins involved in synaptic plasticity and memory formation.\n\nGiven this information, it is reasonable to suggest that Adar3, as an enzyme involved in RNA methylation, could potentially be involved in learning and memory. However, the specific role of Adar3 in learning and memory has not been extensively studied, and the answer to this question is not as straightforward as it might seem.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c5f2cef1a4c55d80b000022", "messages": [{"role": "user", "content": "There is no drug available to prevent HIV infection, Pre-exposure prophylaxis (PrEP), yes or no?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nPre-exposure prophylaxis (PrEP) is a strategy that involves the use of antiretroviral medications by individuals who are at high risk of acquiring HIV infection to reduce their risk of becoming infected. The medications used in PrEP are the same as those used in antiretroviral therapy (ART) to treat HIV infection, but they are used in a different context.\n\nPrEP has been shown to be effective in reducing the risk of HIV infection in certain populations, such as men who have sex with men, heterosexual men and women at high risk of HIV infection, and people who inject drugs. The effectiveness of PrEP depends on consistent use of the medication, which can be challenging for some individuals.\n\nPrEP is not a substitute for safer sex practices, such as consistent and correct condom use, and it is not recommended for the general population. However, for individuals who are at high risk of HIV infection and who are willing and able to take the medication as prescribed, PrEP can be an effective tool to reduce the risk of HIV infection.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c52cde87e3cb0e23100000e", "messages": [{"role": "user", "content": "Does allele phasing improve the phylogenetic utility of ultraconserved elements?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nUltraconserved elements (UCEs) are highly conserved noncoding DNA sequences that are identical in humans, mice, and rats. They are often used in phylogenetic studies because they are thought to be under strong purifying selection and thus are less likely to be affected by neutral evolution or horizontal gene transfer.\n\nOne of the challenges in using UCEs for phylogenetic analysis is that they are often highly repetitive, which can make it difficult to align them correctly. This is because the repetitive nature of UCEs can lead to paralogous sequences being aligned together, which can distort the phylogenetic signal.\n\nAllele phasing is a technique used to separate the two copies of a gene that are inherited from each parent. In the context of UCEs, allele phasing can help to distinguish between paralogous sequences and ensure that only one copy of a UCE is used in the analysis. This can improve the accuracy of the phylogenetic tree by reducing the chance of aligning paralogous sequences together.\n\nSo, the answer is A. yes, allele phasing can improve the phylogenetic utility of ultraconserved elements by reducing the chance of aligning paralogous sequences together. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c5723a007647bbc4b000019", "messages": [{"role": "user", "content": "Have yeast prions become important models for the study of the basic mechanisms underlying human amyloid diseases?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nYeast prions are proteins that can adopt an abnormal folded state that is able to self-propagate, much like the proteins involved in human amyloid diseases. The study of yeast prions has provided important insights into the basic mechanisms underlying the propagation of misfolded proteins, including the role of chaperones, the importance of protein conformation, and the influence of environmental factors on protein folding.\n\nBy studying yeast prions, researchers have been able to develop tools and techniques that have been applied to the study of human amyloid diseases. For example, the yeast prion model has helped to identify the role of chaperones in the propagation of misfolded proteins, which has implications for the development of therapies for human amyloid diseases.\n\nHowever, it's important to note that while yeast prions are useful models for studying the basic mechanisms of protein misfolding, they do not directly model the specific diseases that affect humans. The human diseases are much more complex and involve a variety of factors that are not present in the yeast model.\n\nSo, the answer is A. Yes, yeast prions have become important models for the study of the basic mechanisms underlying human amyloid diseases. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c6b7bee7c78d6947100002a", "messages": [{"role": "user", "content": "Is dupilumab effective for treatment of asthma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nDupilumab is a monoclonal antibody that targets the interleukin-4 (IL-4) receptor alpha subunit. IL-4 and IL-13 are key cytokines in the pathogenesis of asthma, and dupilumab has been shown to inhibit their signaling. This inhibition can lead to a reduction in inflammation and airway hyperresponsiveness, which are hallmarks of asthma.\n\nSeveral clinical trials have demonstrated the efficacy of dupilumab in the treatment of asthma. In a phase 3 trial, dupilumab was shown to significantly reduce the rate of asthma exacerbations and improve lung function in patients with uncontrolled asthma. Another trial showed that dupilumab was effective in reducing the use of oral corticosteroids in patients with severe asthma.\n\nGiven the evidence from clinical trials, dupilumab is considered an effective treatment for asthma, particularly for patients with severe asthma or those who are not well-controlled on standard therapies.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c6d441d7c78d69471000037", "messages": [{"role": "user", "content": "Does Eucommia ulmoides leaf extract ameliorates steatosis/fatty liver induced by high-fat diet?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.cannot be determined\n<|assistant|>\nEucommia ulmoides, also known as Chinese horse chestnut, is a traditional Chinese medicine that has been used for various health conditions, including liver diseases. One of the potential benefits of Eucommia ulmoides leaf extract is its ability to reduce liver fat accumulation, which is a hallmark of non-alcoholic fatty liver disease (NAFLD).\n\nNAFLD is a common liver disease characterized by the accumulation of fat in the liver cells. It is often associated with obesity, diabetes, and metabolic syndrome. The high-fat diet is a common model used to induce NAFLD in animal studies.\n\nSeveral studies have shown that Eucommia ulmoides leaf extract can reduce liver fat accumulation in mice fed a high-fat diet. For example, one study found that Eucommia ulmoides leaf extract significantly reduced liver fat content and improved liver function in mice fed a high-fat diet. Another study showed that Eucommia ulmoides leaf extract reduced liver fat accumulation and improved insulin sensitivity in mice fed a high-fat diet.\n\nGiven the available evidence, it can be concluded that Eucommia ulmoides leaf extract does ameliorate steatosis/fatty liver induced by a high-fat diet in animal models.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c6b82a17c78d6947100002f", "messages": [{"role": "user", "content": "Is verubecestat effective for Alzheimer\u2019s Disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nVerubecestat is a drug that was being investigated for the treatment of Alzheimer's disease. It is an inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is involved in the production of amyloid beta peptides, a key component in the pathogenesis of Alzheimer's disease.\n\nThe drug was found to be effective in reducing the production of amyloid beta peptides in animal models and in early clinical trials. However, a large phase 3 clinical trial (EPOCH) was conducted to evaluate the efficacy of verubecestat in patients with mild to moderate Alzheimer's disease. The results of this trial were disappointing, as the drug did not show a significant benefit in slowing cognitive decline or improving daily functioning compared to placebo.\n\nGiven the negative results of the EPOCH trial, it is unlikely that verubecestat is effective for the treatment of Alzheimer's disease. However, it is important to note that the drug was not approved for use in Alzheimer's disease due to these results, and further research is needed to identify effective treatments for this condition.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c6f15577c78d69471000053", "messages": [{"role": "user", "content": "Is galcanezumab effective for treatment of migraine?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nGalcanezumab is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP), which is believed to play a role in the pathophysiology of migraine. CGRP is a neuropeptide that is released during migraine attacks and is thought to contribute to the pain and other symptoms of migraine.\n\nSeveral clinical trials have been conducted to evaluate the efficacy of galcanezumab in the prevention of migraine. These trials have shown that galcanezumab is effective in reducing the frequency of migraine headaches and the use of acute migraine medications in patients with episodic migraine. The results of these trials suggest that galcanezumab is a safe and effective treatment option for migraine prevention.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c52028807ef653866000009", "messages": [{"role": "user", "content": "Can mitochondria be inherited by both parents in humans?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nMitochondria are organelles found in the cells of most eukaryotic organisms. They are responsible for producing energy in the form of ATP through the process of cellular respiration. Mitochondria have their own DNA (mtDNA), which is distinct from the nuclear DNA (nDNA) found in the nucleus of the cell.\n\nIn humans, mtDNA is inherited exclusively from the mother. This is because the mitochondria are passed down from the mother's egg cell to the offspring. The father's sperm does not contain mitochondria, so the father's mtDNA is not passed on to the offspring.\n\nSo, the answer is B. No, mitochondria cannot be inherited by both parents in humans. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c71648b7c78d69471000067", "messages": [{"role": "user", "content": "Can Diazepam be beneficial  in the treatment of  traumatic brain injury?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nDiazepam is a benzodiazepine that is commonly used as a sedative and anticonvulsant. It is often used in the treatment of seizures and can be used to control agitation and seizures in the setting of traumatic brain injury (TBI). However, there are some concerns about the use of benzodiazepines in TBI patients.\n\nBenzodiazepines can cause respiratory depression, which is a concern in patients with TBI who may already have compromised respiratory function due to their injury. Additionally, benzodiazepines can cause sedation, which can mask the signs of increased intracranial pressure (ICP) and brain herniation, making it more difficult to monitor and treat these conditions.\n\nDespite these concerns, benzodiazepines can be beneficial in the treatment of TBI in certain circumstances. For example, they can be used to control seizures and to manage agitation, which can be a significant problem in TBI patients. However, their use should be carefully monitored and balanced against the risks of respiratory depression and sedation.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c57216e07647bbc4b000018", "messages": [{"role": "user", "content": "In clinical trials, the H3 R antagonist CEP-26401 has a positive effect on cognition, yes or no?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nCEP-26401 is a histamine H3 receptor antagonist. Histamine H3 receptors are found in the central nervous system and are involved in the regulation of neurotransmitter release, particularly acetylcholine. By blocking the H3 receptors, CEP-26401 is thought to increase the release of acetylcholine, which is important for cognitive function.\n\nIn clinical trials, CEP-26401 has been shown to improve cognitive function in patients with Alzheimer's disease and mild cognitive impairment. These studies have demonstrated that CEP-26401 can improve memory, attention, and executive function in these populations.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c6f6d997c78d69471000055", "messages": [{"role": "user", "content": "Is pimavanserin effective for Parkinson's disease psychosis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nParkinson's disease psychosis (PDP) is a common non-motor complication of Parkinson's disease that can significantly impact quality of life and is associated with increased caregiver burden. PDP is characterized by hallucinations, delusions, and other psychotic symptoms. The treatment of PDP is challenging due to the limited options available and the potential for adverse effects.\n\nPimavanserin is a selective serotonin inverse agonist/antagonist at 5-HT2A receptors and a partial agonist at 5-HT1A receptors. It is approved by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Clinical trials have shown that pimavanserin is effective in reducing the severity of hallucinations and delusions in patients with Parkinson's disease psychosis without worsening motor symptoms or increasing the risk of falls.\n\nSo, the answer is A. yes. Pimavanserin is effective for Parkinson's disease psychosis. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c5b52731a4c55d80b000003", "messages": [{"role": "user", "content": "Is deletion at 6q24.2-26 associated with longer survival of patients with high-grade serous ovarian carcinoma (HGSOCs)?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nHigh-grade serous ovarian carcinoma (HGSOC) is a type of ovarian cancer that is often aggressive and difficult to treat. Deletion at 6q24.2-26 is a chromosomal abnormality that has been associated with HGSOC. This deletion is thought to be associated with the loss of tumor suppressor genes, which can contribute to the development and progression of the disease.\n\nWhile the presence of this deletion may not directly affect the survival of patients with HGSOC, it is a marker that is associated with a more aggressive form of the disease. Patients with HGSOC and the 6q24.2-26 deletion tend to have a worse prognosis compared to those without the deletion.\n\nSo, the answer is A. Yes, deletion at 6q24.2-26 is associated with longer survival of patients with high-grade serous ovarian carcinoma (HGSOCs). Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c65484ee842deac6700001f", "messages": [{"role": "user", "content": "Can mogamulizumab be used for the treatment of cutaneous T-cell lymphoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.uncertain\n<|assistant|>\nMogamulizumab is a monoclonal antibody that targets the CC chemokine receptor 4 (CCR4), which is expressed on the surface of certain T-cells. It is approved for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S\u00e9zary syndrome (SS) after at least one prior systemic therapy.\n\nCutaneous T-cell lymphoma (CTCL) is a group of non-Hodgkin lymphomas that affect the skin. Mycosis fungoides and S\u00e9zary syndrome are the two most common types of CTCL. Mogamulizumab is specifically indicated for the treatment of these two types of CTCL.\n\nSo, the answer is A. yes. Mogamulizumab can be used for the treatment of cutaneous T-cell lymphoma, specifically mycosis fungoides and S\u00e9zary syndrome. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c72ba807c78d69471000076", "messages": [{"role": "user", "content": "Is avelumab effective for bladder cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nAvelumab is a monoclonal antibody that targets the PD-L1 protein, which is involved in the immune checkpoint pathway. This pathway is often exploited by cancer cells to evade the immune system. By blocking PD-L1, avelumab can potentially enhance the immune response against cancer cells.\n\nBladder cancer is a type of cancer that can be treated with immunotherapy, including checkpoint inhibitors like avelumab. In fact, avelumab has been approved by the FDA for the treatment of certain types of bladder cancer that has progressed after other treatments.\n\nSo, the answer is A. Yes, avelumab is effective for bladder cancer. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c6b7a9e7c78d69471000029", "messages": [{"role": "user", "content": "Is cabozantinib effective for Hepatocellular Carcinoma?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nCabozantinib is a tyrosine kinase inhibitor that is used in the treatment of several types of cancer, including hepatocellular carcinoma (HCC). HCC is a type of liver cancer that is often associated with chronic liver disease, such as cirrhosis. The standard treatment for HCC is surgical resection, liver transplantation, or local ablation, but these options are not always feasible due to the advanced stage of the disease or the patient's overall health.\n\nIn recent years, several targeted therapies have been developed for the treatment of HCC. Cabozantinib is one of these drugs. It works by inhibiting multiple tyrosine kinases, including VEGFR2, which is important for angiogenesis (the growth of new blood vessels), and MET, which is involved in cell proliferation and survival.\n\nSeveral clinical trials have shown that cabozantinib can be effective in the treatment of HCC. In one study, patients with advanced HCC who were not candidates for surgery or liver transplantation were treated with cabozantinib. The results showed that cabozantinib significantly improved overall survival compared to placebo.\n\nGiven the evidence from clinical trials, it is reasonable to conclude that cabozantinib is effective for the treatment of hepatocellular carcinoma.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c5839e707647bbc4b00001f", "messages": [{"role": "user", "content": "Is there a link between BCL11B haploinsufficiency and syndromic neurodevelopmental delay?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nBCL11B is a gene that is known to be involved in the development of the central nervous system. Mutations in this gene can lead to a condition called BCL11B-related developmental disorder, which is characterized by a range of symptoms including intellectual disability, developmental delay, and dysmorphic features. This condition is considered to be syndromic because it is associated with a specific genetic cause and presents with a recognizable pattern of symptoms.\n\nHaploinsufficiency refers to the condition where one copy of a gene is missing or not functioning properly. In the case of BCL11B, haploinsufficiency can lead to the symptoms of BCL11B-related developmental disorder. Therefore, there is a link between BCL11B haploinsufficiency and syndromic neurodevelopmental delay.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c6f6ae37c78d69471000054", "messages": [{"role": "user", "content": "Is Lasmiditan effective for migraine?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nLasmiditan is a novel drug that was approved by the FDA in 2019 for the acute treatment of migraine with or without aura in adults. It is a selective 5-HT1F receptor agonist, which means it works by binding to and activating the 5-HT1F receptor, a subtype of serotonin receptors. This action is thought to inhibit the release of neuropeptides that are involved in the pain pathway, leading to the relief of migraine symptoms.\n\nThe efficacy of lasmiditan for migraine has been studied in clinical trials. In one study, patients who received lasmiditan had a significantly greater reduction in pain intensity and a higher rate of pain freedom at 2 hours compared to those who received placebo. Another study found that lasmiditan was effective in reducing the intensity of migraine pain and the need for rescue medication.\n\nGiven the evidence from clinical trials, it is reasonable to conclude that lasmiditan is effective for the acute treatment of migraine.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c6d97497c78d69471000040", "messages": [{"role": "user", "content": "Are there graph kernel libraries available implemented in JAVA?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nGraph kernels are a type of machine learning algorithm that can be used to compare graphs. They are particularly useful in areas such as cheminformatics, where the structure of molecules is often represented as graphs. Graph kernels can be used to measure the similarity between two graphs by comparing their substructures.\n\nThere are several graph kernel libraries available, including those implemented in various programming languages. One of the most popular graph kernel libraries is the Weisfeiler-Lehman Graph Kernel (WL-GK), which is implemented in Python. However, there are also graph kernel libraries available in other languages, including Java.\n\nOne example of a graph kernel library implemented in Java is the GraphKernels library. This library provides a set of graph kernels for various graph representations, including the Weisfeiler-Lehman kernel, the shortest path kernel, and the random walk kernel. It also includes a set of graph kernels for attributed graphs, which are graphs with additional node and edge attributes.\n\nSo, the answer is A. yes, there are graph kernel libraries available implemented in JAVA. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c6df86b7c78d69471000045", "messages": [{"role": "user", "content": "Is baricitinib effective for rheumatoid arthritis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nBaricitinib is a Janus kinase (JAK) inhibitor that is used to treat moderate to severe rheumatoid arthritis (RA) in adults. It works by inhibiting the activity of JAK enzymes, which are involved in the signaling pathways that lead to inflammation and joint damage in RA.\n\nThe efficacy of baricitinib in the treatment of RA has been studied in clinical trials. These trials have shown that baricitinib can significantly reduce the signs and symptoms of RA, improve physical function, and slow the progression of joint damage. Additionally, baricitinib has been shown to be effective in reducing the need for corticosteroids and other disease-modifying antirheumatic drugs (DMARDs) in patients with RA.\n\nGiven the evidence from clinical trials, it is reasonable to conclude that baricitinib is effective for the treatment of rheumatoid arthritis.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c73acf27c78d6947100008a", "messages": [{"role": "user", "content": "Is Semagacestat effective for treatment of Alzheimer's disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nSemagacestat is a gamma-secretase inhibitor that was being investigated as a potential treatment for Alzheimer's disease. Gamma-secretase is an enzyme that is involved in the production of amyloid beta peptides, which are thought to be a key component in the pathogenesis of Alzheimer's disease. By inhibiting gamma-secretase, the hope was that the production of amyloid beta peptides would be reduced, thereby slowing the progression of the disease.\n\nHowever, clinical trials of semagacestat were discontinued in 2010 due to the finding that the drug actually increased the risk of developing skin cancer and did not show any significant benefit in slowing cognitive decline in patients with Alzheimer's disease. In fact, the drug seemed to worsen the symptoms of the disease in some patients.\n\nSo, the answer is B. No, semagacestat is not effective for the treatment of Alzheimer's disease. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c840daf617e120c34000007", "messages": [{"role": "user", "content": "Does Rhamnose have any effect on aging?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nRhamnose is a monosaccharide that is a component of many complex carbohydrates, including glycoproteins and glycolipids. It is also found in some plant gums and mucilages. While it is not a direct antioxidant, it can be part of a larger molecule that has antioxidant properties.\n\nHowever, there is no direct evidence that rhamnose itself has any effect on aging. Aging is a complex process that involves many factors, and while some compounds may have anti-aging effects, there is no specific evidence that rhamnose is one of them.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c7d6b3e45e140a523000001", "messages": [{"role": "user", "content": "Is there any approved treatment for NAFLD?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\n<|assistant|>\nNon-alcoholic fatty liver disease (NAFLD) is a condition where fat accumulates in the liver of people who drink little or no alcohol. It is a common cause of chronic liver disease and is often associated with obesity, diabetes, and metabolic syndrome. While there is no specific treatment for NAFLD, lifestyle modifications such as weight loss, exercise, and dietary changes can help manage the condition and prevent its progression to more serious liver diseases.\n\nThe treatment for NAFLD focuses on managing the underlying risk factors, such as obesity, diabetes, and metabolic syndrome. Weight loss is the most effective treatment for NAFLD, as it can reduce liver fat and improve liver function. Exercise can also help reduce liver fat and improve insulin sensitivity. Dietary changes that focus on reducing calorie intake and increasing the intake of healthy foods, such as fruits, vegetables, and whole grains, can also help manage NAFLD.\n\nThere are no approved medications specifically for the treatment of NAFLD. However, some medications may be used to manage the associated conditions, such as diabetes or high cholesterol, which can help improve liver function and reduce the risk of NAFLD progression.\n\nSo, the answer is C. There is no approved treatment for NAFLD, but lifestyle modifications and management of associated conditions can help manage the disease. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c72bd047c78d69471000077", "messages": [{"role": "user", "content": "Can pazopanib be used for treatment von Hippel-Lindau disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nPazopanib is a tyrosine kinase inhibitor that is used to treat certain types of cancer, including renal cell carcinoma (RCC). Von Hippel-Lindau (VHL) disease is a genetic disorder that can lead to the development of various types of tumors, including renal cell carcinoma. However, pazopanib is not specifically indicated for the treatment of VHL disease or its associated tumors.\n\nWhile pazopanib can be used to treat RCC, it is not a standard treatment for VHL disease. The management of VHL disease typically involves surveillance and treatment of specific tumors as they arise, which may include surgery, radiation therapy, or other targeted therapies. Pazopanib is not typically used as a first-line treatment for VHL-related RCC, as there are other targeted therapies that are more commonly used in this context.\n\nSo, the answer is B. No, pazopanib cannot be used for the treatment of von Hippel-Lindau disease. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c89461675a4a5d219000013", "messages": [{"role": "user", "content": "Is Netrin-1 a secreted protein?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nNetrin-1 is a protein that plays a crucial role in the development of the nervous system. It is a secreted protein that acts as a guidance cue for the growth of axons during development. Netrin-1 is secreted by cells in the environment of developing neurons and binds to receptors on the surface of the axons, guiding them to their correct targets.\n\nThe fact that Netrin-1 is a secreted protein is crucial to its function. If it were not secreted, it would not be able to interact with the axons and guide their growth. Secreted proteins are those that are produced by cells and released into the extracellular space, where they can act on other cells or tissues.\n\nSo, the answer is A. Yes, Netrin-1 is a secreted protein. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c62a529e842deac6700000b", "messages": [{"role": "user", "content": "Is the yeast (Saccharomyces cerevisiae) genome organized into topologically associated domains (TADs)?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nTopologically associated domains (TADs) are regions of the genome that are thought to be insulated from each other by chromatin loops. These loops are believed to help regulate gene expression by keeping certain genes in close proximity to each other and away from other regions of the genome. TADs are a relatively recent discovery in the field of genomics, and their existence has been studied in a variety of organisms, including humans and other mammals.\n\nWhile there is evidence that TADs exist in the genomes of many organisms, including humans, there is less information about their presence in the yeast (Saccharomyces cerevisiae) genome. Yeast is a model organism that has been extensively studied in the field of genetics and molecular biology, but the question of whether its genome is organized into TADs is not as well-established as it is for other organisms.\n\nGiven the current state of knowledge, it is difficult to definitively say whether the yeast genome is organized into TADs. Some studies have suggested that yeast chromosomes may have a similar organization to TADs, but the evidence is not as strong as it is for other organisms. Therefore, the answer is \"maybe\" rather than a definitive yes or no.\n\nSo, the answer is C. maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c72a5ca7c78d6947100006d", "messages": [{"role": "user", "content": "As of Feb 2019, are major brain gangliosides a target for the treatment of Alzheimer's disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nAlzheimer's disease is a neurodegenerative disorder characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. The amyloid plaques are composed primarily of beta-amyloid peptides, and the neurofibrillary tangles are composed of hyperphosphorylated tau proteins.\n\nMajor brain gangliosides are complex lipids found in the outer leaflet of the plasma membrane of neurons and other cells. They are involved in cell signaling, cell adhesion, and other cellular processes. There is some evidence that gangliosides may be involved in the pathogenesis of Alzheimer's disease, as they can bind to beta-amyloid peptides and may contribute to the formation of amyloid plaques. However, there is no direct evidence that targeting gangliosides is a viable treatment for Alzheimer's disease.\n\nCurrently, there are no approved treatments that target gangliosides for the treatment of Alzheimer's disease. The most common treatments for Alzheimer's disease focus on modulating the levels of beta-amyloid or tau, or on improving cognitive function through other mechanisms.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c72f8557c78d69471000080", "messages": [{"role": "user", "content": "Is Miller-Dieker syndrome associated with abnormalities of chromosome 1?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.cannot be determined\n<|assistant|>\nMiller-Dieker syndrome is a rare genetic disorder characterized by severe microcephaly, facial dysmorphisms, and lissencephaly (a condition where the brain's surface is smooth instead of having the normal folds). The syndrome is caused by a deletion on chromosome 17p13.3, which is a region that contains the LIS1 gene. This gene is important for normal brain development, and its deletion leads to the symptoms of Miller-Dieker syndrome.\n\nChromosome 1 is not associated with Miller-Dieker syndrome. The syndrome is caused by a deletion on chromosome 17, not chromosome 1. Therefore, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c93e6a1ecadf2e73f00001b", "messages": [{"role": "user", "content": "Does the interaction of MOV10 and RNASEH2 promote L1 retrotransposition?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nMOV10 (Molecular Motors and Vesicle Trafficking 10) is a protein that has been shown to have multiple functions, including the regulation of retrotransposons. Retrotransposons are mobile genetic elements that can move within the genome by a \"copy and paste\" mechanism, which involves the production of RNA intermediates that are then reverse transcribed into DNA and inserted into new genomic locations.\n\nRNASEH2 (Ribonuclease H2) is an enzyme that is involved in the degradation of RNA. It is particularly important in the process of DNA replication, where it helps to remove RNA primers from Okazaki fragments during DNA synthesis.\n\nThe interaction between MOV10 and RNASEH2 is not well understood, but it is known that MOV10 can bind to RNASEH2 and that this interaction is important for the regulation of retrotransposons. Specifically, MOV10 has been shown to inhibit the activity of RNASEH2, which is necessary for the reverse transcription step of retrotransposition. By inhibiting RNASEH2, MOV10 may help to prevent the reverse transcription of retrotransposons, thereby reducing their mobility within the genome.\n\nSo, the answer is A. yes. The interaction of MOV10 and RNASEH2 does promote L1 retrotransposition by inhibiting the activity of RNASEH2, which is necessary for the reverse transcription step of retrotransposition. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c8cfca70101eac870000005", "messages": [{"role": "user", "content": "Has the protein SIRT2 been associated to cervical cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nSIRT2 is a member of the sirtuin family of proteins, which are known for their role in regulating various cellular processes, including cell growth, apoptosis, and metabolism. SIRT2 is a NAD+-dependent deacetylase that is involved in the regulation of the cell cycle and the maintenance of genomic stability.\n\nWhile there is some evidence that sirtuins, including SIRT2, may be involved in the pathogenesis of certain cancers, there is no specific evidence that SIRT2 has been directly associated with cervical cancer. However, given the role of sirtuins in cellular processes and the fact that cervical cancer is a common type of cancer, it is possible that SIRT2 could be involved in the development of this disease.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c6438a5e842deac67000016", "messages": [{"role": "user", "content": "Are recessive coding variants responsible for the majority of undiagnosed nonconsanguineous individuals?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nThe question asks about the role of recessive coding variants in the undiagnosed cases of nonconsanguineous individuals. Consanguinity refers to the mating of two related individuals, which can increase the likelihood of recessive disorders because both parents carry the same recessive variant and can pass it on to their offspring.\n\nIn nonconsanguineous individuals, recessive disorders are less common because the parents are less likely to carry the same recessive variant. However, recessive disorders can still occur in nonconsanguineous families if one parent is a carrier of a recessive variant and the other parent is unaffected but carries a different recessive variant. If these two variants are in the same gene, they can combine to cause a recessive disorder in the offspring.\n\nGiven this information, it is possible that recessive coding variants could be responsible for some undiagnosed cases in nonconsanguineous individuals. However, it is not the majority of cases, as the majority of undiagnosed cases are likely due to other genetic or non-genetic factors.\n\nSo, the answer is C. Maybe. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c6445f0e842deac67000017", "messages": [{"role": "user", "content": "Is the NLM medical text indexer (MTI) still useful and relevant?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nThe NLM Medical Text Indexer (MTI) is a tool developed by the National Library of Medicine (NLM) to assist in the indexing of biomedical literature. It is a computer-assisted indexing system that uses natural language processing techniques to identify relevant concepts in biomedical literature and assign them to the Medical Subject Headings (MeSH) vocabulary.\n\nThe MTI has been in use since the 1990s and has undergone several updates and improvements over the years. It is still considered a valuable tool for indexing biomedical literature, as it helps to ensure consistency and accuracy in the indexing process. The MTI is particularly useful for large-scale indexing projects, where manual indexing by humans can be time-consuming and prone to errors.\n\nHowever, it is important to note that the MTI is not the only tool used for indexing biomedical literature. Other tools and methods, such as manual indexing by humans, are also used. The choice of which tool to use depends on the specific needs and resources of the indexing project.\n\nSo, the answer is A. yes, the NLM medical text indexer (MTI) is still useful and relevant. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c8972d4d558e5f232000006", "messages": [{"role": "user", "content": "Has strimvelis been approved by the European Medicines Agency?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.not yet\n<|assistant|>\nStrimvelis is a gene therapy treatment for severe combined immunodeficiency (SCID) caused by adenosine deaminase (ADA) deficiency. It was developed by GlaxoSmithKline and approved by the European Medicines Agency (EMA) in 2016. The treatment involves the transplantation of autologous hematopoietic stem cells that have been genetically modified to produce functional ADA.\n\nThe approval of Strimvelis was a significant milestone in the field of gene therapy, as it was the first gene therapy treatment to be approved in the European Union. The treatment is only available in Europe and is not yet approved in the United States.\n\nSo, the answer is A. yes. Strimvelis has been approved by the European Medicines Agency. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c83f858617e120c34000003", "messages": [{"role": "user", "content": "Is treatment with Bacillus Calmette Guerin used for bladder cancer?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nBacillus Calmette Guerin (BCG) is a vaccine that is used to prevent tuberculosis. It is not used as a treatment for bladder cancer. The treatment for bladder cancer typically involves surgery, chemotherapy, or radiation therapy, depending on the stage and grade of the cancer.\n\nBCG is sometimes used as an immunotherapy for bladder cancer, but it is not the primary treatment for the disease. It is used in a procedure called intravesical immunotherapy, where BCG is instilled into the bladder to stimulate the immune system to attack any remaining cancer cells after surgery or other treatments.\n\nSo, the answer is B. no. BCG is not used as a primary treatment for bladder cancer. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c73acf17c78d69471000089", "messages": [{"role": "user", "content": "Is eculizumab used for treatment of myasthenia gravis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nEculizumab is a monoclonal antibody that is used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It works by inhibiting the complement system, which is a part of the immune system that helps to protect the body from infections and foreign substances.\n\nMyasthenia gravis is a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. It is not treated with eculizumab because the mechanism of action of eculizumab is not relevant to the pathophysiology of myasthenia gravis.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c928afeecadf2e73f000018", "messages": [{"role": "user", "content": "Can cardiospheres be produced from skin fibroblasts?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.it depends\n<|assistant|>\nCardiospheres are clusters of cardiac progenitor cells that can be isolated from the heart and used in regenerative medicine. They are known to have the ability to differentiate into cardiomyocytes, smooth muscle cells, and endothelial cells, which are the three main cell types found in the heart.\n\nSkin fibroblasts are a type of cell found in the connective tissue of the skin. They are not typically associated with the heart or cardiac tissue. While it is possible to reprogram skin fibroblasts into induced pluripotent stem cells (iPSCs), which can then be differentiated into cardiac cells, the process is not as direct as starting with cardiac progenitor cells.\n\nSo, the answer is B. no. Cardiospheres cannot be produced from skin fibroblasts in the same way as they are from cardiac tissue. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c73ad347c78d69471000098", "messages": [{"role": "user", "content": "Does Axitinib prolong survival of Pancreatic Cancer patients?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\nD.cannot be determined\n<|assistant|>\nAxitinib is a tyrosine kinase inhibitor that is used to treat certain types of cancer, including renal cell carcinoma and thyroid cancer. It works by inhibiting the activity of certain enzymes that are involved in the growth and spread of cancer cells.\n\nPancreatic cancer is a particularly aggressive form of cancer with a poor prognosis. While there are several treatments available, including surgery, chemotherapy, and radiation therapy, the overall survival rate for pancreatic cancer remains low.\n\nThere is currently no evidence that axitinib, or any other tyrosine kinase inhibitor, prolongs the survival of pancreatic cancer patients. In fact, the use of tyrosine kinase inhibitors in pancreatic cancer is not standard practice due to the lack of clinical evidence supporting their efficacy in this setting.\n\nGiven the current state of knowledge, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c5217fd7e3cb0e231000005", "messages": [{"role": "user", "content": "Is there any association between suicide and autism in adolescents, yes or no?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nThere is a well-established association between autism spectrum disorder (ASD) and suicide risk in adolescents. Individuals with ASD are at a higher risk for suicide compared to the general population. This is due to a variety of factors, including social isolation, communication difficulties, and challenges with emotional regulation.\n\nStudies have shown that individuals with ASD are more likely to experience depression, anxiety, and other mental health issues, which can increase the risk of suicide. Additionally, the social isolation and difficulties with communication that are common in ASD can make it more difficult for individuals to seek help or to be aware of warning signs in themselves or others.\n\nGiven the evidence, it is appropriate to conclude that there is an association between suicide and autism in adolescents.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c8c05c70101eac870000001", "messages": [{"role": "user", "content": "Is lactotransferrin a tumour suppressor?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nLactotransferrin is a protein that is found in breast milk and is also produced by cells in the mammary glands. It is a member of the transferrin family of proteins, which are involved in iron transport and storage. Lactotransferrin has been studied for its potential role in breast cancer.\n\nSome studies have suggested that lactotransferrin may have a protective effect against breast cancer. For example, one study found that women with higher levels of lactotransferrin in their breast milk had a lower risk of developing breast cancer. This suggests that lactotransferrin may have a tumor suppressor effect.\n\nHowever, other studies have not found a consistent association between lactotransferrin levels and breast cancer risk. Additionally, the mechanisms by which lactotransferrin might act as a tumor suppressor are not fully understood.\n\nGiven the mixed evidence and the need for further research, it is difficult to definitively say that lactotransferrin is a tumor suppressor. Therefore, the answer is C. \"May be.\" Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c6ad3be7c78d69471000021", "messages": [{"role": "user", "content": "Are there tools for visualizing and processing long-read sequencing data?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nLong-read sequencing technologies, such as those based on single-molecule real-time (SMRT) sequencing or nanopore sequencing, produce much longer reads than traditional short-read sequencing methods. These longer reads can provide more accurate and complete information about the genome, but they also present challenges for visualization and analysis.\n\nOne of the main challenges with long-read sequencing data is that it can be difficult to align to a reference genome due to the high error rate and the presence of structural variants. This makes it more challenging to use traditional alignment-based tools for visualization and analysis.\n\nHowever, there are tools that have been developed specifically for visualizing and processing long-read sequencing data. For example, tools like Canu and Flye are used for genome assembly from long-read data, and tools like Nanopolish and LoRDEC are used for base calling and error correction. There are also visualization tools like Long Ranger and Nanoplot that are designed to display long-read data.\n\nSo, the answer is A. Yes, there are tools for visualizing and processing long-read sequencing data. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c674eac7c78d6947100001b", "messages": [{"role": "user", "content": "Has Hesperidin any role as a Neuroprotective Agent?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nHesperidin is a flavonoid glycoside found in citrus fruits and has been studied for its potential health benefits, including its antioxidant and anti-inflammatory properties. However, there is limited evidence to suggest that hesperidin has a specific role as a neuroprotective agent.\n\nNeuroprotection refers to the prevention of damage to the brain or nervous system. While hesperidin has been shown to have antioxidant and anti-inflammatory effects, these properties are not specifically associated with neuroprotection. There is no strong evidence that hesperidin can prevent or treat neurological conditions such as Alzheimer's disease, Parkinson's disease, or other neurodegenerative disorders.\n\nWhile hesperidin may have some beneficial effects on overall health, there is no clear evidence that it has a specific role as a neuroprotective agent.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c8857e975a4a5d219000009", "messages": [{"role": "user", "content": "Are apoE mimetics being considered as a treatment against Alzheimer's disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.not yet\n<|assistant|>\nApoE is a protein that is involved in the metabolism of cholesterol and other lipids in the brain. The ApoE gene has three common alleles: ApoE2, ApoE3, and ApoE4. The ApoE4 allele is associated with an increased risk of Alzheimer's disease, while the ApoE2 allele is protective against the disease.\n\nApoE mimetics are compounds that are designed to mimic the function of ApoE, particularly the ApoE2 allele, which is known to be protective against Alzheimer's disease. The idea behind these mimetics is that they could potentially reduce the risk of Alzheimer's disease by mimicking the protective effects of ApoE2.\n\nResearch into ApoE mimetics as a potential treatment for Alzheimer's disease is ongoing, but it is not yet clear if they will be effective in clinical trials. However, there is a lot of interest in this area, and it is a promising avenue for future research.\n\nSo, the answer is C. Maybe. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c6d9a157c78d69471000041", "messages": [{"role": "user", "content": "Can you computationally predict Molecular Recognition Features (MoRFs) regions in Intrinsically Disordered Proteins (IDPs)?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nMolecular Recognition Features (MoRFs) are short linear segments within intrinsically disordered proteins (IDPs) that can fold upon binding to a partner molecule. These regions are often involved in protein-protein interactions and can be critical for the function of the protein.\n\nWhile there are computational methods that can predict the presence of MoRFs in IDPs, these predictions are not always accurate. The challenge lies in the fact that MoRFs are often short and can be difficult to identify without experimental validation. Additionally, the context of the protein and its interactions can affect the folding of MoRFs, which can make them more challenging to predict.\n\nSo, the answer is B. no, it is not possible to computationally predict Molecular Recognition Features (MoRFs) regions in Intrinsically Disordered Proteins (IDPs) with 100% accuracy. However, there are methods that can provide useful predictions and help guide experimental validation. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c97a08becadf2e73f000029", "messages": [{"role": "user", "content": "Velocardial facial syndrome, otherwise known as Di George syndrome  is caused by a deletion in chromosome 21, yes or no?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nVelocardiofacial syndrome (VCFS), also known as DiGeorge syndrome, is a genetic disorder that affects many parts of the body. It is characterized by a wide range of symptoms, including heart defects, facial abnormalities, and learning disabilities.\n\nThe syndrome is caused by a deletion of a small piece of chromosome 22, which is known as the 22q11.2 deletion. This deletion disrupts the normal development of several parts of the body, including the heart, face, and immune system.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c8ab614d558e5f23200000d", "messages": [{"role": "user", "content": "Is the protein Asporin related to disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nAsporin is a protein that is involved in the regulation of bone formation and is expressed in cartilage and bone. It is known to be a negative regulator of bone formation, as it inhibits the activity of bone morphogenetic proteins (BMPs), which are important for bone growth and development.\n\nThere is evidence that mutations in the ASPN gene, which encodes Asporin, are associated with certain diseases. For example, a mutation in ASPN has been linked to the development of osteoarthritis, a degenerative joint disease. This mutation leads to increased expression of Asporin, which can contribute to the breakdown of cartilage and the progression of osteoarthritis.\n\nSo, the answer is A. Yes, the protein Asporin is related to disease. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5ca61176ecadf2e73f00004e", "messages": [{"role": "user", "content": "Can TAD disruption lead to disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nTADs, or topologically associating domains, are large-scale chromatin structures that are important for the organization of the genome. They are thought to be involved in the regulation of gene expression and other cellular processes. Disruption of TADs can potentially lead to changes in gene expression patterns and other cellular functions.\n\nThere is evidence that TAD disruption can lead to disease. For example, in cancer cells, TADs are often disrupted, which can lead to the dysregulation of genes and the activation of oncogenes. Additionally, mutations in proteins that are involved in TAD formation or maintenance can lead to diseases such as Cornelia de Lange syndrome and Coffin-Siris syndrome.\n\nSo, the answer is A. Yes, TAD disruption can lead to disease. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c8908a475a4a5d21900000c", "messages": [{"role": "user", "content": "Is L-4F an apoE mimetic peptide?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\n<|assistant|>\nL-4F is a peptide that is known to have cholesterol-lowering effects and is thought to mimic the function of apolipoprotein E (apoE). ApoE is a protein that is involved in the metabolism of lipids and cholesterol, particularly in the transport of lipoproteins from the liver to peripheral tissues. It is also involved in the clearance of cholesterol from the body.\n\nThe L-4F peptide is designed to mimic the structure and function of apoE, which is why it is often referred to as an apoE mimetic peptide. It is believed to work by binding to the same receptors as apoE, which helps to remove cholesterol from the body and prevent its accumulation in the arteries.\n\nSo, the answer is A. Yes, L-4F is an apoE mimetic peptide. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c890c3375a4a5d21900000e", "messages": [{"role": "user", "content": "Can oleuropein aglycone interfere with amyloid aggregation?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nOleuropein aglycone is a compound found in olive oil and other parts of the olive tree. It is known for its antioxidant and anti-inflammatory properties. However, there is no evidence to suggest that oleuropein aglycone interferes with amyloid aggregation, which is the process by which proteins misfold and form clumps known as amyloid plaques, a hallmark of Alzheimer's disease.\n\nWhile there is some research on the potential neuroprotective effects of oleuropein aglycone, particularly in the context of Alzheimer's disease, the focus is on its antioxidant and anti-inflammatory properties, not on its ability to prevent amyloid aggregation. There is no direct evidence that oleuropein aglycone can inhibit the formation of amyloid plaques.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5caa0806ecadf2e73f000057", "messages": [{"role": "user", "content": "Is Apelin usually decreased in diabetes?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be increased or decreased\nD.may be increased\n<|assistant|>\nApelin is a peptide hormone that is involved in the regulation of blood pressure, heart function, and energy metabolism. It is also known to have a role in the regulation of appetite and food intake. In diabetes, there is a complex interplay between various hormones and metabolic factors that can affect the levels of Apelin.\n\nIn general, Apelin levels are decreased in type 1 diabetes, which is characterized by insulin deficiency. This is because insulin is known to increase Apelin levels, and in the absence of insulin, Apelin levels can decrease. However, in type 2 diabetes, which is characterized by insulin resistance and often hyperinsulinemia, Apelin levels may be increased or decreased depending on the severity of the disease and the individual's response to insulin.\n\nGiven this information, the answer is C. Apelin levels may be increased or decreased in diabetes, depending on the type of diabetes and the individual's metabolic state. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5ca0fdb0ecadf2e73f000049", "messages": [{"role": "user", "content": "Is actin present in the nucleus?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nActin is a protein that is a major component of the cytoskeleton in eukaryotic cells. It is involved in cell motility, cell division, and the maintenance of cell shape. Actin is not typically found in the nucleus of a cell. The nucleus is the part of the cell that contains the genetic material, and it is surrounded by a double membrane called the nuclear envelope. The nuclear envelope separates the contents of the nucleus from the cytoplasm and prevents the entry of most proteins into the nucleus.\n\nActin is a cytoplasmic protein and is not normally found in the nucleus. However, there are some exceptions to this general rule. For example, in certain types of cells, such as muscle cells, actin is present in the nucleus during muscle differentiation. This is because the muscle cells need to express genes that are involved in muscle contraction, and these genes are regulated by the presence of actin in the nucleus.\n\nSo, the answer is B. Actin is not typically present in the nucleus. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c8fea130101eac87000000d", "messages": [{"role": "user", "content": "Can miR-122 target RUNX2?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nMiR-122 is a microRNA that is highly expressed in the liver and is known to have a role in the regulation of lipid metabolism. It is also involved in the regulation of gene expression by binding to the 3' untranslated region (3' UTR) of target mRNAs and promoting their degradation or translational repression.\n\nRUNX2 is a transcription factor that is involved in the regulation of osteoblast differentiation and bone formation. It is not typically considered a target of miR-122, as miR-122 is primarily associated with liver function and not bone metabolism.\n\nGiven the specific roles of miR-122 and RUNX2, it is unlikely that miR-122 would target RUNX2. Therefore, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c960d88ecadf2e73f00001f", "messages": [{"role": "user", "content": "Tocilizumab is an anti-TNF antibody, yes or no?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nTocilizumab is an anti-IL-6 receptor monoclonal antibody, not an anti-TNF antibody. It is used to treat conditions such as rheumatoid arthritis and systemic juvenile idiopathic arthritis, where IL-6 is thought to play a role in the pathogenesis of the disease.\n\nTNF (tumor necrosis factor) is a cytokine that plays a role in inflammation and is a target of other biologic therapies such as etanercept, adalimumab, and infliximab. These are all anti-TNF antibodies.\n\nSo, the answer is B. no. Tocilizumab is not an anti-TNF antibody. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c9e6ab9ecadf2e73f000035", "messages": [{"role": "user", "content": "Is it possible to analyze exosomes with FACS?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nExosomes are small vesicles that are released by cells into the extracellular space. They are typically 30-100 nm in diameter and contain a variety of biomolecules, including proteins, lipids, and nucleic acids. Exosomes are often studied for their role in intercellular communication and as potential biomarkers for various diseases.\n\nFlow cytometry, or FACS (fluorescence-activated cell sorting), is a technique used to analyze cells and particles based on their physical and chemical properties. It involves labeling cells or particles with fluorescent dyes or antibodies and then passing them through a laser beam. The laser excites the fluorescent labels, and the emitted light is detected and analyzed to determine the properties of the cells or particles.\n\nGiven that exosomes are small vesicles, it is possible to analyze them with FACS. However, there are some considerations to keep in mind. Exosomes are often isolated from biological fluids such as plasma or urine, and they may be present in low concentrations. Therefore, it is important to optimize the isolation and labeling procedures to ensure that enough exosomes are available for analysis and that they are properly labeled for detection by the FACS machine.\n\nSo, the answer is A. yes, it is possible to analyze exosomes with FACS. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c915e51ecadf2e73f00000c", "messages": [{"role": "user", "content": "Can prevnar 13 be used in children?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be used\nD.may not be used\n<|assistant|>\nPrevnar 13 is a vaccine that protects against 13 different strains of Streptococcus pneumoniae, which are bacteria that can cause pneumonia, meningitis, and other serious infections. It is recommended for children starting at 2 months of age and is given in a series of shots.\n\nThe vaccine is safe and effective for children, and it is part of the routine childhood immunization schedule in many countries. It is important to follow the recommended schedule to ensure that children are protected against these potentially serious infections.\n\nSo, the answer is A. Yes, Prevnar 13 can be used in children. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c9160bcecadf2e73f00000d", "messages": [{"role": "user", "content": "Was stelara developed by Amgen?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nStelara (ustekinumab) is a biologic medication used to treat a variety of autoimmune conditions, including psoriasis, psoriatic arthritis, and Crohn's disease. It is a monoclonal antibody that targets the interleukin (IL)-12 and IL-23 cytokines, which are involved in the inflammatory response.\n\nAmgen is a biotechnology company that develops and commercializes pharmaceuticals and biologics. However, Stelara is not one of their products. Stelara is developed and marketed by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson.\n\nSo, the answer is B. No, Stelara was not developed by Amgen. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c9e766becadf2e73f000038", "messages": [{"role": "user", "content": "Can mitochondria pass through membrane nanotubes?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nMitochondria are organelles that are found in the cytoplasm of eukaryotic cells. They are responsible for generating energy in the form of ATP through the process of oxidative phosphorylation. Mitochondria have their own DNA and are thought to have evolved from endosymbiotic bacteria that were engulfed by early eukaryotic cells.\n\nOne of the key features of mitochondria is that they are enclosed by a double membrane. The inner membrane is highly folded into cristae, which increases the surface area available for the electron transport chain and oxidative phosphorylation. The outer membrane is more permeable than the inner membrane, allowing the passage of small molecules and ions.\n\nMembrane nanotubes are structures that can form between cells or within a cell. They are thin, tubular extensions of the plasma membrane that can be used for various functions, including cell-cell communication, the transfer of organelles, and the exchange of vesicles.\n\nGiven the structure of mitochondria and the properties of membrane nanotubes, it is possible for mitochondria to pass through membrane nanotubes. This has been observed in various cell types, including neurons, where mitochondria can be transferred between cells via nanotubes. This process is thought to be important for maintaining mitochondrial function and homeostasis in the cell.\n\nSo, the answer is A. yes. Mitochondria can pass through membrane nanotubes. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c9f1b0cecadf2e73f00003c", "messages": [{"role": "user", "content": "Are protamines ubiquitously expressed?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.uncertain\n<|assistant|>\nProtamines are a family of small, basic proteins that are found in the sperm of many animals, including humans. They are involved in the condensation of DNA during sperm maturation and are essential for the packaging of DNA into the compact head of the sperm cell. This process is known as spermatid condensation.\n\nThe expression of protamines is specific to the cells that are involved in sperm production, which are the spermatids. These cells are found in the testes of males. Therefore, protamines are not ubiquitously expressed, but rather are expressed in a specific tissue type.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c891d5075a4a5d219000011", "messages": [{"role": "user", "content": "Are Crocus sativus compounds being considered against Alzheimer's disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.not yet\n<|assistant|>\nCrocus sativus, commonly known as saffron, is a spice that has been used in traditional medicine for various conditions, including cognitive disorders. In recent years, there has been an increased interest in the potential of saffron and its compounds for the treatment of Alzheimer's disease (AD).\n\nSeveral studies have investigated the effects of saffron extract or its components on AD. These studies have shown that saffron may have neuroprotective and anti-inflammatory properties, which could be beneficial in the treatment of AD. For example, safranal, a component of saffron, has been shown to reduce amyloid-beta (A\u03b2) aggregation, which is a hallmark of AD pathology.\n\nHowever, the research on the use of saffron or its compounds in the treatment of AD is still in its early stages. While there is promising evidence from preclinical studies, clinical trials are needed to determine the safety and efficacy of saffron in humans with AD.\n\nGiven this, the answer is C. Maybe. While there is some evidence that suggests saffron compounds may be considered against Alzheimer's disease, more research is needed to confirm their efficacy and safety in humans. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5ca0848aecadf2e73f000044", "messages": [{"role": "user", "content": "Are there any anti-amyloid antibody approved as drug for Alzheimer's disease treatment?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.not sure\n<|assistant|>\nAlzheimer's disease is a progressive neurodegenerative disorder characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. The amyloid plaques are composed of beta-amyloid peptides, which are the result of the cleavage of the amyloid precursor protein (APP) by beta- and gamma-secretases. The accumulation of beta-amyloid peptides is thought to be a key factor in the pathogenesis of Alzheimer's disease.\n\nThere are several anti-amyloid antibodies that have been developed as potential treatments for Alzheimer's disease. These include antibodies that target beta-amyloid, such as bapineuzumab and solanezumab, and antibodies that target other aspects of the disease, such as gantenerumab and aducanumab. However, none of these antibodies have been approved as a drug for the treatment of Alzheimer's disease.\n\nThe clinical trials for these antibodies have shown mixed results, with some showing a reduction in amyloid plaques but no clear evidence of cognitive improvement. The trials have also raised concerns about the safety of these treatments, including the potential for microhemorrhages and amyloid-related imaging abnormalities (ARIA).\n\nGiven the current state of research, there are no anti-amyloid antibodies that have been approved as drugs for the treatment of Alzheimer's disease.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c891e5575a4a5d219000012", "messages": [{"role": "user", "content": "Do Crocus sativus extracts loosen the blood-brain barrier?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nCrocus sativus, commonly known as saffron, is a spice derived from the flower of the saffron crocus. It has been used in traditional medicine for various purposes, including as a treatment for depression and anxiety. However, there is no evidence that saffron extracts loosen the blood-brain barrier.\n\nThe blood-brain barrier is a highly selective barrier that protects the brain from harmful substances in the blood. It is formed by endothelial cells that line the blood vessels in the brain and tightly regulate the passage of substances into the brain. There is no known substance that can loosen the blood-brain barrier without causing significant damage to the brain.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5ca0fa96ecadf2e73f000048", "messages": [{"role": "user", "content": "Are artificial blood cells available?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nArtificial blood cells, also known as blood substitutes, are substances that can temporarily replace the function of red blood cells (RBCs) in the body. They are designed to carry oxygen to tissues and remove carbon dioxide from tissues, just like RBCs do.\n\nThe development of artificial blood cells has been ongoing for decades, but there are currently no artificial blood cells that are approved for widespread clinical use. The closest thing to an artificial blood cell is a hemoglobin-based oxygen carrier (HBOC), which is a synthetic version of the hemoglobin found in RBCs. HBOCs have been studied for use in trauma, surgery, and other situations where blood loss is a concern, but they have not been widely adopted due to safety concerns and the availability of blood transfusions.\n\nSo, the answer is B. No, artificial blood cells are not currently available for widespread clinical use. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c895cf0f9c2ba6b28000001", "messages": [{"role": "user", "content": "Have apolipoprotein mimetics been used in clinical trials?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nApolipoprotein mimetics are synthetic molecules that mimic the structure and function of endogenous apolipoproteins. They are designed to bind to lipids and transport them through the bloodstream, similar to the way natural apolipoproteins do. The goal is to use these mimetics to lower cholesterol levels and reduce the risk of cardiovascular disease.\n\nClinical trials have been conducted to evaluate the safety and efficacy of apolipoprotein mimetics. One such trial, the MIMIC-2 trial, was a phase 2 study that evaluated the efficacy and safety of an apolipoprotein mimetic called Mipomersen in patients with familial hypercholesterolemia. The results of this trial showed that Mipomersen was effective in lowering LDL cholesterol levels and was generally well-tolerated.\n\nSo, the answer is A. Yes, apolipoprotein mimetics have been used in clinical trials. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5ca10fefecadf2e73f00004a", "messages": [{"role": "user", "content": "Is the Philadelphia chromosome a fusion between parts of chromosomes 1 and 9?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nThe Philadelphia chromosome is a genetic abnormality that is associated with chronic myeloid leukemia (CML) and certain types of acute lymphoblastic leukemia (ALL). It is a translocation between the long arms of chromosomes 9 and 22, which results in the formation of a new chromosome, designated as chromosome 22q11.2. This translocation is symbolized as t(9;22)(q34;q11.2).\n\nThe Philadelphia chromosome is not a fusion between parts of chromosomes 1 and 9. Instead, it is a translocation between chromosomes 9 and 22, which results in the fusion of the ABL1 gene on chromosome 9 with the BCR gene on chromosome 22. The resulting BCR-ABL1 fusion gene is responsible for the production of the BCR-ABL1 tyrosine kinase, which is a key driver of the leukemogenesis in CML and certain types of ALL.\n\nSo, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c9f7bb6ecadf2e73f00003e", "messages": [{"role": "user", "content": "Can therapeutic levels of  Vedolizumab be found in the breast milk of nursing mothers following treatment for Inflammatory bowel disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.uncertain\nD.undetermined\n<|assistant|>\nVedolizumab is a monoclonal antibody that is used to treat inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. It works by binding to the alpha-4 beta-7 integrin, which is expressed on the surface of certain immune cells, thereby preventing these cells from entering the gastrointestinal tract and causing inflammation.\n\nThe safety of Vedolizumab during breastfeeding has not been established. While there is no specific data on the transfer of Vedolizumab into breast milk, it is a large molecule that is unlikely to be absorbed by the infant's gastrointestinal tract in significant amounts. However, given the lack of data, it is generally recommended that breastfeeding mothers avoid using Vedolizumab or other biologic therapies unless the benefits outweigh the risks.\n\nSo, the answer is B. no. There is no evidence that therapeutic levels of Vedolizumab can be found in breast milk. However, due to the lack of data, it is not certain that no levels can be found, so the answer is not C. uncertain. The answer is not D. undetermined because there is no evidence to suggest that the levels are undetermined. The answer is B. no, because there is no evidence that therapeutic levels of Vedolizumab can be found in breast milk. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c8fe71b0101eac87000000b", "messages": [{"role": "user", "content": "Does RUNX2 inhibit astrocyte differentiation?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nRUNX2 is a transcription factor that is known to play a critical role in osteoblast differentiation and bone formation. It is a key regulator of the osteoblast lineage and is essential for the development of bone and cartilage. RUNX2 is also involved in the differentiation of other cell types, including adipocytes and chondrocytes.\n\nAstrocytes are a type of glial cell that supports and nourishes neurons in the central nervous system. While there is some evidence that RUNX2 can be expressed in astrocytes, it is not known to be a primary regulator of astrocyte differentiation. In fact, the primary transcription factors involved in astrocyte differentiation are SOX9 and SOX10, which are not related to the RUNX family.\n\nGiven the specific role of RUNX2 in osteoblast differentiation and the lack of evidence for its primary role in astrocyte differentiation, the answer is B. no. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c9906dcecadf2e73f00002f", "messages": [{"role": "user", "content": "Are cardenolides inhibitors of Na+/K+ ATPase?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nCardenolides are a class of cardiac glycosides that are commonly found in plants such as Digitalis purpurea (foxglove) and are used in the treatment of heart failure. They are known for their positive inotropic and chronotropic effects on the heart, which are due to their ability to inhibit the Na+/K+ ATPase pump in cardiac muscle cells.\n\nNa+/K+ ATPase is an enzyme that is responsible for maintaining the proper balance of sodium and potassium ions across the cell membrane. Inhibition of this enzyme leads to an increase in intracellular sodium and a decrease in intracellular potassium, which in turn leads to an increase in the force of contraction of the heart muscle cells. This is because the increased intracellular sodium concentration causes calcium to enter the cell more easily, which then leads to an increase in the amount of calcium available to bind to troponin C and trigger muscle contraction.\n\nSo, the answer is A. yes. Cardenolides are inhibitors of Na+/K+ ATPase. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c900779ecadf2e73f000001", "messages": [{"role": "user", "content": "Can antisense threapy be used for Huntington's disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\nD.unlikely\n<|assistant|>\nHuntington's disease is a genetic disorder that causes the progressive breakdown (degeneration) of nerve cells in the brain. It is caused by an expansion of a CAG trinucleotide repeat in the huntingtin gene on chromosome 4. This expansion leads to the production of a mutant huntingtin protein that is toxic to neurons.\n\nAntisense therapy is a type of gene therapy that involves the use of short strands of DNA or RNA that are complementary to a specific sequence of a gene's mRNA. When these antisense oligonucleotides bind to the mRNA, they can prevent the mRNA from being translated into protein, thereby reducing the production of the toxic protein.\n\nGiven that Huntington's disease is caused by the production of a toxic protein, antisense therapy could potentially be used to reduce the production of this protein and slow the progression of the disease. However, this type of therapy is still in the early stages of development and has not yet been approved for use in Huntington's disease.\n\nSo, the answer is C. Maybe. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5ca5127eecadf2e73f00004c", "messages": [{"role": "user", "content": "Is collagen matrix of human articular cartilage changing with disease?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.maybe\nD.unsure\n<|assistant|>\nArticular cartilage is a specialized connective tissue that covers the ends of bones in the joints. It is composed of a matrix of collagen fibers, proteoglycans, and water. The collagen matrix provides the tensile strength and structural integrity of the cartilage, while the proteoglycans help to maintain the water content and provide compressive strength.\n\nIn diseases such as osteoarthritis, the collagen matrix of articular cartilage can indeed change. Osteoarthritis is characterized by the breakdown of cartilage, which leads to the loss of proteoglycans and water, as well as the degradation of collagen fibers. This can lead to a loss of the normal structure and function of the cartilage, which can contribute to the pain and stiffness associated with osteoarthritis.\n\nSo, the answer is A. Yes, the collagen matrix of human articular cartilage can change with disease. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c9162b5ecadf2e73f00000e", "messages": [{"role": "user", "content": "Is ustekinumab a polyclonal antibody?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nUstekinumab is a monoclonal antibody that is used to treat autoimmune diseases such as psoriasis and Crohn's disease. It is a human monoclonal antibody that targets the p40 subunit of interleukin-12 and interleukin-23, which are cytokines involved in the immune response. Monoclonal antibodies are produced by a single clone of B cells, which means they are not polyclonal. Polyclonal antibodies are produced by multiple clones of B cells and are typically used for immunization or as a diagnostic tool.\n\nSo, the answer is B. Ustekinumab is not a polyclonal antibody. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5cb37f76ecadf2e73f00005c", "messages": [{"role": "user", "content": "Is Pim-1 a protein phosphatase?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "<|assistant|>\nPim-1 is a serine/threonine kinase, not a protein phosphatase. Protein kinases are enzymes that transfer a phosphate group from a phosphate donor, such as ATP, to a protein substrate, thereby phosphorylating it. Protein phosphatases, on the other hand, remove phosphate groups from proteins, thereby dephosphorylating them.\n\nPim-1 is a member of the Pim family of serine/threonine kinases, which are known to play important roles in cell proliferation, survival, and apoptosis. They are often overexpressed in various cancers and are considered potential therapeutic targets.\n\nSo, the answer is B. no. Pim-1 is not a protein phosphatase. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5cb38a56ecadf2e73f00005e", "messages": [{"role": "user", "content": "Is myc a tumour suppressor gene?\nA.yes\nB.no"}, {"role": "assistant", "content": "B"}], "cot": "C.may be\n<|assistant|>\nMyc is a proto-oncogene that encodes a transcription factor that regulates the expression of genes involved in cell growth, proliferation, and apoptosis. When mutated or overexpressed, Myc can lead to the uncontrolled growth of cells, which is a hallmark of cancer. However, Myc is not typically considered a tumour suppressor gene because it is not involved in the direct suppression of tumour formation. Instead, Myc is more commonly associated with the promotion of tumour growth and progression.\n\nTumour suppressor genes, on the other hand, are genes that normally inhibit cell growth and division. When these genes are mutated or inactivated, cells can grow and divide uncontrollably, leading to cancer. Examples of tumour suppressor genes include p53, Rb, and APC.\n\nSo, the answer is B. Myc is not a tumour suppressor gene. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5cb3a2dd99d1e53537000001", "messages": [{"role": "user", "content": "Is CD63 an exosomal marker?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nCD63 is a protein that is commonly used as a marker for exosomes. Exosomes are small vesicles that are released by cells and contain a variety of proteins, lipids, and nucleic acids. CD63 is a tetraspanin protein that is found on the surface of exosomes and is often used as a marker to identify them.\n\nTetraspanins are a family of proteins that are known to be involved in the formation and function of exosomes. CD63 is one of the most commonly used tetraspanins as a marker for exosomes. It is often used in conjunction with other markers such as CD9 and CD81 to confirm the presence of exosomes.\n\nSo, the answer is A. yes. CD63 is an exosomal marker. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5ca0c81eecadf2e73f000047", "messages": [{"role": "user", "content": "Is subdural empyema a complication of sinusitis?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nSubdural empyema is a collection of pus in the subdural space, which is the space between the dura mater and the arachnoid mater. It is a serious infection that can lead to brain abscesses and other complications.\n\nSinusitis is an inflammation of the sinuses, which are air-filled cavities in the skull. While sinusitis can lead to complications such as orbital cellulitis or meningitis, it is not typically associated with subdural empyema. Subdural empyema is more commonly associated with infections that spread from the ear or the mastoid air cells, or from a dental infection that spreads to the skull base.\n\nSo, the answer is B. No, subdural empyema is not a complication of sinusitis. Therefore, the answer is B", "prediction": "B"}
{"dataset": "bioasq", "id": "5c98ac7fecadf2e73f00002b", "messages": [{"role": "user", "content": "Anaplasma phagocytophilum is an obligate gram-negative, intracellular bacterium, yes  or no\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nAnaplasma phagocytophilum is an obligate intracellular bacterium that infects and replicates within the cytoplasm of granulocytes, particularly neutrophils. It is a member of the Anaplasmataceae family, which includes other obligate intracellular bacteria such as Ehrlichia chaffeensis and Ehrlichia canis.\n\nAnaplasma phagocytophilum is a gram-negative bacterium, but it is not free-living in the environment. Instead, it requires a host cell to survive and replicate. It is transmitted by ticks and can cause human disease, such as human granulocytic anaplasmosis.\n\nSo, the answer is A. yes. Anaplasma phagocytophilum is an obligate intracellular bacterium. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5cb380b8ecadf2e73f00005d", "messages": [{"role": "user", "content": "Is the crystal structure of Pim-1 available?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nPim-1, also known as proviral integration site for Moloney murine leukemia virus 1, is a serine/threonine kinase that is involved in cell proliferation and survival. It is a member of the Pim kinase family, which includes Pim-1, Pim-2, and Pim-3.\n\nThe crystal structure of Pim-1 has been determined by X-ray crystallography. The structure of Pim-1 has been solved in complex with various inhibitors and substrates, which has provided insights into its catalytic mechanism and the design of inhibitors targeting this enzyme.\n\nSo, the answer is A. yes. The crystal structure of Pim-1 is available. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c92159becadf2e73f000012", "messages": [{"role": "user", "content": "Do tumour-associated macrophages have a prognostic role in gliomas?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.may be\nD.may not be\n<|assistant|>\nTumour-associated macrophages (TAMs) are a type of immune cell that can be found in the tumor microenvironment. They are often classified as M2 macrophages, which are associated with a pro-tumorigenic phenotype. In gliomas, TAMs have been shown to promote tumor growth, angiogenesis, and invasion, and they can also contribute to the immunosuppressive environment within the tumor.\n\nStudies have shown that the presence of TAMs in gliomas is associated with a worse prognosis. For example, a high density of TAMs in glioblastoma multiforme (GBM) is correlated with a shorter overall survival. This is likely due to the pro-tumorigenic role of TAMs in gliomas.\n\nSo, the answer is A. Yes, tumour-associated macrophages have a prognostic role in gliomas. They are associated with a worse prognosis in gliomas, particularly glioblastoma multiforme. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c9f0dabecadf2e73f00003b", "messages": [{"role": "user", "content": "Is TNF-\u03b1 an activator of pancreatic stellate cells?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "C.maybe\n<|assistant|>\nPancreatic stellate cells (PSCs) are the main source of extracellular matrix (ECM) production in the pancreas. They are activated in response to various stimuli, including inflammation, injury, and fibrogenic cytokines. One of the key cytokines involved in the activation of PSCs is tumor necrosis factor-alpha (TNF-\u03b1).\n\nTNF-\u03b1 is a pro-inflammatory cytokine that is known to play a role in the pathogenesis of various inflammatory diseases, including pancreatitis. In the context of pancreatic injury, TNF-\u03b1 can activate PSCs, leading to their transformation into myofibroblasts and subsequent ECM production. This process is a key step in the development of pancreatic fibrosis, which is a hallmark of chronic pancreatitis and pancreatic cancer.\n\nSo, the answer is A. yes. TNF-\u03b1 is an activator of pancreatic stellate cells. Therefore, the answer is A", "prediction": "A"}
{"dataset": "bioasq", "id": "5c9e738decadf2e73f000037", "messages": [{"role": "user", "content": "Can mitochondria transfer from cell to cell?\nA.yes\nB.no"}, {"role": "assistant", "content": "A"}], "cot": "<|assistant|>\nMitochondria are organelles found in eukaryotic cells that are responsible for generating energy through the process of cellular respiration. They are often described as the \"powerhouses\" of the cell because they convert the energy stored in nutrients into a form that cells can use.\n\nOne of the key features of mitochondria is that they have their own DNA (mtDNA), which is separate from the DNA in the nucleus. This mtDNA is responsible for encoding some of the proteins that are essential for mitochondrial function.\n\nNow, let's address the question: Can mitochondria transfer from cell to cell?\n\nThe answer is yes, mitochondria can transfer from cell to cell. This process is known as mitochondrial transfer or mitochondrial fusion. Mitochondrial fusion is a normal process that occurs in cells and is important for maintaining the integrity of the mitochondrial network and for ensuring proper mitochondrial function.\n\nMitochondrial fusion involves the merging of two mitochondria to form a single, larger mitochondrion. This process allows for the sharing of mitochondrial components, such as mtDNA, and can help to maintain the stability of the mitochondrial genome.\n\nMitochondrial transfer can also occur between cells, such as during cell division or when cells fuse together. This can be important for the maintenance of mitochondrial function in the daughter cells or in the fused cells.\n\nSo, the answer is yes, mitochondria can transfer from cell to cell.\n\nSo, the answer is A. yes. Therefore, the answer is A", "prediction": "A"}
